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Abstract 
 
Cathepsin proteases have been identified in many parasitic organisms and are involved in 
roles as diverse as tissue and skin penetration, virulence and immune invasion.  
Involvement in these key functions renders them potential targets at which to direct novel 
chemotherapeutic agents.  The inhibitor N-benzoyl-L-Leu-Gly nitrile prepared in this 
laboratory was shown to possess significantly greater inhibitory potency on the liver 
fluke Fasciola hepatica cysteine cathepsin L like endoproteases over the known 
commercial inhibitor Z-Phe-Ala-CHN2 at varying concentrations.   
 
The synthesis, structural characterisation and biological evaluation of a series of 
analogues of this active compound is now reported.  Addition of fluorine atoms to the N-
terminal benzoyl group and selective modification of the N-terminus is reported.  These 
dipeptidyl derivatives were synthesized using the standard DCC/HOBt or EDC/HOBt 
protocols.  These novel Cathepsin L inhibitors have been characterized by a wide range 
of spectroscopic techniques including 1H, 13C, 19F NMR and ESIMS. The biological 
activity of these novel compounds was determined in a bioassay using Z-Phe-Arg-
NHMec as a fluorogenic substrate. 
 
Resveratrol is a naturally occurring phyloalexin found in several plants but mainly in the 
skins of grapes.  It has been shown to be produced in response to bacterial and fungal 
infections.  It has been shown to exhibit various biological activities including anticancer, 
antifungal, antiviral, neuroprotective, anti-aging, and anti-inflammatory effects.  The 
synthesis of fluorinated stilbenes containing the 3,5,4’-substituted backbone was 
accomplished.  The compounds were synthesised via the Wittig reaction and the 
decarbonylative Heck reaction.  In conjunction with fluorine, nitrogen was also used as a 
replacement for the oxygen atoms of the resveratrol structure.  Full structural 
characterisation of these compounds was carried out followed by preliminary biological 
screening. 
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Thesis Introduction 
This thesis reports the synthesis, structural characterisation and biological activity of 
potential chemotherapeutic agents. Chemotherapy can be described as the treatment of 
disease using chemical agents or drugs that are selectively toxic to the causative agent of the 
disease, such as a virus, bacterium, or other microorganism. Chemotherapeutic agent is a 
generic term or description for any potential drug that displays biological activity against one 
or more bioorganisms. This thesis is divided into two separate sections, based on the disease 
targeted for inhibition and prevention. A common trait in this thesis is the inclusion of the 
fluorine atom in compounds synthesised. Fluorine has been shown to have many beneficial 
effects in medicinal chemistry and in today’s world is an important factor in the preparation 
of many biologically potent compounds. 
 
The initial section of this thesis concentrates on the preparation of potential inhibitors of an 
essential enzyme of the liver fluke parasite. By inhibiting this cysteine protease, cathepsin L, 
it is hoped to procure an increase in potency compared to what is currently available in the 
market place today. In recent years in Dublin City University, biologists have isolated the 
cathepsin L protease from this parasite and as a result studies have targeted this as a potential 
method of inhibiting this disease. From literature and past research experience in DCU, 
continued improvement of candidates for inhibition has led to the optimisation of a dipeptide 
structure. Modification of compounds has shown that the leucine glycine nitrile dipeptidyl 
scaffold as the most efficient for inhibition. As a result, a series of compounds with 
fluorobenzoyl N-terminal derivatives and a variety of substituted N-terminus dipeptides were 
prepared and evaluated for inhibitory potential. 
 
The second section of this thesis involves the preparation of novel compounds with anti-
cancer activity. Fluorinated derivatives of the stilbene resveratrol were synthesised. The 
triphenolic stilbene, resveratrol is a phytoalexin, i.e. produced in plant species in response to 
stress. Resveratrol has been shown to have a vast array of biological properties, ranging from 
anti-cancer activity to oestrogenic activity to inhibition of platelet aggregation. By 
maintaining the basic substitution pattern, fluorinated analogues where prepared containing 
hydroxyl bioisosteres, amines. Further to this, deriviatives were synthesised containing 
substituted amines and also potential prodrugs amino acid substituted stilbenes were 
prepared. 
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Section 1 
 
Protease Inhibitors 
  2 
1.0  Proteases and their inhibition 
 
1.1 Introduction 
 
Amino acids are essential basic building blocks of proteins.  They are naturally 
occurring organic acids with an amine at one terminus and a carboxylic acid group at 
the other.  These combine to form peptides which furthermore combine to form much 
larger macromolecules known as proteins. 
 
A proteinase or protease is a catalyst for peptide bond cleavage.  Proteolytic cleavage 
of peptide bonds is one of the most frequent and therefore one of the most important 
processes of enzymatic modification of proteins. Proteases can only catalyse the 
hydrolysis of a peptide bond.  Despite this, their diversity of function has made them 
one of the most interesting and widely studied groups of enzymes.  Regulation of 
physiological processes including differentiation, fertilization and growth is as a result 
of their control over protein synthesis.  Various treatments of serious medical 
conditions such as cancer and HIV have resulted from the inhibition of such 
proteases1,2. 
 
Investigations into inhibition, specificity, determination of amino acid sequence, 
kinetics and physical properties have led to the identification of their active sites.  As 
a result of this determination of the mechanisms of action is also possible.  Proteases 
can be classed into certain families or groups, dependent on similarity of structure and 
comparable mechanisms of action and active sites.  They are split into four 
mechanistic classes, and within these classes, six families of proteases are present.  
Peptidases are members of the peptidase family.  Proteolytic enzymes can by split into 
two categories; enzymes that require the presence of an unsubstituted N- or C-
terminus in the substrate, these are known as exopeptidases whilst enzymes that do 
not have such a requirement are called endopeptidases.  Exopeptidases can be further 
divided as follows: 
• Aminopeptidases 
• Dipeptidases 
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• Peptidyl-peptidases 
• Dipeptidyl-peptidases 
• Tripeptidyl-peptidases 
• Carboxypeptidases 
• Omega peptidases 
Exopeptidases remove a single amino acid, dipeptide or tripeptide from one terminus, 
actions which are the basis for their definition.  However, the secondary and tertiary 
structure formations of protein substrates usually foil attack by exopeptidases. 
 
On the other hand, endopeptidases are categorised on their active sites and not on 
their mode of action.  The action of the endopeptidase is generally not favoured by the 
presence of a free N- or C-terminus close to the scissile bond.  The scissile bond is the 
bond to be cleaved.  This category is subdivided into four main groups, as recognised 
by the International Union of Biochemistry, as follows3: 
• Serine Proteases 
• Cysteine Proteases 
• Aspartic Proteases 
• Metalloproteases 
Serine peptidases react with organophosphate compounds in such a way that by 
acylating a single serine residue, they catalyse their own death at the active site, 
essentially an irreversible step.  Essential to the catalytic mechanism of the cysteine 
peptidase is the thiol group of the individual cysteine moiety.  This group is subject to 
oxidation and can react with a variety of reagents such as heavy metals, e.g. mercury 
(Hg).  The aspartic peptidases are recognised by their highly acidic pH optima.  The 
metallopeptidases are identified by their susceptibility to inhibition by chelating 
agents such as ethylenediamine tetraacetic acid (EDTA) 4. 
 
In terms of endopeptidases, it was clear from kinetic studies that the binding of 
substrates (and inhibitors) involved interaction at a number of active sites4.  The 
nomenclature to describe this interaction is shown in Figure 1.1. 
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 Figure 1.1: Subsite interactions between peptide substrate and endopeptidase active site 
 
The amino acids of the polypeptide chain bind with the subsites in the endopeptidase 
active site.   The subsite of the enzyme in the diagram is referred to as ‘S’ and the 
substrate amino acids ‘P’.  The amino acid adjacent to the scissile site ( ) on the N-
terminus are labelled P1, P2, P3 etc and on the C-terminus P1’, P2’, P3’ etc, with the 
P1/P1’ being closest to the cleavage site.  The complementary sites on the 
endopeptidase are labelled S1, S1’, S2 etc.  The specificity of different proteases is due 
to differing amino acid residue substitution in the primary substrate binding site P1/P1’ 
and minor difference in the secondary binding sites (P2-P8/P2’-P8’).  An example is the 
serine protease α-chymotrypsin which prefers an aromatic side chain on the substrate 
at P1’.  The reason for this preference is because the bulky aromatic side chain can fit 
tightly into a slit-like hydrophobic pocket near the active site5. 
 
 
1.2 Protease Mechanism 
 
As previously mentioned, there are four classes of proteolytic enzyme each with 
independent mechanisms.  These four classes can be subdivided further into two 
major mechanistic groups, which is of profound consequence since the strategy for 
inhibition is totally different for these two classes. 
 
The two enzymes of the first mechanistic class, namely serine and cysteine proteases, 
form covalent enzyme complexes, and at the catalytic site have strongly nucleophilic 
amino acids.  The second mechanistic group consists of aspartic and metalloproteases 
and do not form covalent enzyme complexes.  These proteases catalyse the hydrolysis 
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of peptide bonds without nucleophilic attack by a functional group of the enzyme.  
They rely more on the acid/base catalysis of the attack of a water molecule and as a 
result the residues are lacking the aggressive nucleophilicity of the serine and cysteine 
peptidases. 
 
The serine peptidases are the most extensively studied of all classes of proteases, 
possibly the most studied in all of enzymology.  The important components of the 
mechanism of the serine peptidase enzymatic family are shown in Scheme 1.1.  The 
key feature of this formation is the esterification reaction between the oxygen of 
serine 195 (chymotrypsin numbering system) and the acyl portion of the substrate, 
with the loss of the amino portion as the initial product, or P1.  The ester formed will 
be the same for a series of substrates, which differ in their leaving groups.  The other 
factor of importance in the serine protease mechanism is the presence of two 
backbone -NH- groups that are available for hydrogen bonding with the oxygen anion 
of the peptide substrate involved6.  The mode of action of the serine proteases 
involves the binding of the substrate in the active site to form a Michaelis complex.  
This is shown in Scheme 1.1. 
 
The active site serine hydroxyl, activated by the imidazole side chain of His57, 
nucleophilicly attacks the carbonyl group of the scissile amide bond.  The resulting 
tetrahedral intermediate then forms the oxyanion hole, stabilized by hydrogen 
bonding to the N-H backbone of Ser195 and Gly193.  Proton transfer from the His57 
residue to the amine of the tetrahedral intermediate eliminates the C-terminal 
fragment as a leaving group.  The covalent acyl-enzyme complex is attacked by a 
water molecule activated by the imidazole side chain of His57, with formation of a 
new tetrahedral intermediate.  This intermediate subsequently breaks down via acid 
catalysis to form the carboxy fragment of the cleaved substrate and regeneration of 
the Ser195 residue of the active site. 
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Scheme 1.1: The mechanism of the serine peptidase enzymatic family. 
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Cysteine peptidases have a mode of action comparable to that of the serine peptidases, 
in that a covalent intermediate is formed7-9.  In this mechanism, the nucleophile 
responsible for the attack is thought to be the sulphur atom of the cysteine residue.  As 
in the serine protease mechanism, a histidine side chain is believed to be involved in 
the hydrogen binding to the oxygen anion formed from the attack of the sulphur based 
nucleophile.  Full catalytic activity is still up for debate, regarding the involvement of 
the catalytic pair of Cys25 and His159 as being sufficient10. 
 
The aspartic protease class of enzymes are believed to catalyse the cleavage of 
peptide bonds without the use of nucleophilic attack by a functional group of the 
enzyme11.  Hence, there is no covalent or tetrahedral intermediate formed in the 
mechanism, between the enzyme and the substrate.  The catalysis involves two 
aspartic acid side chains.  Nucleophilic attack does not take place, as a carboxyl group 
is not known as an efficient nucleophile.  However, the belief is that the carboxyl 
groups are involved in the catalysis, due to the low pH optimum of this group of 
enzymes. 
 
Like aspartic peptidases, metalloproteases do not form covalent intermediates.  The 
metalloproteases utilize coordination to a metal ion to exert the catalytic effect on the 
carbonyl group of the bond undergoing cleavage, rather than relying on the hydrogen 
bonding via an ‘oxyanion hole’12.  Zinc is the most common metal, but other 
transition metals can substitute.  To assist in attack by a water molecule, the metal ion 
exerts a strong electrophilic ‘pull’.   
 
 
1.3 Protease Inhibitors 
 
Protease inhibitors are compounds that have an adverse effect on the measured rate of 
hydrolysis of a given substrate.  Whether discovering or characterizing protease 
inhibitors for therapeutic purposes or as functional tools, the kinetics of the reaction 
are important to the degree of inhibition achieved.  The kinetics determine how 
effective the reaction in question will be.  If suppression of the activity of a specific 
proteinase is required, knowledge of the kinetics allows for further information such 
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as amounts required and time needed for complete suppression.  Most protease 
inhibitors can be defined as ‘active-site-directed’, i.e. formation of a tight and stable 
complex via combination with catalytic and substrate-binding sites of the protease13.  
Whether it is a natural or a synthetic inhibitor, they all mimic substrates.  Protease 
inhibitors compete with substrates and many are extremely tight–binding.  In fact, 
many proteinase inhibitors form irreversible complexes with proteinases.  Irreversible 
or tight-binding inhibitors decrease the number of active sites available for the 
substrate3. 
 
 
1.4 Inhibition kinetics 
 
Describing the bimolecular reaction between protease (E) and inhibitor (I) which 
results in a stable complex (E-I) formation via an intermediate comparable to 
substrate binding (EI), the key equation for protease inhibition is: 
 
The rates of the reactions are described by the rate constants, k1, k-1 and k2.  Equation 
1 describes an irreversible reaction.  Irreversible inhibitors form covalent bonds with 
the enzyme, and often, on denaturation of the enzyme these bonds remain.  The three 
rate constants mentioned for equation 1, are the parameters that govern the general 
reaction between a protease and an irreversible inhibitor.  The apparent rate of 
inhibition (or association) known as kass is the most important quantity in this type of 
inhibition.  For inhibitors following this mechanism, kass is defined as follows: 
 
 
For practical purposes kass is a sufficient value to describe the rate of reaction of 
irreversible inhibitors. 
 
When an inhibitor binds to an enzyme by means of van der Waals, electrostatic, 
hydrogen bonding and hydrophobic forces, it is known as reversible inhibition.  
E + I EI E-I
k1
k
-1
k2
Equation 1
kass = k1.k2/k-1 Equation 2
  9 
Reversible inhibition can be divided into competitive and non-competitive inhibition. 
A reversible competitive inhibitor typically has close structural similarities to the 
normal substrate for the enzyme, thus it competes with the substrate to bind to the 
active site. The competitive inhibitor binds reversibly to the active site. A non-
competitive inhibitor binds reversibly at a site other than the active site and causes a 
change in the overall three-dimensional shape of the enzyme that leads to a decrease 
in catalytic activity.  
 
Characterising reversible inhibition, equilibrium is formed between the complexed 
form and free enzyme. The equilibrium constant for the reaction Ki, is given by: 
 
The estimation of the efficiency of an inhibitor is the practical side of the usage of 
kinetic constants.  For a particular enzyme/inhibitor reaction, Ki and kass remain 
constant.  Calculation of the IC50 or t1/2 can be made using these constants.  The IC50 
is the concentration of inhibitor required for a 50% reduction in enzyme activity. This 
value is dependent on substrate concentration and the Michaelis-Menten constant (km) 
and is given by Equation 5.  The IC50 value is one of the most common methods of 
comparing protease inhibitors. 
 
Throughout this thesis, compounds will be shown and discussed in the context of their 
biological effects.  However, depending on a number of factors, these results maybe 
represented by either their IC50 or Ki value.  The IC50 value represents the 
concentration of a drug that is required for 50% growth inhibition in vitro, while as 
mentioned above, the Ki value gives the equilibrium dissociation constant between 
enzyme and inhibitor, giving an idea of the efficiency of the inhibitor.  In the case of 
compounds with potential for clinical use, IC50 values have been obtained and are 
stated. Where literature shows no data about the effects on cell growth of these 
compounds, only Ki values are stated. 
Ki Equation 4=
[E][I]
= k
-1/k1_____[EI]
E + I EI
k1
k
-1
Equation 3
= Ki(1+[S]/km) Equation 5IC50
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1.5 Types of Protease Inhibitors 
 
The history of protease inhibitors is intimately interwoven with that of the proteases.  
Protease inhibitors are as diversified as proteases themselves. Protease inhibitors can 
be divided into two distinct groups, naturally occurring protein protease inhibitors and 
active site-specific, low molecular weight synthetic inhibitors. 
 
Hundreds of natural protein protease inhibitors have been isolated from plant, animal 
and bacterial organisms.  Several natural crystalline inhibitors have been used as 
models to help explain the mechanism of protease inhibition.  They combine 
irreversibly with the active site and are converted into a modified form in which a 
peptide bond, corresponding to the primary substrate specificity of the protease, is 
split.  These inhibitors are usually large in nature but can vary in size from fifty 
residues (Bovine Pancreatic Trypsin Inhibitor) to over four hundred residues (α-1-
proteinase inhibitor)3. 
 
Low molecular weight inhibitors can be either synthetic or of bacterial and fungal 
origin.  They irreversibly modify an amino acid residue of the protease active site.  
The most efficient way of separating the different classes of these inhibitors is by their 
specificity, however, they are sometimes classified according to reaction mechanisms, 
origin or structural similarity.  Generally low molecular weight inhibitors are classed 
according to the family of protease that they inhibit, although some are capable of 
inhibiting several enzyme classes. 
 
 
1.5.1 Non-specific protease inhibitors 
α-Macroglobulins are high molecular weight proteins that bind and inhibit most 
proteinases.  These proteins are the only natural inhibitors that fail to discriminate 
among proteinase classes.  Macroglobulins appear to physically entrap the reacting 
protease molecules, as a result of conformational changes following protease 
reaction14.  For this reason they are mechanistically different from the active site 
directed protein inhibitors of proteases.   
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Peptide aldehydes (e.g. leupeptin, antipain 1) are di-, tri- or tetrapeptides containing 
an aldehyde moiety in place of the usual carboxylate.  Reversible inhibitors, they 
often are referred to as ‘transition-state analogues’ because they act by mimicking the 
tetrahedral intermediate formed during a peptide bond hydrolytic reaction.  Antipain 1 
is an example of a peptide aldehyde15, it has inhibitory capability against serine 
proteases (trypsin)3 and cysteine proteases (calpain I)16.  In an attempt to improve 
specificity, many peptide aldehyde derivatives have been synthesised17.  In terms of 
being specific or selective inhibitors, there are two major failings of peptide 
aldehydes.   
 
The first problem is that the lack of selectivity allows for inhibition of other proteases 
other than what is intended and the second drawback is the fact that in aqueous 
solution, most aldehydes exist mainly in the form of hydrates.  Accordingly, the rate-
limiting step for inhibition can be the formation of the aldehyde rather than the 
encounter with a suitable target enzyme18. 
 
One of the first systematic approaches to the study of active site-directed proteinase-
modifying reagents was with the irreversible inhibitors, peptide chloromethyl 
ketones19.  Tosyl-lysine chloromethyl ketone 2 (TLCK) and tosylamido-2-
phenylethylchloromethyl ketone 3 (TPCK) are the two most common members of this 
group of inhibitors. 
 
 
 
 
 
 
 
H
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N
N
H
H
N
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H2N Cl
O
NH
SO O
Cl
O
NH
SO O
(2)
(3)
 
 
 
From the mechanism of inactivation of serine proteases it is clear that inhibition 
results from the protease binding the inhibitor in a substrate-like manner, preceded by 
alkylation of the active site histidine by the chloromethyl moiety20.  Although 
unproven, it is thought that chloromethyl ketones also inactivate cysteine proteinases 
in a similar mechanistic way. 
 
The basis for the classification of the metalloproteinases is the presence of a metal ion 
(usually zinc), which participates in catalysis.  This differentiates them from other 
proteases like calpains and some trypsin-like serine proteases, whose activities are 
stabilised by, but not necessarily dependent on, the presence of calcium.  Chelating 
agents such as EDTA 4 and EGTA 5 can inactivate both the zinc-dependent metallo-
proteinase and some calcium-stabilised proteinases from other classes. 
 
 
 
 
 
 
 
 
 
  13 
 
 
Inhibition by Zn2+ is due to the formation of zinc monohydroxide that bridges the 
catalytic zinc ion to a side chain in the active site of the enzyme21.  This inhibition is 
therefore, competitive with the substrate.  The non-competitive inhibition by the other 
heavy metal ions is attributed to binding of the ion to a site distinct from the active 
site22. 
 
 
1.5.2 Class-Specific Inhibitors 
Substrate specificity with particular emphasis placed on the nature of the residue 
present at P1, is used to classify serine protease inhibitors.  The most common types of 
inhibitors are trypsin-like, elastase-like, and chymotrypsin-like.  The trypsin-like 
inhibitors prefer positively charged residues such as lysine and arginine at P1, the 
elastase-like favour small hydrophobic residues like alanine and valine, while the 
chymotrypsin-like inhibitors prefer hydrophobic residues such as phenylalanine and 
leucine at P1.  The interactions with inhibitors, of various serine proteases such as 
trypsin, α-chymotrypsin, thrombin etc., are available online and are demonstrated by 
X-ray crystal structural data (Protein Data Bank: http://www.rcsb.org/pdb).  In order 
for an inhibitor to have the capability to inhibit only one protease in a mixture, 
maximum selectivity is the main target in inhibitor design and synthesis.  Such 
inhibitors should have an inhibition rate constant (kass) for that particular protease of 
one thousand fold less than for any other protease in the mixture. 
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1.5.2.1 Serine protease inhibitors 
Thrombin protease inhibition 
Thrombin is a trypsin-like serine protease, which plays a key role in blood 
coagulation and hemostasis23.  In recent years this enzyme has become a highly 
investigated drug design target with potential use as antithrombotic drugs24,25.   
 
 
Figure 1.2: Stereoview of the active site region in the thrombin-N,N-diphenylcarbamoyl 
complex, showing the residues participating in recognition of the acylating N,N-
diphenylcarbamoyl molecule (labelled I)23. 
 
Thrombin is formed through the cleavage of prothrombin by the serine protease factor 
Xa (Fxa).  It is responsible for many aspects in the blood coagulation cascade and 
cleaves numerous substrates such as blood factors V, VIII, XIII and fibrinogen, and is 
also responsible for activating the platelet thrombin receptor26.  Thrombin converts 
fibrinogen to an active form that assembles into fibrin, which when polymerised  
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makes up the core of a blood clot.  Thrombin therefore results in blood clotting, which 
in turn, prevents us from bleeding to death; but an excess of this protease can lead to 
internal clotting resulting in undesired thrombosis, often leading to death by stroke.  
The substrate pocket S1 of the thrombin protease is optimised for arginine side chain 
recognition.  Argatroban 6 is a small synthetic molecule containing the arginine 
moiety27 and inhibits platelet aggregation by clot-associated thrombin28.  It is a 
mixture of 21-(R) and 21-(S) diastereomers with the latter being twice as potent in an 
in vitro assay but also less soluble in aqueous buffer29.  In the mid 1990’s, Bristol-
Myers Squibb developed a potent thrombin inhibitor known as BMS-189090 730.  The 
ability of this compound to inhibit the thrombin hydrolysis of the chromogenic 
substrate S-2238 was tested and an IC50 value of 18 µM reported.  Because of its 
potency and selectivity, BMS-189090 was subjected to further evaluations in vitro 
and in vivo.  The in vivo potency of BMS-189090 (ID50 = 0.11 mpk, iv; 29 mpk po) 
was significantly superior to that of Argatroban (ID50 = 1.6 mpk, iv; >100 mpk, po).  
BMS-189090 competitively and reversibly inhibited thrombin in vitro (Ki = 3.44±0.05 
nM) without showing time dependent kinetics31.  The binding of the thrombin 
protease with inhibitor 7 can be seen in the crystal structure shown in Figure 1.3.  The 
three dimensional structure shows the bound conformation of the inhibitor, the active 
site residues and solvent molecules in the active site.  From this crystal structure it can 
be seen that the binding of BMS-189090 and thrombin is in an antiparallel sequence.  
In the BMS-189090 complex, a water molecule fills the space left in the specificity 
pocket by the shortening of the arginine inhibitor side chain. 
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Figure 1.3: Three dimensional structure of α-thrombin complexed with BMS-18909030. 
 
From the crystal structure of the complex formed between compound 7 and human α-
thrombin, we can see that effective inhibitors form numerous close contacts (both 
hydrogen bonded and hydrophobic) with the protein. 
 
Over the last few decades, antithrombotic activity via oral administration was the 
ultimate goal in developing potent inhibitors.  This property was concentrated on in 
conjunction with selectivity over other serine proteases, appropriate half-life, and an 
improved side effect profile relative to warfarin.  Melagatran 8 and its prodrug 
Ximelagatran 9 are the most advanced thrombin inhibitors and have recently been 
launched in a number of European countries for the prevention of venous 
thromboembolic events in elective hip or knee replacement surgery32,33. 
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Recent research into potent orally active thrombin inhibitors is concentrated on 
derivatives based on the D-Phe-Pro-Arg lead structure.  One of the most active of 
these derivatives published to date is compound 1034.  The schematic representation 
and X-ray structure of inhibitor 10 shows binding to the active site of thrombin and 
can be seen in Figure 1.4.  The cyclohexyl ring of the inhibitor is engaged in 
hydrophobic interactions in the lipophilic D pocket.  The side chains of Ile174, Leu99 
and Trp215 come in close contact with the cyclohexyl moiety of D-cyclohexylalanine.  
The pyrroline ring occupies the P pocket with contacts to Tyr60A, His57 and Trp60D.  
The amidine group at the pyridyl ring of the inhibitor forms strong hydrogen bonds 
with the carboxylic group of Asp189 at the bottom of the S pocket in thrombin. 
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Figure 1.4: Schematic representation and X-ray structure of compound 10 bound to the active 
site of thrombin34. 
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The in vitro IC50 value of inhibitor 10 was determined in a chromogenic substrate 
assay with S-2238 as substrate, against thrombin.  The authors responsible for this 
research, in consecutive publications, have reported two differing IC50 values, 1.00 
nM and 1.80 nM, for the hydrochloride salt and for the corresponding acetate 
respectively34, 35. 
 
Lee et al have developed a highly potent orally active diphenylalanine derivative 12 
(Ki = 0.004 nM)36.  This compound was synthesised based on the optimisation of 
known thrombin inhibitor 1137.  Although the initial inhibitor 11 showed a better Ki 
value of 0.003 nM in vitro, clinical trials revealed a short duration of action and 
bioavailability.  The optimised inhibitor 12, when tested showed slightly less potent 
inhibition than its predecessor, however the bioavailability was superior.  Lee et al 
also synthesized inhibitor 13, and this N-carboxymethyl derivative has a Ki value of 
0.015 nM.  Despite the five-fold higher Ki potency, the anticoagulant efficacy of 13 
compares favourably to that of inhibitor 11. 
 
The N-carboxymethyl derivative 13, demonstrated the best overall profile, which is 
potent, selective, metabolically stable and orally bioavailable.  This inhibitor also 
displayed excellent anticoagulant and antithrombotic activity in venous thrombosis 
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models of rat and rabbit.  In the last couple of years inhibitor 13 has undergone further 
preclinical and clinical development36. 
 
Based on a previously reported thrombin inhibitor 1438 (Ki = 1.5nM), Stauffer et al 
optimised a series of potent thrombin inhibitors.  Inhibitor 15, with a Ki value of 0.4 
nM showed a good improvement in potency.  It also displayed good stability in 
human liver microsomal preparations, a long half-life, excellent pharmacokinetic 
properties in dogs and rhesus monkeys and a significant free fraction in human 
plasma protein binding experiments.  Addition of a chlorine atom at the 7-position of 
the 4-azafluorenyl ring proved to produce an even more potent inhibitor 16.  It 
displayed the greatest absolute potency for trypsin in the series, with a Ki value of 
0.042 nM.  This is 38-fold more potent than the lead structure 14.  Despite this high 
potency, compound 16 did not maintain this improvement over 15 in the stability 
assays mentioned above39. 
 
Taking into consideration all of the key preclinical properties of inhibitor 15, it 
represents an inhibitor with considerable potential for development as an oral 
antithrombotic agent.  These examples are useful to demonstrate that although an 
inhibitor can have a very high potency, it may not be the most suitable as 
chemotherapeutic agent. 
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Elastase protease inhibition 
Elastase is a serine protease that has been implicated as a primary mediator of various 
diseases such as adult respiratory distress syndrome (ARDS), cystic fibrosis, 
pulmonary emphysema, smoking related chronic bronchitis, rheumatoid arthritis and 
other inflammatory airway diseases40,41.  Neutrophil elastase has plays a major role in 
the pathogenesis of acute lung injury42,43.  Elastase released from activated 
neutrophilis damages lung tissues, and causes epithelial injury44, vascular 
hyperpermeability45 and airway hyperresponsiveness46.  The inhibition of elastase has 
led to the development of numerous therapeutic agents.  Ono Pharmaceuticals Co. 
Ltd. developed sivelestat 17, a potent neutrophil elastase inhibitor.  This compound 
has been shown to inhibit the early and late asthmatic responses in allergic sheep47.  
Sivelestat also improved the airway hyperresponsiveness caused by ozone exposure in 
guinea pigs48.  Further studies have shown that with sivelestat treatment, airway 
hyperresponsiveness induced by epithelial injury or lipopolysaccharide (LPS), may be 
prevented by stopping elastase release49. 
 
Emphysema is a condition resulting from destruction of the alveoli resulting from an 
imbalance in the lung between human leukocyte elastase (HLE) and endogenous 
inhibitor (elevated elastase or insufficient inhibitor).  Hlasta et al have identified WIN 
63294 18 as a potent (Ki = 0.008 nM) HLE inhibitor, however the bioavailability was 
poor compared to inhibitors 19 and 20.  These compounds are not as potent as 18 (Ki 
= 0.014 & 0.013 nM respectively).  WIN 64733 19 and WIN 63759 20 are selective, 
mechanism-based inhibitors of HLE which are also bioavailable40. 
 
Chronic obstructive pulmonary disease (COPD) is a term referring to two lung 
diseases, chronic bronchitis and emphysema.  A potent inhibitor used in the treatment 
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of COPD is the cyclic thiol inhibitor MR 889 2150.  It is a slow binding, reversible 
inhibitor with specific activity towards neutrophil elastase (Ki = 1.38 µM). 
 
In the normal feedback mechanism of injury and repair in the lung, fragmented 
heparan sulphate proteoglycans (HSPGs) from damaged extracellular matrix and 
cells, are believed to interact with elastases to limit their activity.  An imbalance in the 
HSPG-elastase response is thought to play a role in situations of uncontrolled lung 
injury, leading to diseases such as emphysema.  The main option used for treating this 
imbalance is by supplementing the system with artificial elastase inhibitors.  One 
inhibitor that circumvents some of these problems is heparin 22, an anticoagulant 
drug that has been used for many years51.  Native heparin is a polymer with a 
molecular weight ranging from 6 kDa to 40 kDa, although the average molecular 
weight of most commercial heparin preparations is in the range of 12 kDa to 15 kDa.  
As an inhibitor, heparin is extremely potent against human neutrophil elastases 
(HNEs), with studies confirming the activity of 22 and its derivatives, both in vitro 
and in vivo52.  Activity is highly sensitive to specific properties of the heparin 
structure, including molecular mass, chain length, degree of sulphation charge 
density, specific rotation and iduronic acid content.  Research has also shown that 
structural modification of heparin can remove the anticoagulant action, while 
retaining the inhibitory activity of 22, which is a major advantage in clinical use53. 
 
The ability of heparin and HSPGs to modulate proteolytic activity indicates that this 
ubiquitous class of complex polysaccharides plays a central role in regulating tissue 
injury.  Current studies are investigating the full role of endogenous HSPGs in 
regulating elastase-mediated tissue injury51. 
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Otto et al synthesised potent pseudosaccharinamine derivatives that have shown good 
activity against human leukocyte elastase (HLE) and porcine pancreatic elastase 
(PPE)54.  Compounds 23 and 24 showed the best activity, with Ki values for HLE of 
1.3 µM and 0.8 µM, respectively.  Inhibitor 23 showed 50% inhibition at 5 µM 
concentration against HLE and 47% inhibition of PPE at 0.5 mM concentration.  
Inhibitor 24 showed 69% inhibition of HLE at 5 µM concentration while a very weak 
inhibition of PPE (7% at 0.5 mM concentration) was observed.  It is well reported that 
valine or alanine moieties (valine present in 23) fit in the S1 pocket of HLE55.  The 
presence of isoleucine at the P1 position of the inhibitor is also reported56. 
 
 
 
Tryptase protease inhibitors 
Tryptase is a homotetrameric, trypsin-like serine protease that constitutes 20-25% of 
the total protein mast cells.  Since it is stored in a catalytically active form within the 
secretory granules and released on stimulation, this enzyme is highly relevant to mast 
cell dependent inflammatory conditions.  Indeed, tryptase has been directly implicated 
in the pathology of asthma57.  Inhibitors of human mast cell tryptase have therapeutic 
potential for treating allergic or inflammatory disorders such as asthma, vascular 
injury (e.g. restenosis and atherosclerosis), inflammatory bowl disease and 
psoriasis58,59,60.  Tryptase inhibitors are divided into four selective classes, of which 
three are synthetic and the fourth one is of natural origin59.  The first class are called 
peptidic inhibitors and includes the Johnson & Johnson developed inhibitors APC-
366 25, subsequently RWJ-56423 2657. Compound 25 has a Ki value of 330 nM and 
progressed to phase 2 clinical trials before being discontinued58,59.  Resulting from 
this active inhibitor, Johnson & Johnson developed 26, a potent, reversible inhibitor 
with a Ki value of 10 nM and it is currently undergoing clinical trials.  Palmer et al 
synthesised another potent peptidic inhibitor 2761.  With a Ki value of 2.5 nM, this 
compound 27 is also undergoing preclinical trials at present. 
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The second class of selective tryptase inhibitors is the dibasic inhibitors.  This is the 
most studied group of tryptase inhibitors.  Publication of a resolved crystal structure 
has revealed that the active enzyme consists of four identical subunits assembled with 
the four active sites pointing towards an oval central pore62.  This array of the four 
negatively charged S1 binding pockets represents an ideal basis for the rational design 
of divalent/dibasic inhibitors.  Albericio et al63 have developed two of these 
inhibitors, 28 and 29, based on a 2,5-diketopiperazine scaffold.  With Ki values of 2.4 
and 2.2 µM respectively, these two compounds represent highly potent dibasic 
tryptase inhibitors. 
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The third and last synthetic class of tryptase inhibitors are zinc-mediated inhibitors.  
The best known inhibitor of this type is bis(5-amidino-2-benzimidazolyl)methane 
(BABIM) 3064.  It has an inhibitor range of 10-25 µM, and displays a high-affinity 
binding mode in which a Zn2+ ion is tetrahedrally coordinated between two chelating 
nitrogens of BABIM and two active site residues, His57 and Ser195.  The distinct Zn2+ 
coordination geometry implies a strong dependence of affinity on substituents65.  This 
unique structural paradigm has enabled development of potent, highly selective, Zn2+ 
dependent inhibitors of several therapeutically important serine proteases, using a 
physiologically ubiquitous metal ion. 
 
 
The final class of trypsin inhibitors are the compounds with natural origin and are 
known as haparin antagonists. An example of this type of inhibitor is lactoferrin63.  
This inhibitor is an iron transporting glycoprotein. It was originally isolated from 
bovine milk, where it is found as a minor protein component of whey proteins 
Lactoferrin contains 703 amino acids and has a molecular weight of 80 kilodaltons. In 
addition to its presence in milk, it is also found in exocrine secretions of mammals 
and is released from neutrophil granules during inflammation. 
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1.5.2.2 Cysteine protease inhibitors 
Cysteine proteases are generally classed into three structurally distinct groups, papin-
like (e.g. cathepsins), ICE-like (interlukin-1 converting enzyme) or picorna-viral 
proteases.  Cathepsins are the most common and therefore the most studied of the 
cysteine proteinases.  At present, eleven human papain-like cysteine proteases have 
been described: the cathepsins A, B, C, F, K, L, O, S, V, W and X66.  Cysteine 
proteases contain a thiol moiety that is involved in catalysis, much the same way as 
the hydroxy group of the serine protease is involved and this is the only real 
difference in the mechanism of amide hydrolysis of cysteine over serine proteinases.  
The biggest hurdle involved in the development of new cysteine proteases is the 
similarity in their substrate affinities and proteolytic mechanisms with serine 
proteases. 
 
Cathepsin protease inhibition 
In 1929, Willstätter and Bamann introduced the term cathepsins to describe a protease 
that is active at acidic pH but can be differentiated from pepsin10.  Cathepsins A, B 
and C have been suggested as the intercellular counterparts of pepsin, trypsin and α-
chymotrypsin67.  Cathepsins inhibitors are promising therapeutics for the treatment of 
diseases characterised by excessive bone loss such as osteoporosis and inflammatory 
and traumatic processes such as rheumatoid arthritis and cancer metastasis68.   
 
Among the earliest reported inhibitors were the peptidyl diazomethyl ketones and 
aldehydes.  These are a group of peptidyl derivatives in which the hydroxyl of the 
terminal carboxylate is replaced with a diazomethyl moiety.  Inhibition is irreversible 
and is thought to proceed, via a thiohemiketal intermediate, to the formation of an 
alkyated active-site cysteine existing as a thio-ether to the methyl group of the 
inhibitor.  Diazomethyl ketones inactivate cathepsin B by alkylation of the active site 
cysteine residue.  One of the most active inhibitors of this type is compound 31.  
Reports have shown this inhibitor to be potent against cathepsin B and C69.  This 
inhibitor is also the commercially available inhibitor of cathepsin L. 
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Singh et al have synthesised a series of potent cathepsin B protease inhibitors70.  
These 6-substituted amino-4-oxa-1-azabicyclo[3,2,0]heptan-7-one derivatives were 
synthesized on the basis of molecular modeling, with has suggested that the 1-N atom 
of the bicyclic side chain can be involved in hydrogen bonding to the protonated 
histidine in the active site of cysteine proteases, therefore acting as an effective 
inhibitor.  Of the compounds reported by Singh et al, inhibitor 32 was the most potent 
against cathepsin B, with an IC50 value of 1.76 µM.  Unfortunately 32 was found to be 
potent against other cathepsins such as L, K and S, with nanomolar inhibition often 
occurring. 
 
Cathepsin K is a cysteine protease that is highly expressed in osteoclasts, which are 
cells that break down bone and is responsible for bone resorption.  The primary role 
of cathepsin K is the degradation of type I collagen, one of the main components of 
bone matrix.  Bone mass is regulated by the continuous equilibrium between the bone 
resorbing and the bone forming processes.  Thus, selective inhibition of cathepsin K 
provides efficient therapeutic treatment for bone diseases such as osteoporosis. The 
inhibitor 33 (IC50 = 6.4 nM) was developed by Novartis and has been shown to be a 
non-covalent binder and reversible71.  This lead compound 33 has led to the synthesis 
of many new potent cathepsin inhibitors such as 34 (IC50 = 4.5 nM)72, which are 
undergoing preclinical and clinical studies. 
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GlaxoSmithKline have developed a series of potent ketoamide based inhibitors of 
cathepsin K73.  Compound 35 is the most potent of this series with an IC50 value of 
1.6 nM, although it also is potent against cathepsin S (IC50 = 2.56 nM).  This lack of 
selectivity is a major disadvantage. 
 
The peptidyl nitrile based compound 36 is another potent inhibitor and has been 
shown to reduce bone loss.  The leucine glycine nitrile scaffold of the inhibitor has 
been a successful design feature of potent cysteine protease inhibitors.  Inhibitor 36 
has a reported IC50 of 0.2 nM and at a concentration of 10 nM, has been shown to 
substantially reduce bone resorption. 
 
 
Human cathepsin L shows the highest proteolytic activity of all lysosomal proteases 
and is an ubiquitously expressed lysosomal cysteine endopeptidase.  Cathepsin L has 
been implicated in a wide range of intra- and extracellular pathological and 
physiological processes including antigen presentation, ovulation, tumour 
metastasis74, progression, osteo and rheumatoid arthritis, as well as bone resorption75.  
L-trans-epoxysuccinyl-leucylamide-(4-guanido)-butane (E-64) 37 is a naturally 
occurring cysteine protease inhibitor with high potency against cathepsin B, F, K and 
L proteases76.  E-64 offers a potential treatment for metastasis as the epoxide inhibitor 
37 inhibits cathepsin L on a nanomolar scale (IC50 = 0.9 nM).  This was one of the 
early lead compounds for cathepsin L inhibition and remains to this day an important 
standard.  Orally bioavailable azepanone-based inhibitors, which were initially 
designed to target cathepsin K77, but now provide a general template for the inhibition 
of cathepsin L.  This is due to the similarities in the homologies of cathepsins K and L 
as well as reports that have suggested that cathepsin L may play a role in the 
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resorption phase of bone remodelling73.  The azepanone 38 as reported by Marquis et 
al, has a Ki value of 0.43 nM and shows excellent selectivity towards cathepsin L over 
cathepsins K, S and B.  Inhibitor 38 has a greater than 20,000-fold selectivity for 
cathepsin L over K (Ki = >10,000 nM), a 36-fold selectivity over cathepsin S (Ki = 
15.6 nM) and a 340-fold selectivity over B (Ki = 150 nM). 
 
 
In recent years much emphasis has been directed at the synthesis of inhibitors with 
electrophilic sites able to interact with the active thiol, which has led to the 
investigation of peptidyl nitriles66.  Peptide nitriles bind to the active site thiol via a 
reversible formation of a covalent thioimidate linkage as demonstrated in Scheme 1.2.   
 
Nitriles are class selective protease inhibitors, which strongly inhibit cysteine 
proteases while serine proteases are not or weakly affected.  Gütschow et al have 
reported a structure-activity relationship study of dipeptide derived nitriles as 
inhibitors of cysteine proteases, namely cathepsins L, S and K66.  Inhibitor 39 
containing a bicyclic aromatic side chain was one of the most active compounds 
synthesised in this SAR study, showing good potency and selectivity against the three 
 
Scheme 1.2: Reversible formation of thioimidates from peptide nitriles and cysteine proteases. 
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cathepsins tested.  Ki values of 0.12, 0.083 and 83 µM were calculated for cathepsins 
L, S, and K, respectively. 
 
 
Using a substrate screening method, Ellman et al have synthesised a highly selective, 
nonpeptidic nitrile inhibitor of cathepsin S78.  This 1,2,3-triazole inhibitor 40 is a 
potent (Ki = 15 nM) and low molecular weight (413 Da) inhibitor of cathepsin S.  This 
compound has shown to have greater than 1000-fold selectivity over all closely 
related human cathepsins, such as cathepsin B, K and L. 
 
 
Caspase protease inhibition 
Caspases are proteases that fit into the interlukin-1 converting enzyme-like group of 
cysteine proteases.  Interlukin-1 converting enzyme is more commonly known as 
caspase-1, hence the group name ICE-like.  Caspases are known to play major roles in 
the initiation and propagation of apoptoic signals79 and neurodegenerative diseases 
such as Alzheimer’s, Parkinson’s and Huntington’s disease80.  Caspases cleave 
proteins after aspartic acid residues, hence their name being derived from cysteine-
aspartate-specific proteases.  To date, eleven caspases have been identified in humans, 
known as caspase-1, caspase-2 etc.  The majority of early discovery programs 
targeting caspases centred on the development of reversible inhibitors of caspases-181.  
One of the most commonly known and used inhibitors of ICE-like proteases was 
developed by Merck and is known as Z-VAD.FMK 4182.   
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Carbobenzyloxy-valyl-alanyl-aspartyl-[o-methyl]-fluoromethyl ketone 41 is a broad-
spectrum irreversible tripeptide inhibitor of caspases and is widely used for its 
apoptosis inhibition.  41 is also used for peripheral administration to treat cerebral 
ischemia in humans which is a condition that restricts the blood flow to the brain.  
Dissociation constants (Ki) and first-order rate constants of irreversible caspase 
inactivation (k3) for inhibitors 41 and 42, against mouse caspase 1 and human 
recombinant caspases 2, 3, 6, 8 and 9 are shown in Table 1.1.  
 
 mCasp1 Casp2 Casp3 Casp6 Casp8 Casp9 
Z-VAD.FMK       
   Ki (nM) 1.0 50 10 30 20 10 
   k3 (1/min) 0.72 0.021 0.58 0.046 0.12 0.025 
       
IDN-5370       
   Ki (nM) 10 180 820 590 10 2.1 
   k3 (1/min) 0.13 0.028 0.54 0.1 0.05 0.032 
       
Table 1.1: Profiles of caspases inhibition by the broad-spectrum irreversible caspases inhibitors 
41 and 4284. 
 
In the late 1990’s Idun Pharmaceuticals reported highly potent irreversible caspase-3 
inhibitors83.  The oxoazepinoindoline IDN-5370 42 was one of their earlier potent 
compounds, and showed a broad-spectrum activity of low nanomolar range against 
caspases 1, 2, 3, 6, 8 and 9.  Compared to the commonly used broad-spectrum 
inhibitor Z-VAD.FMK 41, the non-covalent binding of 42 to caspases 1 and 3 as 
measured by its Ki is about 10 and 100 times tighter, respectively, with comparable or 
better first order rate constants of irreversible inactivation84.  Recently Idun 
Pharmaceuticals have developed IDN-6556 43, the first irreversible caspase-3 
selective inhibitor to enter clinical development85.  This compound is currently in 
Phase II clinical trials for the treatment of liver disease. 
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Picornaviral protease inhibition 
Picornaviral proteases are present in picornaviruses. Pathogens that belong to the 
picornavirus family include hepatitis A virus (HAV) and human rhinovirus (HRV).  
These viruses have a single-stranded, positive-sense RNA genome, which is translated 
into a polyprotein precursor.  3C and 2A picornaviral proteases process these 
precursors in order to generate mature viral proteins and functional enzymes and 
therefore ensure viral replication.  These proteases are cysteine proteases, however 
these enzymes have a topology similar to those of the chymotrypsin-like serine 
proteinases. Vederas et al, based at the University of Alberta, have carried out an 
extensive study on new types of warheads (thiol reactive groups) as highly selective 
inhibitors of HAV and HRV 3C proteinases86.  The azodicaboxamide inhibitor 44 has 
been shown to have potency against both HAV and HRV 3C proteases, with IC50 
values of 10 and 12 µM, respectively.  These inhibitors were designed based on 
substrate specificity for HAV 3C, and contain the mimicked p1 (Gln) and P2’ (Phe) 
residues important for enzyme recognition.  It is believed that the active site cysteine 
thiolate adds to the azo nitrogen in a Michael type fashion, thereby forming a covalent 
adduct and irreversibly inactivating the enzyme.   
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A competitive series of phthalhydrazido analogues were also synthesised and tested 
for inhibition, with the most active inhibitor 45 having a Ki of 9 µM against hepatitis 
A virus 3C protease, which is a 7-fold increase in activity compared to its precursor, 
which was lacking the tripeptide side chain required for enzymatic recognition.  
Vederas et al have also generated a series of pseudoxazolones, which they have 
shown to be good time-dependent inhibitors of HAV and HRV 3C proteases.  Testing 
of the HAV proteases with the trans and cis isomer of 46 resulted in IC50’s of 4 and 6 
µM, respectively, and when tested against the HRV 3C protease, the trans and cis 
isomers of 46 gave IC50’s of 17 and 16 µM, respectively.  The time-dependent 
inhibition displayed by the pseudoxazolones is presumably the result of irreversible 
modification of the enzyme, likely from the addition of the enzyme’s cysteine thiolate 
to the imine-carbon. 
 
The human rhinovirus is the major cause of the common cold.  At this moment, only 
symptomatic treatment is available to medicate rhinovirus infections.  However, 
ViroPharma have developed a novel, orally bioavailable drug 47 that is in the late-
stages of clinical trials87.  Pleconaril88 47 is also able to cross the blood-brain barrier 
and target the viruses responsible for causing meningitis and is in clinical trials 
relating to this viral infection89. 
 
To date there are very few electrophilic isosteres appropriate for developing selective, 
reversible inhibitors of cysteine proteases.  This may be the reason for the lack of 
cysteine protease inhibitors that have progressed to clinical trials.  C-terminal 
aldehydes and ketones, which react with the cysteine active site to form reversible 
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thioacetal transition state analogues, are the most common moieties for developing 
reversible cysteine protease inhibitors.  The main problem with the aldehyde moiety is 
the lack of selectivity shown to proteases.  In contrast to this, there have been many 
functional groups incorporated into peptides capable of irreversibly alkylating the 
active site cysteine, including epoxide, nitriles and diazomethyl ketones.  These 
functional groups are activated electrophiles that are generally cysteine selective over 
the serine proteases.  Even still, the vast majority of these compounds are too reactive 
towards various nucleophiles in the body.  These concerns have severely limited the 
development of such irreversible inhibitors as therapeutic agents.   
 
 
1.5.2.3 Aspartic Acid protease inhibitors 
Aspartic acid proteases constitute a therapeutically relevant class of enzymes that play 
an important role in the regulation of various physiological processes, such as the 
control of blood pressure (renin)90, digestion (pepsin)91, or degradation of 
endocytosed proteins (cathepsin D)92.  Further, they actively propagate the 
progression of severe diseases caused either by parasites, such as malaria 
(plasmepsin)93, or viruses, such as human immunodeficiency virus (HIV protease)94, 
or neurodegenerative disorders including Alzheimers disease (β-secretase)95.  On the 
basis of the mechanism of peptide bond hydrolysis employed by aspartate proteases, 
several structurally diverse transition state analogues have been designed by replacing 
the dipeptide-encoded scissile bond within the specific substrates.  A key structural 
element in most transition state isosteres is a hydroxy moiety that interacts with the 
catalytic site aspartic acid side chains via hydrogen bonds.  This secondary hydroxy 
group further replaces the catalytic water molecule normally bound between both 
aspartates and simultaneously mimics the tetrahedral geometry that is intermediately 
formed in the initial steps of the amide bond hydrolysis of a peptide substrate.  
 
Raised blood pressure is associated with significant cardiovascular morbidity and 
mortality, and the incidence of cardiovascular complications (predominantly stroke 
and coronary heart disease) rises exponentially with increasing blood pressure.  As the 
most common cause of strokes, reversible cause of heart failure and a preventable 
cause of ischaemic heart disease (IHD) in diabetics, hypertension is estimated to 
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affect approximately 1 billion people worldwide96.  Renin represents a key player in 
the renin-angiotensin system (RAS) for controlling blood volume, arterial pressure 
and cardiac and vascular function, its manipulation also provides a means for the 
therapeutic treatment of hypertension and heart failure.  In the renin-angiotensin 
system, angiotensin II is produced via a two-step process in which angiotensinogen, 
synthesised primarily in the liver, is cleaved by the aspartic peptidase, renin, produced 
in the kidney, to give rise to angiotensin I. This biologically inactive decapeptide is 
then converted to the active octapeptide angiotensin II by angiotensin converting 
enzyme (ACE).  Angiotensin II acts to increase arterial tone, adrenal aldosterone 
secretion, renal sodium reabsorption, sympathetic neurotransmission, and cellular 
growth.  Although the idea of renin or ACE inhibition as a method of blocking this 
system is well known, potent drugs identified have been abandoned as 
antihypertensive agents due to inadequate oral bioavailability properties (e.g. low 
stability, poor solubility).  Furthermore, compared to the ACE targeting drugs, renin 
inhibitors require interaction with additional subsites for tight binding resulting in the 
requirement of higher molecular weight compounds and hence non-cost-effective 
syntheses. Nevertheless, in contrast to renin, ACE is implicated in alternative 
pathways and its inhibition therefore results in side effects (cough, angioneurotic 
edema). 
 
 
Pepstatin 48, which is a naturally occurring compound, was the first known 
inhibitor97.  Pepstatin (Iva-Val-Val-Sta-Ala-Sta) contains the novel amino acid statine 
[(3S,4S)-4-amino-3-hydroxy-6-methyl heptanoic acid], and inhibits most aspartic 
inhibitors.  This inhibitor lacked the selectivity and bioavailability to be a success, but 
its isolation led to development of better compounds, such as the Abbott designed 
inhibitor, enalkiren 49 and remikiren 50 produced by Hoffman-La Roche.  The 
reported IC50’s of 49 and 50 are 14 and 0.8 nmol/L with plasma half lives of 1.6±0.4 
and 9.4±4.1 hours, respectively97.  Enalkiren and remikien, as well as all of the first 
generation renin inhibitors failed to complete clinical testing.  These inhibitors were 
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dropped due to low bioavailability attributable to poor gastrointestinal absorption with 
large variability between individuals and substantial first-pass metabolism, short 
duration of action and weak blood-pressure-lowering activity97,98.   
 
 
At this point in time, the first non-peptide orally active renin inhibitor, aliskiren 51, 
developed by Novartis, is nearing the end of phase-III clinical trials99,100.  Compound 
51 has percentage oral bioavailability of 2.7%, IC50 of 0.6 nmol/L and a plasma half 
life of 23.7±7.6 hours. With a half life at almost 24 hours, the compound is suitable 
for once-daily administration. Compared to other orally active renin inhibitors, such 
as enalkiren 49 and remikiren 50, aliskiren 51 is the most of the most potent renin 
inhibitor identified, with high specificity for primate renin100.  Aliskiren 51 is 
currently undergoing three phase-III trials at Novartis.  The first trial is testing the 
effects of aliskiren 51 on intermediate markers of target-organ damage (ALLAY, reg. 
no. [http://clinicaltrial.gov] NCT00219141).  The second trial that Novartis are 
undertaking (ALOFT, NCT00219011) is the comparison with a placebo given in 
addition to optimum standard treatment, with the primary endpoint is the fall of 
plasma concentration of brain natriuretic peptide.  Finally, in the third trial (AVOID, 
NCT00219206), aliskiren and a placebo will be added to treatment with losartan to 
study the reduction in the urinary albumin-to-creatinine ratio.  Each of these trials will 
be performed on 300-500 patients97. 
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Pfizer have published many compounds in a structure-activity relationship of novel 
substituted amino-aryl-piperidine-based renin inhibitors.  Of the published results, the 
ketopiperazine-based inhibitor 52 is most active101.  Compound 52 has shown a strong  
 
potency against renin as anticipated with an IC50 value of 0.18 nM.  This inhibitor 52 
was also evaluated for its propensity to inhibit the cytochrome P450 3Aa isozyme 
(CYP3A4)102, showed a potency with IC50 (BFC) value of 14 nM. In a review by 
Scott Sieburth, the potency of silanediol inhibitors and their corresponding ketone 
derivatives against angiotensin-converting enzyme (ACE) is reported103.  Inclusion of 
the silanediol moiety is not a widely used group but this report has shown that various 
compounds have differing potencies to their corresponding ketone derivative, 
depending largely on the stereochemistry.  Compounds 53 and 54, and alternatively 
55 and 56, indicate that the orientation of the other substituents in vicinity of the 
relevant moiety largely affects the inhibitory potency of these compounds. 
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Inhibitors 53 and 54, displaying the methyl group in cis-orientation and the benzyl 
group trans-, with respect to the carboxylic acid functionality, showed IC50 values of 
3.8 and 1.0 nM, respectfully.  The inhibitors synthesized with the methyl trans- and  
the benzyl group cis- showed far less potency, with reported IC50’s of 72 and 3200 
nM, respectfully. 
 
Malaria protease inhibition 
Malaria has in recent years re-emerged as one of the most serious infectious diseases 
in the world.  The most dangerous of the malaria-causing parasites, Plasmodium 
falciparum, infects 300-660 million people each year.  The plasmepsins (PMs) are a 
family of Plasmodium aspartic proteases that digest human hemoglobin and deliver 
amino acids that are required for growth.  In search for targets for new antimalarial 
therapies, the mutually redundant proteolytic activity of plasmepsins for hemoglobin 
requires inhibitors that are broadly active against all hemoglobin-degrading 
plasmepsins (PM I, PM II, PM IV and HAP, a histo-aspartic proteinase) while 
remaining inactive against the most closely related human aspartic proteases 
(cathespins D and E; hCat D and E)104.  Among the plasmepsins, only the structure of 
PM II has been extensively studied and characterized.   
 
 
Unfortunately, no vaccine is currently available to stop the infection of malaria.  
Instead preventative drugs are taken continuously to reduce the risk of malaria. Such 
prophylactic drug treatments are simply too expensive for most individuals living in 
endemic areas. Malaria infections are treated through the use of antimalarial drugs 
such as chloroquine 57, although drug resistance is increasingly common.  
Chloroquine is a 4-aminoquinoline drug long used in the treatment or prevention of 
malaria. As it also mildly suppresses the immune system, it is used in some 
autoimmune disorders, such as rheumatoid arthritis and lupus erythematosus. After 
the malaria parasite Plasmodium falciparum started to develop widespread resistance 
against chloroquine, new potential utilisations (e.g. HIV and cancer inhibition) of this 
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cheap and widely available drug have been investigated105.  Combining chloroquine 
with other antimalarial inhibitors such as proguanil, may be more effective against 
chloroquine-resistant Plasmodium falciparum than treatment with chloroquine alone, 
but is no longer recommended by the Centres for Disease Control and Prevention in 
the United States, due to the availability of more effective combinations.   
 
Due to the every increasing resistance to antimalarial treatments like chloroquine, 
research into developing efficient antiparasitic agents should target not only one but 
several of the plasmepsins.  Hallberg et al have developed a series of nanomolar 
active PM I and II inhibitors with considerable discrimination versus the most 
homologous human aspartic protease cathepsin D.  Inhibitor 58 has shown inhibitory 
activity against PM I and PM II with Ki values of 25 and 85 nM, respectively.  This 
compares favourably to the Ki recorded against Cat D of >2000 nM106.  Diederich et 
al have recently reported compound 59 which is active against PM I, II, IV and Cat D.  
However, it is only PM II and IV that are in the low nanomolar range (IC50 = 45 & 10, 
respectively) while the other two aspartic proteases are 100-fold higher104. 
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HIV protease inhibition 
The human immunodeficiency virus type 1 (HIV-1) pandemic has emerged in many 
regions of the developing world already suffering from the burden of malaria107.  In 
developed countries, HIV-1 protease inhibitors have dramatically reduced the effects 
of HIV disease.  The target of these inhibitors is the HIV-1 protease, a member of the 
aspartic protease family.  Inhibition of aspartic proteases as a way of hindering the 
human immunodeficiency virus is only a recent phenomenon.  At the end of the 20th 
century, identification of the C2-symmetric HIV protease enzyme was complete108,109.  
Development of C2-symmetric inhibitors of this enzyme such as 60 followed quickly 
and presented less complex compounds for exploration110. 
 
 
In the previously mentioned review by Sieburth, they demonstrated their silanediol 
derivative 61 of inhibitor 60 as having good inhibitory potency against the HIV 
protease enzyme.  Sieburth reported a Ki value for 61 of 2.7 nM.  While this is not as 
potently active as inhibitor 60 (Ki = 0.37 nM), it not only inhibits the HIV protease 
enzyme, but also protects whole cells against HIV infection, indicating that it can 
penetrate cell walls106. 
 
Recently, cyclic urea structures have been reported to constitute an entirely new class 
of potent and prospective non-peptidic inhibitors of aspartic proteases.  A 
fundamental feature of the cyclic urea inhibitors is the carbonyl oxygen that mimics 
the hydrogen-bonding features of the key structural water molecule present in the 
active site of the aspartic protease111. The presence of this structural water 
distinguishes the retroviral protease from human aspartic proteases pepsin and renin. 
The success of the design in both displacing and mimicking the structural water 
molecule that bridges the substrate to the flaps of the protein by hydrogen bonds was 
confirmed by X-ray crystallographic studies112.  Cyclic ureas proved to be highly 
selective structures with decreased conformational flexibility, low molecular weight, 
improved water solubility and oral bioavailability.  DuPont Merck has developed a 
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highly potent HIV inhibitor of wild-type HIV; XV638 62 has a Ki value of 0.03 nM 
against reconstructed mutant viruses113 
 
This inhibitor 62 was the most potent of a series of cyclic urea derivatives developed 
by DuPont Merck, and were optimised based on inhibitory potency of a set of viral 
strains selected for resistance to the four HIV aspartic protease inhibitors that where 
either approved for marketing (saquinavir 63, ritonavir 64, indinavir) or where in 
advanced clinical development (VX478) at the time.  Developed by Vertex, 
amprenavir or VX478 was approved by the FDA in 1999 but production was 
discontinued by the manufacturer and licensee, GlaxoSmithKline, in 2004. 
 
Inhibitor Wild type (µM) Knockout IC50 (% of wild 
type IC50) 
Saquinavir 63 5.7 ± 0.8 133 
Ritonavir 64 7.9 ± 1.1 113 
Atazanavir 65 35.0 ± 0.4 120 
   
Table 1.2: Activity of HIV-1 protease inhibitors against P. falciparum-2 knockout parasites114. 
 
 
Up to 2004, there were 19 compounds formally approved for the treatment of human 
immunodeficiency virus infections.  They can be classified into 4 groups, (i) 
nucleoside reverse transcriptase inhibitors (NRTIs), (ii) nucleotide reverse 
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transcriptase inhibitor (NtRTI), (iii) non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) and (iv) the protease inhibitors (PI).  To achieve the highest possible 
benefit, these drugs have to be combined in multiple-drug regimens.  Those that have 
generally been used consist of two NRTIs, or one NRTI and one NtRTI, to which is 
then often added one NNRTI or one PI115.  Saquinavir 63 is manufactured and 
marketed by Roche Pharmaceuticals, and was the first HIV aspartic protease inhibitor 
to gain approval for use in the treatment of humans.  Despite low bioavailability due 
to poor adsorption and extensive first pass degradation by cytochrome P450 3A4, it 
received FDA approval in 1995.  Inhibitor 63 acts by restricting the enzyme, which 
cleaves viral protein molecules into smaller fragments, and this enzyme is vital for 
both the replication of the virus within the cell and also the release of mature viral 
particles from an infected cell.  Saquinavir 63 was administered in combination with 
nucleoside analogues and is equally active in cell culture against both HIV-1 and 
HIV-2 viruses116.  The most common side effects experienced from the use of 
inhibitor 63 are gastrointestinal including diarrhoea and nausea117.  In the early part of 
2006, Roche Pharmaceuticals issued a statement withdrawing the use of Saquinavir 
63 in its initial form (Fortovase®) but remains in clinical use under the trade name 
Invirase®, which is combined with ritonavir 64118. 
 
Ritonavir 64 was another early protease inhibitor to receive approval in 1996.  
Developed by Abbott Laboratories, this inhibitor is used, as in 63, in combination 
with nucleosides or as monotherapy for the treatment of HIV infection115.  Considered 
both as a potent inhibitor and an inducer of the cytochrome P450 metabolic pathway, 
it is metabolised primarily through cytochrome P450 3A4117.  As with inhibitor 63, 
HIV-1 and -2 are equally susceptible to ritonavir inhibition.  Nausea and vomiting are 
the two most common side effects that result from use of inhibitor 64.  The addition 
of ritonavir to a course of saquinavir therapy boosts inhibition levels 20-fold based on 
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the ritonavir potent inhibition of the cytochrome P450 3A4.  As a result, doses of both 
drugs can be reduced, thereby potentially limiting side effects.   
 
One of the more widely used HIV protease inhibitors is known as atazanavir 65, 
formerly known as BMS-232632, and now trading under the name Reyataz®.  
Atazanavir was approved for treatment in 2003 and is the first protease inhibitor 
approved for once-daily dosing115.  The Bristol-Myers Squibb inhibitor 65 shows side 
effects common among HIV inhibitors, such as increased probability of kidney 
stones, metabolic abnormalities including cholesterol elevations and bizarre body 
shape alterations known as lipodystrophy, however in the case of atazanavir they are 
far less severe than its predecessors.  In October 2006, the FDA approved a new 
formulation of atazanavir to be taken as part of combination drug therapy and should 
reduce the dosage amounts119.  Atazanavir prevents the formation of mature virions 
by inhibiting the processing of viral gag and gag-pol polyproteins in HIV-infected 
cells.  The unique, signature mutation for atazanavir resistance in isolates from 
antiretroviral therapy-naive patents was an isoleucine to leucine substitution at amino 
acid residue 50 of the HIV-1 protease gene.  This mutation was atazanavir 65 specific 
and conferred increased susceptibility to other protease inhibitors.  However, in 
antiretroviral therapy-experienced patients who had never previously received 
atazanavir, susceptibility was reduced in the presence of multiple mutations 
associated with resistance to other protease inhibitors.  There was a high cross-
resistance to 65 in patients with prior exposure to at least three other PIs120. 
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Tipranavir 66, is a nonpeptidic protease inhibitor (PI) with the trade name Aptivus® 
and developed by Boehringer Ingelheim Pharmaceuticals, Inc.  Inhibitor 66 was 
approved by the FDA in 2005.  It is used in combination therapy to treat HIV 
infection.  Tipranavir has the ability to inhibit the replication of viruses that are 
resistant to other protease inhibitors.  Resistance to tipranavir itself seems to require 
multiple mutations. Like most peptidomimetic protease inhibitors, tipranavir 66 is 
given in combination with low-dose ritonavir in order to boost its systemic 
availability.  Like atazanavir 65, it is very potent and is effective in salvage therapy 
for patients with some drug resistance. However, it tends to have more side effects121. 
 
 
Inhibitor 67, known as TMC-144 or darunavir, and prescribed under the name 
Prezista®, is the most recent HIV inhibitor to gain FDA approval.  Receiving approval 
in June 2006, darunavir 67 is manufactured by Tibotec Therapeutics, a division of 
Ortho Biotech Products.  Inhibitor 67 has exhibited a Ki value of 14 pM and antiviral 
IC50 of 3 nM122.  Darunavir has been shown to have antiviral activity against the 
mutant and the wild type viruses123.  Prezista is approved to be co-administered with a 
low-dose of ritonavir and other active anti-HIV agents. Ritonavir 64 slows the 
breakdown of Prezista in the body thereby increasing the concentration of 67 in the 
patient's system. 
 
Alzheimer’sDisease protease inhibition 
Alzheimer’s disease (AD) is the most common age-related neurodegenerative 
disorder and currently affects nearly 2% of the population in industrialized 
countries124.  One in 10 individuals over 65, and nearly half of those over 85, are 
likely to be struck by the disease.  The increase of the older population in the 
developed countries will turn AD into a dramatic issue for healthcare systems 
worldwide in the near future.  Until now, there has been no cure for AD.  Intensive 
investigation has provided insight into the biology of the disease and revealed several 
options for treatment.  Brains of patients struck by AD are characterized by two 
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hallmark proteinaceous aggregates: amyloid plaques and neurofibrillary tangles125.  β-
Amyloid plaques are specific for AD126.  The “amyloid hypothesis”, assigns the 
central role to the accumulation of β-amyloid peptide (Aβ) in the brain.  Aβ peptides 
derive from the abnormal cleavage of the β-amyloid precursor protein (β-APP), a 
protein found throughout the body whose normal function remains obscure. β -
Secretase (BACE-1), a member of the pepsin family of aspartyl proteases, plays a 
critical role in this amyloid cascade. Recent reports have demonstrated a direct 
correlation between increased β-site amyloid precursor protein cleaving enzyme 
(BACE-1) activity and Aβ production in AD brain tissue127.  Several aspartic 
proteases have been targeted successfully for drug development; therefore, BACE-1 
inhibition has been recognized by several companies and academic groups as a 
suitable therapeutic approach to slow or halt the progression of AD128. 
 
 
To date, numerous BACE-1 inhibitors have been published.  Most of these inhibitors 
share a peptidic character and mimic the scissile amide bond of the natural substrate 
by a noncleavable transition state isostere.  Up until recent years, most inhibitors were 
of this nature, peptidelike.  Novartis have recently reported on the design and 
synthesis of 15- to 17-membered macroheterocyclic peptidomimetic inhibitors of β-
secretase129.  Inhibitor 68 was the most potent of these novel macrocyclic 
hydroxyethylene inhibitors and showed good activity against BACE-1 with an IC50 of 
0.19 µM.  However, this inhibitor along with all in the series, when tested against two 
other aspartic protease enzymes (Cat D and pepsin), showed significantly better 
potency with IC50 values of 0.01 and <0.01 µM, respectively. 
 
Despite all progress made in the design of peptidelike molecules, they have the same 
problems as all peptidic structures: low oral bioavailability and poor blood-brain 
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barrier permeation.  Therefore, nonpeptidic compounds are now at the forefront in the 
hunt for a potent β-secretase inhibitor.  The exploration of the potential of tetronates 
and tetramates as BACE-1 inhibitors is an exciting area that is showing promise, with 
Hoffman La Roche having recently applied for a patent in this area130.  Schmidt et al 
have identified tetronic, tetramic, and N-substituted tetramic acids that inhibit BACE-
1 in the micromolar range131.  These scaffolds were chosen because they are related to 
the homologous 4-hydroxypyran-2-one class of HIV active site inhibitors, which 
includes tipranavir 66.  Of the vast library of compounds screened for β-secretase 
inhibition, only a select few showed potency in the micromolar range or better.  The 
tetramic acid inhibitor 69 was the most active of all compounds assayed with a 
calculated IC50 of 60 µM.  Further optimization is required and is in progress, based 
around modification of the enol functionality, as the results from the SAR indicate 
that the m-trifluoromethyl aryl group separated by a S-CH2 moiety increases activity. 
 
 
These recent publications show how difficult an enzyme β-secretase is to inhibit.  
Although active, the previously reported compounds are very weak in terms of 
potency.  Several inhibitors of β -secretase have been identified in cellular assays but, 
more often than not, the true nature of the inhibition mechanism was not reported.  
Broad-spectrum protease inhibitors such as pepstatin 48, known aspartic protease 
inhibitors from renin, and HIV protease programs, as well as cocktails thereof, have 
little inhibitory effect and gave misleading results.  The consequent utilization of the 
Swedish mutation and the SAR of early compounds made by Bristol-Myers Squibb132 
resulted in the development of OM99-2 70 and its successful cocrystallization with 
BACE.  Activities have been reported for Leu-Ala hydroxyethylene isosters such as 
71, which provide insight into the binding mode.  However, these compounds do not 
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really invite drug development because the obstacles for Alzheimer therapy are even 
higher in comparison to those for the inhibition of renin and HIV protease133,134.   
 
Significant efforts were made to reduce the molecular weight and the flexibility of the 
lead structure.  Inclusion of an alanine instead of a valine residue improved binding to 
the pocket S2’.  This replacement and the omission of the small contributions from 
P4-Glu- and P4’-Phe-binding were first steps taken on a bumpy road towards 
optimization.  The Elan compounds 72 and 73 have lost a good part of their peptidic 
heritage, which is mandatory to obtain sufficient oral absorption and blood-brain 
barrier penetration135,136,137. 
 
Despite all efforts made by pharmaceutical companies and academic groups, 
nonpeptidic lead structures for BACE inhibition are very scarce.  Takeda reported the 
tetraline 74, which is not an obvious scaffold for protease inhibition and is likely to 
originate from high-throughput screening efforts138.  The activity is poor (IC50 = 100 
µM) and the mode of action is insecure.  Latifolin 75, isolated from the heartwood of 
Dalbergia sissoo, was found to inhibit Aβ synthesis with an IC50 value of 180 µM, 
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again a rather weak potency139.  However, steady assay development will help provide 
further nonpeptidic leads.  For example, protease-cleavable luciferases, which can be 
used in protease determination and screening for protease inhibitors, were suggested 
for use with the BACE sequence140, but the reported method needs improvement. 
 
 
1.5.2.4 Metalloprotease inhibitors 
Metalloproteases, like aspartic proteases, do not form covalent intermediates, but have 
evolved with a more direct solution to the necessity for catalytic effect on the 
carbonyl group of the bond undergoing cleavage.  Rather than rely on hydrogen 
bonding, the metalloproteases utilise coordination to a metal ion to exert this effect3.  
In the vast majority of cases this metal is zinc, although in some proteases other 
transition metals such as copper and nickel are present. The currently accepted 
mechanism of catalysis of the metalloproteases involves a Zn2+ ion tetrahedrally 
coordinated to three donor groups from the enzyme and a water molecule.  By being 
hydrogen bonded to the carboxylic acid side chain of a glutamic acid residue, the 
water molecule is activated for nucleophilic attack.  The coordination of the carbonyl 
moiety of the scissile amide bond to zinc is followed by nucleophilic attack by the 
water molecule with a proton transfer to the carboxylate giving a tetrahedral zinc 
intermediate.  The transfer of a proton from the glutamic acid to the amide nitrogen is 
followed by collapse of the tetrahedral intermediate with the generation of a salt 
bridge between the glutamic acid and the free amine of the cleaved substrate.  The 
design of inhibitors has focused on binding the catalytic zinc ion to hinder the 
mechanism.  Synthetic inhibitors generally contain a moiety such as a thiol, 
carboxylic acid or hydroxamic acid moiety as the warhead, capable of coordinating to 
a zinc atom attached to a series of other groups that are designed to fit the specificity 
pockets of a particular protease141.  With numerous selective and potent inhibitors of 
metalloproteases being approved for clinical administration, this hypothesis of 
inhibition has turned out to be very successful. 
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One of the most frequently expressed zinc metalloproteases, angiotensin converting 
enzyme (ACE) is found in tissues including the heart, the lungs and several regions of 
the brain.  Due to its pivotal role in blood regulation, ACE has received huge amounts 
of attention.  As mentioned earlier, ACE, as a catalyst is responsible for the 
conversion of angiotensin I to angiotensin II in the renin-angiotensin system97.  The 
inhibition of this zinc metalloprotease decreases levels of angiotensin II in the body, 
ultimately leading to a reduction in blood pressure.  ACE inhibition has been studied 
extensively for many years which has resulted in many potent inhibitors receiving 
approval for therapeutic use.  The first ACE inhibitor to gain FDA approval was the 
Bristol-Myers Squibb inhibitor, captopril 76, isolated from snake venom.  Inhibitor 76 
was patented in the late 1970’s and received approval early in the 1980’s for use in 
the treatment of hypertension and some types of congestive heart failure.  The adverse 
effect and pharmacokinetic limitations of captopril stimulated the development of 
enalapril 77 by Merck & Co., and subsequent ACE inhibitors.  These were 
specifically designed to lack the sulfhydryl moiety believed to be responsible for rash 
and taste disturbance142.  
 
Enalapril 77 was the first member of the group of ACE inhibitors known as the 
dicarboxylate-containing ACE inhibitors.  Both of these inhibitors employ a chelating 
group that binds to the active site zinc resulting in high inhibitory potency and 
selectivity.  Most subsequent ACE inhibitors are given as prodrugs, to improve oral 
bioavailability.  
 
In recent times, low molecular weight, lipophilic inhibitors of ACE have been 
developed that are devoid of side effects.  Losartan 78 is an angiotensin II receptor 
antagonist and was the first to be marketed.  Developed by Merck & Co., losartan 78 
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inhibits ACE by antagonising the angiotensin II receptor.  It is beneficially devoid of 
side effects such as cough and rash, associated with other previous ACE inhibitors. 
 
One of the most common angiotensin II receptor antagonists is valsartan (trade name 
Diovan®) 79.  Inhibitor 79 is used in the treatment of high blood pressure, of 
congestive heart failure (CHF), and post-myocardial infarction (MI).  In 2005, 
Novartis announced figures that showed that Diovan® was prescribed more than 12 
million times in the United States143. 
 
Matrix metalloproteases (MMP) are a family of proteases that were first described in 
1962 when Gross and Lapiere identified an enzyme from a tadpole tail with 
proteolytic action capable of attacking collagen144.  MMP’s were initially 
characterised by their ability to degrade components of the extracellular matrix.  
These enzymes require a zinc ion at their active site and are inhibited by zinc and 
calcium chelating agents.  Although matrix metalloproteases are naturally inhibited by 
locally produced tissue inhibitors of metalloproteases (TIMP), an imbalance caused 
by overexpression and activation of MMP results in tissue degradation.  It is thought 
that matrix metalloproteases are important in the growth and spread of malignant 
tumours and development of chronic diseases such as multiple sclerosis and 
arthritis145.  For these reasons matrix metalloproteases are considered to be attractive 
targets for drug design and the treatment of these disorders.   
 
Inhibition of various MMP’s has been an active area of research for the past 30 
years146.  A large number of potent inhibitors have been discovered and some have 
been tested in clinical trials as therapies for cancer and arthritis with great 
expectations.  Although many of these trials were discontinued, a few MMP inhibitors 
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are still undergoing clinical trials.  The first generation inhibitors were designed based 
on peptide substrates attached to a zinc-binding group (ZBG) such as a hydroxamate.  
These were mostly non-specific and broad based MMP inhibitors.  More specific 
inhibitors have been designed using both peptidic and non-peptidic scaffolds, with the 
assistance of enzyme crystal structures.  Also, several different types of ZBGs have 
been reported to work well with different scaffolds147.  One of the most notable and 
well known of the first generation inhibitors was developed by British Biotech and is 
called marimastat 80.  This is a broad-based MMP inhibitor and is not specific against 
any one or group of MMP’s.  Marimastat 80 has undergone several Phase III clinical 
trials148.  A trial for advanced pancreatic cancer failed to detect increased survival for 
the marimastat-treated groups.  However, the highest dose of marimastat was not 
found to be more effective than the conventional therapy.  The vast majority of the 
first generation matrix metalloprotease inhibitors have hydroxamic acid as the ZBG.  
So far progression of broad-spectrum matrix metalloprotease inhibitors (MMPIs) 
through these trials has been hampered due to a prevalent side effect known as 
musculoskeletal syndrome (MSS), which manifests itself as musculoskeletal pain and 
inflammation147.   
 
The second generation of MMP inhibitors are nonpeptidic and are designed on the 
basis of the conformation of the MMP active site determined by NMR and X-ray 
crystallography.  These inhibitors are more specific inhibitors.  The first subgroup of 
these inhibitors also contain hydroxamic acids as ZBG, but the most potent has been 
with rebimastat (BMS 275191) 81.  This inhibitor is a thiol based instead of a 
hydroxamic acid based inhibitor and is undergoing cancer Phase II/III clinical trials.  
The second subgroup developed are tetracycline derivatives have been shown to 
inhibit both the activity and synthesis of MMPs.  Tetracycline analogues with no 
antibiotic activity have been developed for the treatment of cancer.  Metastat (CMT-
2) 82 is one such analogue that is undergoing Phase II trials for Kaposi's sarcoma and 
advanced brain tumours146.   
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For numerous decades, matrix metalloproteinases have been heralded as promising 
targets for cancer therapy on the basis of their massive up-regulation in malignant 
tissues and their unique ability to degrade all components of the extracellular matrix.   
Matrisian et al has stated that a major reason for the failure of MMP inhibitors in the 
clinic appears to be faulty design of clinical trials149.  Most preclinical studies have 
focused on the role of MMPs in the early stages (progression and metastases) of 
cancer, in which MMP inhibition seems to have its greatest effect.  Unfortunately, 
clinical trials of MMP inhibitors were conducted almost uniformly in patients with 
advanced, metastatic disease, and all have failed to show any beneficial effect on 
patients.  It is possible that these same trials could have had different outcomes if they 
were conducted in patients with earlier stages of disease.  Secondly, lack of selectivity 
of the first generation inhibitors (marimastat 80) may have contributed to this failure.  
The second generation inhibitors were designed to be selective for several specific 
MMPs.  But the selectivity of the second generation may not be sufficient enough to 
cause significant inhibition of cancer growth.  Further, most trials use the maximum 
tolerated dose of MMP inhibitors.  At the highest tolerated doses, the inhibitors might 
lose selectivity for specific MMPs.  In some trials, the dosage could have been too 
low to avoid the side effects (most commonly musculoskeletal pain) of MMP 
inhibitors.  Some of these unfavorable side effects may have been caused by the 
hydroxamate group which is common to most of the clinical candidates150. 
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1.6 Fluorine containing protease inhibitors 
 
The addition of fluorine atoms into a drug molecule has been around for many years 
as a fundamental element in the search for increased biological activity.  The 
importance of fluorine substitution in pharmaceutical development is evident in the 
large number of fluorinated derivatives approved by the FDA for use as anticancer, 
antiviral, antidepressant and anesthetic agents.  There are generally two consequences 
of introducing fluorine into a drug molecule151.  Firstly there are the physiochemical 
properties.  Fluorine has the ability to modulate electronic, lipophilic and steric 
parameters that can critically influence the pharmacological properties of a drug 
molecule.  The introduction of a fluorine atom will generally increase lipophilicity, 
decrease basicity and alter the hydrogen bonding interactions of a molecule.  
Secondly, there is the influence of fluorine substitution on the biological stability of a 
drug molecule, e.g. through altering the metabolism of the drug152.  A prime example 
of this is shown in Scheme 1.3, with the discovery of the cholesterol absorption 
inhibitor SCH 58235 84153.  The expected modes of primary metabolism of 83 are 
dealkylation of the N1- and C4-methoxyphenyl groups, para hydroxylation of the 
pendent C3-side chain phenyl group, benzylic oxidation (hydroxylation potentially 
followed by ketone formation) and 2-azetdinone ring opening.  Modification to form 
inhibitor 84 has shown a 50-fold increase in potency by blocking all but one of these 
modes of metabolism. 
 
Scheme 1.3: Example of fluorine substitution on rational drug design. 
 
Compound 84 has been developed as a means of treating hyperlipidemia.  Its half life 
of 22 hours is partly due to the presence of fluorine atoms blocking the unwanted 
metabolic processes mentioned previously.  It has FDA approval for use in 
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combinatioal therapy with statin derivatives for the treatment of 
hypercholesterolemia.  Fluorine has been used as a means to developing safer and 
more reactive pharmaceuticals due to the strength of the carbon-fluorine bond that is 
very difficult to metabolize, so harmful and unproductive side reactions are unlikely 
to occur. 
 
The Van der Waals radius of the fluorine atom is 1.47 Å.  This value is positioned 
between the values of hydrogen (1.20Å) and oxygen (1.53 Å) allowing it to mimic a 
hydroxyl group and to participate in hydrogen bonding interactions.  With an 
electronegativity value of 4.0, fluorine is the most electronegative element, much 
more than carbon (2.5) or hydrogen (2.1).  As a result, the carbon-fluorine bond is one 
of the most stable chemical bonds, while hydrogen-fluorine bonds are the strongest of 
the secondary bonds.  The concept of replacing the hydroxyl moiety of a bioactive 
molecule with a fluorine atom has been a prevalent method for the enhancement of 
biological activity.  Medicinal chemists have recognized for some time that fluorine 
and hydroxyl groups are bioisosteres154.  The introduction of a fluorine atom into a 
bioactive molecule also provides a marker for 19F NMR studies where drug-protein 
interactions can be assessed in vitro and in vivo due to the absence of fluorine in 
living tissue155. 
 
More than eighty years ago, the first fluorine containing protease inhibitors were 
developed and reported, these were phosphonyl and sulphonyl fluorides.  The 
inhibitors diisopropylfluorophosphate (DFP) 85 and phenylmethylsulphonyl fluoride 
(PMSF) 86 are two of the most effective examples of protease inhibitors and are 
generally associated with serine inhibition156.  These inhibitors phosphorlyate or 
sulphonylate the active site serine hydroxy group due to the electrophilicity of the 
phosphorous or sulphur atom induced by the adjacent fluorine atom.  These inhibitors 
show poor selectivity with regards to serine and cysteine proteases and are also 
extremely toxic.  Lamden et al reported the synthesis of more selective phosphonyl  
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fluorides such as inhibitor 87, which incorporates peptidyl character to improve 
potency157.  Inhibitor 87 is a potent inhibitor of elastase with 6-fold selectivity over α-
chymotrypsin. 
 
The incorporation of fluoromethyl ketone moieties into protease inhibitors has led to 
the development of potent transition state inhibitors for a variety of proteases 
including porcine pancreatic elastase and cathepsin B158.  The introduction of a 
fluorine atom into a methyl ketone creates a highly reactive carbon centre that readily 
undergoes nucleophilic attack.  Peptidyl derivatives containing fluoroketones have the 
ability to be potent inhibitors of proteases due to the vastly increased electrophilic 
nature of this carbon centre.  Both di- and trifluoromethyl ketones exist almost 
entirely in the hydrated form in water and thus it seems likely that fluorinated ketones 
would form a hemiketal at the active site of a serine protease or in the case of the 
hydrate, bind tightly to both metallo or aspartyl proteases159.  In contrast to 
chloromethyl ketones, the C-F bond in fluoromethyl ketones is much stronger than the 
C-Cl bond in the chloro analogues.  This suggests that fluoromethyl ketones should be 
much poorer alkylating agents than chloromethyl ketones.  This property should 
reduce the side effects associated with the use of choromethyl ketones. 
 
Akahoshi et al at the Welfide Corporation in Japan, developed a series of inhibitor 
analogues based on earlier work160.   The synthesized compounds were developed as 
novel inhibitors of the chymotrypsin-like serine protease chymase.  The most active 
inhibitor of the series is 88, which was shown to have a Ki value of 2.62 nM towards 
human chymase, a Ki of 28.0 nM toward canine chymase, and high selectivity against 
chymase of other species and their representative human proteolytic enzymes.  Along 
with the high potency towards chymase, the 3-chlorophenyl analogue 88 has a high 
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chymotrypsin/chymase selectivity ratio of 175.  Pharmaceutical studies in rat and dog 
indicated that 88 was absorbed rapidly following oral administration and had 
satisfactory bioavailability (17% and 32%, respectively).  Given its favorable 
biological profile, this inhibitor is undergoing further evaluation to determine its 
therapeutic potential against chymase-induced diseases such as asthma. 
 
Recently, Cai et al (Maxim Pharmaceuticals) have been working on optimizing a 
series of dipeptidyl aspartyl fluoromethylketones as broad spectrum potent caspase 
inhibitors.  MX1153 89 was identified as having the best overall activity in the series, 
with IC50 values ranged between 11-50 nM against caspases-1, -3, -6, -7, -8 and -9. 
Compound 89 was found to be inactive against two cysteine proteases, calpain-1 and 
cathepsin B, as well as the serine protease, factor Xa.  From the figures published, 
inhibitor 89 is >5000-fold selective for caspase-3 versus these three non-caspase 
proteases.  This inhibitor was also shown to provide 50% cell protection against 
apoptosis induced by tumour necrosis factor-α (TNF-α) at a concentration of 200 nM.  
It was found to be active in a mouse liver apoptosis model.  Intravenous 
administration at a dosage of 10 mg/kg showed that there was 83% increase in the 
number of mice surviving after 3 days. 
 
Perhaps the most successful example of a fluorinated protease inhibitor is the 
substrate derived tripeptidyl Michael acceptor-containing human rhinovirus (HRV) 
inhibitor Rupintrivir (AG7088) 90.  This inhibitor, developed by Agouron 
Pharmaceuticals Inc., has emerged as one of the lead candidates for this ailment and is 
presently undergoing phase III trials for intranasal delivery161.  Rupintrivir is a potent 
irreversible inhibitor of HRV 3C protease with an EC50 value of 5 nM.  It is a 
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selective inhibitor of HRV 3C protease with no inhibition of serine or cysteine 
(cathepsin) proteases occurring at a concentration of 10 nM and was shown to be 
stable in human plasma, dog plasma and α-chymotrypsin with half lives of greater 
than 60 minutes.  This drug was one of the first drugs utilized as a potential inhibitor 
of the SARS outbreak in 2003.  Recently, investigative studies have shown that the p-
fluorophenylalanine side chain is too long (or bulky) to fit into the relevant binding 
site of the SARS-coronavirus main proteinase (SARS-CoV Mpro)162.  Because of this, 
KZ7088 91 has been developed with a modified side chain by removing the 
methylene (-CH2-), resulting in a more rigid, shorter side chain.  It is hoped this 
inhibitor 91 will help lead to effective drug candidates for the treatment of SARS. 
 
The incorporation of a fluorine atom has been shown to improve selectivity and 
bioactivity, and has led to development of some of the most successful 
pharmaceuticals on the market today.  Despite this there are still very few examples of 
fluorinated protease inhibitors approved by the FDA for therapeutic use.  The most 
potent series of derivatives have been based on a fluoromethyl ketone scaffold.  
Examples of such derivatives have shown high levels of activity towards both serine 
and cysteine proteases.  They are considerable more stable than their chlorine 
analogues although their alkylating ability often induced toxic aide effects.  The 
introduction of a trifluoromethyl moiety may be a more successful route for the 
inhibition of nucleophilic proteases given the steric size of the CF3 moiety is similar 
to a chlorine atom and also it has the ability to induce an electrophilic centre.  The 
development of potent selective inhibitors such as KZ7088 91 furnishes optimism for 
the development of further fluorinated protease inhibitors. 
 
Dipeptidyl derivatives have been shown to be effective inhibitors of the liver fluke 
Fasciola hepatica cysteine cathepsin L over the known commercial inhibitor Z-Phe-
Ala-CHN2 31 at varying concentrations163,164.  Over the past decade, research in our 
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group has looked at ways of producing potent dipeptidyl protease inhibitors.  It is well 
documented that the inhibition of the protease is due to binding of the inhibitor via the 
iso-butyl side chain.  This has been confirmed by our group by modifying the first 
amino acid in the dipeptide at the P1 position from glycine to phenylalanine.  IC50’s  
 
Figure 1.5: Points of modification of dipeptide protease inhibitors. 
 
calculated from these derivatives range from 11 to >200 µM for N-trans-cinnamoyl-
L-Leu glycine nitrile and N-nicotinoyl-L-Leu-Ala-OMe, respectively163.  
 
Modification at of the second amino acid, at the P2 position and also at the P2’ C-
terminus has also been done.  As with the P1 site, the amino acid was altered to 
compare the effect of changing the R’ group.  Also, using unnatural amino acids such 
as β-alanine and γ-aminobutyric acid, the P2’ position was lengthened.  Alteration of 
the C-terminus of the dipeptide from the esters to nitriles to benzyl amides were 
synthesised.  All the synthesised inhibitors were assayed against the cathepsin L 
endoprotease and the IC50’s compared.  The resulting optimized dipeptide, containing, 
L-leucine at P1, glycine nitrile at the P2 and P2’ positions and a para-substituted 
fluorine at the P3 position was found to have a 50% inhibitory concentration of 3 
µM164.  This report outlines further investigation into optimizing a potent dipeptidyl 
inhibitor of the Fasciola hepatica cysteine cathepsin L endoprotease. 
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1.7 Conclusion and Aims 
 
Historically, the design of protease inhibitors has incorporated highly reactive 
electrophilic warheads that alkylate, acylate, phosphorylate or sulphonate the active 
site residues of proteases.  The initial generation of inhibitors, although very potent, 
showed severe side effects due to their high reactivity and poor selectivity, largely due 
to their lack of peptidyl character.  The incorporation of peptides into potential 
inhibitors has greatly reduced complications associated with the first generation.  The 
replacement of the peptide backbone with peptidomimetics has been very successful 
in further improving the bioavailability and stability of inhibitors in biological 
systems.  Finally, the incorporation of moieties such as thiols and hydroxymates, 
capable of binding to the Zn2+ ion, has results in the most effective metalloproteases 
inhibitors.  Although the degree of potency and selectivity of these metalloprotease 
inhibitors has been high, the majority have lacked good bioavailability.  In recent 
years, the use of molecular modelling in tandem with crystal structures of the enzyme-
inhibitor complexes has played a major role in drug development.  These complexes 
offer important guidelines in the design of inhibitors by displaying a clear picture of 
the relationship between the confirmation of the inhibitor and the active site of the 
enzyme.  When used in combination with library screening, this mechanism of design 
has been particularly productive. 
 
The inhibition of proteases offers great potential for the treatment of various diseases.  
Unfortunately there are very few inhibitors that are on the market today.  Despite the 
impressive progress, there is much to learn about the cross talk between signal 
transduction pathways and protease activation cascades.  Additionally, development 
of successful protease inhibitors for clinical use is reliant on maximising 
bioavailability, specificity and potency of inhibition of the target enzyme.  Ideally, 
localising protease inhibitors to a single target area of the body may also help 
minimise the potential for complications and detrimental side effects. 
 
  59 
The aim of this project was to develop an inhibitor of the cysteine protease, cathepsin 
L. This protease has been isolated from a parasite responsible for the disease liver 
fluke. Previous studies have shown that the L-leucine glycine nitrile scaffold has good 
potency against this protease. A series of novel dipeptidyl analogues were synthesised 
investigating fluorine substitution at the N-terminus substituent of this dipeptide. 
Further to this, dipeptides with a variety of N-terminal modifications were also 
prepared.  
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2.0 Synthesis and characterisation of novel dipeptide 
derivatives 
 
2.1 Introduction 
 
The group of cysteine proteases known as the cathepsins have been shown to play a 
crucial part in diseases such as osteoporosis, rheumatoid arthritis, cancer metastasis 
and infectious diseases1.  Cathepsins are important targets for the development of 
inhibitors as theraputic agents.  Fasciolosis is caused by infection with Fasciola 
hepatica (temperate) and Fasciola gigantica (tropical) parasites.  It is not only an 
important human disease but also affects cattle and sheep.  In 1999 it was estimated 
that Fasciolosis was causing annual worldwide economic losses in the region of two 
billion dollars.  It was also estimated at this time that 2.4 million people are infected 
with liver fluke worldwide2,3.  Fasciolosis is acquired following the ingestion of 
vegetation or water contaminated with the encysted infectious liver fluke larvae, 
known as metacercariae4.  It has long been known that the predominant protease 
activity in this parasite was associated with cells of the gut epithelium5.  Like many 
other parasitic helminthes, Fasciola hepatica liver flukes release proteolytic enzymes 
that belong to the group of cysteine proteases.  It has been suggested by Heffernan et 
al, that these proteases may be required for preventing attack by the host immune 
system, against the parasite6.  The majority of the more recent methodology towards 
cathepsin inhibition utilises molecules of a peptidic nature.  An electrophilic moiety is 
used to replace the hydrolysable amide bond and the catalytic thiol of the enzyme 
reacts with the inhibitor to form a covalent complex.  Electrophilic groups such as an 
aldehyde, halomethyl ketone and epoxide have been shown to be potent cysteine 
protease inhibitors7,8.  Peptidic molecules bearing the electrophilic nitrile moiety have 
been reported as having inhibitory activity towards cathepsins. One of the first such 
examples was the dipeptidyl derivative N-benzoyl-Leu-Gly-CN synthesised by Suzue 
et al in 19689.  Previous work in this laboratory has shown this to be a potent inhibitor 
of the Fasciola hepatica protease10,11.  For this study all of the compounds are based 
on a dipeptidyl scaffold, with the initial study using a fluorobenzoyl dipeptide. The 
second protease inhibitor study will concentrate on modifying the N-terminal of the 
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dipeptide scaffold. The fluorobenzoyl moiety has been shown to be an effective N-
terminal substitution in various potent inhibitors12.  There are generally two 
consequences of introducing fluorine into a drug molecule, the physiochemical 
properties and the altering of susceptibility to metabolism of the drug molecule.  The 
physiochemical properties that are affected by fluorine substitution are an increase in 
lipophilicity, increased acidity, decreased basicity and an alteration in the hydrogen 
bonding properties.  The inductive electron withdrawing effect of fluorine is expected 
due to its electronegative nature, but electron donation by resonance effects attributed 
to the three lone pair electrons is a distinctive property of fluorine.  The second 
consequence of fluorine introduction comes about as a result of the strength of the 
carbon-fluorine bond, which is very difficult to metabolise.  Therefore, potentially 
harmful and unproductive side reactions due to the metabolism of the molecule are 
significantly reduced. 
 
 
2.2 Synthesis of the dipeptidyl derivatives 
 
The synthesis of dipeptides containing the amino acids L-leucine and glycine with N- 
and C-terminal modifications was carried out. The amino acids were coupled using an 
activation agent 1,3-dicyclohexylcarbodiimide (DCC) 92.  The mode of action of 
DCC involves the formation of an O-acylisourea intermediate 93 that is a potent 
acylating agent. 
 
Scheme 2.1: Mode of action of peptide coupling with DCC 
 
Unfortunately there are some disadvantages in using DCC as a coupling agent.  
Activation by 92 is shown to cause racemisation of the carboxy terminal residue.  
Reactive intermediates produced during coupling contain a basic centre, which causes 
an intramolecular proton abstraction from the chiral carbon atom. 
(92)
N C N
O
OHR
H+
H
N
O
N
R
O
(93)
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Scheme 2.2: Mode of racemisation of the carbonyl terminal residue upon activation with DCC 
 
Chiral integrity can be preserved by the use of 1-hydroxybenzotriazole (HOBt) 95.  
HOBt acts as an auxiliary nucleophile and reduces the lifetime of the O-acylisourea 
intermediate thus decreasing the occurrence of racemisation.  An acylating agent of 
lower potency is formed which is still reactive to aminolysis, but is less susceptible to 
racemisation or other side reactions.  1-Hydroxybenzotriazole also offers an acidic 
hydrogen that can be more easily removed by bases than the proton at the chiral 
centre. 
 
Low yields are often another feature of peptide coupling using DCC 92.  These low 
yields can be accounted for due to the formation of an N-acylurea derivative 96 via an 
intramolecular rearrangement of the O-acyl derivative 93 formed by activation with 
DCC 92.  The attack of the activated carbonyl group by the nearby nucleophilic –NH- 
results in an O to N shift yielding an N-acylurea side product 96. 
 
Scheme 2.3: Formation of an N-acyl derivative 96 via intramolecular rearrangement of the O-
acylisourea derivative. 
 
Another disadvantage of coupling peptides with 1,3-dicyclohexylcarbodiimide is poor 
reaction rates.  The employment of HOBt and similar derivatives has greatly 
enhanced the ability of DCC to couple amino acids effectively.  More recently, the 
design of peptide coupling reagents has concentrated in the ability of the reagent to 
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limit the onset of racemisation while at the same time offering a highly competent 
coupling agent whose side products can be easily removed.  This method of design 
has resulted in coupling reagents incorporating the coupling ability of DCC and the 
racemisation suppression activity of HOBt being developed and utilised as effective 
combination type reagents13. 
 
 
2.2.1 N-fluorobenzoyl dipeptidyl nitriles 
The majority of recent research with nitrile derivatives has concentrated on 
developing the N-terminal substituent next to the P2 position with the fluorobenzyl 
moiety showing increased selectivity14.  Dipeptidyl nitrile derivatives are believed to 
function as reversible inhibitors with the nitrile moiety undergoing attack by the 
activated thiol group of cysteine in the active site of the protease (Scheme 2.4).  1H 
NMR studies have shown that inhibition occurs through the formation of a 
thioimidate intermediate and this process is fully reversible15. 
 
Scheme 2.4: Mechanism of nitrile inhibition of cysteine proteases 
 
Dipeptidyl derivatives have been shown to be effective inhibitors of the liver fluke 
Fasciola hepatica cysteine cathepin L over the known commercial inhibitor Z-Phe-
Ala-CHN2 3110,11.  The introduction of a fluorine atom into a system can drastically 
change the biological potency of a drug16.  The synthesis of a series of benzoyl 
dipeptidyl nitriles incorporating fluorine atoms at various positions on the phenyl ring 
was undertaken to assess the effect of the fluorobenzoyl substituent.  It has been 
shown that molecules containing the electrophilic nitrile warhead are potent inhibitors 
of cathepsin proteases17.  A series of derivatives were synthesised as illustrated in 
Scheme 2.5. 
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Scheme 2.5: Synthesis of N-fluorobenzoyl-L-leucine glycine nitrile derivatives 
                       (a)  L-Leu, H2O, NaOH, HCl  (b) DCC, HOBt, TEA, DCM 
The dipeptidyl nitrile derivatives gave yields varying from 20 to 66 % (Table 2.1).  
The highest yield recorded was for the 2,4-difluoro derivative, with a value of 66 %.  
The lowest yield was the 3,4-difluoro compound with an overall value of 20 %.  
These fluorobenzoyl dipeptidyl nitriles were found to be partially insoluble in organic 
solvents while they were completely insoluble in aqueous media.  These solubility 
problems often hindered complete and successful isolation.  A large amount of 
solvent was often required to dissolve  the nitriles completely.  The pentafluoro 
derivatives were found to be the least soluble in organic solvents such as 
dichloromethane, chloroform, ethyl acetate or methanol. 
 
The 1H NMR spectra of these compounds show distinctive amide proton splitting 
patterns.  The amide proton from the L-leucine portion is split into a doublet by the α-
hydrogen and appears in the range of δ 8.50 and 9.28.  The second amide in the 
molecule, the glycine nitrile amide is split into a triplet by the adjacent methylene 
group and is seen between δ 8.75 and 9.01.  The α-hydrogen of leucine appears as a 
multiplet (δ 4.4 - 4.8) coupling with the amide and protons of the isobutyl side chain.  
The 13C NMR spectrum shows a distinctive peak for the nitrile moiety at 
approximately δ 118.  The chemical shifts of the attached methylene units have been 
shifted upfield due to the effect of the nitrile group.  The methylene carbon of the 
amino acid glycine, usually appears at about δ 40.5, but the methylene unit of the 
glycine nitrile was seen to appear at δ 27.5.  The fluorobenzoyl moiety causes the 
carbon atoms of the phenyl ring to appear as doublets and triplets due to 13C-19F 
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coupling.  The 19F NMR spectra of these compounds shows the fluorine peaks 
appearing as multiplets due to 19F-1H coupling, with the exception of the 
trifluoromethyl derivatives (110-112).  
 
 
 
Compound X % Yield 
97 3-F 25 
98 2,3-F 48 
99 2,4-F 66 
100 2,5-F 60 
101 2,6-F 38 
102 3,4-F 20 
103 3,5-F 28 
104 2,3,6-F 24 
105 2,3,4-F 44 
106 2,4,5-F 55 
107 3,4,5-F 45 
108 2,3,4,5-F 42 
109 Penta-F 40 
110 o-CF3 43 
111 m-CF3 37 
112 p-CF3 33 
 
  
Table 2.1: N-fluorobenzoyl dipeptidyl nitrile derivatives 
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2.2.2 N-protected dipeptidyl nitriles 
The N-benzoyl-L-Leu-Gly scaffold has been shown to be crucial for the inhibition of 
various cathepsins.  From work previously carried out in this laboratory, it has been 
shown that modification of the C-terminus of this scaffold yielded best activity when 
converted to a nitrile group10,11.  This moiety was explored with modifications at the 
N-terminal, namely the benzoyl group.  It is hoped that by modification of the N-
terminus, and subsequently the physiochemical properties, an improvement in the 
potency can be yielded.  Due to the aforementioned problems incurred during 
purification of the fluorinated series, the coupling agent was changed to N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) 113. 
 
This series of derivatives includes substituted benzoyl groups, modified chain lengths 
and non-aromatic cyclic moieties were introduced.  Also the effect of converting the 
leucine amide to a tertiary amide was investigated.  This series was synthesised as 
shown in Scheme 2.6. 
 
Scheme 2.6: Synthesis of N-substituted L-leucine glycine nitrile derivatives 
                     (a) EDC, HOBt, TEA, DCM  (b) piperidine, anhy. THF  (c) EDC, HOBt, TEA, DCM  
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The N-modified derivates gave a broad range of yields from 12 to 95% (Table 2.2).  
The highest yield of 95 % was found for the FMOC protected dipeptide 131, which 
was also the initial step in the synthetic scheme of these compounds.  The lowest yield 
calculated was for 1,2-benzisothiazolin-3-one L-leucine glycine nitrile 133, at 12 %, 
as isolation of this compound required several columns.  This compound came about 
serendipitously.  The anticipated compound would have had a free thiol group at the 
ortho position.  On isolation, it was proposed that the thiol had cyclised with the 
leucine amide, which was confirmed by a combination of NMR and mass 
spectrometry.  Insolubility problems of some of these products proved a hindrance for 
complete and successful isolation. Yields reported are for final step of reaction 
sequence, previous steps generally provided quantitative yields. 
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(120) 
 
35 (130) 
 
52 
(121) 
 
80 (131) 
 
95 
(122) 
 
45 (132) 
 
62 
(123) 
 
74 (133) 
 
12 
(`124) 
 
54 
 
  
Table 2.2: N-substituted dipeptidyl nitrile derivatives 
 
The 1H NMR spectra of these compounds show distinctive amide proton splitting 
patterns, as seen in the previous series of fluorinated dipeptide inhibitors.  The amide 
proton from the L-leucine amino acid is split into a doublet by the α-hydrogen.  The 
second amide in the molecule, the glycine nitrile amide, is split into a triplet by the 
adjacent methylene group.  Both these amides have different chemical shifts 
depending on its environment in the molecule and these are outlined in Table 2.3.  
The α-hydrogen of leucine appears as a multiplet (δ 4.0 - 4.8) due to coupling with the 
amide and protons of the isobutyl side chain.  The exception to this is for compound 
133, where the α-hydrogen appears further up field at δ 5.34 – 5.38.  The 13C NMR 
spectrum shows a distinctive peak for the nitrile moiety at approximately δ 118.  Due 
to the nitrile moiety, the doublet of the attached methylene units has shifted upfield.  
The methylene carbon of the amino acid glycine, usually appears at about δ 40.5, but 
the methylene unit of the glycine nitrile was seen to appear at δ 27.5.   
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Compound Leucine amide (δ) Glycine amide (δ) 
115 8.59 8.73 
116* 8.76 - 8.81 8.76 - 8.81 
117 8.72 8.84 
118 8.46 8.74 
119 8.62 8.77 
120 8.39 8.82 
121 8.42 8.80 
122 8.37 8.81 
123 8.41 8.71 
124 8.69 8.75 
125 8.97 8.80 
126 8.80 8.89 
127 8.56 8.71 
128 8.51 8.70 
129 6.99 8.61 
130 7.00 8.57 
131 7.68 8.75 
132 N/A 8.89 
133 N/A 7.54 
 
Table 2.3: Chemical shifts of amide protons in N-substituted dipeptidyl 
nitrile derivatives 
 
* both amides appear together as a multiplet 
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3.0 Biological activity of novel dipeptide derivatives 
 
3.1 Introduction 
 
Cathepsins are a complex group of cysteine proteases that cleave peptide bonds.  They 
have been implicated as essential components of various diseases such as liver fluke, 
rheumatoid arthritis, cancer and malaria1.  Their broad spectrum biological activity 
renders them as key therapeutic targets.  Fasciolosis or liver fluke as it is commonly 
known, has been estimated to be present in up to 2 million humans worldwide and its 
economic losses on cattle and sheep livestock is estimated at $2 billion annually2,3.  
Increasing resistance to the present chemotherapy against fasciolisis in animals asks 
for novel chemotherapeutic approaches.  A series of potential cathepsin inhibitors 
have been developed and their bioactivity was assessed with the cathepsin protease 
Fasciola hepatica that has been implicated in the reproduction of the parasites4. 
 
Commercially available peptide substrates with substituents added to either the N- or 
C-termini are most commonly used to assay, characterise and perform inhibition 
studies on proteases.  The C-terminal substituents usually involve a chromophoric 
amine such as 4-naphthylamine (-NHNap) or a fluorogenic group such as 7-amino-4-
methylcoumarin (-NHMec).  These species are highly absorbant or fluorescent when 
cleaved from the substrate and can be detected spectrophotometrically or 
fluorometrically.  The fluorogenic substrates are far more sensitive due to the ability 
of fluorescence to be detected against a low background in contrast to absorption 
spectrophotometry that requires measurement of transmitted light relative to high 
incident light levels at the same wavelength5.  Although these substrates are useful in 
evaluating the inhibitory potency of potential therapeutic agents, in vivo testing has 
shown the physiochemical properties of the enzyme can vary against natural protein 
substrates. 
 
 
 
  83 
3.2 Fluorescent assay  
 
A standard fluorometric assay has been developed using a fluorogenic substrate to test 
the activity of dipeptidyl derivatives.  In this assay, activity was determined by 
measuring the release of the fluorescent species 7-amino-4-methyl-coumarin (-
NHMec) 135 from the substrate Z-Phe-Arg-NHMec 134, upon enzymatic hydrolysis 
by a cathepsin L protease isolated from Fasciola hepatica.   
 
Scheme 3.1: Hydrolysis of Z-Phe-Arg-NHMec 134 by cathepsin L protease with liberation of 
the fluorescent 7-amino-4-methylcoumarin (-NHMec) 135. 
 
Assays were carried out using a final concentration of 10 µM substrate in 0.1 M 
sodium acetate buffer pH 5, containing 100 mM dithiotheritol (DTT) and 500 mM 
ethylenediaminetetraacetic acid (EDTA), in a final volume of 1 ml.  The mixture of 
enzyme and inhibitor were incubated together at 37oC for 15 mins.  The substrate was 
then added and the mixture was further incubated for 30 mins.  The reaction was 
stopped by the addition of 10% acetic acid solution.  The amount of 7-amino-4-
methyl-coumarin (-NHMec) 135 released was measured using a Perkin-Elmer 
fluorescence spectrophotometer with excitation at 370 nm and emission at 440 nm.  
The positive control contained only the enzyme extract and the substrate Z-Phe-Arg-
NHMec 134.  There were two negative controls used.  One contained the enzyme and 
inhibitor while the second contained just the inhibitor and the substrate.  All assays 
were performed in triplicate with the mean result being taken. 
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3.3 Biological Results 
 
The N-benzoyl-L-leucine-glycine nitrile scaffold has been shown to be an effective 
inhibitor of Fasciola hepatica cathepsin L endoproteases6,7.  The electrophilic nature 
of the nitrile moiety is believed to be crucial for the effectiveness of this compound as 
a potent protease inhibitor.  It is hoped that fluorination of the benzoyl N-terminus can 
increase the activity.  The inhibition displayed by the entire series of fluorinated 
derivatives were all in the low micromolar range, with the exception of the meta-
trifluoromethyl derivative.  The IC50 of this derivative was approximately 10-fold 
higher than the series average.  The most active analogue was 3,5-difluorobenzoyl-L-
leu-gly-CN 103 with an IC50 of 3.0 µM.  From the assays undertaken in this study it is 
clear that the addition of fluorine to the molecule has had a significant impact on the 
inhibition of cathepsin L.  From the calculated inhibitory concentrations, it is clear 
that the position and number of fluorine atoms on the benzoyl group has little effect 
on the activity of the molecule.  However, when compared to the non-fluorinated 
dipeptide, N-benzoyl-L-leucine-glycine (IC50 = 11 µM)6, the combination of fluorine 
substitution and conversion of the C-terminus to a nitrile, reduced the IC50 value.   
 
 
 
Compound X IC50 µM 
97 3-F 3.1 
98 2,3-F 3.4 
99 2,4-F 5.5 
100 2,5-F 3.1 
101 2,6-F 3.7 
102 3,4-F 3.1 
103 3,5-F 3.0 
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104 2,3,6-F 6.0 
105 2,3,4-F 4.1 
106 2,4,5-F 4.5 
107 3,4,5-F 3.4 
108 2,3,4,5-F 3.4 
109 Penta-F 4.4 
110 o-CF3 4.1 
111 m-CF3 29.1 
112 p-CF3 3.2 
 
Table 3.1: Inhibitory activity of N-fluorobenzoyl dipeptidyl 
nitrile derivatives 
 
The activity of Fasciola hepatica cysteine cathepsin L endoprotease against the 
substrate Z-Phe-Arg-NHMec 134 can be blocked by micromolar concentrations of the 
commercially available diazomethane Z-Phe-Ala-CHN2 318.  From the previous 
studies carried out in our laboratories, the IC50 of inhibitor 31 was found to be 3.0 
µM11, which is comparable to the inhibitory concentrations found for the majority of 
the N-fluorobenzoyl-L-leucine glycine nitrile derivatives, particularly compound 103.  
From the variable concentration assays preformed, it can be seen that the 
commercially available inhibitor 31 is more potent at lower concentrations up to about 
50% inhibition where inhibitors 97, 103 and 112 showed comparable results.  At 
higher concentrations, greater than 5 µM, the nitrile derivatives showed higher 
inhibition in contrast to the substrate Z-Phe-Arg-NHMec 134 towards Fasciola 
hepatica cysteine cathepsin L endoprotease.  A representative bar chart showing these 
values is displayed in Figure 3.1 
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Figure 3.1: Bar chart illustration of the % inhibition of compounds 31, 97, 103 and 112 
towards Fasciola hepatica cysteine cathepsin L endoprotease at varying concentration (µM) 
 
 To date, of the second series of modified N-terminal dipeptides, biological activity 
has been carried out on two of the compounds isolated.  Compounds 129 and 133 
were assayed again using the standard fluorometric assay mentioned previously using 
Z-Phe-Arg-NHMec 134 as substrate.  Dipeptide 129, cyclopentanoyl-L-leucine 
glycine nitrile showed comparable activity to that of the first series of fluorinated 
analogues and an IC50 value of 4.3 µM was calculated for the fluorescence readings.  
The second inhibitor assayed was the 1,2-benzoisothiazolin-3-one dipeptide 133.  The 
IC50 of this analogue was calculated to be 1.4 µM, which makes it the most 
biologically active compound tested.  Compounds 115-128 and 130-132 are set for 
assaying in the near future. 
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4.0 Conclusion  
 
In summary, we have identified potent inhibitors of the Fasciola hepatica liver fluke 
cathepsin L proteases with the two most successful derivatives being the nitrile 
compounds 103 and 133. From the protease inhibition results it is very clear that the 
presence of an electrophilic isostere adjacent to the P1 position is essential for 
effective inhibition.  However, it has been shown from the initial series of fluorinated 
analogues that the position of the isostere may not be of major importance to the 
activity of the inhibitor.  Further to this, the number of fluorine substituents attached 
to the N-terminal benzoyl group has little if any improvement on the biological 
activity.  Despite this, it is evident that almost all of the derivatives offer real 
inhibitory potency against Fasciola hepatica cysteine cathepsin L endoprotease.  It is 
hoped that with continuing testing, further improvement in bioactivity can be made.  
The inhibitory potency of the nitrile compounds N-3,5-difluorobenzoyl-L-leucine-
glycine nitrile 103 and 1,2-benzoisothiazolin-3-one-L-leucine-glycine nitrile 133 
relative to the commercial inhibitor Z-Phe-Ala-CHN2 31 shows that such benzoyl 
dipeptidyl derivatives may have a role to play as commercial inhibitors of Fasciola 
hepatica cathepsin L endoproteases. 
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5.0  Experimental 
 
All chemicals were purchased from Sigma-Aldrich, Lennox Chemicals or Fluorochem 
Limited; and used as received.  Commercial grade reagents were used without further 
purification procedures. When necessary all solvents were purified and dried; and 
stored under argon.  Tetrahydrofuran was distilled from Na/benzophenone and 
triethylamine distilled and stored over potassium hydroxide pellets.   Riedel-Haën 
silica gel was used for thin layer and column chromatography.  Melting point 
determinations were carried out using a Griffin melting point apparatus and are 
uncorrected.  Elemental Analysis was carried out by the Microanalytical Laboratory at 
Univeristy College Dublin.  Electrospray ionisation mass spectra were obtained on a 
Bruker Esquire 3000 series ion trap mass spectrometer.  IR spectra were obtained on a 
Perkin-Elmer Spectrum GX FT-IR system. NMR spectra were obtained on a Bruker 
AC 400 NMR spectrometer operating at 400 MHz for 1H NMR 376 MHz for 19F 
NMR and 100 MHz for 13C NMR.  The 1H and 13C NMR chemical shifts (δ) are 
relative to trimethylsilane and the 19F NMR chemical shifts (δ) are relative to 
trifluoroacetic acid.  All coupling constants (J) are in Hertz (Hz). 
 
General procedure for the synthesis of N-fluorobenzoyl dipeptides: 
N-3-fluorobenzoyl-L-leucine-glycine nitrile 97 
N-3-Fluorobenzoyl-L-leucine (2.59 g, 10.24mmol) 
was dissolved in dichloromethane (50ml) with 
glycine nitrile hydrochloride (0.95 g, 10.24 mmol), 
1-hydroxybenzotriazole (1.38 g, 10.24 mmol) and 
triethylamine (1.42 ml, 10.24 mmol). The mixture was cooled to 0 ˚C, and 1,3-
dicyclohexylcarbodiimide (2.11 g, 10.24 mmol) was added. After 30 min. the solution 
was raised to room temperature and the reaction was allowed to proceed for 48 hrs. 
The precipitated N,N-dicyclohexylurea was removed by filtration and the filtrate was 
washed with brine, sat. potassium hydrogen carbonate, 10% citric acid and dried over 
sodium sulphate. The solvent was evaporated in vacuo and isolation by column 
chromatography and recrystallisation from ethyl acetate/hexane furnished 97 as a 
white powder (1.72 g, 57%).  
m.p. 131-134 ˚C.  
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[α]D25 = -10.0° (c, 2.1, EtOH). 
Anal. calcd. for C15H18N3O2F1: C, 61.84; H, 6.23; N, 14.42.  
Found C, 61.88; H, 6.16; N, 14.35. 
IR (KBr): υ 3329, 2927, 2106, 1637, 1552, 1493, 1050, 842 cm-1. 
Mass Spectrum: {M+Na]+ found 314.1. 
C15H18N3O2F1Na1 requires 314.31. 
1H NMR (400 MHz, DMSO-d6): δ 8.75 (1H, t, J = 5.6 Hz, -NH-), 8.69-8.71 (1H, d, J 
= 8 Hz, -NH-), 7.72-7.79 (2H, m, -ArH 2 & 6), 7.51-7.56 (1H, m, -ArH 5), 7.40-7.43 
(1H, m, -ArH 4), 4.48-4.53 (1H, m, α-H),
 
4.14 (2H, d, J  = 5.6 Hz, -CH2-), 1.48-1.75 
(3H, m, -CH2- & -CH-), 0.91 (3H, d, J = 6.4 Hz, -CH3), 0.87 (3H, d, J = 6.4 Hz, -
CH3). 
13C NMR (100 MHz, DMSO-d6): δ 173.2 (-CONH-), 165.5 (-ArCO-), 163.45 (d, -
ArC 3), 136.5 (d, -ArC 1), 130.7 (d, -ArC 5), 124.2 (d, -ArC 6), 118.6 (d, -ArC 4), 
118.0 (-CN), 114.8 (d, -ArC 2), 52.0 (α-C), 40.3 (-CH2, -VE DEPT), 27.5 (-CH2, -VE 
DEPT), 24.8 (-CH), 23.4 (-CH3), 21.5 (-CH3). 
19F NMR (376 MHz, DMSO-d6): δ –36.94 - -37.01 (m). 
 
N-2,3-difluorobenzoyl-L-leucine-glycine nitrile 98 
N-2,3-difluorobenzoyl-L-leucine (1.33 g, 4.9 mmol) 
and glycine nitrile hydrochloride (0.45 g, 4.9 mmol) 
were used.  Isolation by column chromatography 
and recrystallisation from ethyl acetate/hexane 
furnished 98 as a white powder (0.73 g, 48%). 
m.p. 103-105 ˚C. 
[α]D25 = -13.0° (c, 2.1, EtOH). 
Anal. calcd. for C15H17N3O2F2: C, 58.25; H, 5.54; N, 13.59.  
Found C, 57.95; H, 5.52; N, 13.36. 
IR (KBr): υ 3280, 2928, 2198, 1637, 1548, 1483, 1272, 1050, 803 cm-1. 
Mass Spectrum: {M+Na]+ found 332.2. 
C15H18N3O2F1Na1 requires 332.3. 
1H NMR (400 MHz, DMSO-d6): δ 8.82-8.85 (1H, t, J = 5.4 Hz, -NH-), 8.74-8.76 (1H, 
d, J = 8 Hz, -NH-), 7.57-7.60 (1H, m, -ArH 6), 7.43-7.46 (1H, m, -ArH 5), 7.31-7.35 
(1H, m, -ArH 4), 4.53-4.55 (1H, m, α-H),
 
4.21 (2H, d, J  = 4 Hz, -CH2-), 1.49-1.82 
(3H, m, -CH2- & -CH-), 0.95 (6H, t, J = 8.4 Hz, -CH3). 
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13C NMR (100 MHz, DMSO-d6): δ 172.8 (-CONH-), 163.2 (-ArCO-), 151.2 (dd, -
ArC 3), 146.3 (dd, -ArC 2), 126.5 (d, -ArC 1), 125.5 (d, -ArC 4), 125.1 (d, -ArC 5), 
119.6 (d, -ArC 6), 117.9 (-CN), 51.8 (α-C), 40.5 (-CH2, -VE DEPT), 27.5 (-CH2, -VE 
DEPT), 24.6 (-CH-), 23.3 (-CH3), 21.6 (-CH3). 
19F NMR (376 MHz, DMSO-d6): δ –62.40 - -62.51 (m), -64.0 - -64.10 (m). 
 
N-2,4-difluorobenzoyl-L-leucine-glycine nitrile 99 
N-2,4-difluorobenzoyl-L-leucine (1.47 g, 5.4 mmol) 
and glycine nitrile hydrochloride (0.5 g, 5.4 mmol) 
were used.  Isolation by column chromatography 
and recrystallisation from ethyl acetate/hexane 
furnished 99 as a white powder (1.1 g, 66%). 
m.p. 108-111 ˚C. 
[α]D25 = -10.9° (c, 2.1, EtOH). 
Anal. calcd. for C15H17N3O2F2: C, 58.25; H, 5.54; N, 13.59.  
Found C, 57.96; H, 5.50; N, 13.37. 
IR (KBr): υ 3201, 2987, 2110, 1640, 1507, 1301, 1089, 775 cm-1. 
Mass Spectrum: {M+Na]+ found 332.2. 
C15H18N3O2F1Na1 requires 332.3. 
1H NMR (400 MHz, DMSO-d6): δ 8.77-8.79 (1H, t, J = 4 Hz, -NH-), 8.50-8.52 (1H, 
d, J = 9.2 Hz, -NH-), 7.71-7.73 (1H, m, -ArH 6), 7.31-7.40 (1H, m, -ArH 5), 7.17-7.25 
(1H, m, -ArH 3), 4.45-4.55 (1H, m, α-H),
 
4.17 (2H, d, J  = 5.2 Hz, -CH2-), 1.46-1.78 
(3H, m, -CH2- & -CH-), 0.91 (6H, t, J = 6.8 Hz, -CH3). 
13C NMR (100 MHz, DMSO-d6): δ 172.9 (-CONH-), 163.4 (d, -ArC 4), 162.5 (-
ArCO-), 158.9 (dd, -ArC 2), 132.4 (dd, -ArC 6), 120.8 (dd, -ArC 1), 117.9 (-CN), 
111.8 (dd, -ArC 3), 104.7 (t, -ArC 5), 51.8 (α-C), 40.6 (-CH2, -VE DEPT), 27.5 (-
CH2, -VE DEPT), 24.6 (-CH-), 23.3 (-CH3), 21.6 (-CH3). 
19F NMR (376 MHz, DMSO-d6): δ –30.29 - -30.38 (m), -32.90 - -32.98 (m). 
 
N-2,5-difluorobenzoyl-L-leucine-glycine nitrile 100 
N-2,5-difluorobenzoyl-L-leucine (2.1 g, 7.75 mmol) 
and glycine nitrile hydrochloride (0.72 g, 7.75 mmol) 
were used.  Isolation by column chromatography and 
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recrystallisation from ethyl acetate/hexane furnished 100 as a white powder (1.43 g, 
60%). 
m.p. 101-104 ˚C. 
[α]D25 = -9.3° (c, 2.1, EtOH). 
Anal. calcd. for C15H17N3O2F2: C, 58.25; H, 5.54; N, 13.59.  
Found C, 58.28; H, 5.56; N, 13.40. 
IR (KBr): υ 3290, 2911, 2102, 1651, 1437, 1078, 985m-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.75-8.78 (1H, t, J = 5.6 Hz, -NH-), 8.62-8.64 (1H, 
d, J = 7.6 Hz, -NH-), 7.36-7.46 (3H, m, -ArH 3,4 & 6), 4.46-4.8 (1H, m, α-H),
 
4.17 
(2H, d, J  = 5.6 Hz, -CH2-), 1.60-1.68 (3H, m, -CH2- & -CH-), 0.91 (6H, t, J = 6.4 Hz, 
-CH3). 
13C NMR (100 MHz, DMSO-d6): δ 172.3 (-CONH-), 162.7 (-ArCO-), 157.5 (d, -ArC 
2), 155.5 (d, -ArC 5), 125.1 (dd, -ArC 1), 118.9 (dd, -ArC 6), 117.9 (dd, -ArC 3), 
117.5 (-CN), 116.3 (dd, -ArC 4), 51.5 (α-C), 39.9 (-CH2, -VE DEPT), 27.1 (-CH2, -
VE DEPT), 24.2 (-CH-), 22.9 (-CH3), 21.3 (-CH3). 
19F NMR (376 MHz, DMSO-d6): δ –42.38 - -42.48 (m), -43.38 - -43.45 (m). 
 
N-2,6-difluorobenzoyl-L-leucine-glycine nitrile 101 
N-2,6-difluorobenzoyl-L-leucine (2.23 g, 8.23 mmol) 
and glycine nitrile hydrochloride (0.76 g, 8.23 mmol) 
were used.  Isolation by column chromatography and 
recrystallisation from ethyl acetate/hexane furnished 
101 as a white powder (0.98 g, 39%). 
m.p. 159-163 ˚C. 
[α]D25 = -20.3° (c, 2.1, EtOH). 
Anal. calcd. for C15H17N3O2F2: C, 58.25; H, 5.54; N, 13.59.  
Found C, 58.18; H, 5.49, N, 13.51. 
IR (KBr): υ 3190, 2875, 2055, 1675, 1688, 1402, 1075, 626 cm-1. 
Mass Spectrum: {M+Na]+ found 332.1 
C15H18N3O2F1Na1 requires 332.3. 
1H NMR (400 MHz, DMSO-d6): δ 9.03-9.01 (1H, d, J = 8.4 Hz, -NH-), 8.85-8.88 
(1H, t, J = 5.6 Hz, -NH-),  7.10-7.55 (1H, m, -ArH 4), 7.13-7.17 (2H, m, -ArH 3 & 5), 
4.40-4.57 (1H, m, α-H),
 
4.18 (2H, d, J  = 2.4 Hz, -CH2-), 1.41-1.78 (3H, m, -CH2- & -
CH-), 0.91 (3H, d, J = 4.4 Hz, -CH3), 0.89 (3H, d, J = 4.4 Hz, -CH3). 
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13C NMR (100 MHz, DMSO-d6): δ 172.5 (-CONH-), 160.45 (d, -ArC 2), 159.96 (-
ArCO-), 157.95 (d, -ArC 6), 131.91 (-ArC 4), 117.9 (-CN), 115.5 (t, -ArC 1), 112.1 
(dd, -ArC 3 & 5), 51.5 (α-C), 40.8 (-CH2, -VE DEPT), 27.4 (-CH2, -VE DEPT), 24.5 
(-CH-), 23.3 (-CH3), 21.6 (-CH3). 
19F NMR (376 MHz, DMSO-d6): δ –37.54 - -37.58 (m). 
 
N-3,4-difluorobenzoyl-L-leucine-glycine nitrile 102 
N-3,4-difluorobenzoyl-L-leucine (2.3 g, 8.5 mmol) 
and glycine nitrile hydrochloride (0.79 g, 8.5 mmol) 
were used.  Isolation by column chromatography 
and recrystallisation from ethyl acetate/hexane 
furnished 102 as a white powder (0.52 g, 20%). 
m.p. 139-142 ˚C. 
[α]D25 = -19.6° (c, 2.1, EtOH). 
Anal. calcd. for C15H17N3O2F2: C, 58.25; H, 5.54; N, 13.59.  
Found C, 58.05; H, 5.51; N, 13.29. 
IR (KBr): υ 3198, 2654, 2063, 1641, 1567, 1246, 1098, 803 cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.76-8.82 (1H, t, J = 11.4 Hz, -NH-), 8.71-8.73 
(1H, d, J = 7.7 Hz, -NH-), 7.97-8.00 (1H, m, -ArH 6), 7.81-7.84 (1H, m, -ArH 2), 
7.54-7.61 (1H, m, -ArH 5), 4.47-4.52 (1H, m, α-H),
 
4.14 (2H, d, J  = 5.6 Hz, -CH2-), 
1.59-1.75 (3H, m, -CH2- & -CH-), 0.91 (3H, d, J = 6.4 Hz, -CH3), 0.86 (3H, d, J = 6.4 
Hz, -CH3). 
13C NMR (100 MHz, DMSO-d6): δ 173.1 (-CONH-), 164.64 (-ArCO-), 153.0 & 
150.64 (dd, -ArC 4), 150.52 & 148.16 (dd, -ArC 3), 131.55 (t -ArC 1), 125.52 (dd, -
ArC 2), 117.9 (-CN), 117.8 (d, -ArC 5), 117.3 (d, -ArC 6), 52.0 (α-C), 40.3 (-CH2, -
VE DEPT), 27.5 (-CH2, -VE DEPT), 24.7 (-CH-), 23.3 (-CH3), 21.5 (-CH3). 
19F NMR (376 MHz, DMSO-d6): δ –58.33 - -58.41 (m), –62.09 - -62.20 (m). 
 
N-3,5-difluorobenzoyl-L-leucine-glycine nitrile 103 
N-3,5-difluorobenzoyl-L-leucine (2.3 g, 8.5 mmol) 
and glycine nitrile hydrochloride (0.79 g, 8.5 mmol) 
were used.  Isolation by column chromatography 
and recrystallisation from ethyl acetate/hexane 
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furnished 103 as a white powder (0.62 g, 22%). 
m.p. 150-153 ˚C. 
[α]D25 = -16.0° (c, 2.1, EtOH). 
Anal. calcd. for C15H17N3O2F2: C, 58.25; H, 5.54; N, 13.59.  
Found C, 58.94; H, 5.37; N, 12.83. 
IR (KBr): υ 3281, 2967, 2146, 1641, 1543, 1298, 1023, 754 cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.78-8.80 (2H, m, -NH- ), 7.64-7.67 (2H, m, -ArH 
2 & 6), 7.53-7.45 (1H, m, -ArH 4), 4.47-4.53 (1H, m, α-H),
 
4.14 (2H, d, J  = 5.6 Hz, -
CH2-), 1.55-1.74 (3H, m, -CH2- & -CH-), 0.91 (3H, d, J = 6.4 Hz, -CH3), 0.87 (3H, d, 
J = 6.4 Hz, -CH3). 
 
13C NMR (100 MHz, DMSO-d6): δ 172.99 (-CONH-), 164.27 (-ArCO-), 163.73 (d, -
ArC 3), 161.27 (d, -ArC 5), 137.62 (t, -ArC 1), 117.94 (-CN), 111.35 (dd, -ArC 2 & 
5), 107.22 (t, -ArC 4), 52.1 (α-C), 40.2 (-CH2, -VE DEPT), 27.5 (-CH2, -VE DEPT), 
24.7 (-CH-), 23.3 (-CH3), 21.5 (-CH3). 
19F NMR (376 MHz, DMSO-d6): δ –32.61 - -32.68 (m). 
 
N-2,3,6-trifluorobenzoyl-L-leucine-glycine nitrile 104 
N-2,3,6-trifluorobenzoyl-L-leucine (1.05 g, 3.63 
mmol) and glycine nitrile hydrochloride (0.34 g, 
3.63 mmol) were used.  Isolation by column 
chromatography and recrystallisation from ethyl 
acetate/hexane furnished 104 as a white powder (0.28 g, 24%). 
m.p. 157-160 ˚C. 
[α]D25 = -27.2° (c, 2.1, EtOH). 
Anal. calcd. for C15H16N3O2F3: C, 55.05; H, 4.93; N, 12.84.  
Found C, 55.13; H, 4.98, N, 12.67. 
IR (KBr): υ 3276, 2961, 2252, 1660, 1541, 1492, 1025, 814 cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 9.13-9.15 (1H, d, J = 8.2 Hz, -NH-), 8.90-8.93 
(1H, t, J = 11.8 Hz, -NH-), 7.55-7.64 (1H, m, -ArH 4), 7.18-7.24 (1H, m, -ArH 5), 
4.51-4.57 (1H, m, α-H),
 
4.20 (2H, d, J  = 3.2 Hz, -CH2-), 1.41-1.78 (3H, m, -CH2- & -
CH-), 0.91 (3H, d, J = 5.4Hz, -CH3), 0.89 (3H, d, J = 5.4Hz, -CH3). 
13C NMR (100 MHz, DMSO-d6): δ 172.3 (-CONH-), 158.77 (-ArCO-), 154.5 (d, -
ArC 2), 147.9 (d, -ArC 6), 145.4 (t, -ArC 3), 118.70 (dd, -ArC 4), 117.87 (-CN), 
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117.0 (t, -ArC 1), 112.4 (d, -ArC 5), 51.5 (α-C), 40.8 (-CH2, -VE DEPT), 27.4 (-CH2, 
-VE DEPT), 24.5 (-CH-), 23.2 (-CH3), 21.6 (-CH3). 
19F NMR (376 MHz, DMSO-d6): δ –42.18 - -42.25 (m), –61.096- -61.18 (m), –66.48 - 
-66.62 (m). 
 
N-2,3,4-trifluorobenzoyl-L-leucine-glycine nitrile 105 
N-2,3,4-trifluorobenzoyl-L-leucine (1.17 g, 4 mmol) 
and glycine nitrile hydrochloride (0.37 g, 4 mmol) 
were used.  Isolation by column chromatography 
and recrystallisation from ethyl acetate/hexane 
furnished 105 as a white powder (0.58 g, 44%). 
m.p. 116-119 ˚C. 
[α]D25 = -4.2° (c, 2.1, EtOH). 
Anal. calcd. for C15H16N3O2F3: C, 55.05; H, 4.93; N, 12.84.  
Found. C, 54.43; H, 5.95; N, 12.58. 
IR (KBr): υ 3287, 2964, 2249, 1657, 1547, 1496, 1045, 828 cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.85-8.87 (1H, t, J = 5.6 Hz, -NH-), 8.75-8.77 (1H, 
d, J = 8 Hz, -NH-),  7.41-7.55 (2H, m, -ArH 5 & 6), 4.52-4.56 (1H, m, α-H),
 
4.21 (2H, 
d, J  = 5.6 Hz, -CH2-), 1.51-1.75 (3H, m, -CH2- & -CH-), 0.96 (3H, d, J = 6.4 Hz, -
CH3), 0.92 (3H, d, J = 6.4 Hz, -CH3). 
 
13C NMR (100 MHz, DMSO-d6): δ 172.7 (-CONH-), 162.53 (-ArCO-), 150.46-
153.02 (dd, -ArC 4), 147.46-150.09 (dd –ArC 2), 137.91-140.70 (dt, -ArC 3), 125.02 
(dd, -ArC 5), 122.24 (t, -ArC 1), 117.89 (-CN), 113.02 (dd, -ArC 6), 51.8 (α-C), 40.5 
(-CH2, -VE DEPT), 27.5 (-CH2, -VE DEPT), 24.6 (-CH-), 23.3 (-CH3), 21.6 (-CH3). 
19F NMR (376 MHz, DMSO-d6): δ –55.67 - -55.79 (m), –58.916- -59.02 (m), –84.95 - 
-85.08 (m). 
 
N-2,4,5-trifluorobenzoyl-L-leucine-glycine nitrile 106 
N-2,4,5-trifluorobenzoyl-L-leucine (1.94 g, 6.7 
mmol) and glycine nitrile hydrochloride (0.62 g, 6.7 
mmol) were used.  Isolation by column 
chromatography and recrystallisation from ethyl 
acetate/hexane furnished 106 as a white powder 
(1.20 g, 55%). 
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m.p. 104-108 ˚C. 
[α]D25 = -5.1° (c, 2.1, EtOH). 
Anal. calcd. for C15H16N3O2F3: C, 55.05; H, 4.93; N, 12.84.  
Found C, 54.75; H, 4.90, N, 12.63. 
IR (KBr): υ 3282, 2959, 2261, 1657, 1537, 1465, 1031, 824 cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.81-8.84 (1H, t, J = 5.4 Hz, -NH-), 8.65-8.67 (1H, 
d, J = 8 Hz, -NH-), 7.68-7.80 (2H, m, -ArH 3 & 6), 4.50-4.53 (1H, m, α-H),
 
4.20 (2H, 
d, J  = 5.6 Hz, -CH2-), 1.55-1.73 (3H, m, -CH2- & -CH-), 0.95 (6H, t, J = 6.4 Hz, -
CH3). 
 
13C NMR (100 MHz, DMSO-d6): δ 172.7 (-CONH-), 162.3 (-ArCO-), 154.05-156.55 
(dd, -ArC 2), 149.61-151.98 (dd –ArC 5), 144.85-147.22 (dd, -ArC 4), 120.85 (d, -
ArC 1), 118.55 (d, -ArC 6), 117.90 (-CN), 107.20 (dd, -ArC 3), 51.9 (α-C), 40.6 (-
CH2, -VE DEPT), 27.5 (-CH2, -VE DEPT), 24.6 (-CH-), 23.3 (-CH3), 21.6 (-CH3). 
19F NMR (376 MHz, DMSO-d6): δ –37.97 - -38.07 (m), –54.57- -54.70 (m), –66.76 - 
-66.90 (m). 
 
N-3,4,5-trifluorobenzoyl-L-leucine-glycine nitrile 107 
N-3,4,5-trifluorobenzoyl-L-leucine (2 g, 7 mmol) 
and glycine nitrile hydrochloride (0.65 g, 7 mmol) 
were used.  Isolation by column chromatography 
and recrystallisation from ethyl acetate/hexane 
furnished 107 as a white powder (1.20 g, 52%). 
m.p. 146-149 ˚C. 
[α]D25 = -0.2° (c, 2.1, EtOH). 
Anal. calcd. for C15H16N3O2F3: C, 55.05; H, 4.93; N, 12.84.  
Found C, 54.83; H, 4.87, N, 12.73. 
IR (KBr): υ 3247, 2943, 2253, 1653, 1529, 1476, 1040, 794 cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.77-8.81 (2H, m, -NH-), 7.87-7.91 (2H, m, -ArH 
2 & 6), 4.45-4.52 (1H, m, α-H),
 
4.14 (2H, d, J  = 6 Hz, -CH2-), 1.53-1.73 (3H, m, -
CH2- & -CH-), 0.91 (3H, d, J = 6.0 Hz, -CH3), 0.87 (3H, d, J = 6.0 Hz, -CH3). 
 
13C NMR (100 MHz, DMSO-d6): δ 172.9 (-CONH-), 163.6 (-ArCO-), 149.05-151.59 
(dd, -ArC 3 & 6), 139.94-142.47 (dt –ArC 4), 130.43 (-ArC 1), 117.91 (-CN), 112.93-
113.14 (dd, -ArC 2 &6), 52.2 (α-C), 40.3 (-CH2, -VE DEPT), 27.5 (-CH2, -VE 
DEPT), 24.7 (-CH-), 23.3 (-CH3), 21.5 (-CH3). 
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19F NMR (376 MHz, DMSO-d6): δ–58.22 - -58.30 (m), –80.76 - -80.91 (m). 
 
N-2,3,4,5-tetrafluorobenzoyl-L-leucine-glycine nitrile 108 
N-2,3,4,5-tetrafluorobenzoyl-L-leucine (1.54 g, 5 
mmol) and glycine nitrile hydrochloride (0.46 g, 5 
mmol) were used.  Isolation by column 
chromatography and recrystallisation from ethyl 
acetate/hexane furnished 108 as a white powder (0.72 
g, 42%). 
m.p. 97-101 ˚C. 
[α]D25 = -2.2° (c, 2.1, EtOH). 
Anal. calcd. for C15H15N3O2F4: C, 52.18; H, 4.38; N, 12.17.  
Found C, 52.02; H, 4.33, N, 12.06. 
IR (KBr): υ 3294, 2962, 2252, 1648, 1521, 1482, 1361, 1238, 1031, 881 cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.80-8.84 (2H, m, -NH-), 7.61-7.63 (1H, m, -ArH 
6), 4.44-4.50 (1H, m, α-H),
 
4.17 (2H, d, J  = 5.6 Hz, -CH2-), 1.48-1.73 (3H, m, -CH2- 
&
 
-CH-), 0.92 (3H, d, J = 6.4 Hz, -CH3), 0.89 (3H, d, J = 6.4 Hz, -CH3). 
 
13C NMR (100 MHz, DMSO-d6): δ 172.5 (-CONH-), 161.5 (-ArCO-), 146.38-147.48 
(d, -ArC 2),144.00-145.00 (d, -ArC 5), 141.53-142.48 (d, -ArC 4), 138-91-139.95 (d, 
-ArC 3), 120.64 (-ArC 1), 117.87 (-CN), 112.13 (d, -ArC 6), 51.9 (α-C), 40.6 (-CH2, -
VE DEPT), 27.5 (-CH2, -VE DEPT), 24.6 (-CH-), 23.3 (-CH3), 21.6 (-CH3). 
19F NMR (376 MHz, DMSO-d6): δ–63.08 - -63.34 (2F m), –76.97 - -77.12 (1F m), –
79.43 - -79.54 (1F t). 
 
N-2,3,4,5,6-pentafluorobenzoyl-L-leucine-glycine nitrile 109 
N-2,3,4,5,6-pentafluorobenzoyl-L-leucine (1.52 g, 6.6 
mmol) and glycine nitrile hydrochloride (0.6 g, 6.6 
mmol) were used.  Isolation by column 
chromatography and recrystallisation from ethyl 
acetate/hexane furnished 109 as a white powder (1.20 
g, 51%). 
m.p. 131-133 ˚C. 
[α]D25 = -13.0° (c, 2.1, EtOH). 
Anal. calcd. for C15H14N3O2F5: C, 49.60; H, 3.88; N, 11.57.  
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Found C, 49.70; H, 3.87, N, 11.40. 
IR (KBr): υ 3265, 3077, 2962, 2252, 1654, 1554, 1521, 1343, 1115, 991 cm-1. 
Mass Spectrum: {M+Na+] found 386.1. 
C15H14N3O2F5Na1 requires 386.29 
1H NMR (400 MHz, DMSO-d6): δ 9.26-9.28 (1H, d, J  = 7.2 Hz, -NH-), 8.96-8.99 
(1H, t, J  = 5.6 Hz, -NH-), 4.51-4.57 (1H, m, α-H),
 
4.20 (2H, d, J  = 2.8 Hz, -CH2-), 
1.60-1.68 (3H, m, -CH2- & -CH-), 0.92 (6H, t, J = 6.8 Hz, -CH3). 
 
13C NMR (100 MHz, DMSO-d6): δ 172.1 (-CONH-), 156.9 (-ArCO-), 135.95, 
138.41, 142.19, 142.72, 144.69 (m, –ArC 2,3,4,5,6), 117.81 (-CN), 112.6 (t, -ArC 1), 
51.7 (α-C), 40.8 (-CH2, -VE DEPT), 27.4 (-CH2, -VE DEPT), 24.5 (-CH-), 23.2 (-
CH3), 21.5 (-CH3). 
19F NMR (376 MHz, DMSO-d6): δ–65.65 - -66.11 (2F, m), –76.99 - -77.11 (1F, m), –
85.50 - -86.71 (2F, m). 
 
N-2-trifluoromethylbenzoyl-L-leucine-glycine nitrile 110 
N-2-trifluoromethylbenzoyl-L-leucine (2.27 g, 7.5 
mmol) and glycine nitrile hydrochloride (0.70 g, 7.5 
mmol) were used.  Isolation by column chromatography 
and recrystallisation from ethyl acetate/hexane 
furnished 110 as a white powder (1.30 g, 51%). 
m.p. 163-166 ˚C. 
[α]D25 = -4.0° (c, 2.1, EtOH). 
Anal. calcd. for C16H18N3O2F3: C, 56.30; H, 5.32; N, 12.31.  
Found C, 56.07; H, 5.28; N, 12.17. 
IR (KBr): υ 3292, 2958, 2247, 1642, 1547, 1341, 1283, 1173, 1121, 1068, 692 cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.79-8.81 (1H, d, J = 8 Hz, -NH-), 8.75-8.77 (1H, 
t, J = 5.6 Hz, -NH-), 7.73-7.79 (2H, m, -ArH 4 & 5), 7.66-7.68 (1H, d, J = 7.6 Hz, -
ArH 3), 7.58-7.60 (1H, d, J = 7.2 Hz, -ArH 6), 4.41-4.55 (1H, m, α-H),
 
4.19 (2H, d, J  
= 5.6 Hz, -CH2-), 1.44-1.79 (3H, m, -CH2- & -CH-), 0.91 (3H, d, J = 2.8 Hz, -CH3), 
0.90 (3H, d, J = 2.8 Hz, -CH3). 
13C NMR (100 MHz, DMSO-d6): δ 172.9 (-CONH-), 167.5 (-ArCO-), 136.2 (-ArC 1) 
132.6 (-ArC 6), 130.2 (-ArC 4), 129.2 (-ArC 3), 126.5 (t, -ArC 5), 125.4-126.2 (d, -
ArC 2), 122.7 (d, -CF3),  117.9 (-CN), 51.6 (α-C), 40.4 (-CH2, -VE DEPT), 27.5 (-
CH2, -VE DEPT), 24.5 (-CH-), 23.3 (-CH3), 21.4 (-CH3). 
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19F NMR (376 MHz, DMSO-d6): δ +18.08 (3F) 
 
N-3-trifluoromethylbenzoyl-L-leucine-glycine nitrile 111 
N-3-trifluoromethylbenzoyl-L-leucine (2.27 g, 7.5 
mmol) and glycine nitrile hydrochloride (0.70 g, 
7.5 mmol) were used.  Isolation by column 
chromatography and recrystallisation from ethyl 
acetate/hexane furnished 111 as a white powder 
(0.9 g, 36%). 
m.p. 104-107 ˚C. 
[α]D25 = -33.5° (c, 2.1, EtOH). 
Anal. calcd. for C16H18N3O2F3: C, 56.30; H, 5.32; N, 12.31.  
Found C, 56.21; H, 5.34; N, 12.11. 
IR (KBr): υ 3295, 2962, 2246, 1637, 1540, 1333, 1278, 1178, 1119, 1073, 696 cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.94-8.96 (1H, d, J = 7.4 Hz, -NH-), 8.82-8.85 
(1H, t, J = 5.6 Hz, -NH-), 8.33 (1H, -ArH 2), 8.26-8.27 (1H, d, J = 7.6 Hz, -ArH 4), 
7.94-7.96 (1H, d, J = 8 Hz, -ArH 6), 7.75-7.79 (1H, t, J = 7.6 Hz, -ArH 5), 4.55-4.62 
(1H, m, α-H),
 
4.19 (2H, d, J  = 5.6 Hz, -CH2-), 1.58-1.82 (3H, m, -CH2- & -CH-), 0.95 
(3H, d, J = 6.4 Hz, -CH3), 0.91 (3H, d, J = 6.4 Hz, -CH3). 
13C NMR (100 MHz, DMSO-d6): δ 173.1 (-CONH-), 165.4 (-ArCO-), 135.05(-ArC 
1), 132.2 (-ArC 4), 129.9 (-ArC 5), 129.4 (d, -ArC 3), 128.3 (d, -ArC 6), 124.55 (d, -
ArC 2),123.0 (-CF3), 117.9 (-CN), 52.0 (α-C), 40.3 (-CH2, -VE DEPT), 27.5 (-CH2, -
VE DEPT), 24.7 (-CH-), 23.3 (-CH3), 21.5 (-CH3). 
19F NMR (376 MHz, DMSO-d6): δ +14.94 (3F). 
 
N-4-trifluoromethylbenzoyl-L-leucine-glycine nitrile 112 
N-4-trifluoromethylbenzoyl-L-leucine (1.52 g, 5 
mmol) and glycine nitrile hydrochloride (0.46 g, 5 
mmol) were used.  Isolation by column 
chromatography and recrystallisation from ethyl 
acetate/hexane furnished 112 as a white powder 
(0.5 g, 28%). 
m.p. 153-157 ˚C. 
[α]D25 = -26.0° (c, 2.1, EtOH). 
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Anal. calcd. for C13H18N3O2S: C, 55.69; H, 6.47; N, 14.99.  
Found C, 55.37; H, 6.09; N, 14.86. 
IR (KBr): υ 3291, 2968, 2249, 1635, 1544, 1335, 1281, 1176, 1112, 1074, 691 cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.90-8.92 (1H, d, J = 8 Hz, -NH-), 8.82-8.85 (1H, 
t, J = 5.6 Hz, -NH-), 8.16 (2H, d, J = 8 Hz, -ArH 2 & 6), 7.91 (2H, d, J = 8.4 Hz, -ArH 
3 & 5), 4.54-4.63 (1H, m, α-H),
 
4.19 (2H, d, J  = 5.6 Hz, -CH2-), 1.57-1.83 (3H, m, -
CH2- & -CH-), 0.96 (3H, d, J = 6.4 & 17.2 Hz, -CH3), 0.92 (3H, d, J = 6.4 & 17.2 Hz, 
-CH3). 
13C NMR (100 MHz, DMSO-d6): δ 173.1 (-CONH-), 165.7 (-ArCO-), 137.99 (-ArC 
1), 131.62 (d, -ArC 4), 128.89 (-ArC 2 & 6), 125.6 (q, -ArC 3 & 5), 122.9 (-CF3), 
117.9 (-CN), 52.0 (α-C), 40.3 (-CH2, -VE DEPT), 27.5 (-CH2, -VE DEPT), 24.8 (-
CH-), 23.3 (-CH3), 21.5 (-CH3). 
19F NMR (376 MHz, DMSO-d6): δ +14.71 (3F) 
 
General procedure for the synthesis of N-substituted dipeptides: 
L-leucine-glycine nitrile 114 
N-(9-Fluorenylmethoxycarbonyl)-L-leucine-glycine nitrile 130 
(2.0g, 4.76 mmol) was dissolved in anhydrous tetrahydrofuran 
(20mls).  To this solution, 20mls of 10% piperidine in 
anhydrous THF was added under argon.  The solution was 
stirred for 2 hours with repeated TLC monitoring.  The piperidine/THF solution was 
removed under vacuum to yield yellow and white residues. These residues were taken 
up in diethyl ether and repeatedly washed with hexane to remove white FMOC by-
product.  Solvent was removed to yield 114, as a yellow thick oil (0.74g, 90%). 
1H NMR (400 MHz, CDCl3): δ 7.93 (1H, s, -NH-), 4.12-4.14 (2H, d, J = 6.14 Hz, -
CH2-), 3.38-3.41 (1H, d, J = 12 Hz, α-H), 1.65-1.69 (2H, m, -CH2-), 1.49 (2H, s, -
NH2) 1.26-1.31 (1H, m, -CH-), 0.91 (3H, d, J = 3.1 Hz, -CH3), 0.87 (3H, d, J = 3.1 
Hz, -CH3).  
 
N-benzoyl-L-leucine-glycine nitrile 115 
Benzoyl-L-leucine (1.57 g, 6.7 mmol) and glycine 
nitrile hydrochloride (0.6 g, 6.7 mmol) were used.  
Isolation by column chromatography and 
recrystallisation from ethyl acetate/hexane furnished 
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115 as a white powder (1.50 g, 82%). 
m.p. = 165-167 oC 
[α]D25 = -2.2° (c, 2.1, EtOH). 
Anal. calcd. for C15H19N3O2: C, 65.91; H, 7.00; N, 15.37.  
Found C, 65.89; H, 7.06; N, 15.23. 
IR (KBr): υ 3283, 3190, 3046, 2957, 1157, 1657, 1635, 1540, 1253, 1039, 694, 657 
cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.71-8.74 (1H, t, J = 5.5 Hz, -NH-), 8.58-8.60 (1H, 
d, J = 8 Hz, -NH-), 7.91-7.93 (2H, d, J = 8.4 Hz, -ArH 2 & 6), 7.53-7.55 (1H, t, J = 4 
Hz, -ArH 4), 7.45-7.49 (2H, t, J = 7.8 Hz, -ArH 3 & 5) 4.48-4.55 (1H, m, α-H),
 
4.13 
(2H, d, J  = 5.2 Hz, -CH2-), 1.53-1.76 (3H, m, -CH2- & -CH-), 0.92 (3H, d, J = 6.4 Hz, 
-CH3), 0.86 (3H, d, J = 6.4 Hz, -CH3). 
13C NMR (100 MHz, DMSO-d6): δ 173.4 (-CONH-), 166.8 (-ArCO-), 134.2 (-ArC 1), 
131.7 (-ArC 4), 128.5 (-ArC 2 & 6), 128.0 (-ArC 3 & 5), 118.0 (-CN), 51.8 (α-C), 
40.3 (-CH2, -VE DEPT), 27.5 (-CH2, -VE DEPT), 24.8 (-CH-), 22.4 (-CH3), 21.6 (-
CH3). 
 
N-2-naphthoyl-L-leucine glycine nitrile 116 
L-leucine-glycine nitrile (0.75 g, 4.4 mmol) was 
dissolved in dichloromethane (40ml) with 2-
naphthoic acid (0.42 g, 3 mmol). Isolation by 
column chromatography and recrystallisation from 
acetone/hexane furnished 116 as a white powder 
(0.65 g, 74%). 
m.p. = 185-188 oC 
[α]D25 = -0.6° (c, 2.1, EtOH). 
Anal. calcd. for C19H21N3O2 C, 70.27; H, 6.55; N, 12.99.  
Found C, 70.27; H, 6.54; N, 12.84. 
IR (KBr): υ 3341, 3238, 2957, 2241, 1648, 1642, 1537, 1315, 1302, 912, 839, 787, 
681 cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.76-8.81 (2H, m, -NH-), 8.55 (1H, s, -ArH 1), 
7.98-8.06 (4H, m, -ArH 3,4,5 & 8), 7.59-7.65 (2H, m, -ArH 6 & 7), 4.56-4.62 (1H, m, 
α-H),
 
4.16 (2H, d, J  = 5.6 Hz, -CH2-), 1.56-1.82 (3H, m, -CH2- & -CH-), 0.95 (3H, d, 
J  = 6.4 Hz, -CH3), 0.89 (3H, d, J  = 6.4 Hz, -CH3). 
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13C NMR (100 MHz, DMSO-d6): δ 173.0 (-CONH-), 166.5 (-ArCO-), 134.2 (-ArC 2), 
132.0 & 131.2 (–ArC 9 & 10)*, 128.8, 127.9, 127.6, 124.5 (-ArC 3,4,5 & 8)*, 127.7 (-
ArC 1), 127.6, 126.7 (-ArC 6 & 7)*, 117.6 (-CN), 51.6 (α-C), 40.0 (-CH2, -VE 
DEPT), 27.1 (-CH2, -VE DEPT), 24.4 (-CH-), 23.0 (-CH3), 21.2 (-CH3). 
*carbons individually unassignable 
 
N-2-pryidinoyl-L-leucine-glycine nitrile 117 
L-leucine-glycine nitrile (0.9 g, 5.3 mmol) and 2-
picolinic acid (0.65 g, 5.3 mmol) were used.  Isolation 
by column chromatography and recrystallisation from 
ethyl acetate/hexane furnished 117 as a white powder 
(0.68 g, 47%). 
m.p. = 109-112 oC 
[α]D25 = -1.4° (c, 2.1, EtOH). 
Anal. calcd. for C14H18N4O2 C, 61.30; H, 6.61; N, 20.42.  
Found C, 61.05; H, 6.58; N, 20.14. 
IR (KBr): υ 3406, 3391, 3294, 3054, 2983, 2957, 2931, 2875, 2243, 1684, 1667, 
1509, 1465, 1483, 1349, 1000, 822, 751, 695 cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.83-8.86 (1H, t, J = 5.6 Hz, -NH-), 8.70-8.73 (1H, 
d, J = 8.8 Hz, -NH-), 8.68-8.70 (2H, d, -ArH 6), 8.00-8.07 (2H, m, -ArH 3 & 4), 7.62-
7.66 (1H, t, -ArH 5), 4.56-4.62 (1H, m, α-H),
 
4.15 (2H, d, J  = 5.6 Hz, -CH2-), 1.56-
1.76 (3H, m, -CH2- & -CH-), 0.90 (6H, t, J = 5.6 Hz, -CH3). 
 
13C NMR (100 MHz, DMSO-d6): δ 172.4 (-CONH-), 163.6 (-ArCO-), 149.3 (-ArC 
2), 148.5 (–ArC 6), 137.9 (-ArC 4), 126.8 (-ArC 5), 122.0 (-ArC 3), 117.5 (-CN), 51.0 
(α-C), 40.8 (-CH2, -VE DEPT), 27.1 (-CH2, -VE DEPT), 24.4 (-CH-), 22.9 (-CH3), 
21.5 (-CH3). 
 
N-2-furoyl-L-leucine glycine nitrile 118 
L-leucine-glycine nitrile (0.4 g, 2.4 mmol) was 
dissolved in dichloromethane (40ml) with 2-furoic acid 
(0.27 g, 2.4 mmol). Isolation by column 
chromatography and recrystallisation from 
acetone/hexane furnished 118 as a white powder (0.4 g, 60%). 
m.p. = 107-109 oC 
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[α]D25 = -13.6° (c, 2.1, EtOH). 
Anal. calcd. for C13H17N3O3 C, 59.30; H, 6.51; N, 15.96.  
Found C, 59.93; H, 6.84; N, 15.74. 
IR (KBr): υ 3257, 3053, 2956, 2869, 2253, 1685, 1637, 1541, 1472, 1011, 938, 885, 
763 cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.74 (1H, t, J = 5.6 Hz, -NH-), 8.46 (1H, d, J = 8.3 
Hz, -NH-), 7.86 (1H, d, J = 1.6 Hz, -ArH 5), 7.21 (1H, d, J = 3.4 Hz, -ArH 3), 7.21 
(1H, t, J = 1.8 Hz, -ArH 4), 4.43-4.49 (1H, m, α-H),
 
4.12 (2H, d, J  = 5.6 Hz, -CH2-), 
1.48-1.74 (3H, m, -CH2- & -CH-), 0.91 (3H, d, J  = 6.4 Hz, -CH3), 0.84 (3H, d, J  = 6.4 
Hz, -CH3). 
13C NMR (100 MHz, DMSO-d6): δ 172.7 (-CONH-), 157.8 (-ArCO-), 147.3 (-ArC 2), 
145.2 (–ArC 5), 117.6 (-CN), 113.9 (-ArC 3), 111.8 (-ArC 4), 50.6 (α-C), 39.9 (-CH2, 
-VE DEPT), 27.1 (-CH2, -VE DEPT), 24.3 (-CH-), 23.0 (-CH3), 21.1 (-CH3). 
 
N-thiophenoyl-L-leucine-glycine nitrile 119 
 L-leucine-glycine nitrile (0.95 g, 5.6mmol) and 
thiophenecarboxylic acid (0.72 g, 5.6 mmol) was used.  
Isolation by column chromatography and 
recrystallisation from ethyl acetate/hexane furnished 
119 as a white powder (0.91 g, 58%).  
m.p. = 147-149 oC 
[α]D25 = -36.0° (c, 2.1, EtOH). 
Anal. calcd. for C16H18N3O2F3: C, 56.30; H, 5.32; N, 12.31.  
Found C, 56.19; H, 5.32; N, 12.17. 
IR (KBr): υ 3267, 3058, 2960, 2871, 2254, 1658, 1619, 1545, 1513, 1421, 1246, 
1173, 1036, 864, 817, 717, 610 cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.75-8.78 (1H, t, J = 5.5 Hz, -NH-), 8.61-8.63 (1H, 
d, J = 8 Hz, -NH-), 7.93 (1H, d, J = 3.7 Hz, -ArH 5), 7.78 (1H, d, J = 4.9 Hz, -ArH 3), 
7.16 (1H, t, -ArH 4) 4.44-4.50 (1H, m, α-H),
 
4.13 (2H, d, J  = 5.6 Hz, -CH2-), 1.53-
1.72 (3H, m, -CH2- & -CH-), 0.92 (3H, d, J = 6.3 Hz, -CH3), 0.86 (3H, d, J = 6.3 Hz, -
CH3). 
13C NMR (100 MHz, DMSO-d6): δ 172.7 (-CONH-), 161.1 (-ArCO-), 139.29 (-ArC 
1), 131.03 (-ArC 3), 128.71 (-ArC 5), 127.8 (-ArC 4), 117.5 (-CN), 51.2 (α-C), 40.3 (-
CH2, -VE DEPT), 27.1 (-CH2, -VE DEPT), 24.3 (-CH-), 22.9 (-CH3), 21.1 (-CH3). 
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N-cinnamoyl-L-leucine-glycine nitrile 120 
L-leucine-glycine nitrile (0.2 g, 1.2 mmol) and 
cinnamic acid (0.18 g, 1.2 mmol) were used.  
Isolation by column chromatography and 
recrystallisation from ethyl acetate/hexane furnished 120 as a white powder (0.13 g, 
35%). 
m.p. = 155-159 oC 
[α]D25 = -18.2° (c, 2.1, EtOH). 
Anal. calcd. for C17H21N3O2 C, 68.21; H, 7.07; N, 14.04.  
Found C, 67.76; H, 6.98; N, 13.94. 
IR (KBr): υ 3277, 3058, 2956, 2250, 1651, 1538, 1344, 1222, 973, 767, 724, 686 cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.80-8.83 (1H, t, J = 5.6 Hz, -NH-), 8.38-8.40 (1H, 
d, J = 8 Hz, -NH-), 7.56-7.58 (2H, d, -ArH 2 & 6), 7.40-7.46 (4H, m, -ArH 3,4,5 & -
ArCH-), 6.71-6.75 (1H, d, J = 16 Hz, -CHCO- ), 4.41-4.46 (1H, m, α-H),
 
4.13 (2H, d, 
J  = 5.6 Hz, -CH2-), 1.48-1.64 (3H, m, -CH2- & -CH-), 0.91 (3H, d, J = 6.4 Hz, -CH3), 
0.86 (3H, d, J = 6.4 Hz, -CH3). 
 
13C NMR (100 MHz, DMSO-d6): δ 172.8 (-CONH-), 164.9 (-ArCO-), 139.1 (-
COCH-), 134.8 (–ArC 1), 129.5 (–ArC 4), 129.0 (-ArC 2 & 6), 127.5 (-ArC 3 & 5), 
121.8 (-ArCH-), 117.6 (-CN), 50.8 (α-C), 40.7 (-CH2, -VE DEPT), 27.1 (-CH2, -VE 
DEPT), 24.3 (-CH-), 22.9 (-CH3), 21.4 (-CH3). 
 
N-2-furylacryloyl-L-leucine glycine nitrile 121 
L-leucine-glycine nitrile (0.5 g, 2.9 mmol) was 
dissolved in dichloromethane (40ml) with 2-
furylacrylic acid (0.4 g, 2.9 mmol). Isolation by 
column chromatography and recrystallisation 
from acetone/hexane furnished 121 as a white powder (0.66 g, 80%). 
m.p. = 162-165 oC 
[α]D25 = -13.4° (c, 2.1, EtOH). 
Anal. calcd. for C15H19N3O3 C, 62.27; H, 6.62; N, 14.52.  
Found C, 61.97; H, 6.68; N, 14.23. 
IR (KBr): υ 3255, 2958, 2872, 2246, 1655, 1627, 1536, 1340, 1232, 1030, 976, 769, 
687 cm-1. 
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1H NMR (400 MHz, DMSO-d6): δ 8.80 (1H, t, J = 5.6 Hz, -NH-), 8.42 (1H, d, J = 8.1 
Hz, -NH-), 7.80 (1H, d, J = 1.6 Hz, -ArH 5), 7.25 (1H, d, J  = 15.6 Hz, -CH-), 6.78 
(1H, d, J = 3.2 Hz, -ArH 3), 6.59 (1H, t, J = 1.6 Hz, -ArH 4), 6.51 (1H, d, J  = 15.6 
Hz, -CH-), 4.38-4.40 (1H, m, α-H),
 
4.13 (2H, d, J  = 5.6 Hz, -CH2-), 1.48-1.64 (3H, m, 
-CH2- & -CH-), 0.91 (3H, d, J  = 6.4 Hz, -CH3), 0.85 (3H, d, J  = 6.4 Hz, -CH3). 
13C NMR (100 MHz, DMSO-d6): δ 172.8 (-CONH-), 164.8 (-ArCO-), 150.9 (-ArC 2), 
144.9 (–ArC 5), 126.4 (-CH-), 119.0 (-CH-), 117.6 (-CN), 113.9 (-ArC 3), 112.4 (-
ArC 4), 50.8 (α-C), 40.6 (-CH2, -VE DEPT), 27.0 (-CH2, -VE DEPT), 24.2 (-CH-), 
22.9 (-CH3), 21.4 (-CH3). 
 
N-3-(2-thienyl)acryloyl-L-leucine-glycine nitrile 122 
L-leucine-glycine nitrile (1.04 g, 6.1 mmol) and 
3-(2-thienyl)acrylic acid (0.95 g, 6.1 mmol) were 
used.  Isolation by column chromatography and 
recrystallisation from ethyl acetate/hexane 
furnished 122 as a white powder (0.84 g, 45%). 
m.p. = 173-176 oC 
[α]D25 = -2.8° (c, 2.1, EtOH). 
Anal. calcd. for C15H19N3O2S1 C, 58.99; H, 6.27; N, 13.76.  
Found C, 58.72; H, 6.26; N, 13.46. 
IR (KBr): υ 3276, 3061, 2957, 2251, 1668, 1645, 1615, 1538, 1230, 1207, 961, 706 
cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.78-8.84 (1H, t, J = 5.6 Hz, -NH-), 8.36-8.38 (1H, 
d, J = 8 Hz, -NH-), 7.61-7.63 (1H, d, J = 5.6 Hz, -ArH 4), 7.57-7.61 (1H, d, J = 15.6 
Hz, -ArCH-), 7.38-7.39 (1H, d, J = 3.2 Hz, -ArH 2), 7.10-7.13 (1H, t, J = 5.6 Hz, -
ArH 3), 6.47-6.51 (1H, d, J = 15.6 Hz, -CHCO-), 4.35-4.42 (1H, m, α-H),
 
4.13 (2H, d, 
J  = 5.6 Hz, -CH2-), 1.47-1.63 (3H, m, -CH2- & -CH-), 0.91 (3H, d, J = 6.4 & 17.6 Hz, 
-CH3), 0.85 (3H, d, J = 6.4 & 17.6 Hz, -CH3). 
 
13C NMR (100 MHz, DMSO-d6): δ 172.8 (-CONH-), 164.7 (-ArCO-), 149.0 (-ArC 
2), 132.1 (–ArCH-), 130.7 (-ArC 2), 128.3 (-ArC 3), 128.0 (-ArC 4), 120.5 (-CHCO-), 
117.5 (-CN), 50.9 (α-C), 40.6 (-CH2, -VE DEPT), 27.1 (-CH2, -VE DEPT), 24.2 (-
CH-), 22.9 (-CH3), 21.4 (-CH3). 
 
N-4-methylbenzoyl-L-leucine glycine nitrile 123 
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L-leucine-glycine nitrile (0.5 g, 3 mmol) was 
dissolved in dichloromethane (40ml) with 4-
methylbenzoic acid (0.42 g, 3 mmol). Isolation by 
column chromatography and recrystallisation from 
acetone/hexane furnished 123 as a white powder (0.65 g, 74%). 
m.p. = 172-176 oC 
[α]D25 = -23.8° (c, 2.1, EtOH). 
Anal. calcd. for C16H21N3O2 C, 66.88; H, 7.37; N, 14.62.  
Found C, 67.01; H, 7.49; N, 14.33. 
IR (KBr): υ 3308, 3055, 2954, 2870, 2250, 1662, 1636, 1545, 1504, 1329, 1280, 
1038, 836, 753 cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.71 (1H, t, J = 5.6 Hz, -NH-), 8.41 (1H, d, J = 8 
Hz, -NH-), 7.83 (2H, d, J = 8 Hz, -ArH 2 & 6), 7.28 (2H, d, J = 8 Hz, -ArH 3 & 5), 
4.47-4.53 (1H, m, α-H),
 
4.13 (2H, d, J  = 5.6 Hz, -CH2-), 2.36 (3H, s, -CH3) 1.49-1.76 
(3H, m, -CH2- & -CH-), 0.92 (3H, d, J  = 6.4 Hz, -CH3), 0.85 (3H, d, J  = 6.4 Hz, -
CH3). 
13C NMR (100 MHz, DMSO-d6): δ 173.0 (-CONH-), 166.2 (-ArCO-), 141.2 (-ArC 1), 
131.0 (–ArC 4), 128.6 (-ArC 2 & 6), 127.5 (-ArC 3 & 5), 117.6 (-CN), 51.3 (α-C), 
39.9 (-CH2-), 27.0 (-CH2, -VE DEPT), 24.3 (-CH, -VE DEPT), 22.9 (-CH3), 21.1 (-
CH3), 20.9 (-CH3). 
 
N-4-chlorobenzoyl-L-leucine glycine nitrile 124 
L-leucine-glycine nitrile (0.5 g, 3 mmol) was 
dissolved in dichloromethane (40ml) with 4-
chlorobenzoic acid (0.46 g, 3 mmol). Isolation by 
column chromatography and recrystallisation from 
acetone/hexane furnished 124 as a white powder (0.49 g, 54%). 
m.p. = 184-187 oC 
[α]D25 = -19.2° (c, 2.1, EtOH). 
Anal. calcd. for C15H18N3O2Cl C, 58.54; H, 5.89; N, 13.65.  
Found C, 58.48; H, 5.99; N, 13.38. 
IR (KBr): υ 3277, 3054, 2958, 2246, 1675, 1634, 1535, 1330, 844, 684 cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.75 (1H, t, J = 5.6 Hz, -NH-), 8.69 (1H, d, J = 8 
Hz, -NH-), 7.94 (2H, d, J = 8.8 Hz, -ArH 2 & 6), 7.56 (2H, d, J = 8.8 Hz, -ArH 3 & 
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5), 4.47-4.53 (1H, m, α-H),
 
4.13 (2H, d, J  = 5.6 Hz, -CH2-), 1.51-1.76 (3H, m, -CH2- 
&
 
-CH-), 0.92 (3H, d, J  = 6.4 Hz, -CH3), 0.86 (3H, d, J  = 6.4 Hz, -CH3). 
13C NMR (100 MHz, DMSO-d6): δ 172.8 (-CONH-), 165.3 (-ArCO-), 136.1 (-ArC 1), 
132.5 (–ArC 4), 129.5 (-ArC 2 & 6), 128.2 (-ArC 3 & 5), 117.5 (-CN), 51.5 (α-C), 
39.9 (-CH2, -VE DEPT), 27.1 (-CH2, -VE DEPT), 24.4 (-CH-), 23.0 (-CH3), 21.2 (-
CH3). 
 
N-4-nitrobenzoyl-L-leucine-glycine nitrile 125 
L-leucine-glycine nitrile (0.8 g, 4.7 mmol) was 
dissolved in dichloromethane (40ml) with 4-
nitrobenzoic acid (0.31 g, 4.7 mmol), 1-
hydroxybenzotriazole (0.63 g, 4.7 mmol) and 
triethylamine (0.65 ml, 4.7 mmol). The mixture was cooled to 0 ˚C, and N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (0.9 g, 4.7 mmol) was 
added. After 30 min. the solution was raised to room temperature and the reaction was 
allowed to proceed for 48 hrs. The precipitated N, N-dicyclohexylurea was removed 
by filtration and the filtrate was washed with brine, sat. potassium hydrogen 
carbonate, 10% citric acid and dried over sodium sulphate. The solvent was 
evaporated in vacuo and isolation by column chromatography and recrystallisation 
from ethyl acetate/hexane furnished 125 as a white powder (0.96 g, 65%). 
m.p. = 161-165 oC 
[α]D25 = -4.0° (c, 2.1, EtOH). 
Anal. calcd. for C15H18N4O4 C, 56.60; H, 5.70; N, 17.60.  
Found C, 56.33; H, 5.69; N, 17.30. 
IR (KBr): υ 3279, 3053, 2955, 2873, 2254, 1167, 1639, 1602, 1535, 1436, 1353, 
1273, 1214, 1154, 1169, 1015, 873, 845, 787, 704, 633 cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.96-8.98 (1H, d, J = 8 Hz, -NH-), 8.79-8.81 (1H, 
t, J = 5.2 Hz, -NH-), 8.33-8.35 (2H, d, -ArH 3 & 5), 8.13-8.15 (2H, d, -ArH 2 & 6), 
4.50-4.55 (1H, m, α-H),
 
4.15 (2H, d, J  = 5.6 Hz, -CH2-), 1.55-1.74 (3H, m, -CH2- & -
CH-), 0.93 (3H, d, J = 6.4 Hz, -CH3), 0.87 (3H, d, J = 6.4 Hz, -CH3). 
 
13C NMR (100 MHz, DMSO-d6): δ 172.5 (-CONH-), 164.8 (-ArCO-), 149.0 (-ArC 
4), 139.4 (–ArC 1), 129.0 (-ArC 3 & 5), 123.3 (-ArC 2 & 6), 117.5 (-CN), 51.6 (α-C), 
40.2 (-CH2, -VE DEPT), 27.1 (-CH2, -VE DEPT), 24.4 (-CH-), 23.0 (-CH3), 21.2 (-
CH3). 
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N-4-cyanobenzoyl-L-leucine glycine nitrile 126 
L-leucine-glycine nitrile (0.62 g, 3.7 mmol) and 
4-cyanobenzoic acid (0.54 g, 3.7 mmol) were 
used.  Isolation by column chromatography and 
recrystallisation from ethyl acetate/petroleum 
ether (40:60) furnished 126 as a white powder (0.75 g, 69%). 
m.p. = 147-151 oC 
[α]D25 = -10.4° (c, 2.1, EtOH). 
Anal. calcd. for C16H18N4O2 C, 64.41; H, 6.08; N, 18.78.  
Found C, 64.15; H, 6.26; N, 118.49 
IR (KBr): υ 3273, 3068, 2961, 2933, 2231, 1672, 1640, 1548, 1500, 1327, 1247, 864, 
768 cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.89 (1H, d, J = 7.9 Hz, -NH-), 8.80 (1H, t, J = 5.5 
Hz, -NH-), 8.07 (2H, d, J = 8.4 Hz, -ArH 2 & 6), 7.99 (2H, d, J = 8.4 Hz, -ArH 3 & 5), 
4.48-4.55 (1H, m, α-H),
 
4.15 (2H, d, J  = 5.6 Hz, -CH2-), 1.52-1.77 (3H, m, -CH2-, -
CH-), 0.89 (3H, d, J = 6.3 Hz, -CH3), 0.92 (3H, d, J = 6.3 Hz, -CH3). 
13C NMR (100 MHz, DMSO-d6): δ 172.6 (-CONH-), 165.1 (-ArCON-), 137.8 (-ArC 
1), 132.3 (-ArC 2,6), 128.5 (-ArC 3,5), 118.3 (-ArCN), 117.6 (-CH2CN), 113.7 (-ArC 
4), 51.6 (α-C), 40.1 (-CH2, -VE DEPT), 27.1 (-CH2, -VE DEPT), 24.4 (-CH-), 23.0 (-
CH3), 21.2 (-CH3). 
 
N-3,5-dimethoxybenzoyl-L-leucine-glycine nitrile 127 
3,5-dimethoxybenzoyl-L-leucine (2.59 g, 
8.75mmol) and glycine nitrile hydrochloride (0.8 
g, 8.8 mmol) were used.  Isolation by column 
chromatography and recrystallisation from ethyl 
acetate/hexane furnished 127 as a white powder 
(1.62 g, 55%). 
m.p. = 153-156 oC 
[α]D25 = -2.8° (c, 2.1, EtOH). 
Anal. calcd. for C17H23N3O4 C, 61.25; H, 6.95; N, 12.60.  
Found C, 61.21; H, 6.92; N, 12.49. 
N
H
O
H
N
O
N
N
N
H
O
H
N
O
N
O
O
  109 
IR (KBr): υ 3243, 3057, 2959, 2230, 1673, 1629, 1595, 1548, 1461, 1343, 1240, 
1195, 1158, 1063, 859, 762, 678 cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.69-8.72 (1H, t, J = 5.6 Hz, -NH-), 8.55-8.57 (1H, 
d, J = 8 Hz, -NH-), 7.09 (2H, -ArH 2 & 6), 6.67 (1H, -ArH 4), 4.47-4.54 (1H, m, α-
H),
 
4.13 (2H, d, J  = 5.2 Hz, -CH2-), 3.8 (6H, -OCH3), 1.52-1.73 (3H, m, -CH2- & -
CH-), 0.92 (3H, d, J = 6.4 Hz, -CH3), 0.87 (3H, d, J = 6.4 Hz, -CH3). 
13C NMR (100 MHz, DMSO-d6): δ 172.9 (-CONH-), 165.9 (-ArCO-), 160.2 (-ArC 3 
& 5), 135.9 (-ArC 1), 117.6 (-CN), 105.5 (-ArC 2 & 6), 103.3 (-ArC 4), 55.4 (-
OCH3), 51.5 (α-C), 40.1 (-CH2, -VE DEPT), 27.1 (-CH2, -VE DEPT), 24.4 (-CH-), 
23.0 (-CH3), 21.3 (-CH3). 
 
N-4-butylbenzoyl-L-leucine glycine nitrile 128 
L-leucine-glycine nitrile (0.56 g, 3.4 mmol) 
was dissolved in dichloromethane (40ml) 
with 4-butylbenzoic acid (0.60 g, 3.4 
mmol). Isolation by column 
chromatography and recrystallisation from ethyl acetate/petroleum ether (40:60) 
furnished 128 as a white powder (0.69 g, 63%). 
m.p. = 101-104 oC 
[α]D25 = -16.6° (c, 2.1, EtOH). 
Anal. calcd. for C19H27N3O2 C, 69.27; H, 8.26; N, 12.75.  
Found C, 69.08; H, 8.27; N, 12.61. 
IR (KBr): υ 3290, 3059, 2955, 2930, 2870, 2248, 1657, 1633, 1544, 1504, 1242, 849, 
761, 626 cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.70 (1H, t, J = 5.6 Hz, -NH-), 8.51 (1H, d, J = 8 
Hz, -NH-), 7.85 (2H, d, J = 8 Hz, -ArH 2 & 6), 7.29 (2H, d, J = 8 Hz, -ArH 3 & 5), 
4.49-4.55 (1H, m, α-H),
 
4.13 (2H, d, J  = 5.6 Hz, -CH2-), 2.63 (2H, t, J = 7.6 Hz, -
CH2CH2-), 1.51-1.77 (5H, m, -CH2CH2-, -CH2- & -CH-), 1.25-1.34 (2H, sex, J = 7.6, 
-CH2CH3), 0.88-0.92 (9H, m, -CH3). 
 
13C NMR (100 MHz, DMSO-d6): δ 173.1 (-CONH-), 166.3 (-ArCO-), 146.0 (-ArC 
1), 131.3 (–ArC 4), 128.0 (-ArC 2 & 6), 127.7 (-ArC 3 & 5), 117.6 (-CN), 51.4 (α-C), 
39.9 (-CH2, -VE DEPT), 34.6 (-CH2, -VE DEPT), 32.9 (-CH2, -VE DEPT), 27.1 (-
CH2, -VE DEPT), 24.4 (-CH-), 23.0 (-CH3), 21.7 (-CH2, -VE DEPT), 21.2 (-CH3), 
13.7 (-CH3). 
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N-cyclopentanoyl-L-leucine-glycine nitrile 129 
L-leucine-glycine nitrile (0.84 g, 5 mmol) and 
cyclopentane carboxylic acid (0.54 g, 5 mmol) were 
used.  Isolation by column chromatography and 
recrystallisation from ethyl acetate/hexane furnished 
129 as a white powder (0.76 g, 58%). 
m.p. = 143-145 oC 
[α]D25 = -40.2° (c, 2.1, EtOH). 
Anal. calcd. for C14H23N3O2: C, 63.37; H, 8.74; N, 15.84.  
Found C, 63.08; H, 8.59; N, 15.73. 
IR (KBr): υ 3272, 3066, 2957, 2870, 2242, 1668, 1641, 1543, 1228, 1039, 904, 691 
cm-1. 
Mass Spectrum: {M+Na+] found 288.2. 
C14H23N3O2Na1 requires 288.34. 
1H NMR (400 MHz, CDCl3): δ 8.59-8.62 (1H, t, J = 5.5 Hz, -NH-), 6.98-7.00 (1H, d, 
J = 8 Hz, -NH-), 4.56-4.62 (1H, m, α-H),
 
4.05 (2H, d, J  = 5.2 Hz, -CH2-), 2.51-2.60 
(1H, p, -CHCO-) 1.46-1.78 (11H, m, -CH2-, -CH- & -cycloCH2-), 0.88 (3H, d, J = 6.1 
Hz, -CH3), 0.82 (3H, d, J = 6.1 Hz, -CH3). 
13C NMR (100 MHz, DMSO-d6): δ 177.3 (-cycloCO-), 173.8 (-CONH-), 116.1 (-CN), 
51.4 (α-C), 45.1 (-CHCO-), 41.0 (-CH2, -VE DEPT), 31.0, 30.0, 26.1 & 26.0 (-
cycloCH2, -VE DEPT), 27.5 (-CH2, -VE DEPT), 24.8 (-CH), 22.7 (-CH3), 22.1 (-
CH3). 
 
N-tert-butoxycarbonyl-L-leucine-glycine nitrile 130 
BOC-L-leucine (1 g, 4.3mmol) and glycine nitrile 
hydrochloride (0.4 g, 4.3 mmol) were used.  
Rcrystallisation from ethyl acetate/hexane furnished 
130 as a white powder (0.96 g, 82%). 
m.p. = 116-119 oC 
[α]D25 = -33.0° (c, 2.1, EtOH). 
IR (KBr): υ 3335, 3311, 2963, 2240, 1671, 1523, 1274, 1164, 1051, 896, 850, 644 cm-1. 
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1H NMR (400 MHz, DMSO-d6): δ 8.55-8.58 (1H, t, J = 5.4 Hz, -NH-), 7.01 (2H, d, J 
= 8 Hz, -NH-), 4.11 (2H, d, J  = 5.8 Hz, -CH2-), 3.95 (1H, m, α-H), 1.37-1.63 (12H, m, 
-CH2-,-CH- & t-CH3), 0.88 (3H, d, J = 6.6 Hz, -CH3), 0.84 (3H, d, J = 6.6 Hz, -CH3). 
13C NMR (100 MHz, DMSO-d6): δ 173.3 (-CONH-), 155.4 (-OCO-), 117.6 (-CN), 
78.1 (-C(CH3)3-), 52.4 (α-C), 40.3 (-CH2, -VE DEPT), 28.1 (-CH3), 27.0 (-CH2, -VE 
DEPT ), 24.2 (-CH-), 22.9 (-CH3), 21.3 (-CH3). 
 
 
 
N-(9-fluorenylmethoxycarbonyl)-L-leucine-glycine nitrile 131 
FMOC-L-leucine (10.6 g, 30mmol) and 
glycine nitrile hydrochloride (2.78 g, 30 
mmol) were used.  Rcrystallisation from ethyl 
acetate/hexane furnished 131 as a white 
powder (12.24 g, 95%). 
m.p. = 160-163 oC 
[α]D25 = -38.8° (c, 2.1, EtOH). 
Anal. calcd. for C22H23N3O3 C, 70.01; H, 6.14; N, 11.13.  
Found C, 70.14; H, 6.39; N, 10.36. 
IR (KBr): υ 2963, 2588, 2273, 1720, 1566, 1508, 1428, 1357, 1256, 1223, 1106, 
1055, 1028, 884, 861, 758, 739, 728, 656 cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.73-8.76 (1H, t, J = 5.6 Hz, -NH-), 7.90 (2H, d, J 
= 7.5 Hz, - ArH 5-), 7.75 (2H, t, J = 5.4 Hz, -ArH 3), 7.67 (1H, d, J = 8.2 Hz, -NH-), 
7.43 (2H, t, J = 14.7 Hz, -ArH 4), 7.31-7.36 (2H, m, -ArH 2), 4.15-4.37 (3H, m, -
CHCH2O-), 4.15 (2H, d, J  = 5.6 Hz, -CH2-), 4.06 (1H, m, α-H), 1.39-1.67 (3H, m, -
CH2- & -CH-), 0.91 (3H, d, J = 6.5 Hz, -CH3), 0.86 (3H, d, J = 6.5 Hz, -CH3). 
13C NMR (100 MHz, DMSO-d6): δ 173.1 (-CONH-), 156.0 (-OCO-), 143.7 (d, -ArC 
1), 140.7 (d, -ArC 6), 127.6 (-ArC 4), 127.0 (-ArC 2), 125.3 (-ArC 3), 120.1 (-ArC 5), 
117.6 (-CN), 65.6 (-CHCH2O, -VE DEPT), 52.7 (α-C), 46.7 (-CHCH2O-), 40.3 (-
CH2, -VE DEPT), 27.1 (-CH2, -VE DEPT), 24.3 (-CH-), 22.9 (-CH3), 21.3 (-CH3). 
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N-phthalimide-L-leucine-glycine nitrile 132 
N-phthalimide-L-leucine (1.93 g, 7.4 mmol) and glycine 
nitrile hydrochloride (0.7 g, 7.4 mmol) were used.  
Isolation by column chromatography and 
recrystallisation from ethyl acetate/hexane furnished 
132 as a red powder (1.38 g, 62%). 
m.p. = 217-220 oC 
[α]D25 = -38.8° (c, 2.1, EtOH). 
Anal. calcd. for C16H17N3O2 C, 67.83; H, 6.05; N, 14.83.  
Found C, 64.02; H, 5.78; N, 13.96. 
IR (KBr): υ3325, 2928, 2851, 2267, 1625, 1577, 1536, 1437, 1312, 1244, 1089, 893, 
641 cm-1. 
1H NMR (400 MHz, DMSO-d6): δ 8.88-8.90 (1H, t, J = 5.2 Hz, -NH-), 7.93-7.99 (4H, 
m, -ArH), 4.78-4.82 (1H, m, α-H),
 
4.17 (2H, d, J  = 5.2 Hz, -CH2-), 2.17 (1H, t, -CH2-
), 1.94 (1H, t, -CH2-), 1.38 (1H, m, -CH-), 0.91 (6H, t, J = 6.4 Hz, -CH3). 
13C NMR (100 MHz, DMSO-d6): δ 169.3 (-CONH-), 167.5 (-ArCO-), 134.7 (-ArC 2 
& 5), 131.4 (-ArC 1 & 6), 123.3 (-ArC 3 & 4), 117.4 (-CN), 50.9 (α-C), 36.4 (-CH2, -
VE DEPT), 27.4 (-CH2, -VE DEPT), 24.5 (-CH-), 23.1 (-CH3), 20.8 (-CH3). 
 
N-1,2-benzoisothiazolin-3-one-L-leucine-glycine nitrile 133 
L-leucine-glycine nitrile (0.7 g, 4.12 mmol) and 
thiosalyicyclic acid (0.64 g, 4.12 mmol) were used.  
Isolation by column chromatography and recrystallisation 
from ethyl acetate/hexane furnished 133 as a white 
powder (0.15 g, 12%). 
m.p. = 122-125 oC 
[α]D25 = -8.8° (c, 2.1, EtOH). 
IR (KBr): υ 3209, 3045, 2955, 2920, 2252, 1681, 1622, 1550, 1446, 1329, 1243, 
1032, 736, 673 cm-1. 
Mass Spectrum: {M+Na+] found 326.09. 
C15H17N3O2S1Na1 requires 326.1. 
1H NMR (400 MHz, ACN-d3): δ 7.94 (1H, d, J = 8 Hz, -ArH 6-), 7.79 (1H, d, -ArH 3) 
7.68 (1H, t, -ArH 5), 7.54 (1H, t, J = 5.6 Hz, -NH-), 7.45 (1H, t, -ArH 4), 5.34-5.38 
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(1H, dd, J = 5.0 & 9.6 Hz α-H),
 
4.08 (2H, d, J  = 2 Hz, -CH2-), 1.82-1.98 (2H, m, -
CH2-), 1.34-1.47 (1H, m, -CH-), 0.93 (6H, d, J = 7.3 Hz, -CH3). 
13C NMR (100 MHz, ACN-d3): δ 171.1 (-CONH-), 166.3 (-ArCON-), 142.2 (-ArC 1), 
133.2 (-ArC 6), 126.9 (-ArC 3), 126.5 (-ArC 5), 124.6 (-ArC 2), 121.9 (-ArC 4), 117.5 
(-CN), 55.1 (α-C), 40.6 (-CH2, -VE DEPT), 28.2 (-CH2, -VE DEPT), 25.3 (-CH-), 
23.0 (-CH3), 21.5 (-CH3). 
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6.0 Resveratrol 
 
6.1 Introduction 
 
“Resveratrol, found in nuts, ahh..........grapes and, ah..........stuff!” 
 
Quote taken from Oral Presentation,  
60th Irish Universities Chemistry Research Colloquium, 
 UCC, 11th-13th June 2008. 
 
Resveratrol 136 (3, 4’, 5-trihydroxy-trans-stilbene) was first isolated from the roots of 
white hellebore (Veratrum grandiflorum) in 1940. This natural polyphenolic 
compound is found in several plant species, including mulberries, peanuts, grapes, 
pines, and legumes. A phytoalexin, or plant antibiotic, resveratrol is produced in 
response to stress, such as fungal infection, UV radiation, and temperature changes. 
Resveratrol is present in high concentrations in fresh grape skin, and its concentration 
in specific types of red wine can reach up to 14 mg/L. Research over the past several 
decades has revealed that resveratrol exerts a multitude of biological effects, including 
potent antioxidant, anti-inflammatory, anti-platelet, and anti-proliferative effects1. 
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In addition to trans-resveratrol, naturally occurring analogues are the cis-isomer 137 
and resveratrol-3-O-β-D-glucoside derivative (piceid) 138. Resveratrol-3-sulphate 
139, resveratrol-3-O-glucuronide 140 and dihydroresveratrol 141 are known 
metabolites of resveratrol1. 
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As a result of research into a commonly known phenomenon, the “French Paradox”, 
resveratrol has come to prominence. Epidemiological studies have revealed an inverse 
correlation between red wine consumption and the incidence of cardiovascular 
disease. This is in relation to the fact that the incidence of heart infarction in France is 
about 40% lower than the rest of Europe, despite a diet being traditionally high in 
saturated fat2. This led to the discovery of resveratrol in red wine and a possible link 
to this phenomenon. Indeed, resveratrol protects the cardiovascular system by a large 
number of mechanisms including defence against ischemic-reperfusion injury, 
promotion of vasorelaxation, promotion and maintenance of intact endothelium, anti-
atherosclerotic properties, inhibition of low-density lipoprotein oxidation, suppression 
of platelet aggregation and oestrogen-like actions3. 
 
The effects of resveratrol are pleiotropic, besides its effects on the cardiovascular 
system resveratrol exhibits a remarkable inhibitory potential in various stages of 
tumour development. The antitumour activity of resveratrol was first revealed by its 
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ability to reduce the incidence of carcinogen-induced development of cancers in 
experimental animals4. Resveratrol causes an arrest at the S/G2 phase transition of the 
cell cycle and is capable of inducing differentiation and apoptosis in a multitude of 
human tumour cell lines, such as leukaemia, colon, breast, prostate, and oesophageal 
cells. Resveratrol was also identified as an effective inhibitor of ribonucleotide 
reductase (RR). Ribonucleotide reductase catalyzes the rate-limiting step of de novo 
DNA synthesis, namely the reduction of ribonucleotides into the corresponding 
deoxyribonucleoside triphosphates (dNTPs)5. The importance of all these targets for 
cancer development is well known and therefore resveratrol can beneficially 
contribute to cancer prevention. 
 
Furthermore, resveratrol has been shown to have neuroprotective effects. Neural 
dysfunction and metabolic imbalances underlie many progressive neurodegenerative 
maladies such as Alzheimer’s, Huntington’s, and Parkinson’s diseases. Resveratrol 
induces a multitude of effects that depend on the cell type (e.g. NF-κB modulation in 
cancer cells vs. neural cells), cellular condition (normal, stressed or malignant) and 
concentration (proliferative vs. growth arrest) and can have opposing activities. 
Resveratrol targets whole pathways and sets of intracellular events rather than a single 
enzyme and therefore offers a less specific but more gentle (fewer side effects) and 
possibly more effective strategy for therapy to restore homeostasis. 
 
Due to its striking inhibitory effects on cellular events associated with cancer 
initiation, promotion and progression, resveratrol has been suggested as a potential 
cancer chemopreventative agent6. This triphenolic stilbene has also displayed in vitro 
growth inhibition in a number of human cells7. The mechanistic basis for the whole 
wide range of biological activity of resveratrol remains unknown. Numerous studies 
point to its ability to function as a cellular antioxidant while others have demonstrated 
the inhibition of signalling kinases as its key function. 
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6.2 Biosynthetic pathway of resveratrol 
 
The resveratrol biosynthetic pathway consists of four enzymes: phenylalanine 
ammonia lyase (PAL), cinnamic acid 4-hydroxylase (C4H), 4-coumarate:CoA ligase 
(4CL) and stilbene synthase (STS)8. Using three molecules of malonyl CoA as a chain 
extension, the stilbene resveratrol is derived from a p-coumaroyl CoA starter unit.  
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Scheme 6.1: The biosynthetic pathway of resveratrol 
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The starter unit, p-coumaroyl CoA is derived from phenylalanine while malonyl CoA 
is derived from the elongation of acetyl CoA units. Through oxidative deamination, 
phenylalanine loses the amino moiety with the enzyme phenylalanine ammonia lyase 
(PAL) acting as catalyst. This results in the production of cinnamic acid which is then 
converted to p-coumaric acid via C4H enzymatic hydroxylation. P-coumaric acid is 
then transformed to p-coumaroyl CoA after treatment with the free co-enzyme of a 
specific CoA ligase (4CL). The next step in the biosynthetic pathway of resveratrol 
involves the condensation of three malonyl CoA units with 4-hydroxycinnamoyl-CoA 
or p-coumaroyl CoA. This reaction forms a polyketide with further undergoes an 
enzymatic inducted (stilbene synthase) Aldol condensation to yield a carboxylated 
stilbene. This stilbene is then decarboxylated to form resveratrol. For every mole of 
resveratrol formed, four moles of carbon dioxide are released9. Stilbene synthase 
(STS) is a member of the type III polyketide synthases and has extensive homology to 
chalcone synthase (CHS). Chalcone synthase is responsible for the formation of 
chalcones in many higher plants – chalcones are starting molecules for all flavonoid 
compounds. Although chalcone synthase is ubiquitous in plants, stilbene synthase is 
only found in species that accumulate resveratrol and related compounds. Therefore, 
stilbene synthase is essential for the bioengineering of resveratrol. It exists as a 
soluble homodimer with a molecular weight of ~40 kDa (Figure 6.1)10. Similar to 
chalcone synthase, the internal active site has a conserved Cys-His-Asn catalytic triad. 
Both enzymes synthesize the same long-chain polyketide intermediate. Structure–
function analysis suggests that STS uses an Aldol-switch mechanism to 
regiospecifically carry out a C2–C7 cyclisation, instead of the C6–C1 cyclisation of 
chalcone synthase10. This reaction is followed by thioester hydrolysis to produce 
resveratrol. 
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Figure 6.1: Structure of stilbene synthase (STS) 
 
 
6.3 Synthesis of resveratrol 
 
Although resveratrol is a natural product, it is only found in very small quantities in 
nature. It is found in many plant sources but its quantity depends on the stress 
situation of the plant. For this reason, isolation from natural sources is not viable. 
Levels of resveratrol in dried roots of Cassia q. Rich (30 mg/kg)11 and dried grape 
skins (92 mg/kg)12 have been reported. Because of these low levels, reliable and 
efficient synthetic routes to resveratrol are therefore highly desirable. The first 
synthetic preparation of the stilbene resveratrol was carried out by Späth and Kromp 
in 1941 via a Perkins type condensation with p-anisyl acetic acid sodium salt and 1,3-
dimethoxy benzaldehyde as starting materials13. The synthesis of carbon-carbon 
double bonds can be achieved by various reactions including the Perkin and Suzuki 
reactions but it was not until the Wittig reaction in 1953 that research in this area of 
chemistry grew rapidly. The majority of published routes for the synthesis of 
resveratrol are based on the Wittig or Wittig-like reactions.  
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Scheme 6.2: Retrosynthetic analysis of resveratrol 
 
The Perkin-type condensation reaction involves combining an arylacetic acid and a 
substituted benzaldehyde, followed by a decarboxylation reaction to form the basic 
stilbene structure. The Suzuki-type reaction employs an ethenyl halide and a 
substituted boronic acid in the presence of a palladium catalyst to produce substituted 
stilbenes. The Wittig reaction involves phosphorous ylides as nucleophilic carbon 
species. A ylide is a molecule that has a contributing Lewis structure with opposite 
charges on adjacent atoms. Phosphorous ylides are stable, but usually quite reactive 
compounds. They can be represented by two limiting resonance structures, which are 
sometimes referred to as the ylide and ylene forms (Scheme 6.3). The ylene form is 
pentavalent at phosphorous and implies involvement of phosphorous 3d orbitals. 
Using trimethylphosphonium methylide as an example, the two forms are  
 
P+
CH2-
P
CH2
ylide ylene
 
Scheme 6.3: Resonance structures of trimethylphosphonium methylide 
 
Phosphorous ylides are usually prepared by deprotonation of phosphonium salts. The 
phosphonium salts most often used are alkyltriphenylphosphonium halides, which can 
be prepared by the reaction of triphenylphosphine with an alkyl halide. 
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Scheme 6.4: Formation of ylide 
 
The alkyl halide must be one that is reactive toward SN2 displacement. 
Alkyltriphenylphosphonium halides are only weakly acidic, so strong bases are used 
for deprotonation. The ylides are not normally isolated so the reaction is carried out 
either with the carbonyl compound present or it may be added immediately after ylide 
formation. The reaction of a phosphorous ylide with an aldehyde or ketone introduces 
a carbon-carbon double bond in place of the carbonyl bond. The mechanism proposed 
is an addition of the nucleophilic ylide carbon to the carbonyl group to yield a dipolar 
intermediate, followed by elimination of phosphine oxide. The elimination is 
presumed to occur after formation of a four-membered oxaphosphetane intermediate. 
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Scheme 6.5: Synthesis of resveratrol via the Wittig reaction 
 
The synthesis of resveratrol via this method has been reported by Pettit et al6. In order 
for this reaction to proceed, the hydroxyl groups of the starting materials must be 
protected. Successful protection and deprotection of the hydroxyl moieties has been 
achieved with a wide range of substituents but mainly methyl, acetyl and more 
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recently tert-butyldimethylsilyl groups14. The main disadvantage of the Wittig 
reaction is the lack of stereoselectivity in relation to the formation of the new vinylic 
double bond. The lack of stereoselectivity of the Wittig reaction is believed to be the 
result of steric effects which develop as the ylide and carbonyl compound approach 
one another. The three phenyl substituents on phosphorous impose large steric 
demands which govern the formation of the diastereomeric adducts. Stereoselectivity 
has been improved with the use of trialkyl phosphines, a change in solvent or by the 
addition of salts. The E- and Z- resveratrol isomers formed by the Wittig reaction 
were separated by column chromatography6. 
 
The condensation of non-enolisable aromatic aldehydes with anhydride is called the 
Perkin reaction. When the anhydride has two α-hydrogens present, dehydration 
always occurs giving an aromatic alkenyl carboxylic acid derivative. Usually the salt 
of the acid is used so that nucleophilic attack on the anhydride regenerates the 
anhydride. This compound can then be decarboxylated using a variety of reagents to 
furnish a mixture of Z- and E- isomers with the cis isomer generally being the most 
abundant. 
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Scheme 6.6: Mechanism of the Perkin reaction 
 
 
In this condensation reaction, the carbanion is obtained by the removal of an α-
hydrogen from a molecule of an anhydride, the anion of the corresponding acid acting 
as the necessary base. The carbonyl acceptor is generally confined to aromatic 
anhydrides. The carbanion attacks the carbonyl carbon of the aldehyde in the usual 
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way to yield the alkoxide anion. Internal transfer of the acetyl group in this anion is 
believed to take place from the carboxyl oxygen atom to the alkoxy oxygen atom via 
a cyclic intermediate, thereby forming a more stable species. Removal of an α-H from 
this anion by MeCO2- results in loss of the good leaving group MeCO2- from the 
adjacent β-position to yield the anion of the αβ-unsaturated acid, which readily 
hydrolyses on work up with weak acid to form cinnamic acid. Some support for this 
mechanism is provided by the observation that on reaction with anhydrides of the 
form (R2CHCO)2O, where there would be no α-hydrogen to remove in the 
intermediate following opening of the cyclic structure, it is possible to isolate the 
analogue of the intermediate as the end product of the reaction15. Although this 
mechanism has been accepted for years, recent investigations into the Perkin 
condensation by Chandraekhar et al has resulted in a revised mechanism and new 
methodology for the reaction16. 
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Scheme 6.7: Gem-diacetate formation from aldehyde 
 
This proposed mechanism is based around the derivitisation of the enolate of the gem-
diacetate (from the aromatic aldehyde and acetic anhydride, Scheme 6.7). This is in 
contrast to the enolate formation of acetic anhydride itself in the original mechanism, 
both of which are involved in the addition to the aldehyde in the key step of the 
mechanism. The deprotonation of the diacetate to the enolate appears to be 
electrophilically assisted by the neighbouring acetate group. 
 
The synthesis of resveratrol using the Perkin condensation has been reported by 
Solladié et al17. This synthesis was carried out using 3,5-diisopropoxybenzaldehyde 
and 4-isopropoxyphenylacetic acid in the presence of acetic acid. Isopropyl ethers 
were used as the protecting groups as they can be easily removed at lower 
temperatures than that of their methyl counterparts thus avoiding isomerisation of the 
product. Decarboxylation was carried out using copper chromate yielding the 
protected resveratrol analogue in a ratio of 79:21 cis:trans. Isomerisation from cis to 
trans was achieved by refluxing the mixture with phenyl disulphide in THF. This step 
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was followed by deprotection of the isopropyl ethers using boron trichloride at -78oC, 
resulting in a final resveratrol yield of 85%. 
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Scheme 6.8: Synthesis of resveratrol via the Perkin Reaction 
 
The third of the three recognised synthetic pathways outlined in Scheme 6.2, involves 
palladium cross-coupling of boronic acids with organic halides. This cross coupling 
reaction is known as the Suzuki reaction. The cross-coupling reaction of organoboron 
reagents with organic halides or related electrophiles represents one of the most 
straightforward methods for carbon-carbon bond formation. The reaction proceeds 
under mild conditions, being largely unaffected by the presence of water, tolerating a 
broad range of functionalities, and yielding non-toxic byproducts.  
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R''-Pd(II)-XR''-Pd(II)-R'
R''X
R'-B(OH)2B(OH)2-X
R'-R''
Oxidative 
Addition
Transmetalation
Reductive
Elimination
  
Figure 6.2: General catalytic cycle for cross-coupling reactions of organometallics 
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A general catalytic cycle for the cross-coupling reaction of organometallics, which 
involves oxidative addition-transmetalation-reductive elimination sequences, is 
depicted in Figure 6.2. Although each step involves further complex processes 
including ligand exchanges, there is no doubt about the presence of those 
intermediates (R’’-Pd(II)-R’ and R’’-Pd(II)-X) which have been characterised by 
isolation and spectroscopic analysis18. Oxidative addition is often the rate-determining 
step in a catalytic cycle. The relative reactivity decreases in the order of I > OTf > Br 
>> Cl. A very wide range of palladium(0) catalysts or precursors can be used for 
cross-coupling reactions. Pd(PPh3)4 is most commonly used, but PdCl2(PPh3)2 and 
Pd(OAc)2 plus PPh3 of other phosphine ligands are also efficient since they are stable 
in air and readily reduce to the active Pd(0) complexes with organometallics or 
phosphines used for the cross-couplings19-21. Reductive elimination of organic 
partners from R’’-Pd(II)-R’ reproduces the palladium(0) complex22. Although the 
mechanism of oxidative addition and reductive elimination sequences are reasonably 
well reported and are fundamentally common for all cross-coupling reactions of 
organometallics, little is known about the transmetalation step. This is because the 
mechanism is highly dependent on organometallics or reaction conditions used for the 
couplings. 
 
This reaction has been utilised by Eddarir et al in the preparation of fluorinated 
analogues of the resveratrol stilbene23. The initial step in this synthetic pathway 
involved the synthesis of a bromofluoroolefin from the reaction of 
tribromofluoromethane with an aldehyde in the presence of a tertiary phosphine and 
zinc dust activated by cupric sulphate. Protection of the hydroxyl groups was 
achieved using the methoxymethyl ether protecting group. The Suzuki cross-coupling 
step was carried out using the bromofluoroolefin and a MOM-protected 
hydroxyphenylboronic acid, catalysed by a palladium species. This reaction is most 
likely to occur via oxidative addition of Pd(0) to a carbon-boron bond. The boronic 
acid was prepared from 4-(OMOM)phenyl bromide using triisopropyl borate as the 
trapping agent. Deprotection of the hydroxyl groups was achieved by weak acid 
hydrolysis. 
  127 
O
O
O
Br
F
MOMO
OMOM
B
OH
HO
OMOM
O
MOMO
OMOM
Br
OMOM
H
CFBr3
Zn (Cu)
PPh3
Triisopropyl borate
n-BuLi
O
O
O
F
OH
OH
HO
F
PdCl2(PPh3)2
PPh3
HCl
 
Scheme 6.9: Synthesis of fluorinated resveratrol derivative using the Suzuki coupling method 
 
Resveratrol has been prepared using a variety of synthetic methodologies. The 
discovery of the Wittig reaction has been instrumental in the synthesis of resveratrol 
and its analogues. To date the majority of synthetic routes available for the synthesis 
of stilbenes are based loosely on the Wittig reaction with deviations such as the 
Wadsworth-Emmons and Wittig-Horner the main examples. The widespread use of 
these reactions is largely due to the commercial availability of starting materials. The 
main disadvantage of this type of reaction is lack of stereoselectivity leading to low 
yields. 
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Scheme 6.10: Mechanism of the Wadsworth-Emmons reaction 
 
The Wadsworth-Emmons reaction is a deviation of the classic Wittig reaction. In 
1958, Horner et al published a modified Wittig reaction using phosphonate-stabilized 
carbanions24, and this was further altered by William Wadsworth and William 
Emmons25. In contrast to phosphonium ylides used in the Wittig reaction, 
phosphonate-stabilized carbanions are more nucleophilic and more basic. Likewise, 
phosphonate-stabilized carbanions can be alkylated, unlike phosphonium ylides. 
Other advantages of the Wadsworth-Emmons variation over the Wittig reaction 
include the fact that the dialkylphosphate salt byproduct is water soluble and therefore 
easily removed by aqueous extraction. Also, the reaction is stereospecific therefore 
the yield of the trans- isomer is greatly increased.  Under strongly basic conditions at 
elevated temperatures the isomerisation of cis-stilbene to trans-stilbene occurs, which 
is contrary to the initial reports of Wadsworth and Emmons who believed that the 
reaction was like its predecessor in being non-stereospecific26. The phosphonate esters 
can be produced via the Michaelis-Arbuzov reaction by reacting benzyl bromide with 
triethyl phosphite. The Wadsworth-Emmons reaction combines this phosphonate ester 
with benzaldhyde, in the presence of a strong base such as sodium hydride to yield a 
trans-stilbene as the product. Scheme 6.10 shows the mechanism of the reaction for 
the synthesis of a stilbene. The phosphoryl- stabilized carbanion attacks the carbonyl 
in a stepwise manner, to give an oxyanion intermediate, which then decomposes via a 
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transient four-centred intermediate, to yield an olefin. Although direct observation of 
intermediates in the reaction has not been generally possible, there are several kinetic 
and spectroscopic studies that shed light on the course of this process27. Synthesis of 
resveratrol and a fluorinated derivative have been reported using the Horner-
Wadsworth-Emmons methodology. An isotopically labelled fluorinated version was 
also synthesised for positron emission tomography (PET) studies via this method28. 
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Scheme 6.11: Copper- and manganese-catalysed cross-couplings of organostannanes with 
organic iodides 
 
In recent years, new synthetic routes for stilbene production have become more 
prevalent, such as the Stille, Negishi and Heck reactions29. These methodologies offer 
a stereospecific synthesis of stilbenes. The major advantage of these reactions is due 
to the increased stereospecificity and as a result, a much higher yield of a particular 
isomer is achieved. The other key component in the synthesis of resveratrol analogues 
is the protection of the hydroxyl groups with stable but easily removable protecting 
groups. 
 
The palladium-catalysed coupling of organotin reagents with organic electrophiles 
such as aryl and vinyl halides or triflates is known as the Stille reaction. In 
comparison to Suzuki coupling, the Stille reaction does not require the addition of a 
base and is applicable to a wider spectrum of electrophiles, including saturated 
aliphatic halides and some alcohol derivatives. However, although organostannanes 
are extremely valuable synthetic intermediates because of their compatibility with 
most functional groups and mildness of their reaction conditions, few syntheses of 
stilbene derivatives via Stille vinylation have been reported in the literature. Kang et 
al have reported copper and manganese-catalysed cross-couplings of organostannanes 
with organic iodides affording stilbenes in good yields (Scheme 6.11)30.  
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In order to obtain a Z-configuration of the double bond in stilbenes, Bosanac and 
Wilcox have utilised a variant of the Negishi reaction. In this palladium-catalysed 
reaction, an organozinc reagent was coupled with an organohalide to yield the Z-
adduct, as shown in Scheme 6.1231. 
 
Br
OTBS OH
1)  t-BuLi, -78 to 0 oC;
     ZnCl2, THF, 0 to 23 oC
2) Pd(PPh3)4, reflux,
    2'-bromo-4-phenylstyrene
3) TBAF
 
Scheme 6.12: Z-stilbene synthesis using modified Negishi reaction 
  
The palladium-catalysed olefination of aryl halides is known as the Heck reaction (or 
Mizoroki-Heck reaction). Because it is highly stereoselective and amenable to a large 
variety of starting materials, it has become one of the most commonly used pathways 
for the synthesis of stilbenes. The reaction is catalysed by either Pd(0) or Pd(II) 
complexes in solution, usually in the presence of a stoichiometric amount of a base. A 
coordinating ligand, most often a phosphine, is added. In this synthetic pathway, 
stilbenes may be afforded by coupling a styrene with an aryl halide. Three possible 
products may be formed, both E- and Z- isomers, and 1,1-diphenylethylene, however 
careful choice of reaction conditions can control the regioselectivity of the addition. 
The Heck reaction has provided ready access to the synthesis of oligomeric 
styrylpyrroles32, oligo(phenylenevinylene) derivatives33, stilbenoid dendrimers34, and 
non linear optical electron donor-acceptor substituted stilbene derivatives35. The 
synthetic preparation of resveratrol has been published by Guiso et al using the Heck 
reaction with an overall yield of 70%36. 
 
 Scheme 6.13: Synthesis of resveratrol via Heck reaction 
 
The classic Heck reaction afforded new carbon-carbon bonds using aryl halides as 
electrophiles. This reaction has severe drawbacks associated with it resulting from 
oxidative degradation and other side reactions observed with phosphines, hence the 
importance of investigating non phosphine-based complexes as catalytic precursors. 
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Indeed, nitrogen-, oxygen-, and sulphur-containing palladacycles can provide 
excellent alternatives to their phosphorus-based counterparts. Many variations of the 
Heck reaction has been successfully utilised in stilbene synthesis over the years. 
Besides halides, other electrophiles have been tested in Heck-type reactions. For 
example, aryldiazonium salts are even more reactive than aryl iodides and do not 
require the presence of a base nor phosphine ligands. Indeed, coupling reactions with 
diazonium salts are fast and proceed smoothly, but usually require a relatively large 
amount of palladium (1-2 mol%). However, the coupling products are generally 
obtained in lower yields37 
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N N+
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Scheme 6.14: Stilbene synthesis using aryldiazonium salt species 
 
Symmetrical trans-stilbenes may be formed by a two-fold coupling of ethylene with 
two equivalents of bromoarene. The ratio of stilbene to byproducts (styrene and 1,1-
substituted adducts) depends on the solvent, the ethylene pressure, and the 
bromoarene concentration. Addition of lithium chloride increases the regioselectivity. 
This approach leads to the formation of small amounts of oligomers and polymers of 
poly(p-phenylenevinylene). The optimum conditions for the palladium-catalysed 
coupling of bromobenzene with ethylene are summarized in Scheme 6.1538. 
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Scheme 6.15: Synthesis of symmetrical stilbenes with ethylene 
 
One of the most commonly used synthetic pathways for the production of resveratrol 
and its derivatives is the decarbonylative Heck reaction. This version of the Heck 
reaction has been known since the beginning of the eighties. Spencer et al first 
reported the palladium-catalysed coupling of alkenes to aroyl chlorides in the 
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presence of a tertiary amine39.  The arylation of ethylene to styrene and stilbene 
derivatives was also described by Spencer et al40. The reaction involves a highly 
efficient decarbonylation of the aroyl chloride. The reaction is not particularly 
sensitive to substituents on the aroyl chloride although strongly electron-donating 
moieties have been shown to be advantageous. With mono-substituted alkenes the 
trans-isomer is form with total isomeric specificity. 
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Scheme 6.16: The decarbonylative Heck reaction 
 
The best results from the decarbonylative Heck reaction have been obtained using 
tertiary bases with pKa values in the range 7.5 to 11. Weak bases were shown to 
facilitate a slower reaction whereas strong bases would react with the aroyl chloride41. 
N-Ethylmorpholine was shown to be the most effective base as it did not react with 
aroyl chlorides nor did it cleave the bond between strongly electron-withdrawing 
groups and the aroyl chloride. The solvent used was p-xylene as optimisation of the 
reaction showed that the best results were achieved at 120-130 oC. 
 
In the initial publication of this version of the Heck reaction, Blaser and Spencer 
proposed a mechanism41. Only the reacting groups are shown as little is known about 
the ligands occupying the vacant coordination sites. The first step is believed to 
involve oxidative addition of the aroyl chloride to a palladium (0) species. The Pd(0) 
moiety is believed to be the product of a preliminary reduction of palladium acetate 
perhaps caused by the alkene or base. If there are no strongly bound ligands 
occupying the other coordination sites, aryl migration to the metal should be 
facilitated. The release of carbon monoxide is expected as there are no ligands present 
capable of stabilising a palladium (0) carbonyl at high temperature. Alkene 
coordination is proposed as the next step although it is quite probable that the alkene 
is present as a ligand throughout the reaction. Syn addition of the alkene gives an 
intermediate that undergoes internal rotation about the central carbon-carbon bond to 
  133 
place H and H-Pd-Cl syn to each other. Following this the palladium is cleaved, and 
the double bond is formed with the regeneration of Pd(0). It has been shown that the 
cumulative effect of multiple electron-withdrawing groups has a detrimental effect on 
the yield of the reaction. The decarbonylative Heck reaction gives almost complete 
specificity for the formation of E-isomers with mono-substituted alkenes. There are 
no sterically bulky ligands present so this steric specificity must be due to electronic 
factors.  
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Scheme 6.17: Proposed mechanism of the decarbonylative Heck reaction 
 
The expense of this reaction is somewhat reduced due to the regeneration of a 
palladium adduct, however this is not always easy to recover. More recently this 
procedure has been used in the preparation of the phytoalexin resveratrol and provides 
a very efficient stereospecific method to yield trans-stilbenes42. With an overall yield 
of 53%, the decarbonylative Heck approach requires only four steps from the 
commercially inexpensive α-resorcylic acid (3,5-dihydroxybenzoic acid) to produce 
resveratrol. 
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6.4 Bioactivity of Resveratrol 
 
A primary impetus for research on resveratrol was initiated from the paradoxical 
observation that a low incidence of cardiovascular diseases may co-exist with a high-
fat diet intake and moderate consumption of red wine, a phenomenon known as the 
“French Paradox”2. Resveratrol has been identified as an effective candidate for 
cancer chemoprevention due its ability to block each step in the carcinogenesis 
process by inhibiting several molecular targets. Examples of these molecular targets 
include kinases, cyclooxygenases, ribonucleotide reductase, and DNA polymerases. 
In addition, resveratrol protects the cardiovascular system by a large number of 
mechanisms, including defence against ischemic reperfusion injury, promotion of 
vasorelaxation mediated by NO (nitric oxide) release, protection and maintenance of 
intact endothelium, anti-atherosclerotic properties, inhibition of low-density 
lipoprotein oxidation, and suppression of platelet aggregation, thereby strongly 
supporting its role in the prevention of coronary disease. Promising data regarding 
progressive neurodegenerative maladies such as Alzheimer’s, Huntington’s, and 
Parkinson’s diseases has been reported in recent years5. Some of these effects may be 
due in part to resveratrol being a phytooestrogen, i.e. a plant compound that has 
biologically similar properties to those of oestrogens43. More recent results provide 
interesting insights into the effect of this compound on the lifespan of yeasts and flies, 
implicating its potential as an anti-aging agent in treating age-related human 
diseases44. 
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Figure 6.3: Major biological activities of resveratrol 
 
6.4.1 Anticancer activity 
One of the most intensely investigated biological properties of resveratrol has been its 
cancer-chemopreventative or anticancer properties. This was first demonstrated by 
Jang et al who showed that resveratrol possesses cancer-chemopreventative and 
cytostatic properties in each of the three major stages of carcinogenesis, i.e. initiation, 
promotion and progression11. Since this discovery, there has been a flurry of papers 
and reviews reporting the implication of resveratrol in cancer chemoprevention 
through a wide range of actions that are not necessarily fully understood. From 
published reports, resveratrol has been shown to appear to help detoxify carcinogens, 
to reduce the synthesis of various cancer related compounds and to interfere with cell 
survival programmes. For example, resveratrol has been shown to promote apoptosis 
in cancer cells by blocking anti-apoptotic protein expression or by inhibiting signal 
transduction through the phosphoinositide 3-kinase (PI3K), mitogen-activated protein 
kinase (MAPK) or NF-κB pathways44. 
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Most of the scientific evidence that demonstrate the bioactivity of resveratrol is based 
on in vitro studies in which the cis/trans diastereomers have been tested. However, 
from in vivo studies we know that the predominant isomer that is orally ingested with 
foods is trans-resveratrol glucoside (piceid) 138, which is biotransformed and rapidly 
eliminated12. In addition, these derivatives might be less biologically active due to 
their esterified hydroxyl groups. However, the chemopreventive activity of orally 
administered trans-resveratrol has been demonstrated in cancer-induced animal 
models45. 
 
Skin cancer is one of the most common types of human malignancy. It can be split 
into 2 groups, melanoma and non-melanoma skin cancer. As with most cancers, many 
studies have concentrated on the biological effect of resveratrol on both types. As 
non-melanoma skin cancer is the most frequent, the majority of skin cancer studies 
have concentrated on this. Much of the work regarding skin tumourigenesis has 
focused on the effects of UVB radiation, whereas much less is known about UVA-
induced signalling pathways and their role in tumour promotion. Jang et al assessed 
the chemopreventive effects of resveratrol, employing UVB-mediated skin 
tumourigenesis in the SKH-1 hairless mouse model11. Topical application of 
resveratrol either pre- or post-UVB significantly inhibited tumour incidence and 
delayed the onset of new tumour development. Similarly in a standard chemical 
carcinogenesis mouse tumour protocol using a two stage, DMBA (7,12-
dimethylbenz(a)anthracene)-initiated and TPA (12-O-tetradecanoylphorbol-13-
acetate)-promoted murine skin cancer model showed a 98% reduction in skin 
tumours11.  Orally administered resveratrol was also shown to inhibit DMBA/croton 
oil-induced mouse skin papillomas, correlated with prolonging the latent period of 
tumour occurrence and inhibiting croton oil-induced enhancement of epidermal ODC 
activities46.  
HO
OH
OH
OH (142)
 
 
Niles et al displayed the inhibition of growth and induction of apoptosis in melanoma 
cells lines by resveratrol47. However, in a human melanoma xenograft model, they 
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reported that resveratrol did not have a statistically significant effect on melanoma 
growth, and it might even stimulate tumour growth at high dose levels. In addition 
piceatannol 142, a major resveratrol metabolite, did not effect the in vitro growth of a 
murine melanoma cell line, but significantly stimulated the number of lung 
metastases48. 
OH
HO
(143)
 
 
Resveratrol is structurally similar to the synthetic oestrogen diethylstilbestrol (DES) 
143. It can bind to oestrogen receptors (agonism) in the low micromolar range and 
can act as a weak competitor or antagonist to DES. However, despite low receptor 
binding affinity it can activate hormone receptor-mediated gene transcription 
(superagonism). Furthermore, resveratrol can prevent oestrogen-induced processes by 
modulating parallel pathways with opposing effects, for example proliferation, 
transformation and progression49. Resveratrol promotes proliferation at low doses but 
at higher dose levels it is apoptotic. Resveratrol can bind to both α- and β-oestrogen 
receptors, and activates oestrogen receptor-dependent transcription in human cancer 
cells. Although numerous studies have been performed on breast cancer cells, using 
both hormone-sensitive and hormone-resistant strains, the oestrogen-modulatory 
effects of resveratrol remain debatable. In some cell types, such as oestrogen receptor 
(ER)-positive MCF-7 and T47D cells, resveratrol is seen to act as a superagonist, 
whereas in other cell types it produces activation levels equal to or less than that of 
the hormone oestradiol 144. 
OH
H
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By antagonising the growth-stimulatory effect of oestradiol in a dose-dependent 
manner, resveratrol (>1 µM) inhibited the growth of MCF-7 cells50. It has also been 
reported that resveratrol inhibited the highly invasive MDA-MB-435 cells51. In a 
study by Bhat et al, resveratrol was observed to carry out mixed oestrogen 
agonist/antagonist activities in some breast caner cell lines in the absence of oestradiol 
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144. However when oestradiol was present resveratrol was shown to act as an anti-
oestrogen52. By inhibiting the levels of autocrine growth stimulators, transforming 
growth factor-α (TGF-α), PC cell-derived growth factor, insulin-like growth factor I 
receptor and increasing the growth factor inhibitor TGF-β2, resveratrol was also 
shown to inhibit the proliferation of the oestrogen-receptor negative human mammary 
carcinoma cell line, MDA-MB-46850. Along with these studies, research has shown 
that resveratrol also promotes the accumulation of growth inhibitory/pro-apoptotic 
ceramide, the induction of quinine reductase (a phase II detoxification enzyme) and 
induces caspase-independent apoptosis through Bcl-2 downregulation. It has also 
been shown to suppress Src tyrosine kinase activity, nitric oxide generation and the 
NFκB pathway5. From these examples of in vitro results on mammary cell lines, it is 
clear the chemopreventative effects of resveratrol are very complex and not yet fully 
understood. 
 
The main causes for gastric cancer are believed to be exposure to chemical 
carcinogens and/or chronic infection with Helicobacter pylori. Resveratrol has been 
shown to be effective in inhibiting the replication of this bacterium, therefore 
intervention studies into the use of resveratrol for combating gastric cancer are 
ongoing53. In colon cancer cells, resveratrol activates various caspases and triggers 
apoptosis. This involves the accumulation of the pro-apoptotic proteins Bax and Bak 
and redistribution of the death receptor FasR in membrane rafts. Relatively high 
concentrations also substantially downregulate telomerase activity54. The in vivo 
efficiency of resveratrol has been assessed in two different animal models of 
colorectal cancer, dimethylhydrazine-induced AOM and mutant min mice, by 
Tessitore et al55 and Schneider et al56, respectively. Resveratrol was found to 
significantly reduce the number of AOM-induced aberrant crypt foci (ACF, the 
earliest stages of colon cancer) associated with Bax and p21 expression55. In the case 
of the mutant min mice, a 70% reduction in the formation of small intestinal tumours 
and prevention of colon tumour development was observed after receiving resveratrol. 
Treatment led to the downregulation of genes that are directly involved in cell cycle 
progression or cell proliferation and the upregulation of genes that are involved in the 
recruitment and activation of immune cells. It also showed inhibition of the 
carcinogenic process and tumour expansion suggesting the multiplicity of the 
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molecular targets and signalling cascades56. An inhibitory effect was also observed in 
experiments conducted in the xenograft gastric tumour model. 
 
(145)
 
 
In human bronchial epithelial cells, resveratrol alters the expression of PAH 
(polycyclic aromatic hydrocarbons)-metabolising genes (e.g. cytochrome P450 1A1), 
microsomal epoxide hydrolase (mEH) and glutathione S-transferase P1 (GSTP1) 
genes. This results in the altered formation of carcinogenic benzo[a]pyrene 145 (BaP) 
metabolites57. BaP is universal environmental pollutant and is also present in cigarette 
smoke. Cigarette smoke contains many carcinogens that are likely to be involved in 
the mechanism of this tumour type. BaP metabolisation requires the induction of the 
cytochrome P450 1A1 through the activation of the aryl hydrocarbon receptor (AhR). 
At various doses of resveratrol, significant reduction in tumour volume (42%), tumour 
weight (44%) and metastatic potential (56%) in mice bearing metastatic Lewis lung 
carcinomas (LLCs) was noted, through the inhibition of DNA synthesis and LLC-
induced neovascularisation and tube formation of human umbilical vein endothelial 
cells (HUVEC)58. 
 
With exposure to benzo[a]pyrene 145 being a known major risk factor to oesophageal 
cancer, resveratrol has been shown to have suppressive growth effects on oesophageal 
cancer cell lines such as EC-9706. The in vivo effects were evaluated in N-
nitrosomethylbenzylamine (NMBA)-induced oesophageal tumourigenesis in rats. 
Resveratrol suppressed both the number and size of NMBA-induced oesophageal 
tumours per rat, by targeting COX enzymes and the prostaglandin E synthase, 
PGE(2)59. 
 
For prostate cancer, the growth inhibitory effect of resveratrol has been demonstrated 
in various cultured cells, both hormone-sensitive and hormone-refractory. These 
mimic the initial and advanced stages of prostate carcinoma, respectively. It is 
reported that resveratrol modulates the growth of these cells and alters the expression 
of multiple sets of functionally related molecular targets. Resveratrol can repress 
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different classes of androgen-responsive genes, such as prostate-specific antigen 
(PSA), human glandular kallikrein-2, androgen receptor-specific coactivator 
(ARA70), and p21WAF1/CIP1 in hormone-responsive cells. It also activates p53-
responsive genes such as PIG7, p300/CBP and Apaf-1, inhibits PI3K/AKT activation 
and increases Bax, Bak, Bid, and Bad60. To date no preclinical studies have been 
reported on prostate carcinogenesis. 
 
Oxidative stress has been implicated in the pathogenesis of liver cancer and, therefore, 
the use of antioxidants as therapeutic or preventative agents has been recommended. 
The blockage of the ROS-potentiated invasion of the hepatoma cells61 and inducing of 
apoptosis62 by resveratrol has been shown through in vitro studies. In an in vivo study 
carried out by Carbo et al, resveratrol was shown to enhance the anti-tumour effect of 
5-fluorouracil (5-FU) 146, suggesting that resveratrol could act as a biochemical 
modulator to enhance the therapeutic activity of 5-FU on hepatocellular carcinomas63. 
It caused a marked decrease of 25% in tumour cell content by inducing apoptosis. In 
this study by Carbo et al, it was reported that resveratrol treatment also induces an 
accumulation of cells in the G2/M phase in rats inoculated with a fast-growing 
tumour. 
 
HN
H
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Resveratrol has been shown to inhibit caspase-7 activation in neuronal-like cells, such 
as the human neuroblastoma SH-SY5Y. It has also displayed degradation of poly-
(ADP-ribose)-polymerase, which occurs in cells exposed to paclitaxel (Taxol™), a 
known anticancer drug64. The mechanism of resveratrol as a neuroprotective agent is 
believed to occur through modulation of the signal pathways, committing these 
neuronal-like cells to apoptosis. Paclitaxel 147 (Taxol™) exerts its activity in the 
mitosis phase of the cell cycle, which is where resveratrol is known to induce S phase 
arrest, preventing SH-SY5Y from entering the phase64.  
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The enhancement of apoptosis in pancreatic cancer cells by trans-resveratrol has been 
reported for in vitro studies which is associated with mitochondrial depolarization and 
cytochrome c release followed by caspase-3 activation. Resveratrol inhibited the 
proliferation of human pancreatic cancer cell lines, PANC-1 and AsPC-1, in a 
concentration and time-dependent manner. Treatment with resveratrol was also shown 
to sensitize MiaPaCa2 cells for tumour necrosis factor-related apoptosis inducing 
ligand (TRAIL)-induced apoptosis through p53-independent induction of p21 and 
p21-mediated cell cycle arrest associated with depletion of the survivin gene65. 
Resveratrol can also inhibit Src tyrosine kinase activity thereby blocking the 
constitutive signal transducer and activator of transcription 3 (Stat3) protein 
activation. This suggests that Src Stat3 signalling is a target for resveratrol in 
pancreatic cancer cells66.  
 
Numerous in vitro studies have showed the antiproliferative effects of resveratrol in 
leukemic cell lines such as U937 and HL-60. It has been shown to induce apoptosis in 
B-lineage leukemic cells (acute lymphoblastic leukaemias). These cells are resistant 
to CD95 signalling, through the CD95-independent, mitochondria/caspase-9-specific 
pathway67. Following resveratrol treatment of chronic leukaemia, downregulation of 
the two anti-apoptotic proteins, iNOS and Bcl-2 was observed in leukemic B cells. 
Interleukin 1beta (IL-1β) plays a key role in the proliferation of acute myeloid 
leukaemia (AML) cells. In the AML cell lines OCIM2 and OCI/AML3, proliferation 
was shown to be inhibited, halting the cells at the S phase. Resveratrol significantly 
reduced the production of IL-1β and suppressed the IL-1β-induced activation of 
NFκB68. At low concentrations resveratrol has demonstrated inhibition of apoptosis in 
human leukaemia cells via NADPH oxidase-dependent elevation of intracellular 
superoxide that blocks mitochondrial hydrogen peroxide production, thus resulting in 
a cellular environment not susceptible to apoptosis induction69.  
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The combined effects of resveratrol have been tested with both cytarabine 148 (Ara-
C) and tiazofurin 149, both chemotherapeutic antimetabolites. The results showed 
synergistic growth inhibition and apoptosis induction in HL-60 cells70. However, in 
vivo research shows resveratrol to have weak anti-leukemic activity. This is despite 
the strong anti-proliferative and pro-apoptotic activities of resveratrol against these 
cells in vitro71. 
 
6.4.2 Antioxidant activity 
Many compounds with aromatic groups are able to function as antioxidants by 
forming stable radicals via resonance structures, thereby preventing continued 
oxidation. Resveratrol contains two phenyl groups and is highly conjugated, and it has 
been shown to have a higher scavenging capacity for ABTS 150 (2,2’-azinobis(3-
ethylbenzthiazoline-6-sulfonic acid)), DPPH 151 (1,1-diphenyl-2-picrylhydrazyl), and 
hydroxyl radicals, than propyl gallate, vitamin C, and vitamin E72. 
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Resveratrol may delay and/or prevent oxidative stress-induced cellular damage and 
disease, in its role as an antioxidant. Cell apoptosis can be induced by oxidative stress 
due to excessive damage. Resveratrol has been shown to inhibit oxidative-induced 
apoptosis in a variety of cell lines including Swiss 3T3 mouse fibroblasts, rat 
pheochromocytoma (PC12), human peripheral blood mononuclear (PBM), and human 
retinal pigment epithelium (RPE) cells73. The reduced incidence of age-related 
macular degeneration (AMD), a leading cause of blindness in the elderly, can be 
associated with reduced oxidative stress in RPE cells by resveratrol. 
 
The antioxidant activity of resveratrol may also be associated with protection against 
the progression of atherosclerosis. The oxidation of low-density lipoproteins (LDL) is 
an important event in the development of this disease. From in vivo studies, Frankel et 
al has shown resveratrol to inhibit copper-catalysed LDL oxidation in two healthy 
human subjects by 81 and 70%74. Blood platelets can also be found at the site of early 
atherosclerosis lesions. Activation of these platelets can generate reactive oxygen 
species (ROS). Resveratrol has been shown to inhibit ROS production and lower lipid 
peroxidation of blood platelets, although not to vitamin C levels. Resveratrol was 
capable of reducing the prooxidant effect of vitamin C, even though there was no 
synergism between them75. 
 
Excessive accumulation of reactive oxygen species may induce the oxidative 
modification of cellular macromolecules (lipid, proteins and nucleic acids) with 
detrimental effects. In fact, DNA damage by ROS has been implicated in 
mutagenesis, oncogenesis and aging. Resveratrol prevents initial DNA damage by two 
different pathways: (i) acting as an antimutagen through the induction of Phase II 
enzymes, such as quinine reductase and (ii) acting as an antioxidant through inhibition 
of DNA damage by ROS. When acting as an antimutagen resveratrol is capable of 
metabolically detoxifying carcinogens by inhibiting COX and cytochrome P450. It 
has been proposed that ROS derived from lipopolysacharides may function as tumour 
initiators. Leonard et al have demonstrated that resveratrol exhibits a protective effect 
against lipopolysaccharides in cell membranes and DNA damage caused by reactive 
oxygen species76. 
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Apart from its antioxidant effects, there are two other biological properties of 
resveratrol that support its coronary disease prevention. Firstly, resveratrol has been 
demonstrated to modulate the production of nitric oxide (NO) from vascular 
endolthelium. This nitrogen species is known to be involved in inflammatory 
responses77. The development of atheromatous plaque is linked to vascular damage 
which in turn can be caused by increased levels of nitric acid. The second biological 
effect that supports the notion of resveratrol preventing coronary disease is its 
oestrogenic activity. Resveratrol inhibits the oestrogen-metabolising phase I enzymes 
and also suppresses the induction of the carcinogen activator cytochrome P450 1A1. 
It does this by interfering with the binding site of the aryl hydrocarbon receptor (AhR) 
to the promoter of the gene78.  
 
Huntington’s disease is a genetic neurological disorder that can occur through a large 
range of ages around a mean occurrence of late forties/early fifties. Huntington's 
disease's most obvious symptoms are abnormal body movements and a lack of 
coordination, but it also affects a number of mental abilities and some aspects of 
behaviour. The Huntington disease gene, also called Huntingtin gene codes for a 348 
kDa protein called huntingtin protein. The exact function of this protein is not known, 
but it plays an important role in nerve cells. Within cells, huntingtin may be involved 
in signalling, transporting materials, binding proteins and other structures, and 
protecting against programmed cell death (apoptosis)79. Mutant huntingtin is toxic to 
cells, leading to mitochondrial dysfunction and oxidative stress, and subsequently to 
neuronal dysfunction and cell death. A recent study by Parker et al has emphasised 
the neuroprotective roles of the human homologue of Sir2, sirtuin 1 (SIRT1) in 
Huntington’s disease. Resveratrol-induced SIRT1 and Sir2 in neurons of Huntington’s 
disease models prevented neuronal dysfunction caused by polyQ toxicity80. 
 
Alzheimer's disease is a degenerative and terminal disease for which there is currently 
no known cure. In its most common form, it occurs in people over 65 years old 
although a less-prevalent early-onset form also exists. It is a complex disorder leading 
to the most common mental illness characterised by the loss of memory and multiple 
cognitive degenerations. It is associated with the presence of intercellular 
neurofibrillary tangles, extracellular β-amyloid (Aβ) peptides, synaptic failure and 
mitochondrial dysfunction. Resveratrol markedly lowers the levels of secreted or 
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intracellular β-amyloid peptides produced by different cell lines. Resveratrol does not 
inhibit β-amyloid peptide production, but acts by promoting the intracellular 
degradation of β-amyloid peptides via a mechanism that implicates the proteasome81. 
Similar to Huntington’s disease neurons, Alzheimer’s disease neurons may be 
protected by the over-expression of SIRT1, however the precise connection between 
over-expression of SIRT1 and protection of neurons from Alzheimer’s disease is not 
clearly understood. 
 
Parkinson's disease is a degenerative disorder of the central nervous system that often 
impairs the sufferer's motor skills and speech, as well as other functions. The primary 
symptoms are the results of decreased stimulation of the motor cortex by the basal 
ganglia, as well as from degenerative changes in the brain stem. Depletion of 
dopamine results in an imbalance between cholinergic and dopaminergic neurons in 
the extrapyramidal system. A study carried out at Lund University, Sweden by 
Karlsson et al determined that resveratrol was found to protect embryonic 
mesenchymalic cells of the rat from tert-butyl hydroperoxide through a radical 
scavenging mechanism that was detected by electron paramagnetic resonance (EPR) 
spectroscopy in conjunction with the nitrone spin trap 5,5-dimethyl-1-pyrroline-N-
oxide (DMPO)82. 
 
When considering resveratrol as an anticancer agent, it has primarily been associated 
with growth and death regulatory pathways. In recent years emerging information 
shows that, under physiological conditions, resveratrol additionally contributes to 
maintaining genome stability. Therefore, resveratrol protects the genome as an 
antioxidant via the inhibiton of inflammation, suppression of metabolic carcinogen 
activation, de novo expression of genes that encode detoxifying proteins and possibly 
even via radical scavenging properties, all at the stage of DNA damage formation83. 
 
The bioactivity of resveratrol is highly complex and there are many proposed 
mechanisms for resveratrol interaction. A proposed mode of action of resveratrol and 
its interaction with DNA has been suggested84. Although resveratrol itself does not 
intercalate with DNA, it has been shown to revert DNA intercalation through 
stabilisation of double-stranded DNA structure, resulting in a protective effect. An 
alternative mechanism of resveratrol interaction giving access to reactive oxygen 
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molecules such as hydrogen peroxide, is in transition metal interactions {e.g. 
copper(II)}, as was reported for various flavonoids by Snyder et al85. It is also 
proposed that through blockage of enzymatic interaction sites on DNA, resveratrol 
may counteract DNA-metabolising processes. Therefore, mere DNA bonding by 
resveratrol could be the basis for resveratrol induced replication stress and 
downstream ATM and ATR signalling86. Adding further to the complexity of the 
effect resveratrol has on the genome structure, it is reported that it may also contribute 
to chromatin remodelling through upregulation of the transcription coactivator gene, 
p300 and activation of SIRT187. 
 
 
6.5 Resveratrol derivatives 
 
Based on the 3,5,4’-trihydroxystilbene structure, many derivatives of resveratrol have 
been synthesised in an effort to improve bioactivity. With so many synthetic routes 
available for stilbene production, the main limitations to synthesis of derivatives are 
the availability of starting materials. Andrus et al, who first published the synthesis of 
resveratrol via the stereoselective decarbonylative Heck reaction, have subsequently 
published ester analogues via this method88. These ester analogues were tested on 
human leukaemia HL-60 cells to determine anti-cancer potential in comparison to 
resveratrol. Of the compounds tested in this report, only one of the ester analogues 
showed a better ED50 value than that of resveratrol. A 4’-acetoxy derivative 152 was 
found to have increased anti-cancer activity with an ED50 value of 17 µM (resveratrol, 
ED50 23 µM). 
 
O
OHO
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(152)
 
  
The addition of fluorine atoms into a drug molecule has been a fundamental element 
in the search for increased biological activity over the years.  There are generally two 
consequences of introducing fluorine into a drug molecule89.  Firstly there are the 
physiochemical properties.  Fluorine has the ability to modulate electronic, lipophilic 
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and steric parameters that can critically influence the pharmacological properties of a 
drug molecule.  The introduction of a fluorine atom will generally increase 
lipophilicity, decrease basicity and alter the hydrogen bonding interactions of a 
molecule.  Secondly, there is the influence of fluorine substitution on the biological 
stability of a drug molecule, e.g. through altering the metabolism of the drug90. In 
2001, Eddarir et al reported the synthesis of fluorinated derivatives of both resveratrol 
and pterostilbene 153 (3,5-dimethoxy-4’-hydroxystilbene)23. Analogues containing 
fluorine substituents on the central vinylic double bond were prepared, such as 154, 
however the biological activity of these compounds was not reported. 
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The replacement of the hydroxyl groups of the resveratrol structure with halogens was 
reported in 2005 by French researchers91. A series of chlorinated and fluorinated 
derivatives were synthesised to investigate the chemical modification of resveratrol in 
order to obtain specific antagonists of dioxins with a higher affinity for the aryl 
hydrocarbon receptor (AhR) but devoid of affinity for oestrogen receptor (ER) 
binding. All substituted trans-isomers showed a higher affinity for the AhR than 
resveratrol with little affinity to ER. 
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Andrus et al reported the synthesis fluorinated analogues aimed at ascertaining their 
chemotherapeutic potency88. A fluorinated series of derivatives was reported 
containing mono-, di- and trifluoro substituted resveratrol, in replacement of the 
hydroxyl groups. However in this report it is stated that they were unable to assess 
toxicity profiles in leukaemia cell lines for these fluorinated analogues. 
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Unpublished data from this laboratory showed that the fluorinated derivatives of 
resveratrol possess a broad array of cytotoxicity92. Preliminary biological results have 
indicated that various fluorinated analogues exhibited anticancer activity against a 
variety of tumour cell lines. Fluorinated analogues such as the 4’-acetoxy derivative 
155, have been shown to possess bioactive potency in the same region as resveratrol. 
When assayed with the lung carcinoma cell line DLKP, 155 has an IC50 of 7 ± 1 µM 
and 10 ± 3 µM against the DLKP-A cell line. These, compared to the resveratrol IC50 
control of 10 ± 2 µM and 15 ± 3 µM, respectively, demonstrated the potential of 
fluorinated analogues. Herein, we report studies in the synthesis of molecules with 
increased bioactivity, utilising a known hydroxyl moiety chemical-isostere, the amino 
group. 
 
 
6.6 Conclusion and Aims 
 
Resveratrol (3,5,4′-trihydroxystilbene) 136, isolated from a plant used in traditional 
Chinese and Japanese medicine was initially characterized as a phytoalexin. 
Resveratrol attracted little interest until 1992, when it was postulated to explain some 
of the cardioprotective effects of red wine. Since then, over 6000 letters and reviews 
have been published in a variety of journals around the world. There have been many 
synthetic routes devised to produce resveratrol, using a variety of reactions and 
methods, each with their own advantages and disadvantages. Recent reaction 
modifications are tending to produce isomerically pure stilbenes.  
 
However, the greatest flourish in research activity it has been in the biological realm. 
The reason for the intensity in research into resveratrol and its analogues is due to the 
vast array of biological properties displayed by this hydroxylated trans-stilbene. The 
screening of resveratrol and its derivatives is ongoing and investigation into its modes 
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of action is continuing. However, the complete biological activity of resveratrol is not 
yet fully understood.  
 
Resveratrol is often referred to as a ‘dirty’ molecule in the pharmaceutical industry, 
meaning that it seems to interact with many different proteins. Thus, its activity 
cannot be presumed in a unique mechanism of action but likely results from various 
complementary actions of different biochemical pathways 
 
Could resveratrol and similar molecules form the next class of wonder-drugs? 
Although it has shown remarkable promise, as a potent chemopreventative agent in 
several bioassay systems, there is a long way to go when it could be developed as an 
agent for chemoprevention/treatment of cancer. In the meantime, we might all do well 
to follow the advice of Antonio Todde, once the world’s oldest man: “Just love your 
brother and drink a good glass of red wine everyday”. 
 
The aim of this research was to investigate the substitution of the hydroxyl groups of 
resveratrol with fluorine and the bioisotere, the amino group. Substituted amines with 
acetyl and trifluoroacetyl derivatives were also synthesised. A tertiary amine was also 
prepared. The potential of a prodrug delivery system was investigated by synthesising 
a series of amino acid derivatives. Comparative analogues with fluorine substitution 
on one aromatic ring and nitrogen substitution on the other were synthesised, 
maintaining the 3,4’,5- substitution pattern of resveratrol.  
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7.0  Synthesis and characterisation of novel fluoro-
amino stilbenes 
 
7.1 Introduction 
 
A series of fluorinated amino stilbenes were synthesised in an attempt to create a 
novel compound with greater bioactivity than that of resveratrol 136. Previous work 
carried out in this laboratory has shown that substitution of the hydroxyl moieties of 
resveratrol by fluorine has a minimal effect on the potency. By maintaining this 
fluorine substitution, a novel series of compounds containing the known hydroxyl 
chemical isostere, the amino group, was generated. As described in the previous 
section, there are many methods for the production of stilbenes. The selection of 
synthetic route was based on factors such as, commercial availability of starting 
materials, cost of starting materials and stereospecificity of each reaction. The first 
series of analogues created had fluorines at the 3 and 5 positions while the amino 
group replaced the 4’-hydroxyl. These amino derivatives were synthesised from the 
reduction of the corresponding nitro analogue. The classic Wittig reaction was chosen 
for the carbon-carbon bond forming synthesis of the basic nitro stilbene. This 
synthesis of (E)-3,5-difluoro-4’-nitrostilbene 156 is outlined in Scheme 7.1. 
 
P+
Ph
Ph
Ph
O2N
H
O
F
F
O
P
Ph
Ph
Ph
F
F
NO2
O2N
F
F Ph
P
Ph
O
Ph
H2N
F
F
-
FeCl3
Fe
NaOH
(156)(158)
 
 
Scheme 7.1: Synthesis of (E)-3,5-difluoro-4’-amino stilbene 158 
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The second series of novel derivatives concentrated on synthesising the reverse of 
those prepared in the first series. In contrast to the first series, stilbene analogues with 
amino groups at the 3 and 5 positions and a fluorine atom at the 4’ position were 
synthesised. Using the stereoselective decarbonylative Heck reaction, the trans-
dinitro-isomer was synthesised. By reacting 3,5-dinitrobenzoyl chloride with 4-
fluorostyrene, trans-3,5-dinitro-4’-fluorostilbene 175 was synthesised. Scheme 7.2 
shows the reaction steps used for the synthesis of the diamino analogue.  
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Scheme 7.2: Synthesis of (E)-3,5-diamino-4’-fluoro stilbene 177 
 
For comparison purposes, the cis-isomer 176 was synthesised via the Wittig reaction. 
All nitro compounds were reduced to yield the amino derivatives and these were 
utilised for further derivatisation. 
  
 
7.2 Synthesis of 3,5-difluoro resveratrol analogues 
 
7.2.1 Synthesis of 3,5-difluoro-4’-nitro stilbene 
The synthesis of 3,5-difluoro-4’-amino stilbene derivatives was successfully achieved 
using the Wittig reaction. This reaction involves the combining of phosphonium ylide 
with an aldehyde to form a stilbene. These phosphonium ylides were prepared by 
stirring the corresponding benzyl chloride in toluene with an excess of 
triphenylphosphine1. Both 3,5-difluoro and 4-nitrobenzyl(triphenylphosphonium) 
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bromide were synthesised. Depending on reaction times, the yield of these 
phosphonium salts ranged from 70 % to quantitative values. From these salts, the 
main starting material for the 4’-amino derivatives was made. Reaction of the 
triphenyl phosphonium bromide compounds with the appropriate substituted 
benzaldhyde in the presence of sodium hydroxide yielded the nitro stilbenes isomers 
156 and 157. 
 
NO2
F
F
NO2
F
F
(156)
(157)
 
 
This Wittig reaction yielded a mixture of isomers as a yellow powder. The isomers 
were formed in equal quantities. Fractional crystallisation from ethanol was used to 
separate the cis and trans isomers. Yields of both isomers ranged from 40-50%. 
Quantitative yields of the isomeric mixture were achieved. Separation of the isomers 
initially proved very difficult. Column chromatography was not possible as the 
isomers would not separate sufficiently. Recrystallisation of the isomeric mixture was 
attempted as a method of isolation of the isomers. Many solvent mixtures were tried 
before recrystallisation from ethanol proved successful. Fractional crystallisation was 
identified as the most efficient method of separation. On addition of warm ethanol, 
the trans product was found to be largely insoluble, and when isolated was a dark 
yellow solid. The Z-isomer was found to be much paler yellow in colour.  
 
7.2.1.1 Determination of isomeric orientation 
Once the isomers were separated, determination of the orientation of each compound 
was necessary. The easiest and most common method of determining the 
stereochemistry of the double bond is from the vinylic proton splitting in the 1H 
NMR. By calculating the coupling constants of the protons of the central double bond, 
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it can be demonstrated which isomer is the E- and which is the Z-derivative. 
Generally the vinylic protons of a trans-isomer would have a coupling constant of 
approximately 16 Hz while the cis-isomer would have a vinylic J value closer to 10 
Hz. However, in the case of 3,5-difluoro-4’-nitrostilbene, the vinylic signals of the cis 
product appear at the same chemical shift as the ortho protons on the fluorinated 
phenyl ring, at approximately δ 6.9. For this reason, further confirmation was required 
to guarantee the stereochemical configuration. Crystals of the trans-isomer were 
grown from toluene for X-ray crystallography. The following crystal structure has 
been deposited at the Cambridge Crystallographic Data Centre and allocated the 
deposition number CCDC 685944. This proved beyond doubt the orientation of the 
double bond and that the insoluble isomer was trans-3,5-difluoro-4’-nitrostilbene 156. 
The monoclinic unit cell of stilbene 156 is shown in Figure 7.1. 
 
 
Figure 7.1: X-ray crystal structure and unit cell of (E)-3,5-difluoro-4’-nitrostilbene 156 
  159 
 
Empirical formula C14H9F2NO2 
Mr 261.22 
Crystal colour Yellow, block 
Crystal system Monoclinic 
Space group P21/n 
a/Å 8.566(4) 
b/Å 12.003(5) 
c/Å 11.885(5) 
α/o 90 
β/o 103.945(10) 
γ/o 90.00 
V/Å3 1186.0(9) 
Z 4 
Temperature/K 273(2) 
Dcalc/gcm-3 1.463 
F(000) 536 
µ/mm-1 0.199 
Crystal dimensions/mm 0.27 x 0.19 x 0.14 
Index ranges h, -10 - 10; k, -14 - 14; l, -14 - 14 
Max. to min. transmission 0.9685 – 0.9835 
Refinement method Full matrix on F2 
Reflections 2093 
Parameters 172 
Goodness of fit 1.030 
Final R indices (I>2σ(I)) 0.0450 (R1), 0.1171 (Rw) 
 
Table 7.1: Crystal data and structure refinement of (E)-3,5-difluoro-4’-nitrostilbene 156 
 
 
 
Bond distances (Å) 
O(1A)-N1 1.224 C(8)-H(8) 0.930 
O(1B)-N1 1.222 C(8)-C(9) 1.467 
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C1-N1 1.465 C(9)-C(10) 1.392 
C(1)-C(2) 1.376 C(10)-C(11) 1.368 
C(2)-C(3) 1.376 C(11)-C(12) 1.374 
C(3)-C(4) 1.393 C(12)-C(13) 1.365 
C(4)-C(5) 1.396 C(13)-C(14) 1.165 
C(5)-C(6) 1.376 C(9)-C(14) 1.388 
C(1)-C(6) 1.380 C(11)-F(11) 1.355 
C(4)-C(7) 1.465 C(13)-F(13) 1.359 
C(7)-C(8) 1.314   
Bond angles (o) 
O(1A)-N1-O(1B) 122.84 C(7)-C(8)-C(9) 127.00 
O(1A)-N1-C(1) 118.68 H(8)-C(8)-C(9) 116.53 
C(4)-C(7)-H(7) 116.71 F(11)-C(11)-C(10) 118.48 
C(4)-C(7)-C(8) 126.49 C(10)-C(11)-C(12) 123.78 
H(7)-C(7)-C(8) 116.80 F(11)-C(11)-C(12) 117.74 
C(7)-C(8)-H(8) 116.47   
 
Table 7.2: Selected bond distances (Å) and angles (o) 156 
 
From the X-ray crystal structure the bond distances and angles of the stilbene 156 can 
be measured. These are displayed in Table 7.2. The nitrostilbene 156 crystallises in 
the monoclinic space group P21/n with four independent molecules per asymmetric 
unit. The phenyl C-C bond distances range from 1.365 Å to 1.396 Å. The carbon-
nitrogen bond measures 1.459 Å while the carbon fluorine bonds are 1.355 and 1.359 
Å. The central double bond of the molecule (C(7)-C(8)) is 1.314 Å. The hydrogen 
bonding of compound 156 is also displayed. The intramolecular contacts occur 
between hydrogen and oxygen, and hydrogen and fluorine. The hydrogen bonding to 
the fluorine atoms is 2.567 Å. The distances of the hydrogen bonding to oxygen atoms 
varies slightly. Distances of 2.530 Å for H(7)-O(1A), 2.650 & 2.661 Å for O(1A) and 
O(1B) to H(12), respectively, and for H(2)-O(1B) is 2.678 Å were measured. These 
are clearly displayed in Figure 7.2. 
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Figure 7.2: Hydrogen-bonding of stilbene 156 
 
Molecular modelling was carried out on the nitrostilbene isomers. The calculations 
were preformed at the HF/3-21G level. Energy optimisation of the structure led to 
the cis form 157. This was then forced into the trans form with the difference in 
energies between the two isomers being 13.77 J/mol (please note Figure 7.3 not 
drawn to scale, energy difference between isomeric levels is minute compared to the 
energy required for transition).  
trans
cis
-2449.76 kJ/mol
-2449.77 kJ/mol
13.77 J/mol
 
Figure 7.3: Energy level diagram of cis-trans isomerisation between 156 & 157 
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The intraspatial distances were calculated using molecular modelling. The distance 
between hydrogens 6 and 14 for the trans isomer was found to be 6.94 Å. The 
distance between H(3)-H(7) and H(7)-H(10) is 2.43 Å and 2.29 Å, respectively. 
Molecular modelling was employed in order to use NMR 2-D experiments to prove 
the orientation of the central double bond. Nuclear overhauser effect spectroscopy 
(NOESY) shows intraspatial correlations between atoms of a molecule within 5 Å. It 
was hoped that this technique could be exploited to determine either the cis or trans 
isomers. The distances from H(7) to the aromatic protons of the second ring were 
selected due to their clarity in the 1H NMR spectra. The signals of these protons do 
not overlap with the signals of other protons of the molecule, such as the 2,6-
hydrogens with the vinylic protons in the cis isomer 157 (δ ~6.9). Molecular 
modelling determined the proton at the 4 position {H(12)} and the aromatic 
hydrogens on the nitrophenyl ring. They ranged from 7.8 to 10.5 Å for the trans 
isomer 156. The cis orientation gave shorter distances as anticipated, however they 
were not within the maximum NOESY distance of 5 Å. The distances ranged from 5.3 
to 8.7 Å which was not close enough for NOESY correlation. 
 
The UV-vis spectra of both isomers (156 and 157) show very different UV 
absorbances. The λmax of (E)-3,5-difluoro-4’-nitrostilbene 156 was present at 337 nm 
while the maximum absorbance of the cis isomer occurs at 314-315 nm. This is due to 
the absorbance of the carbon-carbon double bond and its orientation in the respective 
compounds. This was believed to be another possible way of distinguishing the 
isomers and proving the configuration. 
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 Figure 7.4: UV spectra of cis/trans isomers 156 & 157 
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7.2.1.2 IR study of (E/Z)-3,5-difluoro-4’-nitro stilbene 
The infrared spectra for all of the synthesised fluorinated analogues show very 
complex absorptions, mainly in the fingerprint region. This is largely due to the C-F 
stretching mode which couples strongly with other vibrational modes, especially the 
C-C stretching2. Carbon-fluorine bands can occur in the region of 1400 to 900 cm-1. 
Vinylic carbon stretching generally occurs about 1630 cm-1 and is highly dependent 
on the substituents. A vinylic C=C stretch of a planar molecule generally occurs in the 
region of 1640-1610 cm-1 in infrared spectra. Due to the planarity of the trans isomer 
156, absorption is visible at 1618 cm-1. The cis isomer 157 is in a forced non-planar 
configuration of as a result of steric hindrance, leading to reduced conjugation 
between the vinyl and phenyl groups. As a consequence, the C=C stretching band is 
present at 1660-1630 cm-1. In the spectrum of 157, there is an absorption peak at 1640 
cm-1.  
600110016002100260031003600
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Figure 7.5: Infrared spectrum of (E)-3,5-difluoro-4’-nitrostilbene 156 
 
In general, the characteristic NO2 stretching frequencies appear in the region of 1550-
1475 cm-1 for the asymmetric and 1360-1315 cm-1 for the symmetric NO2 stretch. 
Such frequency lowering, in both of these stretching modes, is attributed to the 
conjunction of NO2 with the aromatic ring. The intensity of symmetric NO2 stretching 
is enhanced by conjugation, and the asymmetric and symmetric stretching bands are 
found to be very similar in peak intensity. The nitro stretching frequencies of 
nitrobenzene occur at 1548 cm-1 and 1360 cm-1 for the asymmetric and symmetric 
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modes, respectively3. For isomers 156 and 157, the NO2 asymmetrical stretch can be 
seen at 1509 and 1503 cm-1, while the symmetrical stretches appear at 1336 and 1340 
cm-1, respectively. Because of the coupling between the C-N vibrational mode and 
other ring vibrations, carbon-nitrogen stretching frequencies of aromatic nitro 
compounds occur in the 1180-860 cm-1 region. The NO2 deformation vibrations, 
which include NO2 scissoring (in-plane), NO2 wagging (out-of-plane), and NO2 
rocking (in-plane), usually occur at frequencies lower than 900 cm-1. For the majority 
of compounds, the scissoring mode possesses the higher vibrational frequency of the 
three deformations, and it is by far the most characteristic deformation mode. The 
NO2 rocking mode, on the other hand has the lowest frequency of these deformations. 
The intense absorptions at approximately 3100 cm-1 are as a result of the carbon-
hydrogen stretching of the phenyl rings, while the aromatic carbon-carbon double 
bonds stretch is weak in intensity and occurs about 1600 cm-1. Monosubstituted C-H 
bending occurs in the range 690-710 cm-1 and 730-770 cm-1, while meta-disubstituted 
bending can be found in the range 680-725 cm-1  and 750-810 cm-1. Although these 
absorptions are strong, the IR spectra of compounds 156 and 157 are complex with 
many peaks present in the fingerprint region. Definitive identification of exact peaks 
is all but impossible but absorptions are present in all the relevant ranges mentioned. 
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Figure 7.6: Infrared spectrum of (Z)-3,5-difluoro-4’-nitrostilbene 157 
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7.2.1.3 NMR study of (E/Z)-3,5-difluoro-4’-nitrostilbene 
The 1H NMR of the trans-stilbene 156 is shown in Figure 7.7. The unsaturated unit 
appears as two doublets δ 7.59 and 7.51 with coupling constants of 16.4 Hz. In the 
case of the cis isomer 157, they should also appear as doublets; however in the proton 
NMR they occur at the same chemical shift as the ortho-protons of the fluorinated 
ring so the coupling constant cannot be calculated. The main difference between E- 
and Z- isomers in 1H NMR is the size of the coupling constant. Z-isomers generally 
record coupling constants between 7 and 11 Hz whereas E-isomers generally are in 
the range of 15-18 Hz4. 
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Figure 7.7: 1H NMR spectrum of (E)-3,5-difluoro-4’-nitrostilbene 156 
 
In the case of both isomers, the aromatic protons of the nitro substituted ring appear as 
doublets as is standard with a para-substituted phenyl ring. These have coupling 
constants in the region of 8-9 Hz. The two hydrogens α to the nitro group are shifted 
the furthest downfield due to the electronic effects of the nitro group. For the trans-
isomer the protons in the 3’ and 5’positions appear at δ 8.27, while for the cis-isomer 
at δ 8.17. The protons in the 2’ and 6’ positions appear at δ 7.86 and 7.48 for 156 and 
157, respectively.  
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Figure 7.8: 1H NMR spectrum of (Z)-3,5-difluoro-4’-nitrostilbene 157 
Fluorine has a spin number of ½, therefore coupling between fluorine and hydrogen 
occurs. The equivalent protons in the ortho-position of the fluorinated ring are 
therefore split by fluorine coupling. However, because fluorine exerts strong long 
range coupling effects, the proton signal is not split into a simple doublet but a 
multiplet. For the (E)-isomer this multiplet is found in the range of δ 7.39-7.48 while 
for the (Z)-isomer it shifts to a range of δ 6.82-6.94. The para-proton of this ring 
shows an interesting splitting pattern, caused by adjacent fluorine atoms. At a 
chemical shift of δ 7.21 and 7.17 for trans 156 and cis 157 respectively, the signal for 
the 4-H is split into a triplet of triplets in the 1H NMR spectra. This triplet of triplets 
has coupling constants of 2.9 and 9.2 Hz for the trans and 2.4 and 9.4 Hz for the cis. 
 
The effect of fluorine coupling is also evident in the 13C NMR spectra. As can be seen 
in the 13C NMR spectrum of (E)-3,5-difluoro-4’-nitrostilbene 156, the meta-carbons 
attached to fluorine are split into doublets because of 13C-19F coupling, and appear at δ 
162.8 and δ 162.6 with J values of 244.2 and 244.0 Hz, respectively. In the case of the 
cis-isomer, the meta-carbons are present at δ 162.4 and δ 162.3, with J values of 245.0 
and 244.7 Hz, respectively. The quaternary carbon at position 1 in both isomers is 
also affected by 13C-19F coupling, being split into a triplet due to coupling to both 
fluorine atoms. This triplet has a coupling constant of 9.9 Hz and occurs at a chemical 
shift of δ 140.2 and δ 139.6 for 156 and 157, respectively. The other carbons in the 
fluorine-substituted phenyl ring also display fluorine-carbon coupling induced 
NO2
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splitting. The ortho-carbons, at positions 2 and 6 are split into doublets while the 
para-carbon at position 4 is split into a triplet. In the case of the trans-isomer 156, the 
doublet from 2,6-C appears at δ 109.9 (J = 25.6 Hz) and the 4-C triplet at δ 103.64 (J 
= 25.9 Hz). For the cis-nitrostilbene 157, the doublet has a chemical shift of δ 111.60 
and a coupling constant of 25.5 Hz, while the triplet of the para-carbon is further 
upfield at δ 103.30 and has a coupling constant of 25.8 Hz. 
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Figure 7.9: 13C NMR spectrum of (E)-3,5-difluoro-4’-nitrostilbene 156 
 
NMR evidence of fluorine coupling to hydrogen and carbon atoms, is not solely 
confined to just 1H and 13C NMR spectra. Signal splitting due to coupling is also seen 
in the 19F NMR, where in the case of the isomers of 3,5-difluoro-4’-nitrostilbene, the 
signal associated with the fluorine atoms is split into a triplet. This is due to the strong 
coupling to the two adjacent protons. For the (E)-stilbene 156, the triplet has a 
chemical shift of δ -109.81 with a coupling constant of 9.4 Hz. For compound 157, it 
has a chemical shift of -109.57 and this signal has a coupling constant of 8.0 Hz. 
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Figure 7.10: 19F NMR spectrum of (E)-3,5-difluoro-4’-nitrostilbene 156 
 
7.2.2  Synthesis of 4’-amino derivatives 
In order to synthesis the targeted amino derivatives, the reduction of the nitro isomers 
was attempted. The initial effort to reduce stilbene 156 was carried out using 
poly(methylhydrosiloxane) (PMHS)5. A combination of palladium (II) acetate, 
aqueous potassium fluoride, and polymethylhydrosiloxane (PMHS) facilitates the 
room-temperature reduction of aromatic nitro compounds to anilines. Although the 
reaction did reduce the nitro group as expected, it also reduced the central double 
bond and yielded the diphenylethane derivative 171.  
 
NH2
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NH2
F
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Further attempts at the reduction of the nitro group were tried under milder 
conditions, for example using zinc in conjunction with ammonium chloride. Tin 
chloride and hydrochloric acid proved unsuccessful as did sodium dithionite, in an 
effort to produce the 4’-amine 158. The specific reduction of the nitro group to an 
amine was achieved using iron and iron (III) chloride6. Both the trans and cis isomers 
(156 and 157) were reduced by this method yielding (E)-3,5-difluoro-4’-
aminostilbene 158 and (Z)-3,5-difluoro-4’-aminostilbene 159 in quantative yields. 
The reduction was carried out in a mixture of ethanol and acetic acid. Care was 
required on addition of the iron (pindust) as attraction to the magnetic stirrer often 
caused the reaction not to proceed as anticipated. Vigorous stirring by a large stirrer 
bar was required to maintain the stirring motion during reflux. Although the reaction 
was very efficient, the reaction was very messy producing a dark brown residue. Hot 
filtration was required to remove unused iron and insoluble by-products. Generally 
the product was isolated pure and did not require further purification. 
N
F
F
R'
R
 
Compound Isomer R R’ % Yield 
158 trans H H 80 
159 cis H H 88 
160 trans CH3 CH3 32 
161 trans H COCH3 70 
162 trans H COCF3 62 
163 cis H CON(CH3)2 20 
164 cis H CON(CH2CH2)2O 29 
 
Table 7.3: 4’-Amino derivatives 158-164 
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A stilbene containing a tertiary amine was prepared via the classical Wittig reaction. 
Reaction of a difluorinated phosphonium ylide with 4-(dimethylamino)benzaldehyde 
in the presence of sodium hydroxide yielded a mixture of isomers. However, the cis-
isomer was found to be in excess, in a ratio of 3:1. Separation of isomers was 
achieved by fractional crystallisation as described for the nitro stilbenes. The trans-
isomer, (E)-3,5-difluoro-4’-(dimethylamino)stilbene 160 was separated in an overall 
reaction yield of approximately 16%. 
N
F
F
(160)
 
 
Resveratrol analogues containing a secondary amide at the 4’ position were 
synthesised. Starting with the trans-aminostilbene derivative 158, two acetyl 
analogues were prepared. By reacting the free amino group with excess acetic 
anhydride in the presence of a catalytic amount of pyridine (1 drop), the aminoacetyl 
derivative 161 was prepared in a yield of 70%. (E)-3,5-Difluoro-4’-
trifluoroacetylaminostilbene 162 was prepared using trifluoroacetic anhydride. 
Recrystallisation from ethyl acetate of the crude reaction mixture gave the desired 
product 162 in a yield of 62%. 
H
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O
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F
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Two cis derivatives 163 and 164, were synthesised containing a carbamyl moiety (-
C(O)NH-). The cis-stilbenes 163 and 164 were prepared by reacting carbamyl 
chloride with (Z)-3,5-difluoro-4’-aminostilbene 159 in the presence of a molar 
equivalent of triethylamine. (Z)-3,5-difluoro-4’-amino(dimethylcarbamyl) stilbene 
163 was isolated as a white powder in low yield (~19 %) by column chromatography. 
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(Z)-3,5-difluoro-4’-(carbamyl-4-morpholine) stilbene 164 was also synthesised in a 
similar fashion employing 4-morpholinecarbonyl chloride. This was purified by 
column chromatography furnishing a white solid with yield of 29 %. 
 
HN
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Four BOC-protected amino acid derivatives were synthesised to investigate a possible 
prodrug delivery system, as displayed in Table 7.3. These analogues were synthesised 
using (E)-3,5-difluoro-4’-aminostilbene 158 as starting material. Using the standard 
EDC coupling reaction, the BOC-protected amino acids was coupled to the free amine 
with N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC) 113 as 
activation agent. Chiral integrity is preserved in this reaction by the use of 1-
hydroxybenzotriazole (HOBt) 95. 
H
N
F
F
O
O
AA
 
Compound Isomer Amino Acid % Yield 
165 trans glycine 17 
166 trans L-alanine 18 
167 trans β-alanine 12 
168 trans L-valine 11 
 
Table 7.4: BOC-protected amino acid derivatives of (E)-3,5-difluoro-4’-aminostilbene 
158 
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(E)-3,5-difluoro-4’-N-(tert-butoxycarbonyl-glycine)aminostilbene 165 was 
synthesised using the protected amino acid, BOC-glycine. (E)-3,5-difluoro-4’-N-(tert-
butoxycarbonyl-L-alanine)aminostilbene 166 was synthesised from EDC coupling 
with N-BOC-protected L-alanine. Filtration from ethyl acetate yielded the desired 
stilbene 166 (yield 4 %) a white solid. A further yield of 14 % of the L-alanine 
analogue 166 was purified by column chromatography using hexane/ethyl acetate as 
eluant.  
 
H
N
F
F
O
N
H O
O
H
N
F
F
O
N
H O
O
(165)
(166)
 
 
Compounds 167 and 168 were again synthesised via the EDC activated peptide 
coupling from the trans-aminostilbene 158. The substituted stilbene 167 was prepared 
using BOC-β-alanine while BOC-L-valine was used to prepare product 168. 
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Deprotection of an amino acid derivative was attempted using the glycine analogue 
165. (E)-3,5-difluoro-4’-N-(tert-butoxycarbonyl-glycine)aminostilbene 165 was 
stirred in a 50 % solution of trifluoroacetic acid in dichloromethane, resulting in 
  173 
complete deprotection. Care was taken due to previous experience from Section A, 
when TFA deprotection destroyed the peptide by not only cleaving protection group 
but also extracting the α-proton from the chiral centre. The crude product isolated on 
evaporation of solvent and excess TFA was found to be highly hydrophilic. From the 
NMR spectra taken of the crude reaction product, it is clear that a salt was formed, 
namely (E)-3,5-difluoro-4’-aminoglycine stilbene trifluoroacetate salt 169, and 
complete removal of the butoxycarbonyl group was achieved. 
 
H
N
F
F
O
NH3+.O- (169)CF3
O
 
 
7.2.2.1 IR study of (E/Z)-3,5-difluoro-4’-aminostilbene 
The infrared spectrum of (E)-3,5-difluoro-4’-aminostilbene 158 confirmed the 
reduction of the nitro group to the amine. The NO2 stretching frequencies, both 
asymmetric (1509 cm-1) and symmetric (1336 cm-1) present in the IR spectrum of 
stilbene 156, have disappeared in the IR spectrum of 158. Asymmetrical and 
symmetrical stretching of a primary amine generally occurs between 3500 and 3300 
cm-1, with the former having the higher wavenumber. 
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Figure 7.11: Infrared spectrum of (E)-3,5-difluoro-4’-aminostilbene 158 
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In the spectrum of 158, two main stretches are evident at 3483 and 3396 cm-1, 
representing these stretchings. A shoulder band usually appears on the lower 
wavenumber side in primary and secondary amines arising from the overtone of the 
N–H bending band. This can be seen in the spectrum at 3206 cm-1. The N-H bending 
vibration of primary amines is observed in the region 1650-1580 cm-1. This bending 
vibration may be one of two peaks observed at 1617 and 1586 cm-1. Another band 
attributed to amines is observed in the region 910-665 cm-1. This strong, broad band is 
due to N-H wag and can be seen in the infrared spectrum of the trans-amino stilbene 
158 at 839 cm-1. All appropriate amine stretching, bending and wagging frequencies 
can also be seen for the cis-isomer 159. The two stretches appear at 3461 and 3372 
cm-1, with the overtone shoulder band appearing at 3214 cm-1. The bending vibration 
is observed at 1616 or 1583 cm-1 while the amine wagging is prominent at 830 cm-1. 
 
7.2.2.2 NMR study of 4’-amino analogues 
The proton NMR of (E)-3,5-difluoro-4’-aminostilbene 158 shows large differences in 
chemical shifts compared to the starting material 156. The hydrogens adjacent to the 
nitro group, at meta-positions 3’ and 5’ have moved from δ 8.27 in the nitro 
compound to δ 6.57 in the amino compound 158. The doublet corresponding to the 
ortho-protons at positions 2’ and 6’ have a chemical shift of ~ δ 7.3 compared to δ 
7.86 for the nitro stilbene 156. The protons of the fluorinated ring have also shifted 
upfield following the reduction of the nitro group. The multiplet from the 2,6-H 
appear as part of a larger multiplet (~ δ 7.25) integrating for 5 protons, containing the 
2’6’-H, the 2,6-H and a vinylic proton. The para-proton, located between the fluorine 
atoms is present as a triplet of triplets and shifted upfield to δ 7.17. The proton nearest 
the fluorinated ring has only moved upfield slightly, to approximately δ 7.2, and is 
one of the protons included in the multiplet in the region δ 7.20-7.30. However, it’s 
the other hydrogen of the double bond that shows the greatest difference. On 
reduction of the nitro group to an amine group, the proton signal has migrated upfield 
from ~ δ 7.6 (156) to a chemical shift of δ 6.89 for the trans-difluoroamino derivative 
158. The coupling constants for these vinylic doublets are 16.4 Hz. The amino group 
appears as a singlet, integrating for 2 hydrogens at δ 5.45. 
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Figure 7.12: 1H NMR spectrum of (E)-3,5-difluoro-4’-aminostilbene 158 
 
The triplet of triplets at δ 7.05 in the 1H NMR of the cis-isomer 159 is due to the 
para-hydrogen. A doublet at δ 6.93, which integrates for 4 is due to the aromatic 
protons positioned at 2 and 6 on fluorinated ring, and 2’ and 6’ on the amino-
substituted phenyl ring. The final 2 aromatic protons occur at δ 6.46 and are the 3’ 
and 5’ hydrogens. The doublets of the vinylic protons have a chemical shift of δ 6.65 
and δ 6.29, and have a J value of 12.4 Hz. The amino group appears as a broad singlet 
at δ 5.34. 
 
The aromatic protons of the amino-substituted phenyl ring appear as doublets at δ 
7.43 and δ 6.72 with J values of 8.8 Hz, in the 1H NMR spectrum of the dimethyl 
amino compound 160. Although the vinylic protons signals appear at the same 
approximate chemical shifts of the protons of the fluorinated phenyl ring, their 
intensity is strong enough, compared to the aromatic protons, to estimate the coupling 
constants. One vinylic proton appears with the 2,6-hydrogens in the region of δ 7.24-
7.31. The other vinylic proton appears as a multiplet with the triplet of triplets from 
the para-proton, in the region of δ 6.93-7.03. The coupling constants for this trans-
isomer can be calculated as 16.4 Hz. The two methyl groups of the tertiary amine 
appear at δ 2.94. 
NH2
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For (E)-3,5-difluoro-4’-aminoacetyl stilbene 161, the amide singlet is present at δ 
10.07 in the 1H NMR spectrum. The aromatic protons of the amide ring appear close 
together with chemical shifts of δ 7.62 and δ 7.53, and with coupling constants of 8.8 
and 8.4 Hz, respectively. The vinylic protons appear in the same region as the 
fluorinated ring aromatic protons. A multiplet resulting from a vinylic proton and the 
protons in positions 2 and 6 is present at δ 7.30-7.38. The other vinylic proton occurs 
with the para-aromatic proton in the range δ 7.06-7.16. The three protons of the acetyl 
group have a chemical shift of δ 2.06. 
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Figure 7.13: 1H NMR spectrum of (E)-3,5-difluoro-4’-(trifluoroacetyl)aminostilbene 162 
 
The secondary amide singlet is present at δ 11.38 in the 1H NMR spectrum of the 
trifluoroacetyl derivative 162, while the aromatic protons of the amide-substituted 
phenyl ring have chemical shifts of δ 7.73 and δ 7.66 with coupling constants of 8.8 
and 8.4 Hz. The doublets of the vinylic double bond occur at δ 7.42 and δ 7.24 and 
both have coupling constants of 16.8 Hz. The doublet of the 2,6-protons has a 
chemical shift of 7.35 while the para-proton appears at δ 7.13. The addition of further 
fluorine atoms to the molecule increases the occurrence of splitting with the 
trifluoroacetyl moiety showing a very distinctive pattern in the 13C NMR. The 
splitting of carbons due to the 3,5-difluorine substitution is consistent with that 
H
N
F
F
CF3
O
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described compounds 156-161, with splitting of the carbons directly attached to the 
fluorine into a doublet with coupling constants of 243.7 and 243.6 Hz. These doublets 
both appear at approximately δ 162. The triplet of carbon at position 1 has a chemical 
shift of δ 141.13 and a J value of 9.8 Hz. The ortho-carbons are present as a doublet at 
δ 109.17 while the triplet of the para-carbon appears at a chemical shift of 102.56, 
with coupling constants of 25.4 and 26.0 Hz, respectively.  
 
105110115120125130135140145150155160165170 ppm
10
2.
31
10
2.
57
10
2.
83
10
9.
05
10
9.
11
10
9.
23
10
9.
30
11
1.
31
11
1.
40
11
1.
56
11
4.
27
11
7.
14
12
0.
01
12
0.
83
12
1.
06
12
6.
08
12
6.
11
12
7.
37
12
9.
17
13
0.
55
13
1.
59
13
3.
09
13
3.
57
13
5.
71
13
6.
24
14
0.
92
14
1.
02
14
1.
12
15
3.
80
15
4.
17
15
4.
54
15
4.
91
16
1.
40
16
1.
53
16
3.
84
16
3.
97
 
 
Figure 7.14: 13C NMR spectrum of (E)-3,5-difluoro-4’-(trifluoroacetyl)aminostilbene 162 
 
Figure 7.14 shows the 13C NMR of stilbene 162, with the carbon signals of the 
trifluroacetyl group identified by the red arrows. The carbonyl carbon has a chemical 
shift of δ 154.4 and is split by carbon-fluorine coupling with the adjacent 
trifluoromethyl group. It is split into a quartet with a coupling constant of 36.8 Hz. 
The trifluoromethyl group itself is also split into a quartet spread over a range of 10 
ppm. This quartet appears in the region of δ 111.4-120.0. Due to the fact that this 
carbon has three fluorines directly attached, the coupling constant is large, calculated 
to be as 266.9 Hz. In the 19F NMR both peaks are present with the singlet at δ -73.83, 
integrating for 3 fluorines, the trifluoromethyl group and the triplet at δ -110.14 due to 
the meta-fluorines. This triplet has a coupling constant of 7.5 Hz. 
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Figure 7.15: 19F NMR spectrum of (E)-3,5-difluoro-4’-(trifluoroacetyl)aminostilbene 162 
 
In the 1H NMR spectrum of the cis-derivative 163, the amide proton appears as a 
singlet at δ 8.36. The aromatic protons of the para-substituted phenyl ring appear as 
doublets at δ 7.40 and as part of a multiplet in the range δ 7.06-7.11. The coupling 
constant of the doublet at δ 7.4 is 9.2 Hz. The ortho-protons of the fluorinated ring 
have a chemical shift of δ 6.9. The two doublets at δ 6.68 and δ 6.49 with coupling 
constants of 12.4 and 12 Hz are due to the vinylic protons. The singlet of the methyl 
groups on the terminal tertiary amine is present at δ 2.92. 
 
The amide proton of the cis-morpholine analogue 164 appears as a singlet at of δ 8.64. 
The vinylic protons appear as doublets at δ 6.69 and δ 6.50 with J values of 12.4 Hz. 
The methylene protons of the morpholine ring appear as two distinct multiplets with 
chemical shifts of δ 3.60 and δ 3.42, with the latter signal, due to the protons adjacent 
to the nitrogen. 
 
The 1H NMR spectra of the amino acid derivatives 165-168 shows all the signals 
expected of the difluorostilbenes with the extra peaks of the N-protected amino acid. 
In the spectrum of the BOC-glycine analogue 165, the amide attached to the stilbene 
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appears with a chemical shift of δ 10.05 while the glycine amide triplet is part of a 
multiplet present at approximately δ 7.10, also in this multiplet is the triplet of triplet 
due to the para-proton of the fluorinated phenyl ring. The aromatic doublets of the 
para-substituted ring have chemical shifts of δ 7.62 and δ 7.55 with coupling 
constants of 8.4 and 8.8 Hz. One of the vinylic doublets makes up part of a multiplet 
with the ortho-protons of the fluorinated ring, occurring at a chemical shift of δ 7.34. 
The second doublet of the central double bond protons is found at δ 7.15 and has a 
coupling constant of 16.4 Hz. The methylene hydrogens of glycine have a chemical 
shift of δ 3.73 and are split into a doublet by the neighbouring amide, with a coupling 
constant of 6.0 Hz. The singlet at δ 1.4, integrating for 9 H is due to the tert-butyl 
moiety of the protection group. In the 1H NMR spectrum of the glycine analogue 165 
(Figure 7.16), a second smaller singlet can be seen at δ 1.33. This is due to 
isomerisation of the trans-isomer when in solution. When in solution, pure stilbene 
isomers can isomerises with light. This can be observed in the 1H NMR spectra of the 
glycine analogue. Isomerisation from this trans isomer 165 to the cis isomer results 
can be noted by a peak from the BOC group of the cis derivative. Integration of this 
peak is 0.2 compared to the trans-peak of 9; therefore the ration of trans to cis is 45:1. 
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Figure 7.16: 1H NMR spectrum of (E)-3,5-difluoro-4’-(BOC-Gly)aminostilbene 165 
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In the 1H NMR of (E)-3,5-difluoro-4’-(BOC-L-Ala)amino stilbene 166, the para-
substituted amide appears as a singlet at δ 10.08 while the amide of the amino acid 
appears at the same chemical shift as the triplet of triplets, at δ 7.1. Adjacent to this 
multiplet is one of the vinylic doublets, at δ 7.16 which has a coupling constant of 
16.0 Hz. The α-H at the chiral centre of L-alanine splits into a quintet due to the 
adjacent amide and methyl group. This signal has a chemical shift of δ 4.13 and a 
coupling constant of 7.2 Hz. The t-butyl moiety of the protection group appears as a 
very intense singlet at δ 1.39, while the methyl group of the alanine is split by the α-H 
into a doublet with chemical shift of δ 1.27 and J value of 7.2 Hz. 
 
The 1H NMR spectra of the β-alanine and L-valine compounds (167  and 168) shows 
slight differences between the compounds, with the amide attached to the stilbene 
having a chemical shift of δ 10.07 for the β-Ala analogue 167 and δ 10.13 for the L-
Val derivative 168 When compared to the previous two amino acid derivatives (165 
and 166), the amide of β-alanine and L-valine can be seen at independent chemical 
shifts, to that of the rest of the molecule. The N-terminal hydrogen of β-alanine is split 
into a triplet in the 1H spectrum at δ 6.90 with a coupling constant of 5.6 Hz, due to 
H-H coupling with the protons in the α-position of the amino acid. This α-methylene 
has a chemical shift of δ 2.49 but the triplet is partially masked by the signal of the 
deuterated NMR solvent dimethylsulphoxide (DMSO-d6) at δ 2.51. The β-methylene 
of compound 167 is present as a quartet, due to splitting by the α-CH2 and the N-
terminal amide and appears at δ 3.22 with a J value of 6.4 Hz. The singlet of the t-
butyl group has a chemical shift of δ 1.38. For the L-valine derivative 168, the amino 
acid amide couples with the proton of the α-carbon at the chiral centre and is therefore 
split into a doublet. It has a chemical shift of δ 6.94 and a coupling constant of 8.8 Hz. 
The α-proton of this compound 168 can be found at δ 3.92 as a triplet, with a coupling 
constant of 7.8 Hz. The proton next to the α-hydrogen, at the centre of the isopropyl 
side chain is split into a multiplet with a chemical shift of δ 1.99 while the two 
equivalent methyl groups of the isopropyl side chain are split into a doublet by it, and 
can be seen at δ 0.90 and with a coupling constant of 6.4 Hz. The vinylic coupling 
constants for (E)-3,5-difluoro-4’-N-(tert-butoxycarbonyl-β-alanine)aminostilbene 167 
and (E)-3,5-difluoro-4’-N-(tert-butoxycarbonyl-L-valine)aminostilbene 168 are 16.0 
and 16.4 Hz, respectively.  
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The deprotected glycine stilbene 169 shows some subtle changes to the chemical 
shifts of the main stilbene components compared to the protected stilbene 165, but as 
expected there are more significant changes to the chemical shifts of the glycine 
signals. The amide attached to the stilbene has a chemical shift of δ 10.70 while the 
methylene protons of glycine appear at δ 3.84. However this signal is no longer a 
doublet as in 165, but now exists as a singlet. This is somehow due to the fact that the 
protons that previously coupled to it are now part of a charged amino species and not 
the neutral primary amine. Following on from this, the glycine amide triplet that 
appeared at δ 7.10 for product 165 can now be found as a broad singlet, characteristic 
of a charged amine, at δ 8.25. Further evidence of a charged amine is that this singlet 
integrates for 3 protons. Proof of the trifluoroacetate salt can be seen in the 19F NMR 
with 2 signals present, an intense singlet at δ -73.61 and the known triplet of the meta-
substituted fluorines, occurring at δ -110.20. The carbons of trifluoroacetic acid 
appear as a similar pattern to that described for the trifluoroacetyl derivative 162, with 
the carbonyl carbon split into a quartet at δ 158.26 (J = 52.1 Hz). However the carbon 
of the trifluoromethyl group is split into a doublet in the range δ 115-118 with a 
coupling constant of 298.0 Hz. This is perhaps due to the equivalency of the fluorines 
and is split by the 13C-19F. 
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Figure 7.17: 1H NMR spectrum of (E)-3,5-difluoro-4’-aminoglycine stilbene 
trifluoroacetate salt 169 
H
N
F
F
O
NH3+.O-
CF3
O
  182 
7.2.3 Basic resveratrol structure investigation 
The importance of the substitution pattern of resveratrol was investigated. Research 
previously carried out in this laboratory, showed that the activity of resveratrol 
remained after the hydroxyl groups were replaced with fluorine atoms7. The 
importance of the central double bond of the stilbene structure and the significance of 
the 3,5-aromatic substitution pattern was investigated by synthesising analogues 170-
173. The bioactivity was determined using lung cell carcinoma assays. These 
derivatives were prepared without some of the basic components of the resveratrol 
backbone, while maintaining the 4’-nitro group and its corresponding amino moiety. 
As a by-product of one of the reduction reactions, the central vinyl double bond was 
reduced. This was synthesised using palladium (II) acetate, aqueous potassium 
fluoride and poly(methylhydrosiloxane). By varying the molar equivalents, both the 
reduced nitro and amino compounds were isolated. 1-(3,5-Difluorophenylethyl)-4’-
nitrobenzene 170 was isolated as a beige powder.  
 
NO2
F
F
NH2
F
F
(170)
(171)
 
 
In the proton NMR of this reduced nitro compound, the aromatic protons of the nitro-
substituted ring appear at δ 8.02 and δ 7.39, with the meta-hydrogens the further 
downfield. The three aromatic protons of the fluorinated ring occur as a multiplet in 
the region of δ 6.85-6.92. The methylene protons appear as symmetrical multiplets at 
δ 2.91 and δ 2.83. Confirmation of these as methylenes is clear from the DEPT 135 
NMR, with negative signals at δ 35.76 and δ 35.61.  
 
  183 
2.53.03.54.04.55.05.56.06.57.07.5 ppm
2.
67
8
2.
69
5
2.
70
3
2.
71
7
2.
79
7
2.
81
0
2.
81
8
2.
83
5
4.
86
8
6.
48
4
6.
48
8
6.
50
0
6.
50
4
6.
85
2
6.
87
2
6.
91
0
6.
91
5
6.
93
2
6.
93
7
6.
95
5
6.
96
1
6.
96
7
6.
97
9
6.
98
4
6.
99
0
7.
00
2
7.
00
8
7.
01
4
 
Figure 7.18: 1H NMR spectrum of 1-(3,5-difluorophenylethyl)-4’-aminobenzene 171 
 
The amino derivative 171 was isolated as a dark brown liquid with a boiling point of 
approximately 194oC. The triplet of triplets from the hydrogen at position 4 and the 2, 
6 protons of 1-(3,5-difluorophenylethyl)-4’-aminobenzene 171 are present at δ 6.98 
and δ 6.92 respectively, in the 1H NMR spectrum.  Due to the reduction of the nitro 
group to the amine, the protons of the para-substituted ring have moved upfield with 
the doublet of the ortho protons at δ 6.86, while the meta protons appear at δ 6.49. 
The broad amine signal appears at δ 4.87. As in the 1H NMR spectrum of the nitro 
compound 170, two multiplets are seen as a result of the methylene units at δ 2.81 and 
δ 2.70. The 1H NMR of the amino-diphenylethyl analogue is shown in Figure 7.18. 
The methylene group carbon atoms of the amino analogue 171 are present at δ 37.02 
and δ 35.01. 
NO2
NH2
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(173)
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The importance of the 3,5-substitution pattern was assessed by the preparation of 
nitrostilbene 172 (commercially available, Sigma Aldrich) via the Wittig reaction. In 
an attempt to increase the yield of trans-isomer over the cis, the normal procedure 
using sodium hydroxide was not used; instead a procedure described by Miljanić et al 
was used8. This procedure uses a weaker base, potassium carbonate in conjunction 
with a few crystals of dibenzo-18-crown-6. After work-up, a crude 1H NMR showed a 
mixture of isomers in the ratio of 1.6:1 (trans:cis). Separation of the isomers was 
achieved by fractional recrystallisation from ethanol. The pure trans-isomer was 
isolated as yellow needle-shaped crystals in a yield of 59%. These crystals were 
identified as the trans-isomer 172 by 1H NMR, with vinylic coupling constants of 
16.4 Hz. This trans-nitrostilbene 172 was then reduced using the iron and iron (III) 
chloride procedure, yielding 4-aminostilbene 173. The vinylic doublets (δ 7.07 and δ 
6.90) for the amino derivative had J values of 16.4 Hz. The primary amine formed 
appeared as a singlet at δ 5.32.  
 
 
7.2.4 Synthesis of 4-aminobutan-1-ol derivative 
In an attempt to reduce the nitro group of the stilbene 156, it has been shown that the 
procedure using the siloxane (PMHS) and aqueous potassium fluoride produced the 
completely reduced diphenylethyl compound 171. However, on a few occasions when 
the reaction was allowed proceed for 4 hours, an interesting byproduct was formed. 
On work up of the reaction, TLC analysis showed the formation of two products. 
Column chromatography was used to separate the two products with the less polar 
product being confirmed as the diphenylethyl compound 171. The second product was 
isolated for analysis. NMR data showed that this second product was the n-butan-1-ol 
derivative of the diphenylethyl compound. This product has been fully characterised 
and shown to be 4-(4-(3,5-difluorophenylethyl)phenylamino)butan-1-ol 174. 
 
H
N
F
F
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Reports of the synthesis of n-substituted 4-amino-1-butanols by various two- and 
three-step reaction methods have been published over the years10,11. Recently a one-
step method hydrogenation reaction using palladium on carbon (1 atm) has been 
published12. The procedure using PMHS outlined in this thesis requires approximately 
4 hours compared to 24-36 hours for the hydrogenation reaction reported by Russell 
et al. Although the ring opening of tetrahydrofuran by amines has been reported over 
the years, it normally involves the complexing of the THF with cationic metal 
compounds such as uranium amide compounds13 and zirconium complexes14.  
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Scheme 7.3: Proposed mechanism for the palladium-mediated tetrahydrofuran ring opening12. 
  
However in the recent publication by Russell et al, a free-radical-based mechanism is 
proposed, as shown in Scheme 7.3. This mechanism is based the use of unstabilised 
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THF, allowing for a potential build up of THF hydroperoxide. The cleavage of the 
hydrogen-oxygen bond of the hydroperoxide results in the formation of a peroxide 
free radical I, which can then abstract a hydrogen from the 2-position of THF forming 
radical II. Either radical (I or II) can then remove a hydrogen from the amine to form 
the aminyl radical III which is the resonance stabilized. This in turn could couple to 
radical II to form the intermediate 2-amino-THF IV. Complexing of the palladium to 
the intermediate IV may occur at this point which in turn forces ring opening to form 
the imine V with loss of the palladium, Reduction of the imine double bond can then 
take place to yield the final amino-butanol product VI. The reaction mechanism is 
plausible for the reaction being described in the synthesis of the 4-amino-butan-1-ol 
compound 174. The THF used in this reaction was of anhydrous grade and free of 
inhibitor/stabilizer. It was also a relatively old bottle of solvent (~1 year old), which 
makes the likelihood of hydroperoxide formation a real possibility. A test for peroxide 
was carried out on the THF solvent used in these reactions, using Quantofix® 
peroxide test sticks (Sigma Aldrich). The result of this starch/iodide test proved 
positive for the present of peroxides in the solvent. 
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Figure 7.19: 1H NMR spectrum of 4-(4-(3,5-difluorophenylethyl)phenylamino)butan-1-ol 
174. 
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The 1H NMR of the 4-amino-1-butanol compound 174 maintains all the fluorine 
coupling characteristics discussed for the 4’-amino compounds. The aromatic protons 
of the fluorinated ring can be seen as a multiplet, which also contain the doublet from 
the protons in the 3’ and 5’ positions of the second phenyl ring. The remaining 
aromatic protons have a chemical shift of δ 6.46 and this doublet has a coupling 
constant of 8.4 Hz. In a similar pattern to that reported for compound 171, the central 
double bond, now reduced to two methylene groups appears as two multiplets. They 
have chemical shifts in the ranges δ 2.80-2.84 and δ 2.69-2.72. The protons of the 
amino-butanol side chain are present in the spectrum from approximately δ 1.4-5.5. 
The most downfield signal of these if from the amide proton, which is split into a 
triplet by the adjacent methylene, it has a chemical shift of δ 5.33 and a coupling 
constant of 5.4 Hz. The hydroxyl proton is also split into a triplet by an adjacent 
methylene and can be seen at δ 4.40. This signal has a coupling constant of 5.2 Hz. Of 
the butanol methylene groups, the CH2 in the 1 position (b) beside the hydroxyl is the 
most downfield. This quartet has a coupling constant of δ 3.42 and a coupling 
constant of 6.2 Hz. At a chemical shift of δ 2.95, the CH2 (e) beside the amine is split 
into a quartet with a coupling constant of 6.6 Hz. The remaining protons of the 
butanol side chain, at C-2 (c) and C-3 (d), form a multiplet in the region δ 1.45-1.58. 
The 2D COSY NMR spectrum is shown in Figure 7.20. A labelling system will be 
employed for the 4’-amino-butan-1-ol, giving a letter to each proton signal. 
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Figure 7.20: 2D COSY NMR spectrum of 4-(4-(3,5-difluorophenylethyl)phenylamino)butan-
1-ol 174. 
In the COSY NMR of compound 174, the correlation between adjacent protons can be 
clearly seen. For the hydroxyl proton signal at δ 4.40, a correlation can be seen by the 
box to the b proton (C-1’’) at δ 3.42. From this proton, the chain can be followed to 
the multiplet of the central methylenes (C-2’’ and C-3’’) c and d. Obviously a box 
cannot be drawn for the correlation between protons c and d (δ 1.52) but can for the 
interaction between e (δ 2.95). An interesting note that can be observed from this 2D 
spectrum is that, although comprising of a multiplet, the protons of C-2’’ and C-3’’ 
have slightly different chemical shifts. From the signals in the spectrum, it can be seen 
the proton the correlates to b (δ 3.42) is very slightly more downfield than the 
correlation signal to that of e (δ 2.95). This indicates that the methylene at C-2’’ 
comprises of the left hand side (downfield-side) of the multiplet at δ 1.52. Completing 
the amino-butanol chain, a final box can be drawn between the C-4’’protons e and the 
amide triplet f at δ 5.33. 
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7.3 Synthesis of 4’-fluoro resveratrol analogues 
 
7.3.1 Synthesis of 3,5-dinitro-4’-fluoro stilbene 
The second series of fluorinated amino derivatives of resveratrol contains nitrogen 
moieties at the 3 and 5 positions and a fluorine atom at the 4’ position of the stilbene 
structure. Synthesis of (E)-3,5-dinitro-4’-fluorostilbene 175 was carried out via the 
decarbonylative Heck reaction. The major benefit of using this procedure over the 
Wittig reaction employed for first series is the stereoselectivity of the reaction. The 
decarbonylative Heck reaction solely produces the trans-isomer which as already 
mentioned is the bioactive isomer of resveratrol 136. The procedure was carried out as 
published for the Andrus et al synthesis of resveratrol9. Using 3,5-dinitrobenzoyl 
chloride and 4’-fluorostyreneas starting materials, the (E)-isomer 175 was isolated. 
The reaction was preformed in the presence of a molar equivalent of N-
ethylmorpholine and a catalytic amount of palladium (II) acetate. The solvent used 
was p-xylene as reports have shown the reaction to proceed optimally at 120oC. The 
resulting crude brown solid residue was recrystallised from ethanol to furnish the 
desired product 175 as a mustard yellow powder. Yields of the dinitro compound 
were generally in the range of 60-70 %.  
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The cis-isomer, (Z)-3,5-dinitro-4’-fluorostilbene 176 was prepared for comparative 
purposes. This was synthesised in an isomeric mixture via the classical Wittig 
reaction. 3,5-Dinitrobenzyl(triphenylphosphonium) bromide was prepared from 
benzyl bromide and triphenylphosphine. This was reacted via the ylide, with 4’-
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fluorobenzaldehyde under strong basic conditions, to form an isomeric (E/Z)-mixture 
of compounds 175 and 176. As described for the 4’-nitro compounds (156 and 157), 
separation was achieved by fractional recrystallisation from ethanol. The trans-isomer 
175 was far less soluble than the cis-isomer 176. 
 
7.3.1.1 IR study of (E/Z)-3,5-dinitro-4’-fluorostilbene 
The infra red spectra of isomers 175 and 176 appear very similar. The major structural 
difference, the orientation of the central double bond has very little influence on the 
spectra. Although the vinylic stretching is clearly visible in the IR spectra of both 3,5-
difluoro-4’-nitrostilbenes (156 and 157), they are not as obvious in the reverse 
compounds 175 and 176. Carbon stretching of the vinylic bond generally occurs about 
1630 cm-1 however it is strongly dependent on the substituents. For trans-isomers, due 
the planar orientation of the bond and substituents, the absorption is in the region of 
1640-1610 cm-1 while the forced non-planar configuration of the cis-isomer absorbs at 
a higher wavenumber, generally 1660-1630 cm-1. This is as a result of steric 
hindrance, leading to reduced conjugation between the vinyl and phenyl groups. Both 
3,5-dintiro-4’-nitrostilbene isomers (175 and 176) have two meta-substituted nitro 
groups and this may well be the reason for not being able see these vinylic stretchings. 
As previously mentioned, the nitro group has two main stretches, which are generally 
equal in intensity as each other and are strong absorptions. Asymmetrical stretching of 
the nitro group occurs in the region of 1550-1475 cm-1 while symmetrical stretching 
in the section of 1360-1315 cm-1.  In the IR spectra of these isomers, strong 
absorptions are present at 1533, 1506 and 1343 cm-1 for the trans 175 and at 1535, 
1506 and 1342 cm-1 for the cis 176. The presence of these strong absorptions, 
particularly the asymmetrical mode may be over shadowing the C=C stretching of the 
vinylic double bond. However, an absorption at 1592 and 1600 cm-1 for the trans and 
cis respectively, may be the vinylic stretch and have been shifted from the general 
range by the aromatic substituents present in these molecules. 
 
As with previous molecules discussed, identification of peak absorptions in the 
fingerprint region is very difficult for fluorinated compounds. This is largely due to 
the C-F stretching mode which couples strongly with other vibrational modes, 
especially the C-C stretching. Carbon-fluorine bands can occur anywhere from 1400 
to 900 cm-1. Also specific bands can be seen for mono-substituted and meta-
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disubstituted aromatic compounds, both of which are present in these compounds. All 
these factors lead to a very complex and crowded fingerprint region from 
approximately 600 to 1600 cm-1 and makes definite identification of individual 
absorptions very difficult. 
 
600110016002100260031003600
wavelenght (nm)
 
Figure 7.21: Infra red spectrum of (Z)-3,5-dinitro-4’-fluorostilbene 176 
 
 
7.3.1.2 1H NMR study of (E/Z)-3,5-dinitro-4’-fluorostilbene 
In the 1H NMR spectrum of compound 175 the vinylic protons appear as doublets as 
expected, however the vinylic proton nearest the nitro-substituted ring appears at the 
same chemical shift as the aromatic protons in the 2’ and 6’ positions of the 
fluorinated ring. This results in a multiplet at an approximate chemical shift of δ 7.73. 
The vinylic proton adjacent to the fluorinated ring is present at δ 7.51 with a coupling 
constant of 16.4 Hz, proving trans orientation of the stilbene double bond, and can be 
seen in Figure 7.22. Due to long range coupling across a phenyl ring, splitting can be 
seen for the protons of the dinitrophenyl ring, but with small coupling constants. The 
ortho-protons of this ring appear as a doublet at a chemical shift of δ 8.81 and with a 
coupling constant of 2.0 Hz. The para-proton, situated between the two nitro groups 
is split into a triplet with a J value of 1.8 Hz and a chemical shift of δ 8.66. The most 
upfield protons are observed as a triplet at δ 7.28 and have a coupling constant of 8.8 
Hz. This signal is from the meta-protons beside the fluorine, and is a triplet due to 1H-
1H and 1H-19F coupling. 
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Figure 7.22: 1H NMR spectrum of (E)-3,5-dinitro-4’-fluorostilbene 175 
 
As with the 4’-nitro analogues described previously, fluorine coupling affects not only 
the 1H NMR but also the 13C NMR spectra of the 3,5-dinitro derivatives. Due to 13C-
19F coupling, signal splitting is observed to the aromatic carbons of the fluorinated 
phenyl ring. The largest coupling constant observed is for the aromatic carbon directly 
attached to the fluorine atom at the 4’ position. This signal is split into a doublet with 
a chemical shift of δ 162.32 and a coupling constant of 245.0 Hz. The other aromatic 
carbons of the ring are also split into doublets, with varying coupling constants in 
relation to their proximity to the fluorine atom. The carbons in the 2’ and 6’ positions 
have a chemical shift of δ 129.1 and a coupling constant of 8.2 Hz, while the carbons 
in the 3’ and 5’ positions appear further upfield at δ 115.8 and with a coupling 
constant of 21.5 Hz. The quaternary carbon at position 1’ has a chemical shift of δ 
132.6 and a coupling constant of 3.3 Hz. The ortho-carbons (3,5) of the nitro ring can 
be seen at δ 148.5 and the carbon between the nitro groups is at δ 140.9. The 
quaternary carbon at position 1 has a chemical shift of δ 140.9. The vinylic carbons 
appear at δ 132.6 and δ 124.4. The latter carbon is split by long range fluorine 
coupling and has a coupling constant of 2.3 Hz. The remaining aromatic carbons 
appear at δ 125.9 and δ 116.4 for positions 2 and 6 and for position 4, respectively. 
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Figure 7.23: 13C NMR spectrum of (E)-3,5-dinitro-4’-fluorostilbene 175 
 
The 19F NMR of this para-substituted stilbene 175 shows one signal at a chemical 
shift of -112.30. 19F coupling to both hydrogen and carbon affects the fluorine NMR 
spectra. In the case of this compound 175 and other para-fluorinated stilbene 
analogues discussed later, the signal of the fluorine atom is split into a multiplet. 
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Figure 7.24: 19F NMR spectrum of (E)-3,5-dinitro-4’-fluorostilbene 175 
 
The vinylic protons appear as doublets at δ 6.99 and δ 6.87 in the 1H NMR of the (Z)-
isomer 176, and have coupling constants of 12.0 and 12.4 Hz, confirming cis 
orientation. The proton situated between nitro groups is the furthest downfield due the 
presence of the very strong electron withdrawing groups flanking it. It has a chemical 
shift δ 8.66 and is split into a fine triplet with a coupling constant 2.2 Hz. The 
equivalent protons at the other side of the nitro groups, at positions 2 and 6, are split 
into a doublet at δ 8.40 and with a coupling constant 2.0 Hz. The hydrogens in the 
corresponding position of the fluorinated ring is a multiplet at δ 7.33 while the protons 
adjacent to the fluorine form a triplet with a coupling constant 8.8 Hz at δ 7.17.  
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Figure 7.25: 1H NMR spectrum of (Z)-3,5-dinitro-4’-fluorostilbene 176 
 
Although the vinylic hydrogens of the isomers showed an obvious change in chemical 
shift and coupling constant in the 1H NMR, the difference is not as noticeable for the 
carbon atoms in the 13C NMR spectra. The vinylic carbon adjacent to the dinitro 
phenyl ring has a chemical shift of δ 133.3 whereas the other vinylic carbon beside 
the fluorinated ring is further upfield at δ 126.1. When compared to the vinylic 
chemical shifts of the trans-isomer (δ 132.6 and δ 124.4), the difference is negligible. 
The carbon attached to the fluorine is again split with a coupling constant of 244.4 Hz 
and is present at δ 161.6. The carbons of the fluorinated ring also are split, with 
carbon 1’ (δ 131.5), carbons 2’ and 6’ (δ 130.5), and the carbons at the 3’ and 5’ 
positions (δ 115.7) having a coupling constants of 3.5, 8.1 and 21.3 Hz respectively. 
The multiplet signal in the 19F NMR spectrum of (Z)-3,5-dinitro-4’-fluorostilbene 176 
occurs at δ -113.02 
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7.3.2 Synthesis of (E/Z)-3,5-diamino derivatives 
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The next step in the synthesis of the 3,5-diamino resveratrol derivatives was the 
reduction of the nitro groups to amino groups. The trans 177 and cis 178 diamino 
isomers were synthesised by the iron and iron (III) chloride reduction procedure. The 
trans-isomer was isolated as a brown powder whereas the cis-isomer was a brown 
viscous oil when pure. By increasing the stated equivalents used for the mono-
substituted nitro compounds, complete nitro reduction was achieved. It was found that 
upwards of 3 times the equivalents used for the 4’-nitro compounds was required to 
quantitatively reduced both nitro groups. Each 3,5-dinitro-4’-fluoro isomer was 
individually reduced and the desired product, be it cis or trans was isolated in 
quantitative yields and in 100 % isomeric purity equal to that of the initial starting 
material. 
F
O2N
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By controlling the equivalents of reducing agents used in the reaction, it was possible 
to isolate stilbenes with only one nitro group reduced, and therefore producing 3-
nitro-5-amino-4’-fluorostilbene. This was carried out using both trans 175 and cis 
dinitro-isomers 176 as starting materials, thereby producing (E)-3-nitro-5-amino-4’-
fluorostilbene 179 and (Z)-3-nitro-5-amino-4’-fluorostilbene 180 as orange powders. 
These mono reduced compounds were synthesised in a 1:1 ratio to the diamino 
compounds (177 & 178) previously described. These were purified by column 
chromatography using ethyl acetate and hexane as mobile phase. 
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N
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(181)
(182)
 
 
As for the case of the 3,5-difluoro-4’-amino derivatives, the acetyl derivatives of the 
3,5-diamino-4’-fluoro series were synthesised. These compounds were produced as 
described for the 4’ series using the anhydride with catalytic amounts of pyridine. 
Both the diacetyl analogue 181 and the di(trifluoroacetyl) derivative 182 were 
purified in good yields and recrystallised from ethyl acetate. 
 
F
X
Y
 
Compound Isomer X Y % Yield 
177 trans -NH2 -NH2 77 
178 cis -NH2 -NH2 65 
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179 trans -NO2 -NH2 17 
180 cis -NO2 -NH2 23 
181 trans -NH-CO(CH3) -NH-CO(CH3) 78 
182 trans -NH-CO(CF3) -NH-CO(CF3) 56 
183 trans -NH-Gly-BOC -NH-Gly-BOC 56 
184 trans -NH-L-Ala-BOC -NH-L- Ala -BOC 38 
185 trans -NH-β- Ala-BOC -NH-β-Ala-BOC 60 
186 trans -NH- L-Val-BOC -NH- L- Val -BOC 12 
187 trans -NH- L- Val -BOC -NH2 81 
 
Table 7.5: 3,5-Diamino derivatives 177-187 
 
Compounds 183 -187 were synthesised using (E)-3,5-diamino-4’-fluorostilbene 177 
as starting material. By utilising the classic peptide coupling reaction using EDC as 
activating agent, the stilbenes 183-187 were isolated. Using the N-butoxycarbonyl 
protected amino acids in excess, reasonably good yields were achieved (Table 7.5). In 
all cases for the preparation of the amino acid derivatives, approximately three 
equivalents of reagents were used, relative to the diamino starting material.  All 
products were purified by column chromatography and obtained as white powders, 
with the exception of the L-valine derivative 186. In the case of the valine analogue, 
the disubstituted product was isolated after chromatography as a brown wax. This was 
formed in a relatively low yield, when compared to the other amino acid derivatives.  
 
A major byproduct was isolated in the preparation of the valine stilbene analogue 186. 
This byproduct was separated by column chromatography and from the NMR spectra 
recorded, it was shown to be the monosubstituted product, (E)-3-amino(BOC-L-
valine)-5-amino-4’-fluorostilbene 187. The deprotection of the 3,5-di(amino acid) 
derivatives was attempted on the glycine analogue 183. It was carried out using 
trifluoroacetic acid in dichloromethane with stirring at room temperature for one hour. 
After evaporation of the solvent and excess acid using a nitrogen stream, the solid 
residue was recrystallised from ethyl acetate. NMR spectra showed that the product 
formed is the trifluoroacetate salt of (E)-3,5-diaminoglycine-4’-fluoro stilbene 188. 
The deprotection was achieved in a quantitative yield. The salt was dried to yield a 
beige powder with a melting point of approximately 205oC. 
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7.3.2.1 IR NMR study of (E)-3,5-diamino derivatives 
Evidence of the nitro reduction can be seen from the IR spectra of the diamine-
isomers. Although some of the peaks proposed earlier as nitro based are present in the 
IR spectra of the diamino derivatives. Nitro stretching, asymmetrical and symmetrical 
occur in the general region around 1500 cm-1 and 1340 cm-1. The main peaks in these 
areas mentioned in the IR discussion of compound 175 have mostly disappeared in 
the corresponding IR spectrum of amine 177. However one absorption in particular, 
1509 cm-1, which was identified in the 4’-nitro compound 156 as an asymmetrical 
nitro stretch is also seen in the IR spectrum of the dinitrostilbene 175 (1506 cm-1) and 
is still present in the reduce diaminestilbene 177 (1507 cm-1). Stretching of an amine 
is normally observed between 3500 and 3300 cm-1, with the asymmetrical having a 
higher frequency to that of the symmetrical stretch. The trans-isomer 177 shows four 
absorptions within this region where as just two are observed in this area for the cis, 
with absorptions at 3424 and 3339 cm-1. A shoulder band is normally seen on the 
lower wavenumber side of these stretchings and can be seen for both isomers at 3193 
cm-1 (trans) and 3208 cm-1 (cis). This is due to the overtone of the N-H bending band. 
The N-H bending vibration of primary amines is observed in the spectral region of 
1650-1580 cm-1, and accounts for the strong absorptions at 1593 and 1585 cm-1 for 
trans and cis, respectively. The N-H wag is usually a strong broad band at 
approximately 910-665 cm-1 and is most likely the absorption at 834 cm-1 in the IR 
spectra of both isomers. 
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Figure 7.26: Infra red spectrum of (Z)-3,5-diamino-4’-fluorostilbene 178 
 
 
The IR spectrum of the trans-nitro-amino stilbene 179 is shown in Figure 7.27 is. All 
the relevant stretchings of a nitro and amino substituted trans-stilbene are present in 
this spectrum. The three absorptions seen at the highest frequencies are representative 
of the presence of a primary amine. The asymmetrical amine stretch can be seen at 
3472 cm-1 while the symmetrical stretch at 3373 cm-1. The broad shoulder absorption 
seen at 3224 cm-1 is as an overtone of the N-H bending band. The stretch of a trans-
orientated central stilbene double bond generally appears in the range 1640-1610 cm-
1
, and for compound 177 can be found at 1620 cm-1. The intense broad bands of the 
nitro stretches are also clearly visible. The asymmetrical stretching of the nitro group 
for this compound can be seen at 1531 and 1509 cm-1 while the symmetrical stretch is 
present at 1352 and 1333cm-1. The same clarity of absorptions can be seen in the IR 
of the cis-isomer 180, with the C=C stretch at 1635 cm-1. 
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Figure 7.27: Infra red spectrum of (E)-3-nitro-5-amino-4’-fluorostilbene 179 
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7.3.2.2 1H NMR study of (E)-3,5-diamino derivatives 
In the 1H NMR of the trans isomer, (E)-3,5-diamino-4’-fluorostilbene 177, a major 
chemical shift can be seen in the location of the aromatic protons of the amino-
substituted phenyl ring. The central para-proton in the 4 position has moved from δ 
8.66 to δ 5.80, while the protons at 3 and 5 have moved from δ 8.81 to δ 6.04, on 
reduction to the amine. Both signals maintained their coupling constants of 1.8 Hz 
and 2.0 for the latter. The aromatic protons of the fluorinated ring appear as a 
multiplet at a chemical shift of δ 7.59 for the 2’ and 6’ hydrogens and at δ 7.17 for the 
3’, 5’ triplet (J = 8.8 Hz). On reduction of the nitro groups to amines, the two doublets 
of the central vinylic bonds have merged into a doublet with a coupling constant of 
2.0 Hz and a chemical shift of δ 6.89 shown in Figure 7.28. However, outlining peaks 
at either side of this doublet which look like shadow peaks can be seen. The coupling 
constants between these small peaks and the main doublet are 16.8 Hz, within the 
anticipated coupling constant region for a trans-isomer. This may be due to a 
similarity in the electron-withdrawing effect of an electronegative fluorine versus two 
free amines. The free amines appear as a broad singlet with a chemical shift of δ 4.76.  
 
5.05.56.06.57.07.58.0 ppm
4.
75
6
5.
79
0
5.
79
5
5.
79
9
6.
03
4
6.
03
9
6.
89
0
6.
89
5
7.
15
1
7.
17
3
7.
19
5
7.
56
5
7.
57
0
7.
57
9
7.
58
7
7.
59
6
7.
60
1
 
Figure 7.28: 1H NMR spectrum of (E)-3,5-diamino-4’-fluorostilbene 177 
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The 13C NMR spectrum of the diamino stilbene 177, shown in Figure 7.29, shows 
small variations from that of the dinitro compound 175. The most noticeable shifts 
occur around the central double bond and adjoining aromatic quaternary carbons at 
positions 1 and 1’. After the reduction, the carbon at position 1 has moved slightly 
upfield to δ 137.5 while the doublet of the corresponding carbon on the other phenyl 
ring (1’) has moved down to δ 133.9, maintaining a small coupling constant of 3.0 Hz. 
The vinylic carbon nearest the fluorinated ring has migrated downfield to δ 130.0 with 
a coupling constant of 2.1 Hz, while on the amino side of the molecule, the vinylic 
carbon, like carbon 1 has shifted upfield by approximately 7 ppm to a chemical shift 
of δ 125.1. Large movement in the signals of the aromatic carbon of the amino phenyl 
ring can be seen, however the carbons directly attached to the amines hardly shifted at 
all and are present at δ 149.3. The protonated carbons of this ring show the most 
dramatic effect of reduction with the ortho-carbons moving from δ 125.9 for the 
dinitro compound 175 to δ 101.7 for the compound 177. The para-carbon, between 
the reduced amines also moved upfield to a chemical shift of δ 100.1. The remaining 
carbons of the fluorinated ring, ortho-, meta- and para-carbons retained almost 
identical chemical shifts on reduction. The location of the fluorine multiplet in the 19F 
NMR can be observed at a chemical shift of δ -114.97. 
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Figure 7.29: 13C NMR spectrum of (E)-3,5-diamino-4’-fluorostilbene 177 
F
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A similar signal due the vinylic protons of (Z)-3,5-diamino-4’-fluorostilbene 178 is 
seen in the 1H NMR spectrum, compared to that of the trans-isomer 177. These 
protons appear as a doublet with what appears to be shadow peaks surrounding it. 
This signal is present δ 6.38 and has a coupling constant of 3.2 Hz while coupling 
constant between shadow peaks and doublet is 12.4 Hz. The signals of the protons of 
the fluorinated ring are split due to coupling to the fluorine, with the ortho-protons 
split into a multiplet at δ 7.32 and the meta-protons, a triplet at δ 7.05 with a J value 
of 9.0 Hz. The three protons of the aminated ring appear as a multiplet at δ 5.71, and 
the broad amine singlet has a chemical shift of δ 4.68. 
 
The 1H NMR spectrum of the trans-isomer 179 shows the ortho-proton, adjacent to 
the nitro group as a singlet with a chemical shift of δ 7.58. The other ortho-proton of 
this molecule at position 6, beside the amine also appears as a singlet at δ 7.14. The 
para-proton of this compound, situated between the nitro and amino groups is part of 
the multiplet present in the range δ 7.15-7.35. Also included in this multiplet, which 
integrates for 5, are the vinylic protons and the aromatic hydrogens at positions 3’ and 
5’ on the fluorinated ring. The 2’ and 6’ protons have a chemical shift of δ 7.69 and 
maintain their multiplet splitting. An intense broad singlet, integrating for 2 can be 
observed at δ 5.86 and corresponds to the newly formed amino group.  
 
The 1H NMR of the cis-nitro-amino-stilbene derivative 180 shows an upshift in the 
chemical shifts of most of the proton signals. The ortho-proton has moved upfield to δ 
6.80 while the vinylic protons appear at δ 6.68 and δ 6.59 with coupling constants of 
12.4 and 12.0 Hz, respectively. The remaining six aromatic protons form two 
multiplets in the regions δ 7.23-7.28 and δ 7.10-7.14. The singlet due to the amine has 
is present at δ 5.80. 
 
The 13C NMR spectra of isomers 179 and 180 show interesting differences when 
compared to each other. The nitro and amine substituted carbons appear at δ 150.1 
and δ 149.2 (179) and δ 148.8 and δ 147.4 (180). The aromatic quaternary protons in 
the primary positions (1 and 1’) show the biggest difference in chemical shift. They 
appear at δ 138.9 and δ 133.1 with the 1’proton having a coupling constant of 3.3 Hz, 
for the trans- compound. For the cis-isomer, they can be observed at δ 150.1 and δ 
138.5. However the 1’ carbon is only seen to have one peak in this spectrum. The 
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vinylic carbons can be found at δ 128.9 and δ 127.0 for the trans-isomer and at δ 
130.3 and δ 128.7 for the cis. 
 
The vinylic coupling constant of the diacetylamino stilbene 181 was calculated as 
16.4 Hz from the doublets at δ 7.14 and δ 7.03. The amide protons appear as a singlet 
with a chemical shift of δ 9.99 while the protons of the acetyl groups have a chemical 
shift of δ 2.05, integrating for 2 and 6 respectively. In the 1H NMR of (E)-3,5-
di(trifluoroacetyl)amino-4’-fluorostilbene 182, the amide has a chemical shift of δ 
11.47. One of the vinylic doublets is obscured by the 3’ and 5’ protons signals 
forming a multiplet at δ 7.24 but the more upfield doublet is seen at a chemical shift 
of δ 7.18. This doublet has a coupling constant of 16.0 Hz, proving trans orientation. 
The 19F NMR of compound 182 shows 2 independent signals, integrating for 6 and 1. 
The trifluoroacetyl fluorines have a chemical shift of δ -73.87 and due to their 
equivalency appear as a singlet. The multiplet of the 4’-para-fluorine appears at δ -
113.53.  
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Figure 7.30: 13C NMR spectrum of (E)-3,5-di(trifluoroacetyl)amino-4’-fluorostilbene 182 
 
As with the 4’-trifluoroacetylamino analogue 162, the 13C NMR spectrum (Figure 
7.30) shows extremely large splitting due to 13C-19F coupling. As for all the 
F
H
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F3C
O
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O
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compounds synthesised with a 4’-fluorine, the 4’-carbon is split into a doublet with a 
chemical shift of δ 161.90 and a coupling constant of 243.8 Hz. The carbonyl of the 
trifluoroacetyl moiety is split into a quartet at δ 154.65 with a coupling constant of 
36.9 Hz. The trifluoro group of this moiety has a carbon signal also split into a 
quartet, but at a chemical shift of δ 115.69 with a coupling constant of 286.9 Hz. 
 
F
N
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X
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N
BOC
BOC
H'
H''
H'
H''
 
 
 Amide Chemical Shift (δ) 
 X H’ H’’ 
183 -CH2- 9.99 (s) 7.06* (m) 
184 -CH(CH3)- 9.98 (s) 7.06* (m) 
185 -CH2CH2- 10.00 (s) 6.85 (t) 
186 -CH(iPr)- 10.07 (s) 6.89 (d) 
187† -CH(iPr)- 9.69 (s) 6.81 (d) 
 
Table 7.6: 1H NMR chemical shifts of amide protons of amino acid derivatives 183-187 
                     *amide signal forms part of multiplet, stated chemical shift is central point of multiplet 
                  
†
mono-amino substituted compound 
 
The 1H NMR of the diaminoglycine derivative 183 shows the methylene protons of 
the glycine moiety as a doublet with a chemical shift of δ 3.74 and a coupling constant 
of 6.4 Hz. The methyl groups of the BOC protection group appear as a very intense 
singlet, integrating for 18 and at a chemical shift of δ 1.41. The doublets of the vinylic 
protons appear as part of the multiplets at δ 7.19 and δ 7.06. The fluorine NMR shows 
the 4’-multiplet at a chemical shift of δ -114.02. 
 
In the proton NMR spectrum of the di(amino-L-alanine) derivative 184, as in the case 
of the glycine analogue, the proton doublets of the central double bond appear at a 
similar chemical shift to that of other protons. In this case, one doublet makes up a 
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multiplet with the aromatic protons of the 3’ and 5’ positions while the other doublet 
is part of a multiplet with the alanine amide protons, in the region of δ 7.00-7.25. The 
α-H at the chiral centre of L-alanine is present at a chemical shift of δ 4.14. This 
signal is split into a quintet due to the adjacent methyl group and amide, and has a 
coupling constant of 7.2 Hz. The alanine methyl group appears as a doublet and is 
present at δ 1.27. This doublet has a coupling constant of 7.2 Hz, due to the coupling 
with the α-proton. The protons of the BOC group have a chemical shift of δ 1.39. 
 
The vinylic protons of the β-alanine analogue 185 appear independently as doublets 
and not as part of multiplets as was the case for the previous amino acid derivatives, 
183 and 184. The doublets have a chemical shift of δ 7.13 and δ 7.03 and coupling 
constants of 16.4 and 16.0 Hz. In the amino acid moiety, the methylene protons beside 
the carbonyl are split into a quartet with chemical shift of δ 3.23 and coupling 
constant of 6.8 Hz. The other methylene unit, adjacent to the β-alanine amine appears 
at a chemical shift similar to that of the deuterated solvent, dimethylsulphoxide 
(DMSO), at approximately δ 2.5. The BOC methyl groups for this compound have a 
chemical shift of δ 1.38. 
 
Confirmation of the trans-orientation of compound 186 is achieved from calculation 
of a coupling constant of 16.4 Hz from the vinylic doublet seen at a chemical shift of 
δ 7.08. The other doublet from the stilbene central double bond forms a multiplet with 
the aromatic protons in the 3’ and 5’ positions. The α-proton at the chiral centre of the 
valine unit has a chemical shift of δ 3.98 and is split into a triplet with coupling 
constant of 7.8 Hz. The C-H in the centre of the isopropyl valine side chain is split 
into a multiplet at δ 2.02 while the methyl groups of this side chain is present as a 
doublet at δ 0.94 with a coupling constant of 6.0 Hz. The protons of the protecting 
groups appear at a chemical shift of δ 1.41. 
 
The vinylic protons of (E)-3-amino-BOC-L-valine-5-amino-4’-fluoro stilbene 187 
appear in the same region as the proton in the 2 position, beside the amino acid 
substituent. They form a multiplet, integrating as 3 at a chemical shift of δ 6.99. A 
broad singlet due to the free amine appears at a chemical shift of δ 5.17 and integrates 
for 2 protons. The α-proton at the chiral centre is split into a triplet with coupling 
constant of 10.0 Hz and at a chemical shift of δ 3.91. The central proton of the 
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isopropyl side chain forms a multiplet at approximately δ 2.00 and the methyl groups 
of this side chain a doublet at δ 0.92 with a coupling constant of 2.0 Hz. The BOC 
protons are present at δ 1.40. 
 
 
In the 1H NMR (Figure 7.31), we can see evidence of the salt formation of the 
glycine stilbene 188. The N-terminus of the glycine unit appears a broad singlet which 
often indicates that it is a charged amine. Also the fact that this singlet integrates for 6 
protons is further evidence of its charged nature. The methylene unit of glycine is 
present at δ 3.84 and also occurs as a broad singlet, instead of a doublet as seen in the 
BOC protected compound 183. The amide that links the stilbene structure to the 
glycine is the most downfield signal seen in the 1H NMR. It can be observed as an 
intense singlet with a chemical shift of δ 10.67. The aromatic protons of the 
aminoglycine substituents appear as a singlet and doublet. The proton between the 
substituents, in the para position has a chemical shift of δ 7.89 while the ortho-
protons at δ 7.58 are split into a double with a coupling constant of 1.2 Hz. The 
hydrogens of the para-substituted fluorine ring are both found to be or be part of, a 
multiplet with the 2’ and 6’ protons forming a multiplet at δ 7.70 and the 3’ and 5’ 
protons make up a multiplet with one of the vinylic signals. This has a chemical shift 
of δ 7.22. The second vinylic proton is split into the normal doublet at δ 7.08 and has 
a coupling constant of 16.0 Hz, indicating the trans orientation.  
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Figure 7.31: 1H NMR spectrum of (E)-3,5-di(aminoglycine)-4’-fluorostilbene 
trifluoroacetate salt 188 
 
 
Evidence of the trifluoroacetate salt can be clearly seen from the 19F NMR spectrum. 
This spectrum shows two signals, integrating as 6 and 1 (Figure 7.32). The large 
singlet at δ -73.84 integrates for 6 and is due to the trifluoromethyl group of the salt. 
There are two trifluoroacetate salt moieties in compound 188, each with 3 fluorines. 
The much less intense multiplet is from the para-substituted fluorine. This signal has 
a chemical shift of -113.76.  
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Figure 7.32: 19F NMR spectrum of (E)-3,5-di(aminoglycine)-4’-fluorostilbene trifluoroacetate 
salt 188 
 
 
Evidence of the salt can also be seen in the carbon NMR.  At a chemical shift of δ 
158.4, the quartet of the salt carbonyl can be seen with a coupling constant of 129.7 
Hz. Also the quartet of the trifluoromethyl group is visible, in the approximate range 
of δ 110-120.  
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8.0 Biological activity of novel resveratrol analogues 
 
8.1 Introduction 
 
Resveratrol 136 has been shown to prevent and slow the progression of a wide variety 
of illnesses, including cancer, cardiovascular disease and ischaemic injuries, as well 
as enhance stress resistance and extend the lifespans of various organisms from yeast 
to vertebrates. The mechanism by which resveratrol exerts such a range of beneficial 
effects across species and disease models is not yet clear. Cancer prevention is one of 
the mostly widely researched areas today. Resveratrol has been identified as an 
effective candidate for cancer chemoprevention due to its availability to block each 
step in the carcinogenesis process by inhibiting several molecular targets1. It has been 
shown to inhibit the growth of various cancers cell lines. Resveratrol has also been 
shown to provide cancer chemopreventative effects in different systems based on its 
potent inhibition of diverse cellular events associated with tumour initiation, 
promotion and progression2. 
  
The term cancer is used for diseases which are characterised by uncontrolled, 
abnormal cell division and are capable of spreading and invading other tissues3 
Cancer cells can spread through the blood and lymph systems to other parts of the 
body. It is not just one disease but many diseases. There are more than 100 different 
types of cancer. Most cancers are named for the organ or type of cell in which they 
start, for example basal cell carcinoma is a cancer that originates in the basal cells of 
the skin. There is much reported evidence that resveratrol can act on the 
carcinogenesis process by affecting the three phases: tumour initiation, promotion and 
progression phases. It appears that resveratrol can prevent metabolic activation, ROS 
production, adduct formation and stimulate metabolic inactivation. Resveratrol is also 
able to act against the chemical carcinogens and other various stimuli by several 
mechanisms such as activation of apoptosis, arrest of the cell cycle or inhibition of 
kinase pathways4. Resveratrol can suppress the later steps of carcinogenesis, namely 
angiogenesis and metastasis. Ideally chemopreventive agents act at safe doses 
effectively affecting the carcinogenic process without toxicity. 
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Chemoprevention can be defined as the prevention or reduction of cancer risk by the 
ingestion of natural or synthetic compounds with low toxicity that are able to 
suppress, delay or reverse carcinogenesis. The use of tamoxifen 189 in breast cancer 
is one of the best examples of chemoprevention5. This stilbene derivative is 
administered for five years following surgery for breast cancer and it has been found 
to reduce the risk of tumour recurrence. The cancer chemopreventative activity of 
resveratrol 136 is believed to be due to its ability to activate apoptosis. Apoptosis is a 
type of cell death in which a series of molecular steps in a cell leads to its death. This 
is the body’s normal way of eliminating unneeded or abnormal cells. Commonly used 
chemotherapeutic drugs can induce this programmed cell death. Apoptosis is 
therefore a common mechanism for the removal of unrepairable genetic lesions from 
cells. The enhancement of apoptosis in pancreatic cells by resveratrol has been 
reported for in vitro studies and is associated with mitochondrial depolarization and 
cytochrome c release followed by caspase-3 activation6. It has been reported that 
resveratrol has the ability to selectively induce apoptosis in leukemic cells lines but 
not in normal haematopoietic cells7. The p53 gene is one of the most important 
tumour suppressor genes, and mutation or loss of this gene is believed to be 
responsible for more than half of human cancers8. The p53 gene is critical for 
apoptosis and lack of p53 expression or function is associated with an increased risk 
of tumour formation. Resveratrol induces p53 dependent transcriptional activation. 
Resveratrol triggered apoptosis occurs in cells expressing p53 but not in p53 deficient 
cells. This resveratrol-induced activation of p53 is also partly due to the activities of 
extracellular signal regulated protein kinases and p38 kinase and their 
phosphorylation of p53 at serine 15 that plays a critical role in the stabilization, up-
regulation and functional activation of p539. 
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The biological evaluation of resveratrol derivatives has focussed on assessing the 
inhibition against leukemic cell lines10. Protection of the hydroxyl groups by esters 
and ethers has provided potent cell growth inhibitors of leukaemia. Few published 
inhibitors have reached the levels of bioactivity of resveratrol, with the 4’-acetyl 
derivative 152 showing slightly better potency than that of resveratrol. This analogue 
was part of a series synthesised and tested against human leukaemia HL-60 cells10. 
3,5-Dihydroxy-4’-acetoxystilbene prepared by Andrus et al had an ED50 of 17 µM, 
which when compared to that of resveratrol (23 µM), shows a slight improvement. 
The introduction of a fluorine atom often brings about an improvement in bioactivity 
mainly due to the alteration of metabolism and increased lipophilicity. Fluorination of 
the resveratrol structure has also been reported over the past few years, with fluorine 
substitution on the central vinyl double bond being reported in 200111. Andrus et al 
have also synthesised fluorinated stilbene derivatives, maintaining the resveratrol 
substitution pattern and replacing the hydroxyl groups with fluorine atoms. However 
in this report it is stated that they were unable to assess toxicity profiles in leukaemia 
cell lines for these fluorinated analogues10. Contrary to this statement, identical 
analogues of resveratrol were prepared at the same time in our laboratory12. Testing of 
these derivatives was carried out on non-small cell lung carcinoma cell lines. Results 
generated in our laboratory have shown that these fluorinated analogues possess 
levels of bioactivity comparable to the parent compound resveratrol 136, and in some 
cases increased potency was found. Preliminary biological assays carried out by the 
National Cancer Institute (NCI) have indicated that various fluorinated analogues 
synthesised in our laboratory exhibited anticancer activity against a variety of tumour 
cell lines12.  
 
It is hoped that by maintaining the resveratrol substitution pattern and utilising 
fluorine substitution, the production of potent selective drugs with anticancer activity 
can be achieved. Also by way of a further modification, an alteration of the resveratrol 
structure, utilising a known hydroxyl chemical-isostere, the amino group, greater 
chemotherapeutic effects can be observed. 
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8.2   Lung cell carcinoma assays 
 
For the purpose of this project, the bioactivity of resveratrol derivatives was assessed 
by assaying against non-small cell lung carcinoma cell lines. The in vitro model 
chosen for investigating the potential of the resveratrol compounds was the DLKP-A 
cell line. The DLKP-A cell line is a daughter cell line of DLKP, a poorly 
differentiated squamous cell lung carcinoma. DLKP-A’s main mechanism of 
multidrug resistance (MDR) is via the P-glycoprotein (P-gp) membrane pump. It 
highly expresses P-gp, while expressing very low levels of multidrug resistance 
protein 1 (MRP1). Derivatives that showed inhibitory potency against the lung cell 
lines were then subjected to further investigations into their bioactivity when 
combined with a known chemotherapeutic agent. The known active agent used for 
combination studies was epirubicin 190. 
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Multidrug resistance (MDR) is a major cause of failure of cancer chemotherapy. 
MDR is a phenomenon whereby tumour cells in vitro that have been exposed to one 
cytotoxic agent develop cross-resistance to a range of structurally and functionally 
unrelated compounds. This resistance is often due to the elevation in the expression of 
particular proteins, such as cell membrane transporters, which can result in an 
increased efflux of cytotoxic drugs from the cancer cells13. The protein of interest in 
this report is P-glycoprotein (P-gp). It is a member of the ATP-binding cassette 
(ABC) family. The protein binds ATP and uses the energy to drive the transport of 
various molecules across all cell membranes. P-gp is a transmembrane protein with a 
very broad specificity to the substrates it pumps out of the cells. One effective way of 
overcome P-gp-mediated drug resistance is either to block its drug pump function or 
to inhibit its expression. Many agents that modulate the function of P-gp have been 
identified, including calcium channel blockers, calmodulin antagonists, steroidal 
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agents, protein kinase C inhibitors, immunosuppressive drugs, antibiotics, and 
surfactants14. 
 
A cross section of some 13 compounds synthesised were selected for biological 
investigation. A commercially purchased sample of resveratrol 136 (Sigma Aldrich, 
R5010) was used as a control in all assays performed. These compounds were firstly 
selected on their solubility properties in aqueous solutions. Dimethylsulphoxide was 
used to solubilise the compounds in question, before solubility of the solution was 
tested in media. A minimum concentration of 0.5 mg/ml in the media was required for 
a compound to undergo biological evaluation. This is due to the adverse effects of 
DMSO on the cells. Of the resveratrol derivatives reported in this thesis, thirteen 
analogues passed the preliminary solubility test and were subsequently assessed for 
bioactivity.  
 
 
8.3  Biological Results 
 
As a control and for comparison purposes assays on both cell lines, DLKP and 
DLKP-A, were performed with resveratrol 136. Combination assays with the chemo 
drug epirubicin 190 were also carried out. An IC50 value of 10 ± 2 µM was calculated 
for resveratrol with DLKP while a value of 15 ± 3 µM was found when assayed 
against the daughter cell line DLKP-A. The bar charts shown in Figure 8.1 and 8.2 
demonstrate the increase in activity when 136 is combined with the P-glycoprotein 
substrate, epirubicin.  
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Figure 8.1: Combination assay of 136 with epirubicin on the DLKP cell line.  
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Figure 8.2: Combination assay of 136 with epirubicin on the DLKP-A cell line.  
 
In the DLKP assay, resveratrol inhibits growth by over 60% at the lowest 
concentration used. Some synergy is noted with this combination (Epi 10 nM and Res 
10 µM).  In the assay of cell line DLKP-A, resveratrol causes a 50% growth inhibition 
at 15 ± 3 µM.  In combination with epirubicin synergy is consistently observed in this 
P-glycoprotein rich cell line. 
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The trans-fluorinated nitrostilbenes (156 & 175), were tested for bioactivity and also 
for their effect when in combination with the drug, epirubicin. Solubility was an issue 
with these trans-derivatives, with the 4’-nitro remaining in solution only at 1 mg/ml 
and the 3,5-nitro only just remaining soluble at the limit of 0.5 mg/ml. However, as 
with the reduced stilbene structure 171 these trans-nitro compounds, both 4’-NO2 and 
3,5-NO2, showed no cell kill when assayed with the lung cancer cell line. (E)-3,5-
Difluoro-4’-nitrostilbene 156 showed no alteration in the bioactivity levels in the 
combination tests while the (E)-3,5-dinitro analogue 175 was found to be slightly 
antagonist in combination with epirubicin. The cis-isomers (157 & 176) of the 
respective nitro compounds both failed the solubility pretest so biological activity 
could not be assessed. 
  
The amino derivatives were then subjected to testing. The trans-amino-isomers (158 
& 177) and the cis-amino analogue 159, were subjected to biological investigation. 
(E)-3,5-Difluoro-4’-aminostilbene 158 was readily soluble although when tested, 
results indicated that the presence of this potential inhibitor had an adverse effect and 
actually increased cell growth. No effect was seen for the drug interaction study with 
epirubicin. (Z)-3,5-Difluoro-4’-aminostilbene 159 showed identical results to the 
corresponding trans-isomer, increasing DLKP-A growth and showing no effect in 
combination assays. However, the trans-diamino compound 177 showed positive 
results in the DLKP and DLKP-A assays, albeit with weak potency. The calculated 
IC50 for this compound, with respect to both cell lines was outside the parameters of 
the experiment design (> 50 µM). At 50 µM, analogue 177 caused 22 ± 3 % and 10 ± 
3 % cell kill in the DLKP and DLKP-A cell lines, respectively. Compound 177 shows 
minimal growth inhibition at 50 µM. When in combination with epirubicin an 
increase in activity was observed, as can be seen in Figure 8.3. This suggests that the 
alteration made to the structure had no effect on toxicity but may enhance the effects 
of epirubicin. 
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Figure 8.3: Combination assay of 177 with epirubicin on the DLKP cell line.  
 
Both of the cis-carbamyl derivatives (163 & 164) proved soluble enough for 
determination of biological potency with the lung cancer cell lines. The 
dimethylcarbamoyl derivative 163 displayed an increase in the cell growth after assay 
incubation and was shown to have an antagonistic effect when combined with the 
known P-gp substrate, epirubicin. The morpholine analogue 164 showed no effect in 
either assay, by itself or in combination. Theses results along with the results of other 
cis-isomers tested shows that the trans-orientation is indeed necessary for activity. 
 
 136 161 169 177 181 182 188 
DLKP 10 ± 2 39 ± 2 unknown > 50 > 50 28 ± 4 unknown 
DLKP-A 15 ± 3 n/a* 20 ± 10 > 50 > 50 n/a* > 50 
 
Table 8.1: IC50 values (µM) of selected resveratrol derivatives on the non-small lung cell carcinoma 
cell lines, DLKP and DLKP-A. 
*Due to DMSO effects, IC50 calculations not possible 
 
Of the trans-amino-substituted compounds tested, both acetyl (161 & 181) and the 
ditrifluoroacetyl compound 182 were viable candidates for potency analysis. The 4’-
trifluoroacetyl derivative 162 failed to remain fully in solution when added to media. 
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The three soluble compounds were subjected to assays with both DLKP and its 
daughter cell line, DLKP-A. From the results of the biological tests on the DLKP cell 
line, the calculated IC50 of the 4’-acetyl derivative 161 was found to lie above 30 µM. 
The corresponding alternative compound, the 3,5-diacetyl analogue 181 had a 
calculated IC50 greater than 50 µM, which is outside the parameters of the 
experimental design. Of all the stilbene compounds tested, the best IC50 value 
recorded was seen for the ditrifluoroacetyl compound 182. It was found to have a 
50% inhibitory concentration (IC50) of 28 ± 4 µM against the DLKP cell line. 
Although the diacetyl derivative had IC50’s greater than 50 µM for both cell lines, it 
was estimated from the assay data that at a concentration of 50 µM, there was a 32 
and 44 percentage reduction in cell proliferation in DLKP and DLKP-A cell lines. As 
can be seen in Table 8.1, for the 4’-acetyl 161 and the di(trifluoroacetyl) 182 
compounds an IC50 value was not possible to determine due to the effects of DMSO 
on the DLKP-A assays. 
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Figure 8.4: Combination assay of 161 with epirubicin on the DLKP cell line.  
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Figure 8.5: Combination assay of 182 with epirubicin on the DLKP cell line.  
 
Figures 8.4 and 8.5 show bar charts demonstrating the increases in activity on the 
DLKP cell line when stilbenes 161 and 182 are in combination with epirubicin. At a 
concentration of 39 ± 2 µM, 161 inhibits growth by 50%, which when compared to 
that of resveratrol is less toxic. When in combination with epirubicin, an increase in 
activity is observed. This also suggests that the alterations made to the structure 
decrease its toxicity while maintaining its ability to interact with pathways relevant to 
chemotherapy response in the cell. For the ditrifluoroacetyl stilbene 182, the IC50 
concentration was determined to be of 28 ± 4 µM. This is again less toxic than 
resveratrol. As with the other compounds tested and reported so far, when in 
combination with epirubicin synergy is seen in the DLKP-A cell line. 
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Figure 8.6: Combination assay of 161 with epirubicin on the DLKP-A cell line.  
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Figure 8.7: Combination assay of 182 with epirubicin on the DLKP-A cell line.  
Figure 8.6 illustrates the effect that the analogue 161 can have on the DLKP-A cell 
line alone and in combination with the known chemotherapeutic drug epirubicin 190. 
The IC50 of 161 is not achievable using this method of analysis due to the adverse 
effects of DMSO on the cells at the higher concentrations (indicated by stars). 
However, the combination of 1 µM or 1.5 µM epirubicin with 10 µM stilbene 161 
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yields an additive interaction in this cell line. Significant increases in the activity 
when combined are evident, compared to the values seen individually. As with 161, 
the IC50 of 182 is not achievable due to DMSO concentration (indicated by stars). But 
again when the combination of 10 µM 182 with 1 µM or 1.5 µM epirubicin is studied, 
synergy is evident in the DLKP-A cell line. 
 
Note: 
Analogue 161 at 10 µM requires a 1% DMSO solution while 182 requires a 1.5% 
DMSO solution but this has a negligible effect on cell survival. 
*
  161 30 µM requires a 3% DMSO solution and causes 10% growth inhibition. 
**  161 50 µM and 182 30 µM, require a 5% DMSO solution and causes 44% 
growth inhibition. 
***
  182 50 µM requires an 8.6% DMSO solution and causes 70% growth inhibition. 
 
The final two compounds in this project that were tested were the amino acid salts. 
Only the deprotected compounds were assayed due to solubility, being caused by the 
large aliphatic t-butyl moiety of the protection group. Once deprotected there was no 
issue with solubility or with DMSO effects as the deprotected amino acids were 
isolated as trifluoroaceate salts. This salt formation made the stilbene analogues 
highly hydrophilic and therefore no DMSO was required to solubilise the products. 
Both glycine salt analogues (169 & 188) were assayed against both the DLKP and 
DLKP-A cell lines and in combination with the drug epirubicin 190. The 4’-glycine 
analogue 169 inhibited cell growth by 20% at 10 µM but when the concentration was 
increased to 30 µM, the growth inhibition increased to 100%. From this we can 
conclude that the IC50 of compound 169 is in the region between 10-30 µM, for the 
DLKP cell line. The IC50 of the 3,5-di(glycine) salt 182 was found to be greater than 
50 µM and therefore not viable for further individual assay investigations.  
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Figure 8.8: Combination assay of 169 with epirubicin on the DLKP-A cell line.  
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Figure 8.9: Combination assay of 188 with epirubicin on the DLKP-A cell line.  
 
From the chart displayed in Figure 8.8, we can see the epirubicin has inhibits cell 
growth by 35% at a concentration of 0.5 µM in DLKP-A, and 58 % when the 
concentration is increased to 1.5 µM. The 4’-glycine analogue 169 when tested with 
DLKP-A at 10 µM inhibited growth by 22%. However, when this was combined with 
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epirubicin (0.5 µM) the growth inhibition increased to 40% and when the higher 
concentration of epirubicin was used (1.5 µM) it increased to almost 74%. Therefore 
at the higher concentration, the increase was greatest, increasing by almost 28% 
compared to epirubicin alone. 
 
Figure 8.9 shows the results from the DLKP-A assays of the di(glycine) salt 188 and 
epirubicin. As seen in all of the combination assays epirubicin alone inhibits growth 
by approximately 30 ± 7 % at a concentration of 0.5 µM and 60 ± 8 % at 1.5 µM. This 
bar chart shows combination assays for both P-gp substrate concentrations and at 
three different stilbene concentrations. It is clear that, as with all the other stilbene 
compounds that were tested, a noticeable increase in activity is found when both 
compounds are combined.  This amino acid derivative however only really starts to 
show a significant effect when the concentrations are increased to 50 µM. 
 
A side investigation into the importance of the basic 3,4’,5-substitution pattern and 
the central vinylic bond was assessed by bioassay. Compounds 170-173 were 
analysed for solubility in the media. From this preliminary screen only the amino 
version of the diphenylethene analogue 171 was sufficiently soluble to carry out the 
bioassay against the cell lines, DLKP and DLKP-A. The ethylene derivative 171 was 
found to remain in solution up to a concentration of 5 mg/ml. However, when assayed 
with DLKP-A, no effect was seen. When combined with the known chemotherapeutic 
epirubicin 190, neither an increase nor decrease in the effect of the drug was seen. 
This investigation emphasises the importance of the maintaining the basic structure of 
the resveratrol compound. Whether it is for active site binding factors or for basic 
solubility reasons, substitutions of both phenyl rings and more importantly 
maintaining the central vinylic bond are essential. 
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9.0 Conclusion 
 
In summary, the synthesis and structural characterisation of novel analogues of the 
stilbene resveratrol was preformed. By maintaining the basic resveratrol substitution 
pattern, derivatives were synthesised with a variety of different atoms and functional 
groups as substituents. This was achieved with the aim of emulating or surpassing the 
biological potency of the parent compound resveratrol.  Previous work in our 
laboratory has shown that replacement of the hydroxyl groups by fluorine atoms has 
minor effects on the biological activity of the stilbene analogues. Bearing this in 
mind, two contrasting series of fluorinated analogues were synthesised, one with 3,5-
fluorine substitution on the ‘A’ ring and the other with the 4’-hydroxyl replaced with 
a fluorine. In remaining resveratrol substitution sites, 4’- and 3,5-, respectively, the 
known hydroxyl chemical isostere, the amino group, was utilised. These fluoro-amino 
resveratrol derivatives were synthesised from reduction of the corresponding nitro 
groups. Amino-substituted analogues were also prepared for comparison to 
hydroxylated derivatives previously reported.  
 
The importance of key components of the resveratrol structure was also investigated 
and evaluated on their bioactivity. From results gathered it is shown that the central 
saturated unit of the stilbene structure is critical for maintaining the potency, as is the 
substitution pattern of the phenyl rings. 
 
Although computer modelling studies of the interaction and binding site of resveratrol 
have yet to be carried out, it is clear from assays performed, that a few areas of the 
resveratrol structure are critical for maintaining bioactivity. Firstly, as only the trans-
isomer of resveratrol shows activity, it can be stated that the planar orientation must 
be maintained. This was demonstrated in the synthesis of a variety of cis-analogues 
which all showed no effect when tested with cancer cells. Steric repulsion of the 
phenyl rings and substituents renders the cis-isomer non-planar. Another factor is that 
as resveratrol is such a small simple molecule, this may be the reason for the vast 
array of biological properties reported. Therefore, preserving the simplicity of the 
molecule must be an integral part of the design suitable derivatives. For this reason it 
was attempted to keep the substituents as small and as simple as possible. 
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Solubility was a major factor in the search for increased activity with the nitro 
compounds and this led to the synthesis of amino acid derivatives. Although once 
deprotected, solubility problems did not occur, although the bulk and flexibility of a 
side chain was a concern. The assays preformed on these showed a similar pattern to 
the amino analogues.  
 
Biological evaluation of these fluoro-amino derivatives was assessed by the 
interaction with non-small lung cell carcinomas. Solubility was a constant factor in 
the assays and was the cause of many problems due to required levels of 
dimethylsulphoxide. From the preliminary results of the assays preformed it can be 
assumed that replacement of the hydroxyl moiety by a nitro or an amino group does 
not increase the activity, however certain analogues developed have shown 
encouraging results when in combination with a known chemotherapeutic  drug. 
 
These results indicate that fluorinated amino analogues of resveratrol have the 
potential to be active inhibitors of carcinogenesis but require further modification. It 
is hoped that derivatisation of the amino analogues will improve the potency of these 
derivatives 
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10.0 Experimental 
 
All chemicals were purchased from Sigma-Aldrich, Lennox Chemicals or Fluorochem 
Limited; and used as received.  Commercial grade reagents were used without further 
purification. When necessary all solvents were purified and dried; and stored under 
argon.  Triethylamine distilled and stored over potassium hydroxide pellets.  Riedel-
Haën silica gel was used for thin layer and column chromatography.  Melting point 
determinations were carried out using a Stuart melting point (SMP3) apparatus and 
are uncorrected.  Elemental Analysis was carried out by the Microanalytical 
Laboratory at University College Dublin.  Electrospray ionisation mass spectra were 
obtained on a Bruker Esquire 3000 series ion trap mass spectrometer. IR spectra were 
obtained on a Perkin-Elmer Spectrum GX FT-IR system. UV spectra were obtained 
on a UV-Vis-NIR Perkin-Elmer Lambda 900 spectrometer. NMR spectra were 
obtained on a Bruker AC 400 NMR spectrometer operating at 400 MHz for 1H NMR, 
376 MHz for 19F NMR and 100 MHz for 13C NMR.  The 1H and 13C NMR chemical 
shifts (δ) are relative to trimethylsilane and the 19F NMR chemical shifts (δ) are 
relative to trifluoroacetic acid.  All coupling constants (J) are in Hertz (Hz). 
 
(E/Z)-3,5-difluoro-4’-nitrostilbene 156/157 
3,5-Difluorobenzyl triphenyl phosphonium bromide 
(11.7 g, 25 mmol) and 4-nitrobenzalhyde (4.7 g, 31.25 
mmol) were dissolved in dichloromethane (150 ml) and 
stirred at room temperature. A 50% w/v sodium 
hydroxide solution was added dropwise to the stirred solution [0.4ml NaOH solution 
per 1 mmol of aldehyde]. The solution was stirred at room temperature for 1 hour then 
washed with brine and water. The solvent was removed in vacuo to yield both isomers 
as a yellow solid. Recrystallisation from ethanol gave the trans isomer as a bright 
yellow powder 156 (3.2 g, 49%). Crystals of 156 suitable for X-ray analysis were 
grown from toluene. The resulting mother liquor was evaporated to dryness to yield 
the cis product as a pale yellow powder 157 (3.0 g, 46%).  
Trans isomer (156)  
m.p. 199-201 oC 
Anal. calcd. for C14H9NO2F2: C, 64.37; H, 3.47; N, 5.36.  
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Found C, 64.12; H, 3.47; N, 5.21 
IR (KBr): υ 3085, 2929, 2831, 2442, 2209, 1927, 1793, 1726, 1618, 1589, 1509, 
1439, 1336, 1116, 974, 865, 748, 707, 691, 665 cm-1. 
UV (λmax) (ACN): 337 nm. 
1H NMR (400 MHz, DMSO-d6): δ 8.27 (2H, d, J = 8.8 Hz, -ArH 3’ & 5’), 7.86 (2H, 
d, J = 9.2 Hz, -ArH 2’ & 6’), 7.59 (1H, d, J = 16.4 Hz, -CH), 7.51 (1H, d, J = 16.4 Hz, 
-CH-), 7.43 (2H, m, -ArH 2 & 6), 7.21 (1H, tt, J = 2.4 & 9.2 Hz, -ArH 4). 
13C-NMR (100 MHz, DMSO-d6): δ 162.8 (d, J = 244.2 Hz, -CF ), 162.6 (d, J = 244.0 
Hz, -CF), 146.6 (-ArC 4’), 143.1 (-ArC 1’), 140.2 (t, J = 9.9 Hz, (-ArC 1), 130.8 (-
CH), 129.3 (-CH), 127.6 (-ArC 2’ & 6’), 124.1(-ArC 3’ & 5’), 109.9 (d, J = 25.6 Hz, -
ArC 2 & 6), 103.6 (t, J = 25.9 Hz, -ArC 4). 
19F-NMR (376 MHz, DMSO-d6): δ -109.82 (2F, t, J = 9.4 Hz,). 
Cis isomer (157)  
m.p. 73-75 oC 
Anal. calcd. for C14H9NO2F2: C, 64.37; H, 3.47; N, 5.36.  
Found C, 64.35; H, 3.67; N, 5.16 
IR (KBr): υ 3106, 3081, 2836, 2442, 1928, 1640, 1587, 1503, 1447, 1432, 1340, 
1321, 1179, 1127, 1104,996, 970, 882, 860, 842, 767, 750, 732, 695, 666 cm-1. 
UV (ACN): λmax 314 nm. 
1H NMR (400 MHz, DMSO-d6): δ 8.17 (2H, d, J = 9.2 Hz, -ArH 3’ & 5’), 7.48 (2H, 
d, J = 8.4 Hz, -ArH 2’ & 6’), 7.17 (1H, tt, J = 2.4 & 9.4 Hz, -ArH 4) 6.84-6.92, (4H, 
m, -ArH 2 & 6, -CH, -CH). 
13C-NMR (100 MHz, DMSO-d6): δ 162.4 (d, J = 245.0 Hz, -CF), 162.3 (d, J = 244.7 
Hz, -CF), 146.4 (-ArC 4’), 143.0 (-ArC 1’), 139.6 (t, J = 9.9 Hz, -ArC 1), 130.9 (-CH 
), 130.4 (-CH), 129.8 (-ArC 2’ & 6’), 123.7 (-ArC 3’ & 5’), 111.6 (d, J = 25.5 Hz, -
ArC 2 & 6), 103.3 (t, J = 25.8 Hz, -ArC 4). 
19F-NMR (376 MHz, DMSO-d6): δ -109.57 (2F, t, J = 8.0 Hz,). 
 
(E)-3,5-difluoro-4’-aminostilbene 158 
(E)-3,5-difluoro-4’-nitrostilbene (1.42 g, 5.4 mmol) 
was dissolved in a 10:1 mixture of ethanol and acetic 
acid (22 ml) and heated to reflux temperature.  Iron 
(III) chloride hexahydrate (0.25 g, 0.93 mmol), 
followed by iron pindust (2.22 g, 39.7 mmol) was added with vigorous stirring and 
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the solution refluxed for 3 hours.  The solution was filtered and diluted with water. 
The product was extracted with diethyl ether and dried over sodium sulphate.  
Purification by column chromatography with hexane/ethyl acetate as eluant yielded 
compound 158 as a brown powder (1.1 g, 88%). 
m.p. 110-112 oC 
Anal. calcd. for C14H11NF2: C, 72.72; H, 4.79; N, 6.06.  
Found C, 72.48; H, 4.90; N, 5.97 
Mass Spectrum: [M+H]+ found 232.4 
C14H12NF2 requires, 232.24 
IR (KBr): υ 3483, 3466, 3396, 3380, 3206, 3091, 3025, 1894, 1617, 1586, 1447, 
1429, 1312, 1268, 1183, 1138, 1116, 997, 979, 965, 881, 839, 818, 670 cm-1. 
UV (ACN): λmax 315 nm; 242 (sh), 339 (sh) nm. 
1H NMR (400 MHz, DMSO-d6): δ 7.20-7.30 (5H, m, -ArH 2’, 6’, -CH, -ArH 2 & 6), 
7.00 (1H, tt, J = 2.2 & 9.4 Hz, -ArH 4), 6.89 (1H, d, J = 16.4 Hz, -CH), 6.57 (2H, d, J 
= 8.4 Hz, - ArH 3’ & 5’), 5.45 (2H, s, -NH2). 
13C-NMR (100 MHz, DMSO-d6): δ 162.7 (d, J = 242.9 Hz, -CF ), 162.6 (d, J = 243.0 
Hz, -CF), 149.4 (-ArC 4’), 142.1 (t, J = 9.8 Hz, -ArC 1), 132.1 (-CH ), 128.1 (-ArC 
2’& 6’), 123.7 (-ArC 1’), 120.3 (-CH), 113.7 (-ArC 3’ & 5’), 108.2 (d, J = 25.1 Hz, -
ArC 2 & 6), 101.2 (t, J = 26.1 Hz, -ArC 4). 
19F-NMR (376 MHz, DMSO-d6): δ -110.55 (2F, t, J = 7.5 Hz,). 
 
(Z)-3,5-difluoro-4’-aminostilbene 159 
(Z)-3,5-difluoro-4’-nitrostilbene (1.0 g, 3.8 mmol) was dissolved 
in a 10:1 mixture of ethanol and acetic acid (22 ml) and heated to 
reflux temperature.  Iron (III) chloride hexahydrate (0.18 g, 0.65 
mmol), followed by iron pindust (1.56 g, 28.0 mmol) was added 
with vigorous stirring and the solution refluxed for 3 hours.  The 
solution was filtered and diluted with water. The product was extracted with diethyl 
ether and dried over sodium sulphate.  Purification by column chromatography with 
hexane/ethyl acetate as eluant furnished 159 as a brown oil (1.0 g, 80%). 
b.p. 180-185 oC 
Anal. calcd. for C14H11NF2: C, 72.72; H, 4.79; N, 6.06.   
Found C, 72.52; H, 4.93; N, 5.88 
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IR (ATR): υ 3461, 3372, 3214, 3010, 1616, 1603, 1583, 1514, 1445, 1429, 1307, 
1176, 1113, 988, 966, 871, 830, 794, 666 cm-1. 
UV (ACN): λmax 238 nm; 314, 336(sh) nm. 
1H NMR (400 MHz, DMSO-d6): δ 7.05 (1H, tt, J = 2.2 & 9.2 Hz, -ArH 4) 6.93 (4H, 
d, J = 8.4 Hz, -ArH 2, 6, 2’ & 6’), 6.55 (1H, d, J = 12.4 Hz, -CH), 6.46 (2H, d, J = 8.4 
Hz, -ArH 3’ & 5’), 6.29 (1H, d, J = 12.4 Hz, -CH), 5.34 (2H, s, -NH2). 
13C-NMR (100 MHz, DMSO-d6): δ 162.3 (d, J = 243.8 Hz, -CF ), 162.2 (d, J = 243.7 
Hz, -CF), 148.7 (-ArC 4’), 141.6 (t, J = 9.9 Hz, -ArC 1), 133.0 (-CH ), 129.7 (-ArC 
2’& 6’) , 123.3 (-CH), 122.8 (-ArC 1’), 113.4 (-ArC 3’ & 5’), 111.2 (d, J = 25.1 Hz, -
ArC 2 & 6), 102.0 (t, J = 25.8 Hz, -ArC 4). 
19F-NMR (376 MHz, DMSO-d6): δ -110.47 (2F, t, J = 8.8 Hz,). 
 
(E)-3,5-difluoro-4’-dimethylaminostilbene 160 
3,5-Difluorobenzyl triphenyl phosphonium bromide 
(2.5 g, 5.33 mmol) and 4-dimethylaminobenzaldhyde 
(0.99 g, 6.66 mmol) were dissolved in dichloromethane 
(40 ml) and stirred at room temperature. A 50% w/v 
sodium hydroxide solution (2.6 ml) was added 
dropwise to the vigorously stirred solution [0.4ml NaOH solution per 1 mmol of 
aldehyde] stirring continued at room temperature for a further 3 hours before washing 
with brine and water. The solvent was removed in vacuo to yield a mixture of 
isomers. Recrystallisation from ethanol gave the trans product 160 as yellow crystals 
(0.45 g, 32%). 
m.p. 139-141 oC 
Anal. calcd. for C16H15NF2: C, 74.11; H, 5.83; N, 5.40.  
Found C, 74.19; H, 5.96; N, 5.38 
IR (KBr): υ 3094, 3020, 2898, 2862, 2810, 2359, 1883, 1599, 1522, 1445, 1355, 
1316, 1220, 1194, 1116, 977, 964, 876, 841, 805, 674 cm-1. 
UV (ACN): λmax 364 nm. 
1H NMR (400 MHz, DMSO-d6): δ 7.43 (2H, d, J = 8.8 Hz, -ArH 3’ & 5’), 7.24-7.31 
(3H, m, -ArH 2, 6 & -CH), 6.93-7.03 (2H, m, -ArH 4 & -CH), 6.72 (2H, d, J = 8.8 
Hz, -ArH 2’ & 6’), 2.94 (6H, s, -CH3). 
13C-NMR (100 MHz, DMSO-d6): δ 161.2 (d, J = 243.0 Hz, -CF), 162.7 (d, J = 243.0 
Hz, -CF), 150.3 (-ArC 1’), 142.1 (t, J = 9.5 Hz, -ArC 1), 132.0 (-CH), 128.0 (-ArC 3’ 
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& 5’), 123.9 (-ArC 4’), 121.1 (-CH), 112.0 (-ArC 2’ & 6’), 108.4 (d, J = 19 Hz, -ArC 
2 & 6), 101.4 (t, J = 26.5 Hz, -ArC 4), 39.8 (-CH3). 
19F-NMR (376 MHz, DMSO-d6): δ -110.52 (2F, t, J = 7.5 Hz). 
 
(E)-3,5-difluoro-4’-acetylaminostilbene 161 
(E)-3,5-difluoro-4’-aminostilbene (0.96 g, 4.16 
mmol) was dissolved in ethyl acetate (5ml) and 
three drops of pyridine. Acetic anhydride (1.18 ml, 
12.47 mmol) was added dropwise to this solution 
and the reaction was stirred at room temperature for 
40 min before washing with water and brine. Recrystallisation from hexane/ethyl 
acetate yielded the title compound 161 as a white powder (0.79 g, 70%). 
m.p. 217-220 oC 
IR (KBr): υ 3290, 3098, 3047, 3021, 1663, 1619, 1584, 1522, 1408, 1369, 1314, 
1118, 980, 961, 847, 810, 673 cm-1. 
UV (ACN): λmax 327 nm. 
1H NMR (400 MHz, DMSO-d6): δ 10.07 (1H, s, -NH-), 7.62 (2H, d, J = 8.8 Hz, -ArH 
3’ & 5’), 7.53 (2H, d, J = 8.4 Hz, -ArH 2’ & 6’), 7.30-7.38 (3H, m, -ArH 2, 6 & -CH), 
7.06-7.16 (2H, m, -ArH 4 & -CH), 2.06 (3H, s, -CH3). 
13C-NMR (100 MHz, DMSO-d6): δ 168.3 (-C=O), 162.7 (d, J = 243.0 Hz, -CF), 162.6 
(d, J = 243.1 Hz, -CF), 141.4 (t, J = 9.7 Hz, -ArC 1), 139.5 (-ArC 1’), 131.1 (-CH), 
131.0 (-ArC 4’), 127.3 (-ArC 2’ & 6’), 124.6 (-CH), 119.0 (-ArC 3’ & 5’), 108.9 (d, J 
= 12.0 Hz, -ArC 2 & 6), 102.2 (t, J = 26.0 Hz, -ArC 4), 24.0 (-CH3). 
19F-NMR (376 MHz, DMSO-d6): δ -110.26 (2F, t, J = 7.5 Hz). 
 
(E)-3,5-difluoro-4’-(trifluoroacetyl)aminostilbene 162 
(E)-3,5-difluoro-4’-aminostilbene (1.45 g, 6.28 
mmol) was dissolved in ethyl acetate (10ml) and 
three drops of pyridine. Trifluoroacetic anhydride 
(2.62 ml, 18.83 mmol) was added dropwise to this 
solution and the reaction was stirred at room 
temperature for 40 min before washing with water and brine. Recrystallisation from 
hexane/ethyl acetate yielded compound 162 as a beige powder (1.27 g, 62%). 
m.p. 188-191 oC 
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Anal. calcd. for C16H10NF5O: C, 58.72; H, 3.08; N, 4.28.  
Found C, 58.58; H, 3.09; N, 4.19 
IR (KBr): υ 3296, 3095, 1705, 1619, 1589, 1541, 1450, 1291, 1248, 1186, 1155, 
1118, 984, 958, 913, 841, 808, 734, 669 cm-1. 
UV (ACN): λmax 321 nm. 
1H NMR (400 MHz, DMSO-d6): δ 11.38 (1H, s, -NH-), 7.73 (2H, d, J = 8.8 Hz, -ArH 
3’ & 5’), 7.65 (2H, d, J = 8.4 Hz, -ArH 2’ & 6’), 7.42 (1H, d, J = 16.8 Hz, -CH), 7.36 
(2H, m, -ArH 2 & 6), 7.24 (1H, d, J = 16.8 Hz, -CH), 7.13 (1H, tt, J = 2.2 & 9.2 Hz, -
ArH 4). 
13C-NMR (100 MHz, DMSO-d6): δ 162.8 (d, J = 243.7 Hz, -CF), 162.6 (d, J = 243.6 
Hz, -CF), 154.4 (q, J = 36.8 Hz, -C=O), 141.0 (t, J = 9.8 Hz, -ArC 1), 136.3 (-ArC 1’), 
133.6 (-ArC 4’), 130.6 (-CH), 127.4 (-ArC 2’ & 6’), 126.1 (-CH), 121.1 (-ArC 3’ & 
5’), 115.7 (q, J = 286.9 Hz, -CF3), 109.2 (d, J = 25.4 Hz, -ArC 2 & 6), 102.6 (t, J = 
26.0 Hz, -ArC 4). 
19F-NMR (376 MHz, DMSO-d6): δ -73.83 (3F, s, -CF3), -110.14 (2F, t, J = 7.5 Hz). 
 
 (Z)-3,5-difluoro-4’-amino(dimethylcarbamoyl) stilbene 163 
(Z)-3,5-difluoro-4’-aminostilbene (0.78 g, 3.39 mmol) was 
dissolved in dichloromethane (10 ml) and cooled to 0oC. 
Triethylamine (1.04 ml, 7.46 mmol) was added to stirred 
solution and dimethylcarbamyl chloride (0.62 g, 6.78 mmol) 
was then added dropwise. The reaction was stirred at 0 oC 
for 30 min before warming to room temperature. 
Purification by column chromatography with hexane/ethyl acetate as eluant furnished 
cis-compound 163 as a white solid (0.19 g, 20%). 
m.p. 127-131 oC 
Anal. calcd. for C17H16N2OF2: C, 67.54; H, 5.33; N, 9.27.   
Found C, 67.18; H, 5.47; N, 9.13 
IR (KBr): υ 3276, 3096, 3017, 2924, 1648, 1585, 1512, 1375, 1310, 1255, 1190, 
1118, 991, 969, 875, 841, 756, 669 cm-1. 
UV (ACN): λmax 320 nm. 
1H NMR (400 MHz, DMSO-d6): δ 8.36 (1H, s, -NH-), 7.40 (2H, d, J = 9.2 Hz, -ArH 
3’ & 5’), 7.06-7.11 (3H, m, -ArH 4, 2’ & 6’), 6.91 (2H, m, -ArH 2 & 6), 6.68 (1H, d, J 
= 12.4 Hz, -CH), 6.48 (1H, d, J = 12 Hz, -CH), 2.92 (6H, s, -CH3). 
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13C-NMR (100 MHz, DMSO-d6): δ 162.3 (d, J = 245.0 Hz,-CF ), 162.2 (d, J = 244.0 
Hz, -CF), 155.5 (-C=O), 140.9 (t, J = 9.5 Hz, -ArC 1), 140.4 (-ArC 4’), 132.3 (-CH), 
128.8 (-ArC 1’), 128.6 (-ArC 2’ & 6’), 126.1 (-CH), 119.2 (-ArC 3’ & 5’),  111.4 (d, J 
= 25.0 Hz, -ArC 2 & 6), 102.5 (t, J = 25.5 Hz, -ArC 4), 36.2 (-CH3). 
19F-NMR (376 MHz, DMSO-d6): δ -110.27 (2F, t, J = 8.8 Hz). 
 
(Z)-3,5-difluoro-4’-(carbamyl-4-morpholine) stilbene 164 
 (Z)-3,5-difluoro-4’-aminostilbene (0.45 g, 1.93 mmol) 
was dissolved in dichloromethane (10 ml) and cooled to 0 
oC. Triethylamine (0.44 ml, 3.85 mmol) was added to the 
stirring solution and 4-morpholinecarbonyl chloride (0.44 
ml, 3.85 mmol) was then added dropwise. The reaction 
was stirred at 0 oC for 30 min before warming to room 
temperature. Purification by column chromatography with hexane/ethyl acetate 
yielded 164 as a white solid (0.19 g, 29%). 
m.p. 126-129 oC 
Anal. calcd. for C19H18N2O2F2: C, 66.27; H, 5.27; N, 8.14.   
Found C, 65.59; H, 5.37; N, 8.03. 
IR (KBr): υ 3224, 3095, 2948, 2854, 1631, 1588, 1522, 1429, 1309, 1253, 1118, 989, 
879, 848, 748, 670 cm-1. 
UV (ACN): λmax 301 nm. 
1H NMR (400 MHz, DMSO-d6): δ 8.64 (1H, s, -NH-), 7.41 (2H, d, J = 8.8 Hz, -ArH 
3’ & 5’), 7.06-7.12 (3H, m, -ArH 4, 2’ & 6’), 6.91 (2H, m, -ArH 2 & 6), 6.69 (1H, d, J 
= 12.4 Hz, -CH), 6.50 (1H, d, J = 12.4 Hz, -CH), 3.59-3.61 (4H, m, -OCH2), 3.41-
3.43 (4H, m, -NCH2). 
13C-NMR (100 MHz, DMSO-d6): δ 162.3 (d, J = 243.8 Hz,-CF ), 162.1 (d, J = 244.1 
Hz, -CF), 154.8 (-C=O), 140.8 (t, J = 9.7 Hz, -ArC 1), 140.0 (-ArC 4’), 132.2 (-CH), 
129.0 (-ArC 1’), 128.7 (-ArC 3’ & 5’), 126.2 (-CH), 119.1 (-ArC 2’ & 6’),  111.3 (d, J 
= 25.1 Hz, -ArC 2 & 6), 102.4 (t, J = 25.8 Hz, -ArC 4), 65.9 (-OCH2, -VE DEPT), 
44.1 (-NCH2, -VE DEPT). 
19F-NMR (376 MHz, DMSO-d6): δ -110.21 (2F, t, J = 9.4 Hz). 
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 (E)-3,5-difluoro-4’ -N-(BOC-glycine)aminostilbene 165 
(E)-3,5-difluoro-4’-aminostilbene (0.8 g, 
3.85 mmol) was dissolved in 
dichloromethane (20 ml). N-tert-
butoxycarbonyl-glycine (0.68 g, 3.85 
mmol), 1-hydroxybenzotriazole (0.52 g, 
3.85 mmol) and triethylamine (0.54 ml, 3.85 mmol) were added to stirred solution. 
The reaction mixture was cooled to 0 ˚C, and N-ethyl-N’-(3-dimethylaminopropyl) 
carbodiimide (0.74 g, 3.85 mmol) was added. After 30 min. the solution was raised 
to room temperature and the reaction was allowed to proceed for 48 hrs. The solution 
was washed with brine, sat. potassium hydrogen carbonate, 10% citric acid and dried 
over sodium sulphate. The solvent was evaporated in vacuo and purification was 
achieved by column chromatography with hexane/ethyl acetate. Recrystallisation 
from ethyl acetate/hexane furnished 165 as a white powder (0.25 g, 17%). 
m.p. 189-191 oC 
Anal. calcd. for C21H22N2O3F2: C, 64.94; H, 5.71; N, 7.21.   
Found C, 64.81; H, 5.70; N, 7.12. 
IR (KBr): υ 3414, 3277, 3195, 2977, 1679, 1603, 1509, 1447, 1414, 1371, 1313, 
1277, 1166, 1117, 1056, 962, 844, 670 cm-1. 
UV (ACN): λmax 321 nm. 
1H NMR (400 MHz, DMSO-d6): δ 10.05 (1H, s, -NH) 7.63 (2H, d, J = 8.4 Hz, -ArH 
3’& 5’), 7.55 (2H, d, J = 8.8 Hz, -ArH 2’ & 6’), 7.31-7.38 (3H, m, -ArH 2, 6 & -CH), 
7.15 (1H, d, J = 16.4 Hz, -CH), 7.06-7.12 (2H, m, -ArH 4 & -NH), 3.73 (2H, d, J = 
6.0 Hz, -CH2), 1.40 (9H, s, t-CH3). 
13C-NMR (100 MHz, DMSO-d6): δ 168.3 (-COCH2), 162.8 (d, J = 243.3 Hz, -CF), 
162.6 (d, J = 243.6 Hz, -CF), 155.9 (-COOt-Butyl), 141.4 (t, J = 9.9 Hz, -ArC 1), 
139.1 (-ArC 4’), 131.2 (-CH), 131.1 (-ArC 1’), 127.4 (-ArC 2’ & 6’) 124.8 (-CH), 
119.1 (-ArC 3` & 5`), 109.0 (d, J = 25.4 Hz, -ArC 2 & 6), 102.0 (t, J = 26.2 Hz, -ArC 
4), 78.0 (-C(CH3)3), 43.8 (-CH2, -VE DEPT), 28.2 (-C(CH3)3). 
19F-NMR (376 MHz, DMSO-d6): δ -110.28 (2F, t, J = 7.5 Hz). 
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(E)-3,5-difluoro-4’-N-(BOC-L-alanine)aminostilbene 166 
 (E)-3,5-difluoro-4’-aminostilbene (1.7 
g, 7.36 mmol) and N-tert-
butoxycarbonyl-L-alanine (1.39 g, 
7.36 mmol) were used. Purification by 
column chromatography with 
hexane/ethyl acetate as eluant gave the title compound 166 as a white powder (0.54 g, 
18%). 
m.p. 227-229 oC 
Anal. calcd. for C22H24N2F2O3: C, 65.66; H, 6.01; N, 6.96.  
Found C, 65.38; H, 5.96; N, 6.80 
IR (KBr): υ 3335, 2986, 2939, 1674, 1587, 1517, 1444, 1411, 1366, 1316, 1250, 
1161, 1112, 1073, 979, 959, 841, 666, 630 cm-1. 
UV (ACN): λmax 325 nm. 
1H NMR (400 MHz, DMSO-d6): δ 10.08 (1H, s, -NH) 7.66 (2H, d, J = 8.8 Hz, -ArH 
3’& 5’), 7.56 (2H, d, J = 8.8 Hz, -ArH 2’ & 6’), 7.32-7.39 (3H, m, -ArH 2, 6 & -CH), 
7.06-7.18 (3H, m, -CH, -ArH 4 & -NH), 4.13 (1H, quin, J = 7.2, α-H), 1.39 (9H, s, t-
CH3), 1.28 (3H, d, J = 7.2 Hz, -CH3). 
13C-NMR (100 MHz, DMSO-d6): δ 171.9 (-COCH2), 162.8 (d, J = 243.5 Hz, -CF), 
162.6 (d, J = 243.5 Hz, -CF), 155.2 (-COOt-Butyl), 141.3 (t, J = 10.0 Hz, -ArC 1), 
139.2 (-ArC 4’), 131.2 (-CH), 131.0 (-ArC 1’), 127.4 (-ArC 2’ & 6’) 124.7 (-CH), 
119.2 (-ArC 3` & 5`), 109.0 (d, J = 25.3 Hz, -ArC 2 & 6), 102.3 (t, J = 26.1 Hz, -ArC 
4), 78.0 (-C(CH3)3), 50.4 (α-C), 28.2 (-C(CH3)3), 17.9 (-CH3). 
19F-NMR (376 MHz, DMSO-d6): δ -110.24 (2F, t, J = 9.4 Hz). 
 
(E)-3,5-difluoro-4’-N-(BOC-β-alanine)amino stilbene 167 
 (E)-3,5-difluoro-4’-aminostilbene 
(0.58 g, 2.51 mmol) and N-tert-
butoxycarbonyl-β-alanine (0.48 g, 
2.51 mmol) were used. Purification 
by column chromatography with 
hexane/ethyl acetate as eluant furnished 167 as a white powder (0.12 g, 12%). 
m.p. 213-215 oC 
Anal. calcd. for C22H24N2F2O3: C, 65.66; H, 6.01; N, 6.96.  
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Found C, 65.28; H, 6.07; N, 6.77 
IR (KBr): υ 3353, 2985, 1682, 1619, 1588, 1521, 1446, 1411, 1343, 1281, 1248, 
1167, 1113, 980, 958, 841, 667 cm-1. 
UV (ACN): λmax 326 nm. 
1H NMR (400 MHz, DMSO-d6): δ 10.07 (1H, s, -NH), 7.64 (2H, d, J = 8.4 Hz, -ArH 
3’& 5’), 7.54 (2H, d, J = 8.4 Hz, -ArH 2’ & 6’), 7.31-7.38 (3H, m, -ArH 2, 6 & -CH), 
7.06-7.17 (2H, m, -CH, -ArH 4), 6.90 (1H, t, J = 5.6 Hz, -NH), 3.23 (2H, q, J = 6.4 
Hz, β-H), 2.47-2.52 (m, α-H), 1.38 (9H, s, t-CH3). 
13C-NMR (100 MHz, DMSO-d6): δ 169.5 (-COCH2), 162.8 (d, J = 243.0 Hz, -CF), 
162.7 (d, J = 243.0 Hz, -CF), 155.5 (-COOt-Butyl), 141.3 (t, J = 10.0 Hz, -ArC 1), 
139.3 (-ArC 4’), 131.0 (-CH), 131.0 (-ArC 1’), 127.3 (-ArC 2’ & 6’) 124.7 (-CH), 
119.1 (-ArC 3` & 5`), 109.0 (d, J = 25.0 Hz, -ArC 2 & 6), 102.3 (t, J = 26.0 Hz, -ArC 
4), 77.6 (-C(CH3)3), 36.8 (α-C, -VE DEPT), 36.4 (β-C, -VE DEPT), 28.2 (-C(CH3)3). 
19F-NMR (376 MHz, DMSO-d6): δ -110.25 (2F, t, J = 7.5 Hz). 
 
(E)-3,5-difluoro-4’-N-(BOC-L-valine)aminostilbene 168 
 (E)-3,5-difluoro-4’-aminostilbene (0.97 
g, 4.20 mmol) and N-tert-
butoxycarbonyl-L-valine (0.91 g, 4.20 
mmol) were used. Purification by 
column chromatography with 
hexane/ethyl acetate as eluant yielded 168 as a white powder (0.20 g, 11%). 
m.p. 177-180 oC 
Anal. calcd. for C24H28N2F2O3: C, 66.96; H, 6.56; N, 6.51.  
Found C, 66.71; H, 6.57; N, 6.51 
IR (KBr): υ 3337, 2964, 2871, 1666, 1588, 1516, 1447, 1412, 1367, 1310, 1246, 
1168, 1116, 982, 961, 844, 668 cm-1. 
UV (ACN): λmax 307 nm. 
1H NMR (400 MHz, DMSO-d6): δ 10.06 (1H, s, -NH), 7.65 (2H, d, J = 8.4 Hz, -ArH 
3’& 5’), 7.55 (2H, d, J = 8.4 Hz, -ArH 2’ & 6’), 7.32-7.39 (3H, m, -ArH 2, 6 & -CH), 
7.07-7.18 (2H, m, -CH, -ArH 4), 6.94 (1H, d, J = 8.8 Hz, -NH), 3.92 (1H, t, J = 7.8 
Hz, α-H), 1.96-2.01 (m, -CH(CH3)2), 1.38 (9H, s, t-CH3), 0.90 (6H, d, J = 6.4 Hz, -
CH(CH3)2). 
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13C-NMR (100 MHz, DMSO-d6): δ 170.8 (-COCH2), 162.8 (d, J = 243.5 Hz, -CF), 
162.6 (d, J = 243.5 Hz, -CF), 155.6 (-COOt-Butyl), 141.3 (t, J = 9.8 Hz, -ArC 1), 
139.0 (-ArC 4’), 131.3 (-CH), 131.0 (-ArC 1’), 127.3 (-ArC 2’ & 6’) 124.8 (-CH), 
119.3 (-ArC 3` & 5`), 109.0 (d, J = 25.3 Hz, -ArC 2 & 6), 102.3 (t, J = 26.0 Hz, -ArC 
4), 78.0 (-C(CH3)3), 60.6 (α-C), 30.3 (-C(CH3)2), 28.1 (-C(CH3)3), 19.2 (-CH3), 18.4 (-
CH3). 
19F-NMR (376 MHz, DMSO-d6): δ -110.25 (2F, t, J = 7.5 Hz). 
 
 (E)-3,5-difluoro-4’-(aminoglycine) stilbene trifluoroacetate salt 169 
(E)-3,5-difluoro-4’-(amino-BOC-
glycine)stilbene (0.22g, 0.57mmol) 
was dissolved in dichloromethane (5 
mls). Trifluoroacetic acid (5 ml) was 
added and the reaction was stirred at 
room temperature for 1 hour. The reaction was monitored by thin layer 
chromatography. The solvent and excess TFA was evaporated with nitrogen stream. 
The crude residue was recrystallised from ethyl acetate to yield the title product 169 
as a white powder (0.21g, 92%) 
m.p. 196-199 oC 
IR (KBr): υ 3260, 3116, 2360, 1677, 1589, 1546, 1509, 1434, 1315, 1263, 1201, 1139, 
1121, 958, 842, 800, 724, 670 cm-1. 
UV (ACN): λmax 318 nm. 
1H NMR (400 MHz, DMSO-d6): δ 10.70 (1H, s, -NH) 8.25 (3H, s, -NH3+), 7.66 (2H, d, J 
= 8.8 Hz, -ArH 3’& 5’), 7.61 (2H, d, J = 8.8 Hz, -ArH 2’ & 6’), 7.39 (1H, d, J = 16.4 Hz, 
-CH ), 7.34 (2H, m, -ArH 2 & 6), 7.19 (1H, d, J = 16.4 Hz, -CH), 7.11 (1H, tt, J = 2.2 & 
9.4 Hz, -ArH 4), 3.83 (2H, s, -CH2). 
13C-NMR (100 MHz, DMSO-d6): δ 164.9 (-CO), 162.8 (d, J = 243.5 Hz, -CF), 162.6 (d, J 
= 243.5 Hz, -CF), 158.3 (q, J = 30.0 Hz, -COCF3), 141.2 (t, J = 9.8 Hz, -ArC 1), 138.3 (-
ArC 4’), 131.9 (-ArC 1’), 130.9 (-CH), 127.6 (-ArC 2’ & 6’), 125.2 (-CH), 119.2 (-ArC 3` 
& 5`), 117.2 (d, J = 298.0 Hz, -CF3), 109.1 (d, J = 25.3 Hz, -ArC 2 & 6), 102.4 (t, J = 
26.4 Hz, -ArC 4), 41.0 (-CH2, -VE DEPT). 
19F-NMR (376 MHz, DMSO-d6): δ -73.61 (3F, s), -110.20 (2F, t, J = 9.4 Hz). 
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1-(3,5-difluorophenylethyl)-4’-nitrobenzene 170 
3,5-Difluoro-4’-nitrostilbene (1.26 g, 4.83 mmol) and 
palladium (II) acetate (0.54 g, 2.41 mmol) were 
dissolved in anhydrous tetrahydrofuran (40 ml) under 
an atmosphere of nitrogen.  Aqueous potassium 
fluoride (0.56 g, 9.66 mmol) was added dropwise with 
stirring and the solution cooled on an ice bath prior to the very slow addition of 
PMHS (polymethylhydrosiloxane) (1.16 ml, 19.31 mmol).  The reaction was stirred 
for a further two hours.  After all the stilbene starting material had been consumed, 
the dark black reaction mixture was diluted with diethyl ether and washed repeatedly 
with water.  The organic layers were combined and stirred in celite.  This mixture was 
passed through an alumina/celite plug to yield a brown solution.  Purification by 
column chromatography with hexane/ethyl acetate as eluant yielded the title 
compound 170 as a beige powder (0.29 g, 23%). 
m.p. 102-104 oC 
IR (KBr): υ 3089, 2960, 2851, 1932, 1624, 1593, 1517, 1458, 1341, 1260, 1106, 
1013, 867,851, 798, 749, 705, 668, 662 cm-1. 
UV (ACN): λmax 276 nm. 
1H NMR (400 MHz, DMSO-d6): δ 8.02 (2H, d, J = 8.8 Hz, -ArH 3’ & 5’), 7.39 (2H, 
d, J = 8.8 Hz, -ArH 2’ & 6’), 6.85-6.92 (3H, m, -ArH 2, 4 & 6) 2.89-2.94 (2H, m, -
CH2), 2.81-2.85 (2H, m, -CH2). 
13C-NMR (100 MHz, DMSO-d6): δ 162.3 (d, J = 243.9 Hz, -CF ), 162.2 (d, J = 244.1 
Hz, -CF), 149.3 (-ArC 4’), 145.9 (-ArC 1’), 145.5 (t, J = 9.2 Hz, -ArC 1), 129.7 (-ArC 
2’ & 6’), 123.4 (-ArC 3’ & 5’), 111.5 (d, J = 24.2 Hz, -ArC 2 & 6), 101.4 (t, J = 25.6 
Hz, -ArC 4), 35.8 (-CH2, -VE DEPT), 35.6 (-CH2, -VE DEPT). 
19F-NMR (376 MHz, DMSO-d6): δ -110.53 (2F, t, J = 9.4 Hz). 
 
1-(3,5-difluorophenylethyl)-4’-aminobenzene 171 
3,5-Difluoro-4’-nitrostilbene (1.26 g, 4.83 mmol) and 
palladium (II) acetate (0.54 g, 2.41 mmol) were 
dissolved in anhydrous tetrahydrofuran (40 ml) under 
an atmosphere of nitrogen.  Aqueous potassium 
fluoride (0.56 g, 9.66 mmol) was added dropwise with 
stirring and the solution cooled on an ice bath prior to the very slow addition of 
NO2
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PMHS (polymethylhydrosiloxane) (1.16 ml, 19.31 mmol).  The reaction was stirred 
for a further two hours.  After all the stilbene starting material had been consumed, 
the dark black reaction mixture was diluted with diethyl ether and washed repeatedly 
with water.  The organic layers were combined and stirred in celite.  This mixture was 
passed through an alumina/celite plug to yield a brown solution.  Purification by 
column chromatography with hexane/ethyl acetate as eluant furnished the reduced 
compound 171 as a dark brown oil (0.83 g, 74%). 
b.p. 193-196 oC 
Anal. calcd. for C14H13NF2: C, 72.09; H, 5.62; N, 6.00.  
Found C, 71.74; H, 5.64; N, 5.95 
IR (ATR): υ 1622, 1592, 1516, 1458, 1315, 1274, 1113, 966, 845, 821, 681 cm-1. 
UV (ACN): λmax 244; 296 nm. 
1H NMR (400 MHz, DMSO-d6): δ 6.99 (1H, tt, J = 2.4 & 9.6 Hz, -ArH 4), 6.93 (2H, 
m, -ArH 2 & 6), 6.86 (2H, d, J = 8.0 Hz, -ArH 2’ & 6’), 6.49 (2H, d, J = 8.0, Hz -ArH 
3’ & 5’), 4.87 (2H, s, -NH2), 2.80-2.84 (2H, m, -CH2), 2.68-2.72 (2H, m, -CH2). 
13C-NMR (100 MHz, DMSO-d6): δ 162.3 (d, J = 244.0 Hz, -CF ), 162.4 (d, J = 244.0 
Hz, -CF), 146.6 (m, -ArC 1 & 4’), 128.7 (-ArC 2’ & 6’) , 127.8 (-ArC 1’), 113.9 (-
ArC 3’ & 5’), 111.4 (d, J = 24.0 Hz, -ArC 2 & 6), 101.0 (t, J = 25.5 Hz, -ArC 4), 37.0 
(-CH2, -VE DEPT), 35.6 (-CH2, -VE DEPT). 
19F-NMR (376 MHz, DMSO-d6): δ -110.81 (2F, t, J = 10.0 Hz). 
 
(E)-4-nitrostilbene 172 
A suspension of 4-nitrobenzyl triphenyl phosphonium 
bromide (2.98 g, 6.25 mmol) and benzaldehyde (0.66 g, 
6.25 mmol) in dichloromethane (40 ml) was stirred under 
an atmosphere of nitrogen. To this suspension, potassium 
carbonate (0.99 g, 7.19 mmol) and a few crystals of dibenzo-18-crown-6 were added 
and stirring continued  for a further 48 hrs. The solvent was removed in vacuo to yield 
a crude yellow/brown solid. Recrystallisation from ethanol gave the title product 172 
as yellow crystalline needles (0.83 g, 59%). 
m.p. 157-160 oC 
Anal. calcd. for C14H11NO2: C, 74.65; H, 4.92; N, 6.22.   
Found C, 73.71; H, 5.08; N, 6.05 
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IR (KBr): υ 3102, 3075, 3023, 2918, 2826, 2438, 1632, 1594, 1510, 1449, 1338, 
1190, 1109, 1075, 971, 878, 849, 834, 769, 696 cm-1. 
UV (ACN): λmax 350 nm. 
1H NMR (400 MHz, DMSO-d6): δ 8.24 (2H, d, J = 8.8 Hz, -ArH 3 & 5), 7.87 (2H, d, 
J = 8.8 Hz, -ArH 2 & 6), 7.69 (2H, d, -ArH 2’& 6’), 7.54 (1H, d, J = 16.4 Hz, -CH), 
7.34-7.45 (4H, m, -ArH 3’, 4’, 5’ & -CH). 
13C-NMR (100 MHz, DMSO-d6): δ 146.1 (-ArC 4), 143.9 (-ArC 1), 136.2 (-ArC 1’), 
133.2 (-CH ), 128.8 (-ArC 3’ & 5’), 128.6 (-ArC 4’), 127.2 (-ArC 2 & 6), 127.1 (-ArC 
2’ & 6’), 126.3 (-CH), 123.9 (-ArC 3 & 5).  
 
(E)-4-aminostilbene 173 
4-Nitrostilbene (0.28 g, 1.24 mmol) was dissolved in an 
ethanol:acetic acid solution [10:1].  Iron (III) chloride 
hexahydrate (0.06 g, 0.21 mmol) and iron pindust (0.51 g, 
9.08 mmol) were added.  The impurities were removed by 
filtration and recrystallisation from ethyl acetate yielded compound 173 as a beige 
powder (0.2 g, 94%). 
m.p. 140-144 oC 
IR (KBr): υ 3446, 3361, 3027, 1616, 1590, 1515, 1283, 1262, 1179, 967, 819, 754, 
694 cm-1. 
UV (ACN): λmax 333 nm. 
1H NMR (400 MHz, DMSO-d6): δ 7.50 (2H, d, J = 7.2 Hz, -ArH 2’ & 6’), 7.27-7.34 
(4H, m, -ArH 2, 6, 3’ & 5’), 7.18 (1H, t, J = 7.4 Hz, -ArH 4’), 7.07 (1H, d, J = 16.4 
Hz, -CH), 6.90 (1H, d, J = 16.4 Hz, -CH), 6.57 (2H, d, J = 8.4 Hz, -ArH 3 & 5), 5.32 
(2H, s, -NH2). 
13C-NMR (100 MHz, DMSO-d6): δ 148.8 (-ArC 4), 137.9 (-ArC 1’), 129.1 (-CH), 
128.6 (-ArC 2’ & 6’), 127.6 (-ArC 3’ & 5’), 126.4 (-ArC 4’), 125.7 (-ArC 2 & 6), 
124.6 (-ArC 1), 122.7 (-CH), 113.9 (-ArC 3 & 5). 
 
4-(4-(3,5-difluorophenylethyl)phenylamino)butan-1-ol 174 
3,5-Difluoro-4’-nitrostilbene (0.5 g, 1.92 mmol) and palladium (II) acetate (0.33 g, 
1.44 mmol) were dissolved in anhydrous tetrahydrofuran (20 ml) under an atmosphere 
of nitrogen. Aqueous potassium fluoride (0.33 g, 5.76 mmol) was added dropwise and 
solution cooled on an ice bath prior to very slow addition of PMHS 
NH2
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(polymethylhydrosiloxane) (0.69 ml, 
11.52 mmol).  The reaction was stirred for 
a further four hours.  After all stilbene 
starting material had been consumed, the 
dark black reaction mixture was diluted 
with diethyl ether and washed repeatedly with water.  The organic layers were 
combined and stirred in celite.  This mixture was passed through an alumina/celite 
plug to yield an orange solution.  3,5-Difluoro-4’-nitrostilbene (1.26 g, 4.83 mmol) 
and palladium (II) acetate (0.54 g, 2.41 mmol) were dissolved in anhydrous 
tetrahydrofuran (40 ml) under an atmosphere of nitrogen.  Aqueous potassium 
fluoride (0.56 g, 9.66 mmol) was added dropwise with stirring and the solution cooled 
on an ice bath prior to the very slow addition of PMHS (polymethylhydrosiloxane) 
(1.16 ml, 19.31 mmol).  The reaction was stirred for a further two hours.  After all the 
stilbene starting material had been consumed, the dark black reaction mixture was 
diluted with diethyl ether and washed repeatedly with water.  The organic layers were 
combined and stirred in celite.  This mixture was passed through an alumina/celite 
plug to yield a brown solution.  Purification by column chromatography with 
hexane/ethyl acetate as eluant yielded the title compound 174 as a beige powder (0.15 
g, 25%). 
m.p. 68-70 oC 
IR (KBr): υ 3272, 2920, 2850, 1783, 1616, 1595, 1516, 1495, 1310, 1252, 1116, 
1075, 968, 853, 825, 803, 747, 680 cm-1. 
UV (ACN): λmax 254; 303 nm. 
1H NMR (400 MHz, DMSO-d6): δ 6.90-6.99 (5H, m, -ArH 2’’, 4’’, 6’’, 2’ & 6’), 6.46 
(2H, d, J = 8.4, Hz -ArH 3’ & 5’), 5.33 (1H, t, J = 5.4 Hz, -NH-), 4.40 (1H, t, J = 5.2 
Hz, -OH), 3.42 (2H, q, J = 6.2, -CH2 1), 2.95 (2H, q, J = 6.6, -CH2 4), 2.80-2.84 (2H, 
m, -CH2), 2.69-2.72 (2H, m, -CH2), 1.45-1.58 (4H, m, -CH2 2 & 3). 
13C-NMR (100 MHz, DMSO-d6): δ 162.3 (d, J = 244.0 Hz, -ArCF), 162.1 (d, J = 
243.0 Hz, -ArCF), 147.3 (-ArC 4’), 146.2 (t, J = 9.4 Hz, -ArC 1), 128.7 (-ArC 2’ & 
6’), 127.4 (-ArC 1’), 111.8 (-ArC 3’ & 5’), 111.5 (d, J = 24.0 Hz, -ArC 2’ & 6’), 
101.1 (t, J = 25.8 Hz, -ArC 4), 60.5 (-CH2 1, -VE DEPT), 42.9 (-CH2 4, -VE DEPT), 
37.0 (-CH2, -VE DEPT), 35.5 (-CH2, -VE DEPT), 30.2 & 25.4 (-CH2 2 & 3, -VE 
DEPT). 
19F-NMR (376 MHz, DMSO-d6): δ -110.84 (2F, t, J = 8.0 Hz). 
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(E)-3,5-dinitro-4’-fluorostilbene 175 
3,5-Dinitrobenzoyl chloride (1 g, 4.35 mmol) and 4-
fluorostyrene (0.53 g, 4.35 mmol) were added to a 
solution of palladium (II) acetate (0.05 g, 0.22 mmol) 
and N-ethylmorpholine (0.5 g, 4.35 mmol) in p-xylene 
(30 mls). The solution was heated at 120 °C for 18 hrs and then filtered. The solvent 
was removed in vacuo to yield a crude brown solid. Recrystallisation from 
hexane/ethyl acetate 50:1 gave the title product 175 as a mustard yellow powder (0.91 
g, 65%). 
m.p. 228-230 oC 
Anal. calcd. for C14H9N2FO4: C, 58.34; H, 3.15; N, 9.72.  
Found C, 58.35; H, 3.12; N, 9.83 
IR (KBr): υ 3012, 2870, 1789, 1592, 1533, 1506, 1411, 1343, 1233, 1214, 1161, 
1075, 962, 860, 815, 783, 731, 704, 652 cm-1. 
UV (ACN): λmax 280 nm. 
1H NMR (400 MHz, DMSO-d6): δ 8.84 (2H, d, J = 2.0 Hz, -ArH 2 & 6), 8.68 (1H, t, J 
= 1.8 Hz, -ArH 4), 7.73-7.78 (3H, m, -ArH 2’, 6’ & -CH), 7.54 (1H, d, J = 16.4 Hz, -
CH), 7.29 (2H, t, J = 8.8 Hz, -ArH 3’ & 5’). 
13C-NMR (100 MHz, DMSO-d6): δ 162.31 (d, J = 245.0 Hz, -CF), 148.5 (-ArC 3 & 
5), 140.9 (-ArC 1), 132.6 (-CH), 132.6 (d, J = 3.3 Hz, -ArC 1’), 129.1 (d, J = 8.2 Hz, -
ArC 2’ & 6’), 125.9 (-ArC 2 & 6), 124.4 (d, J = 2.3 Hz, -CH), 116.4 (-ArC 4), 115.8 
(d, J = 21.5 Hz, -ArC 3’ & 5’). 
19F-NMR (376 MHz, DMSO-d6): δ -112.30 (1F, m). 
 
(Z)-3,5-dinitro-4’-fluorostilbene 176 
3,5-Dinitrobenzyl triphenyl phosphonium bromide (2.22 g, 
4.64 mmol) and 4-fluorobenzaldhyde (0.59 g, 5.57 mmol) were 
dissolved in dichloromethane (30 ml) and stirred at room 
temperature. A 50% w/v sodium hydroxide solution was added 
dropwise [0.4ml NaOH solution per 1 mmol of aldehyde]. 
Stirring continued for a further hour before washing with brine and water. The solvent 
was removed in vacuo to yield both isomers as a yellow solid. Recrystallisation from 
ethanol gave the trans isomer 175 as a mustard yellow powder (0.47 g, 35%). The 
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resulting mother liquor was evaporated to dryness to yield the cis isomer 176 as a pale 
yellow powder (0.62 g, 46%). 
m.p. 93-96 oC 
IR (KBr): υ 3102, 2954, 2922, 2869, 2359, 2341, 1903, 1600, 1535, 1506, 1342, 
1314, 1218, 1158, 1076, 955, 916, 860, 841, 826, 816, 752, 730, 644 cm-1. 
UV (ACN): λmax 262 nm. 
1H NMR (400 MHz, DMSO-d6): δ 8.67 (1H, t, J = 2.2 Hz, -ArH 4), 8.40, (2H, d, J = 
2.0 Hz, -ArH 2 & 6), 7.31-7.34 (2H, m, -ArH 2’ & 6’), 7.17 (2H, t, J = 8.8 Hz, -ArH 
3’ & 5’), 6.99 (1H, d, J = 12.0 Hz, -CH), 6.87 (1H, d, J = 12.4 Hz, -CH). 
13C-NMR (100 MHz, DMSO-d6): δ 161.6 (d, J = 244.4 Hz, -CF), 147.9 (-ArC 3 & 5), 
139.7 (-ArC 1), 133.3 (-CH), 131.5 (d, J = 3.5 Hz, -ArC 1’), 130.5 (d, J = 8.1 Hz, -
ArC 2’ & 6’), 128.6 (-ArC 2 & 6), 126.1 (-CH), 116.7 (-ArC 4), 115.7 (d, J = 21.3 
Hz, -ArC 3’ & 5’). 
19F-NMR (376 MHz, DMSO-d6): δ -113.02 (1F, m). 
 
(E)-3,5-diamino-4’-fluorostilbene 177 
(E)-3,5-dinitro-4’-fluorostilbene (1.4 g, 4.86 mmol) 
was dissolved in a 10:1 mixture of ethanol and acetic 
acid (33 ml) and heated to reflux temperature.  Iron 
(III) chloride hexahydrate (1.31 g, 4.86 mmol), 
followed by iron pindust (8.15 g, 0.15 mol) was added with vigorous stirring. The 
solution was refluxed for 3 hours before filtering and dilution with water. The product 
was extracted with diethyl ether and dried over sodium sulphate.  The title product 
177 was purified by column chromatography with hexane/ethyl acetate as eluant, 
furnishing in a brown powder (0.85 g, 77%). 
m.p. 157-160 oC 
Anal. calcd. for C14H13N2F: C, 73.66; H, 5.74; N, 12.27. 
Found C, 72.93; H, 5.87; N, 11.94. 
IR (KBr): υ 3436, 3397, 3360, 3316, 3198, 3062, 3047, 3021, 1896, 1593, 1507, 
1464, 1362, 1333, 1225, 1192, 1159, 1097, 963, 834, 788, 682 cm-1. 
UV (ACN): λmax 312 nm; 260 nm. 
1H NMR (400 MHz, DMSO-d6): δ 7.59 (2H, m, -ArH 2’ & 6’), 7.17 (2H, t, J = 8.8 
Hz, -ArH 3’ & 5’), 6.90 (2H, d, J = 2.0 Hz, HC=CH), 6.04 (2H, d, J = 2.0 Hz, -ArH 2 
& 6), 5.80 (1H, t, J = 1.8 Hz, -ArH 4), 4.76 (4H, s, -NH2). 
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13C-NMR (100 MHz, DMSO-d6): δ 161.3 (d, J = 242.9 Hz, -CF), 149.3 (-ArC 3 & 5), 
137.5 (-ArC 1), 133.9 (d, J = 3.0 Hz, -ArC 1’), 130.0 (d, J = 2.1 Hz, -CH), 128.0 (d, J 
= 7.8 Hz, -ArC 2’ & 6’), 125.1 (-CH), 115.5 (d, J = 21.2 Hz, -ArC 3’ & 5’), 101.7 (-
ArC 2 & 6), 100.1 (-ArC 4). 
19F-NMR (376 MHz, DMSO-d6): δ -114.97 (1F, m). 
 
(Z)-3,5-diamino-4’-fluorostilbene 178 
(Z)-3,5-dinitro-4’-fluorostilbene (1.39 g, 4.83 mmol) was 
dissolved in a 10:1 mixture of ethanol and acetic acid (33 ml) 
and heated to reflux temperature.  Iron (III) chloride 
hexahydrate (1.3 g, 4.83 mmol), followed by iron pindust (8.09 
g, 0.15 mol) was added with vigorous stirring. The solution was refluxed for 3 hours 
before filtering and dilution with water. The product was extracted with diethyl ether 
and dried over sodium sulphate.  Purification by column chromatography with 
hexane/ethyl acetate as eluant yielded 178 as a brown oil (0.72 g, 65%). 
b.p. 190-195 oC 
Anal. calcd. for C14H13N2F: C, 73.66; H, 5.74; N, 12.27  
Found C, 73.12; H, 5.76; N, 12.05. 
IR (KBr): υ 3424, 3339, 3208, 3010, 1614, 1585, 1505, 1460, 1420, 1349, 1218, 
1190, 1157, 1095, 863, 834, 787, 674 cm-1. 
UV (ACN): λmax 252 nm; 222, 286 nm. 
1H NMR (400 MHz, DMSO-d6): δ 7.32 (2H, m, -ArH 2’ & 6’), 7.05 (2H, t, J = 9.0 
Hz, -ArH 3’ & 5’), 6.39 (2H, d, J = 3.2 Hz, HC=CH), 5.72 (3H, m, -ArH 2, 4 & 6), 
4.68 (4H, s, -NH2). 
13C-NMR (100 MHz, DMSO-d6): δ 160.9 (d, J = 242.6 Hz, -CF), 149.3 (-ArC 3 & 5), 
137.7 (-ArC 1), 133.5 (d, J = 3.1 Hz, -ArC 1’), 131.8 (d, J = 1.0 Hz, -CH), 130.6 (d, J 
= 7.9 Hz, -ArC 2’ & 6’), 127.1 (-CH), 114.8 (d, J = 21.1 Hz, -ArC 3’ & 5’), 102.9 (-
ArC 2 & 6), 99.3 (-ArC 4). 
19F-NMR (376 MHz, DMSO-d6): δ -114.94 (1F, m). 
 
(E)-3-nitro-5-amino-4’-fluorostilbene 179 
(E)-3,5-dinitro-4’-fluorostilbene (0.54 g, 1.88 mmol) was dissolved in a 10:1 mixture 
of ethanol and acetic acid (11 ml) and warmed to reflux temperature.  Iron (III) 
chloride hexahydrate (0.17 g, 0.64 mmol), followed by iron pindust (1.53 g, 27.38 
F
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mmol) was added with vigorous stirring. The solution 
was refluxed for 3 hours before filtering and dilution 
with water. The product was extracted with diethyl 
ether and dried over sodium sulphate.  The title product 
179 was purified by column chromatography with hexane/ethyl acetate as eluant, 
furnishing an orange powder (0.08 g, 17%). 
m.p. 138-141 oC 
Anal. calcd. for C14H11N2FO2: C, 65.11; H, 4.29; N, 10.85. 
Found C, 64.99; H, 4.32; N, 10.86. 
IR (KBr): υ 3472, 3372, 3224, 3082, 1895, 1620, 1600, 1578, 1531, 1509, 1447, 
1413, 1352, 1333, 1241, 1159, 1091, 964, 856, 841, 778, 742, 666 cm-1. 
UV (ACN): λmax 290 nm. 
1H NMR (400 MHz, DMSO-d6): δ 7.70 (2H, m, -ArH 2’ & 6’), 7.58 (1H, s, -ArH 2), 
7.17-7.31 (5H, m, -ArH 4, 3’, 5’ & HC=CH), 7.14 (1H, s, -ArH 6), 5.86 (2H, s, -
NH2). 
13C-NMR (100 MHz, DMSO-d6): δ 161.7 (d, J = 242.9 Hz, -CF), 150.1 (-ArC 3), 
149.2 (-ArC 5), 138.9 (-ArC 1), 133.09 (d, J = 3.0 Hz, -ArC 1’), 130.04 (d, J = 2.1 
Hz, -CH), 128.0 (d, J = 7.8 Hz, -ArC 2’ & 6’), 127.0 (-CH), 117.2 (-ArC 6), 115.6 (-
ArC 3’ & 5’), 107.8 (-ArC 2), 106.3 (-ArC 4). 
19F-NMR (376 MHz, DMSO-d6): δ -113.58 (1F, m). 
 
(Z)-3-nitro-5-amino-4’-fluorostilbene 180 
(Z)-3,5-dinitro-4’-fluorostilbene (1.39 g, 4.83 mmol) was 
dissolved in a 10:1 mixture of ethanol and acetic acid (33 ml) 
and warmed to reflux temperature.  Iron (III) chloride 
hexahydrate (1.3 g, 4.83 mmol), followed by iron pindust (8.09 
g, 0.15 mol) was added with vigorous stirring. The solution was refluxed for 3 hours 
before filtering and dilution with water. The product was extracted with diethyl ether 
and dried over sodium sulphate.  Purification by column chromatography with 
hexane/ethyl acetate as eluant furnished compound 180 as an orange powder (0.11 g, 
23%). 
m.p. 116-118 oC 
IR (KBr): υ 3438, 3356, 3232, 3085, 3017, 1635, 1600, 1526, 1508, 1343, 1238, 
1221, 1159, 998, 877, 840, 807, 767, 745, 663 cm-1. 
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UV (ACN): λmax 270 nm. 
1H NMR (400 MHz, DMSO-d6): δ 7.26 (3H, m, -ArH 4, 2’ & 6’), 7.12 (3H, m, -ArH 
2, 3’ & 5’), 6.80 (1H, s, -ArH 6), 6.69 (1H, d, J = 12.4 Hz, -CH), 6.59 (1H, d, J = 12.0 
Hz, -CH), 5.80 (2H, s, -NH2). 
13C-NMR (100 MHz, DMSO-d6): δ 168.4 (d, J = 214.9 Hz, -CF), 150.1 (-ArC 1), 
148.8 (-ArC 3), 147.4 (-ArC 5), 138.5 (-ArC 1’), 130.6 (d, J = 8.0 Hz, -ArC 2’ & 6’), 
130.3 (-CH), 128.7 (-CH), 119.4 (-ArC 6), 115.3 (d, J = 21.2 Hz, -ArC 3’ & 5’), 109.7 
(-ArC 2), 106.0 (-ArC 4). 
19F-NMR (376 MHz, DMSO-d6): δ -113.98 (1F, m). 
 
 (E)-3,5-diacetylamino-4’-fluorostilbene 181 
(E)-3,5-difluoro-4’-aminostilbene (0.5 g, 2.19 
mmol) was dissolved in ethyl acetate (5 ml) and 
pyridine (5 ml) and cooled to 0 oC. Acetic anhydride 
(1.24 ml, 13.16 mmol) was added dropwise to this 
solution and the reaction was stirred at room 
temperature for 40 min before washing with water and brine. Recrystallisation from 
hexane/ethyl acetate yielded the product 181 as a white powder (0.53 g, 78%). 
m.p. 213-215 oC 
Anal. calcd. for C18H17N2FO2: C, 69.22; H, 5.49; N, 8.97.  
Found C, 68.85; H, 5.63; N, 8.83 
IR (KBr): υ 3268, 3099, 1667, 1615, 1599, 1556, 1509, 1456, 1420, 1371, 1276, 
1227, 1159, 1038, 998, 964, 848, 609 cm-1. 
UV (ACN): λmax 258 nm, 298, 307(sh) nm. 
1H NMR (400 MHz, DMSO-d6): δ 9.99 (2H, s, -NH), 7.76 (1H, s, -ArH 4), 7.69 (2H, 
m, -ArH 2’ & 6’), 7.52 (2H, d, J = 1.2 Hz, -ArH 2 & 6), 7.21 (2H, t, J = 9.0 Hz, -ArH 
3’ & 5’), 7.14 (1H, d, J = 16.4 Hz, -CH), 7.03 (1H, d, J = 16.4 Hz, -CH), 2.05 (6H, s, 
-CH3). 
13C-NMR (100 MHz, DMSO-d6): δ 168.4 (-C=O), 161.7 (d, J = 244.0 Hz, -CF), 139.8 
(-ArC 3 & 5), 137.4 (-ArC 1), 133.3 (d, J = 2.0 Hz, -ArC 1’), 128.5 (-ArC 2’ & 6’), 
128.4 (-CH), 127.2 (-CH), 115.5 (d, J = 21.0 Hz, -ArC 3’ & 5’), 112.0 (-ArC 2 & 6), 
109.5 (-ArC 4), 24.0 (-CH3). 
19F-NMR (376 MHz, DMSO-d6): δ -114.09 (1F, m). 
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(E)-3,5-di(trifluoroacetylamino)-4’-fluorostilbene 182 
(E)-3,5-difluoro-4’-aminostilbene (0.56 g, 2.46 
mmol) was dissolved in ethyl acetate (5 ml) and 
pyridine (5 ml). Trifluoroacetic anhydride (2.1 ml, 
14.74 mmol) was added dropwise to this solution 
and the reaction was stirred at room temperature 
for 40 min before washing with water and brine. 
Recrystallisation from hexane/ethyl acetate yielded the title product 182 as a white 
powder (0.58 g, 56%). 
m.p. 247-250 oC 
Anal. calcd. for C18H11N2FO2: C, 51.44; H, 2.64; N, 6.67.  
Found C, 51.85; H, 2.86; N, 6.47. 
IR (KBr): υ 3410, 3325, 3107, 1888, 1732, 1711, 1598, 1562, 1568, 1458, 1322, 
1216, 1149, 1006, 959, 938, 914, 890, 849, 815, 791, 738, 674, 623 cm-1. 
UV (ACN): λmax 260 nm; 296, 307(sh) nm. 
1H NMR (400 MHz, DMSO-d6): δ 11.47 (2H, s, -NH), 8.02 (1H, t, J = 1.6 Hz, -ArH 
4), 7.70-7.74 (4H, m, -ArH 2, 6, 2’ & 6’), 7.16-7.28 (4H, m, -ArH 3’, 5’ and 
HC=CH). 
13C-NMR (100 MHz, DMSO-d6): δ  161.9 (d, J = 243.8 Hz, -CF), 154.7 (q, J = 36.9 
Hz, -C=O), 138.3 (-ArC 1), 137.1 (-ArC 3 & 5), 133.0 (d, J = 3.0 Hz, -ArC 1’), 128.7 
(d, J = 7.9 Hz, -ArC 2’ & 6’), 128.7 (-CH), 127.3 (-CH),  115.7 (q, J = 287.1 Hz ,-
CF3), 116.2 (-ArC 2 & 6), 115.6 (d, J = 21.4 Hz, -ArC 3’ & 5’), 113.1 (-ArC 4). 
19F-NMR (376 MHz, DMSO-d6): δ -73.87 (6H, s), -113.53 (1F, m). 
 
(E)-3,5-di(N-BOC-glycine)amino-4’-fluoro stilbene 183 
 (E)-3,5-diamino-4’-fluorostilbene 
(0.29 g, 1.27 mmol) was dissolved in 
dichloromethane (15 ml) with N-tert-
butoxycarbonyl-glycine (0.67 g, 3.81 
mmol), 1-hydroxybenzotriazole (0.52 
g, 3.81 mmol) and triethylamine (1.06 
ml, 7.62 mmol). The mixture was 
cooled to 0 ˚C, and N-ethyl-N’-(3-
dimethylaminopropyl) carbodiimide (0.73 g, 3.81 mmol) was added. After 30 min. 
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the solution was raised to room temperature and the reaction was allowed to proceed 
for 48 hrs. The solution was washed with brine, sat. potassium hydrogen carbonate, 
10% citric acid and dried over sodium sulphate. The solvent was evaporated in vacuo 
and purification by column chromatography using hexane/ethyl acetate as eluant gave 
a solid. Recrystallisation from ethyl acetate/hexane furnished 183 as a white powder 
(0.26 g, 56%). 
m.p. 138-140 oC 
Anal. calcd. for C28H35N4FO6: C, 61.98; H, 6.50; N, 10.33. 
Found C, 61.58; H, 6.66; N, 9.82 
IR (KBr): υ 3300, 3103, 2976, 2929, 1675, 1599, 1507, 1452, 1366, 1225, 1160, 
1052, 959, 847, 791, 681 cm-1. 
UV (ACN): λmax 257 nm; 298, 309(sh) nm. 
1H NMR (400 MHz, DMSO-d6): δ 9.99 (2H, s, -NH) 7.80 (1H, s, -ArH 4), 7.70 (2H, 
m, -ArH 2’& 6’), 7.55 (2H, s, -ArH 2 & 6), 7.15-7.24 (3H, m, -ArH 3’, 5’ & -CH), 
7.04-7.08 (3H, m, -CH & -NH-), 3.75 (4H, d, J = 6.4 Hz, -CH2), 1.41 (18H, s, t-CH3). 
13C-NMR (100 MHz, DMSO-d6): δ 168.3 (-COCH2), 161.7 (d, J = 243.6 Hz, -CF), 
155.9 (-COOt-Butyl), 139.5 (-ArC 3 & 5), 137.6 (-ArC 1), 133.3 (d, J = 3.1 Hz, -ArC 
1’), 128.5 (-CH), 128.5 (-ArC 2’ & 6’), 127.4 (-CH), 115.6 (d, J = 21.4 Hz, -ArC 3’ & 
5’), 112.1 (-ArC 2 & 6), 109.6 (-ArC 4), 78.0 (-C(CH3)3), 43.7 (-CH2, -VE DEPT), 
28.2 (-C(CH3)3). 
19F-NMR (376 MHz, DMSO-d6): δ -114.02 (1F, m). 
 
(E)-3,5-di(N-BOC-L-alanine)amino-4’-fluoro stilbene 184 
 (E)-3,5-diamino-4’-fluorostilbene 
(1.21 g, 5.31 mmol) and N-tert-
butoxycarbonyl-L-alanine (3.01 g, 
15.92 mmol) were used. Purification 
by column chromatography with 
hexane/ethyl acetate as eluant 
furnished the product 184 as a white 
powder (1.15 g, 38%). 
m.p. 139-141 oC 
Anal. calcd. for C30H39N4FO6: C, 63.14; H, 6.89; N, 9.82.  
Found C, 63.42; H, 6.72; N, 9.66. 
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IR (KBr): υ 3292, 2977, 2931, 1672, 1600, 1508, 1452, 1366, 1288, 1164, 1070, 
1021, 960, 846, 790, 711, 681 cm-1. 
UV (ACN): λmax 258 nm; 298, 307(sh) nm. 
1H NMR (400 MHz, DMSO-d6): δ 9.98 (2H, s, -NH) 7.84 (1H, s, -ArH 4), 7.69 (2H, 
m, -ArH 2’& 6’), 7.55 (2H, s, -ArH 2 & 6), 7.14-7.23 (3H, m, -ArH 3’, 5’ & -CH), 
7.04-7.08 (3H, m, -CH & -NH), 4.14 (2H, quin, J = 7.2 Hz, α-H), 1.39 (18H, s, t-
CH3), 1.27 (6H, d, J = 7.2 Hz, -CH3). 
13C-NMR (100 MHz, DMSO-d6): δ 172.0 (-COCH2), 161.7 (d, J = 243.5 Hz, -CF), 
155.1 (-COOt-Butyl), 139.6 (-ArC 3 & 5), 137.5 (-ArC 1), 133.3 (-ArC 1’), 128.54 (-
CH), 128.46 (-ArC 2’ & 6’) 127.4 (-CH), 115.6 (d, J = 21.3 Hz, -ArC 3’ & 5’), 112.3 
(-ArC 2 & 6), 109.9 (-ArC 4), 78.0 (-C(CH3)3), 50.4 (α-C), 28.2 (-C(CH3)3), 18.0 (-
CH3). 
19F-NMR (376 MHz, DMSO-d6): δ -114.03 (1F, m). 
 
(E)-3,5-di(N-BOC-β-alanine)amine-4’-fluoro stilbene 185 
 (E)-3,5-diamino-4’-fluorostilbene 
(0.52 g, 2.28 mmol) and N-tert-
butoxycarbonyl-β-alanine (1.3 g, 
6.84 mmol) were used. Purification 
by column chromatography with 
hexane/ethyl acetate as eluant 
yielded 185 as a white powder (0.52 
g, 60%). 
m.p. 113-116 oC 
Anal. calcd. for C30H39N4FO6: C, 63.14; H, 6.89; N, 9.82.  
Found C, 62.95; H, 7.24; N, 9.64. 
IR (KBr): υ 3303, 3095, 2975, 2928, 1680, 1599, 1508, 1450, 1366, 1247, 1165, 
1068, 961, 846, 789 cm-1. 
UV (ACN): λmax 257 nm, 298, 308(sh) nm. 
1H NMR (400 MHz, DMSO-d6): δ 9.99 (2H, s, -NH) 7.79 (1H, s, -ArH 4), 7.68 (2H, 
m, -ArH 2’& 6’), 7.56 (2H, s, -ArH 2 & 6), 7.21 (2H, t, J = 8.8 Hz, -ArH 3’ & 5’), 
7.13 (1H, d, J = 16.2 Hz, -CH), 7.03 (1H, d, J = 16.2 Hz, -CH), 6.86 (2H, t, J = 5.4 
Hz, -NH), 3.24 (4H, q, J = 6.4 Hz, -CH2), 2.47-2.50 (m, -CH2), 1.38 (18H, s, t-CH3). 
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13C-NMR (100 MHz, DMSO-d6): δ 169.5 (-COCH2), 161.7 (d, J = 243.5 Hz, -CF), 
155.5 (-COOt-Butyl), 139.7 (-ArC 3 & 5), 137.4 (-ArC 1), 133.3 (d, J = 3.1 Hz,-ArC 
1’), 128.5 (-ArC 2’ & 6’), 128.4 (-CH), 127.2 (-CH), 115.6 (d, J = 21.5 Hz,-ArC 3` & 
5`), 112.2 (-ArC 2 & 6), 109.7 (-ArC 4), 77.6 (-C(CH3)3), 36.7 (-CH2, -VE DEPT), 
36.5 (-CH2, -VE DEPT), 28.2 (-C(CH3)3). 
19F-NMR (376 MHz, DMSO-d6): δ -114.07 (1F, m). 
 
(E)-3,5-di(N-BOC-L-valine)amino-4’-fluoro stilbene 186 
 (E)-3,5-diamino-4’-fluorostilbene 
(0.62 g, 2.72 mmol) and N-tert-
butoxycarbonyl-L-valine (1.35 g, 
6.21 mmol) were used. Purification 
by column chromatography with 
hexane/ethyl acetate as eluant gave 
the title product 186 as a brown wax 
(0.20 g, 12%). 
IR (KBr): υ 3305, 3091, 2964, 2924, 2873, 2358, 2336, 1670, 1508, 1451, 1366, 
1227, 1164, 1024, 847 cm-1. 
UV (ACN): λmax 258 nm; 296, 310 (sh) nm. 
1H NMR (400 MHz, DMSO-d6): δ 10.06 (2H, s, -NH) 7.88 (1H, s, -ArH 4), 7.70 (2H, 
m, -ArH 2’& 6’), 7.60 (2H, s, -ArH 2 & 6), 7.16-7.23 (3H, m, -ArH 3’, 5’ & -CH), 
7.08 (1H, d, J = 16.4 Hz, -CH), 6.89 (2H, d, J = 8.4 Hz, -NH), 3.99 (2H, t, J = 7.8 Hz, 
α-H), 1.94-2.10 (2H, m, -CH), 1.41 (18H, s, t-CH3), 0.94 (12H, d, J = 6.0 Hz, -
CH(CH3)2). 
13C-NMR (100 MHz, DMSO-d6): δ 170.8 (-COCH2), 161.7 (d, J = 243.0 Hz, -CF), 
155.5 (-COOt-Butyl), 139.4 (-ArC 3 & 5), 137.6 (-ArC 1), 133.3 (d, J = 3.0 Hz, -ArC 
1’), 128.5 (-CH), 128.4 (-ArC 2’ & 6’) 127.4 (-CH), 115.5 (d, J = 22.0 Hz, -ArC 3’ & 
5’), 112.5 (-ArC 3 & 5), 110.0 (-ArC 4), 78.0 (-C(CH3)3), 60.6 (α-C), 30.3 (-CH-), 
28.1 (-C(CH3)3), 18.4 & 19.2 (-CH(CH3)2). 
19F-NMR (376 MHz, DMSO-d6): δ -114.01 (1F, m). 
 
(E)-3-N-(BOC-L-valine)amino-5-amino-4’-fluoro stilbene 187 
 (E)-3,5-diamino-4’-fluorostilbene (0.62 g, 2.72 mmol) and N-tert-butoxycarbonyl-L-
valine (1.35 g, 6.21 mmol) were used. Purification by column chromatography with 
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hexane/ethyl acetate as eluant 
furnished the title product 184 as a 
brown powder (0.80 g, 81%). 
m.p. 105-109 oC 
IR (KBr): υ 3300, 2964, 1664, 1613, 1507, 1366, 1225, 1160, 1094,, 1013, 961, 839, 679 
cm-1. 
UV (ACN): λmax 257 nm; 298, 306(sh) nm. 
1H NMR (400 MHz, DMSO-d6): δ 9.69 (1H, s, -NH), 7.64 (2H, m, -ArH 2’& 6’), 7.20 
(2H, t, J = 8.8 Hz, -ArH 3’ & 5’), 6.92-7.04 (3H, m, -ArH 6 & CH=CH), 6.85 (1H, s, -
ArH 2), 6.81 (1H, d, J = 8.4 Hz, -NH), 6.50 (1H, s, -ArH 4), 5.17 (2H, s, -NH2), 3.92 (1H, 
t, J = 8.2 Hz, α-H), 1.92-2.05 (1H, m, -CH), 1.40 (9H, s, t-CH3), 0.92 (6H, d, J = 2.0 Hz, -
CH(CH3)2). 
13C-NMR (100 MHz, DMSO-d6): δ 170.5 (-COCH), 161.5 (d, J = 243.0 Hz, -CF), 155.5 
(-COOt-Butyl), 149.2 (-ArC 5), 139.7, (-ArC 3), 137.5 (-ArC 1), 133.6 (d, J = 3.0 Hz, -
ArC 1’), 129.2 (-CH), 128.2 (d, J = 8.0 Hz, -ArC 2’ & 6’) 126.2 (-CH), 115.5 (d, J = 22.0 
Hz, -ArC 3’ & 5’), 107.5 (-ArC 4), 106.0 (-ArC 6), 105.0 (-ArC 2), 78.0 (-C(CH3)3), 60.5 
(α-C),  30.4 (-CH(CH3)2), 28.2 (-C(CH3)3), 19.2 (-CH3), 18.4 (-CH3). 
19F-NMR (376 MHz, DMSO-d6): δ -114.01 (1F, m). 
 
(E)-3,5-di(aminoglycine)-4’-fluorostilbene trifluoroacetate salt 188 
3,5-di(amino-BOC-glycine)-4’-
fluorostilbene (0.22 g, 0.41 mmol) 
was dissolved in dichloromethane (5 
mls). Trifluoroacetic acid (5 ml) was 
added to this solution and the reaction 
was stirred at room temperature for an 
hour, until all starting material was consumed (monitoring by TLC). The solvent and 
excess TFA were evaporated with nitrogen stream. The crude residue was 
recrystallised from ethyl acetate to yield the title product 188 as a white powder 
(0.22g, 95%) 
m.p. 204-206 oC 
IR (KBr): υ 3095, 3002, 1670, 1626, 1560, 1509, 1458, 1199, 1136, 847, 798, 722 cm-1. 
UV (ACN): λmax 254 nm; 298 nm. 
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1H NMR (400 MHz, DMSO-d6): δ 10.65 (2H, s, -NH) 8.24 (6H, s, -NH3+), 7.88 (1H, s, -
ArH 4), 7.71 (2H, m, -ArH 2’ & 6’), 7.57 (2H, d, J = 1.2 Hz, -ArH 2 & 6), 7.23 (3H, m, -
ArH 3’, 5’ & -CH), 7.07 (1H, d, J = 16.0 Hz, -CH), 3.28 (4H, s, -CH2). 
13C-NMR (100 MHz, DMSO-d6): δ 164.9 (-CO), 161.5 (d, J = 243.8 Hz, -CF), 158.4 (q, J 
= 32.0 Hz, -CO), 139.0 (-ArC 3 & 5), 138.0 (-ArC 1), 133.1 (d, J = 3.2 Hz, -ArC 1’), 
128.6 (d, J = 7.9 Hz, -ArC 2’ & 6’), 128.1 (-CH), 127.9 (-CH), 116.9 (d, J = 297.0 Hz, -
CF3), 115.6 (d, J = 21.5 Hz, -ArC 3’ & 5’), 112.6 (-ArC 2 & 6), 109.6 (-ArC 4), 41.0 (-
CH2, -VE DEPT). 
19F-NMR (376 MHz, DMSO-d6): δ -73.84 (6F, s, -CF3), -113.76 (1F, m, 4’-F). 
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Appendix I 
 
List of abbreviations 
 
(E)   trans 
(Z)   cis 
2D COSY  2 dimension correlation spectroscopy  
4CL   4-courmarate:CoA ligase 
5-FU   5-fluorouracil 
Å   angstrom 
AA   amino acid 
ABTS   2,2’-azinobis(3-ethylbenzthiazoline-6-sulfonic acid) 
ACE   angiotensin converting enzyme 
ACF   aberrant crypt foci 
ACN   acetonitrile  
AD   Alzheimers disease 
AhR   aryl hydrocarbon receptor 
AIDS   aquired immunodeficiency syndrome 
AMD   age-related macular degeneration 
AML   acute myeloid leukaemia 
Anal   analysis 
anhyd   anhydrous 
AOM   azoxymethane 
aq   aqueous 
ARA70  androgen receptor-specific coactivator 
ARDS   adult respiratory distress syndrome 
Arg   arginine 
Asn   asparagine 
Asp   aspartic acid 
ATM   ataxia telangiectasia-mutated 
ATP   adenosine triphosphate 
ATR   ataxia telangiectasia and rad3-related 
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ATR   attenuated total reflection 
av   average 
BABIN  bis(5-amidino-2-benzimiazolyl)methane 
BACE   β-secretase 
BaP   benzo[a]pyrene 
BMS   Bristol Myers Squibb 
Bn   benzyl  
BOC   tert-butoxycarbonyl  
Bu or n-Bu  n-butyl  
Bz   benzoyl  
C4H   cinnamic acid 4-hydroxylase 
calcd   calculated 
Cat   cathepsin 
CHCl3   chloroform  
CHF   chronic heart failure 
CHS   chalcone synthase 
CL1   cathepsin L 
cm–1   wavenumber(s)/ per centimetre 
CNS   central nervous system 
CoA   coenzyme A 
conc   concentration 
COPD   chronic obstructive pulmonary disease 
COX   cyclo-oxygenase 
Cyp   cytochrome P450 
Cys   cysteine 
d   density 
d-   deuterated 
d   doublet (spectral) 
Da   dalton 
DBU   1,8-diazabicyclo[5.4.0]undec-7-ene  
DCC   1,3-dicyclohexylcarbodiimide  
DCM   dichloromethane  
dd   double doublets (spectral)  
DES   diethylstilbestrol 
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DFP   diisopropylfluorophosphate 
DMBA  7,12-dimethylbenz(a)anthracene 
DMPO   5,5-dimethyl-1-pyrroline-N-oxide 
DMSO   dimethyl sulfoxide  
DNA   deoxyribonucleic acid  
dNTPs   deoxyribonucleoside triphosphates 
DPPH   1,1-diphenyl-2-picrylhydrazyl 
DTP   development therapeutic program 
DTT   dithiotheritol 
E-64   L-trans-epoxysuccinyl-leucylamide-(4-guanido)-butane 
ED50   50% effective dose 
EDC    N-ethyl-N¢-(3-dimethylaminopropyl)carbodiimide  
EDTA   ethylenediaminetetraacetic acid  
EGTA   ethylene glycol tetraacetic acid 
Enz   enzyme (s) 
EPR   electron paramagnetic resonance 
eq   equation 
equiv   equivalent(s) 
ER   oestrogen receptor 
ESI-MS  electrospray ionisation mass spectrometry 
Et   ethyl  
EtOAc   ethyl acetate  
EtOH   ethanol 
FDA   food and drug administration 
FMOC   9-fluorenylmethoxycarbonyl  
Fxa   serine protease factor Xa 
g   gram(s) 
GC   gas chromatography 
gem-   geminal 
Gly   glycine 
GSTP1  glutathione S-transferase P1 
H2O   water 
HAP   histo-aspartic proteinase 
HAV   hepatitis A virus 
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HCl   hydrochloric acid 
Hex   hexane  
Hg   mercury 
His   histidine 
HIV   human immunodeficiency virus 
HLE   human leukocyte elastase 
HOBt   1-hydroxybenzotriazole 
hr   hour(s) 
HRV   human rhinovirus 
HSPG   heparan sulphate proteoglycans 
HUVEC  human umbilical vein endothelial cells 
Hz   hertz 
i-Bu   isobutyl  
IC50   concentration required for 50% growth inhibition 
ICE   interlukin-1 converting enzyme 
ID50   infectious dose to 50% of exposed individuals 
IHD   ischaemic heart disease 
Ile   isoleucine 
i-Pr   isopropyl  
IR   infrared 
Iva   isovaline 
J   coupling constant 
kass   rate of irreversible inhibition 
kDa   kilodaltons 
KF   potassium fluoride 
Ki   rate of inhibition 
Km   Michaelis Menten constant 
L   litre(s) 
L-Ala   L-alanine 
LDL   low density lipoprotein 
lit.   literature  
LLCs   Lewis lung carcinomas 
L-Leu   L-leucine 
LPS   lipopolysaccharide 
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L-Val   L-valine 
m-    meta 
M   molar (moles per liter) 
m   multiplet (spectral)  
m/z   mass-to-charge ratio 
M+   molecular ion 
(M+H)+  protonated molecular ion 
MAPK   mitogen-activated protein kinase 
max   maximum 
MDR   mulitdrug resistance 
Me   methyl  
mEH   microsomal epoxide hydrolase 
MeOH   methanol  
MgSO4  magnesium sulfate  
MHz   megahertz 
MI   post-myocardial infarction 
min   minute(s); minimum 
ml   millilitre 
mM   millimolar (millimoles per liter) 
mmol   millimole(s) 
MMP   matrix metalloproteases 
mol wt   molecular weight  
mol   mole(s) 
MOM   methoxymethyl ether 
mp   melting point 
mpk   milligrams per kilogram 
MS   mass spectrometry 
N   normal (equivalents per liter) 
Na2SO4  sodium sulfate  
NADPH  nicotinamide adenine dinucleotide phosphate 
NaOH   sodium hydroxide 
NCI   national cancer institute 
NEM   N-ethylmorpholine 
NF-κB   nuclear factor-kappa B 
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-NHMec  7-amino-4-methylcoumarin 
-NHNap  4-naphthylamine 
nM   nanomolar 
NMBA  N-nitrosomethylbenzylamine 
nmol/L  nanomoles per litre 
NMP   N-methyl-2-pyrrolidone 
NMR   nuclear magnetic resonance 
NNRTI  non-nuclotide reverse transcriptase inhibitors 
NO   nitric oxide 
NOESY  nuclear overhauser effect spectroscopy 
NRTI   nucloside reverse transcriptase inhibitors 
NtRTI   nuclotide reverse transcriptase inhibitors 
Nu   nucleophile 
o-   ortho 
oC   celsius 
ODC   ornithine decarboxylase 
p-    para 
Pa   pascal 
PAH   polycyclic aromatic hydrocarbons 
PAL   phenylalanine ammonium lyase 
PBM   peripheral blood mononuclear 
PE   petroleum ether  
PET   positron emission tomography 
PGE(2)  prostaglandin E synthase 
P-gp   p-glycoprotein 
Ph   phenyl  
Phe   phenylalanine 
PI   protease inhibitor 
PI   protease inhibitor (s) 
PI3K   phosphoinositide 3-kinase 
pKa   acid dissociation constant 
PMHS   polymethylhydrosiloxane 
PMs   plasmepsins 
PMSF   phenylmethylsulphonylfluoride 
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PPE   porcine pancreatic elastase 
ppm   part(s) per million 
Pr   propyl  
Pro   proline 
PSA   prostate-specific antigen 
q   quartet (spectral) 
quin   quintet (spectral) 
r.t.   room temperature 
RAS   renin-angiotensin system 
Ref.   reference (in tables) 
RNA   ribonucleic acid 
ROS   reactive oxygen species 
RPE   retinal pigment epithelium 
RR   ribonucleoside reductase 
s   singlet (spectral); second(s) 
SAR   structural activity relationship 
SARS   severe acute respiratory syndrome 
SARS-CoV MPRO severe acute respiratory syndrome coronavirus main proteinase 
sat.   saturated 
s-Bu   sec-butyl  
Ser    serine 
sex   sextet (spectral) 
soln   solution 
Sta   statine 
STS   stilbene synthase 
t   triplet (spectral) 
t-Bu   tert-butyl  
TEA   triethylamine  
Temp   temperature (in tables) 
TFA   trifluoroacetic acid  
TGF-α   transforming growth factor-α 
THF   tetrahydrofuran  
TIMP   tissue inhibition of metalloproteases 
TLC   thin-layer chromatography 
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TLCK   tosyl-lysine chloromethyl ketone 
TMS   tetramethylsilane  
TMS   trimethylsilyl 
TNF-α   tumour necrosis factor-α 
TPA   12-O-tetradecanoylphorbol-13-acetate 
TPCK   tosylamido-2-phenylethylchloromethyl ketone 
Trp   tryptophan 
tt   triplet of triplets 
UV   ultraviolet 
UVA   ultraviolet A (long range) 
UVB   ultraviolet B (medium range) 
v/v   volume per unit volume (volume-to-volume ratio) 
vol   volume 
w/w   weight per unit weight (weight-to-weight ratio) 
wt   weight 
Z-/CBz  benzoxycarbonyl 
ZBG   zinc-binding group 
Zn2+   zinc 
Z-VAD.FMK carbobenzyloxy-valyl-alanyl-aspartyl-[o-methyl]-fluoromethyl 
ketone 
β-Ala   β-alanine 
γ-ABA   γ-aminobutyric acid 
δ   chemical shift (ppm) 
µM   micromolar 
